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 ﺪﻴﻗ ﻰﻠﻋ ﺖﻨﻛ ﻮﻟ ﻚﻧأ فﺮﻋأ .ﻖﻠﳋا قﺪﺻأ ﺎﻳ و ﺐﻠﻗ ﻰﻘﻧأ ﺎﻳ ، ﻪﺘﻓﺮﻋ نﺎﺴﻧإ ﻢﻈﻋأ ، ﻲﻛﺮﺘﻟا ﲔﺴﺣ ﻲﺑأ حوﺮﻟ
I.ﻢﻴﺣﺮﻟا ﱘﺮﻜﻟا ﻰﻟﻮﳌا ﺪﻨﻋ كﺎﻘﻠﻧ .ﺪﻬﳉا اﺬﻫ يﺪﻫا ﻚﻴﻟإ  ..ﻲﺑ اﺮﺨﻓ تددزﻻ ةﺎﻴﳊا
I
 ﻲﻓ  ﺔﻄﻘَُﻨﳌا فوﺮﳊا ﻞﻜﻟ ًاﺮﻜﺸﻓ ،ﺐﺘﻛا ﻒﻴﻛ ﻲﻨﻴﺘﻤﻠﻋ ﻚﻨﻜﻟو ﺔﺳرﺪﻣ ﻲﻓ ﻲﺳرﺪﺗ ﻢﻟ ،ﻞﻳاﺪﻟا  ةزﻮﻣ ﻪﺒﻴﺒﳊا ﻲﻣﻷ
I.ﻲﻓاﺮﳋا ﻚﺋﺎﻄﻋو ﻚﺒﳊ اﺮﻜﺷ  .. ﺮﻴﺒﻜﻟا ﺮﺘﻓﺪﻟا اﺬﻫ ﺐﺘﻛا نﻷ ﻲﻨﺗﺪﻋﺎﺳ ﻲﺘﻟاو ﺮﻴﻐﺼﻟا يﺮﺘﻓد
I
 هﺬﻫ لﺎﻤﻛا ﺖﻌﻄﺘﺳا ﺎﳌ كﻻﻮﻟو ﺎﻨﻫ ءﻲﺷ ﻞﻜﺑ ﻲﺘﻠﻔﻜﺗ ﺪﻘﻟ .ﺔﺑﺮﻐﻟا ﻲﻓ يﺪﻨﺳو ﻰﻨﻤﻴﻟا يﺪﻳ ،ﺪﻨﻫ ﺔﻴﻟﺎﻐﻟا ﻲﺘﺟوﺰﻟ
I.ﻚﺿﻮﻋا نﺎﺑ كﺪﻋا .ﻲﺗﺎﻴﺣ ﻲﻓ ﻪﻠﺣﺮﳌا
I
 ﻰﻟإ ﺎﻬﺒﺨﺻو ةﺎﻴﳊا ﻖﻴﺿ ﻦﻣ ﻲﻨﺘﻋﺰﺘﻧا ﻲﺘﻟا ﻢﻜﻌﻣ ﻪﺣﺮﳌا تﺎﻈﺤﻠﻟا ﻞﻜﻟ ،نﺎﻄﻠﺳو ﲔﻟو ﻰﳌ ﻰﺋﺎﻨﺑا ﻲﺒﻠﻗ ﺔﺠﻬﳌ
  . ﻢﻜﻨﻋ اﺪﻴﻌﺑ ﺎﻬﺘﻴﻀﻗ ﻲﺘﻟا تﺎﻋﺎﺴﻟا ﻞﻛ ﻦﻋو مﻮﻨﻟا ﻞﺒﻗ ﻢﻜﻠﺒﻗا ﻢﻟ مﻮﻳ ﻞﻛ ﻦﻋ ﻒﺳآ ..  ﺔﻟﻮﻔﻄﻟاو ةءاﺮﺒﻟا ﻢﻟﺎﻋ
I.اﺪﺟ ..اﺪﺟ  ﻢﻜﺒﺣا
I
 ﻰﻠﻋ .ﻢﻜﺒﺣو ﻢﻜﺗاﻮﻋدو ﻢﻜﻤﻋﺪﻟ اﺮﻜﺷ .. ةرﻮﻧو ةﺮﻴﻨﻣو ﻞﻣأ ﻲﺗاﻮﺧأو ﻒﻴﻄﻠﻟاﺪﺒﻋو ﺰﻳﺰﻌﻟاﺪﺒﻋو ﺮﺳﺎﻳ ﻲﻧاﻮﺧﻹ
Iﷲا ءﺎﺷ نإ ﺎﺒﻳﺮﻗ ﻲﻘﺘﻠﻧ دﻮﻟا
I
Iم~ÄÅ ﺮﺒﻤﺘﺒﺳ ~Ç ﺖﺒﺴﻟا
Iﻲﻛﺮﺘﻟا ﲔﺴﺣ ﻦﺑ ﺪﻴﻌﺳ
Iةﺪﺤﺘﳌا ﺔﻜﻠﻤﳌا – جدﺮﺒﻣﺎﻛ
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Abstract	  	  Congenital	  heart	  defects	  (CHD)	  are	  structural	  anomalies	  affecting	  the	  heart,	  are	  found	   in	   1%	   of	   the	   population	   and	   arise	   during	   early	   stages	   of	   embryo	  development.	   Without	   surgical	   and	   medical	   interventions,	   most	   of	   the	   severe	  CHD	  cases	  would	  not	  survive	  after	  the	  first	  year	  of	  life.	  The	  improved	  health	  care	  for	   CHD	   patients	   has	   increased	   CHD	   prevalence	   significantly,	   and	   it	   has	   been	  estimated	   that	   the	   population	   of	   adults	   with	   CHD	   is	   growing	   ~5%	   per	   year.	  Understanding	  the	  causes	  of	  CHD	  would	  greatly	  help	  improve	  our	  knowledge	  of	  the	   pathophysiology,	   family	   counseling	   and	   planning	   and	   possibly	   prevention	  and	  treatment	  in	  the	  future.	  	  	  	  	  Several	   lines	   of	   evidence	   from	   humans	   and	   animal	   models	   have	   supported	   a	  substantial	   genetic	   component	   for	   CHD.	   However,	   gene	   discovery	   in	   CHD	   has	  been	  difficult	  due	   to	   the	  extreme	   locus	  heterogeneity	  and	   the	   lack	  of	  a	  distinct	  genotype–phenotype	   correlation.	   Currently,	   genetic	   causes	   are	   identified	   in	  fewer	  than	  20-­‐30%	  of	  the	  cases,	  most	  of	  which	  are	  syndromic	  while	  the	  isolated	  CHD	  cases	  remain	  largely	  without	  explanation.	  	  	  The	  aim	  of	  my	  thesis	  was	  to	  identify	  novel	  or	  known	  CHD	  genes	  enriched	  for	  rare	  coding	   genetic	   variants	   in	   isolated	   CHD	   cases	   and	   learn	   about	   the	   relative	  performance	   of	   different	   study	   designs.	   High-­‐throughput	   next	   generation	  sequencing	  (NGS)	  was	  used	  to	  sequence	  all	  coding	  genes	  (whole	  exome)	  coupled	  with	   various	   analytical	   pipelines	   and	   tools	   to	   identify	   candidate	   genes	   in	  different	  family-­‐based	  study	  designs.	  	  	  Since	  there	  is	  no	  general	  consensus	  on	  the	  underlying	  genetic	  model	  of	  isolated	  CHD,	  I	  developed	  a	  suite	  of	  software	  tools	  to	  enable	  different	  family-­‐based	  exome	  analyses	   of	  de	  novo	   and	   inherited	   variants	   (chapter	   2)	   and	   then	  piloted	   these	  tools	   in	   several	   gene	   discovery	   projects	   where	   the	   mode	   of	   inheritance	   was	  already	   known	   to	   identify	   previously	   described	   and	   novel	   pathogenic	   genes,	  before	  applying	   them	  to	  an	  analysis	  of	   families	  with	   two	  or	  more	  siblings	  with	  CHD.	  	  Based	   on	   the	   tools	   developed	   in	   chapter	   2,	   I	   designed	   a	   two-­‐stage	   study	   to	  investigate	   isolated	  parent-­‐offspring	   trios	  with	  Tetralogy	  of	  Fallot	   (chapter	   3).	  In	   the	   first	   stage,	   I	   used	  whole	   exome	   sequence	   data	   from	  30	   trios	   to	   identify	  genes	  with	  de	  novo	   coding	  variants.	  This	  analysis	   identified	  six	  de	  novo	   loss-­‐of-­‐function	  and	  13	  de	  novo	  missense	  variants.	  Only	  one	  gene	  showed	  recurrent	  de	  
novo	   mutations	   in	   NOTCH1,	   a	   well	   known	   CHD	   gene	   that	   has	   mostly	   been	  associated	   with	   left	   ventricle	   outflow	   tract	   malformations	   (LVOT).	   Besides	  
NOTCH1,	  the	  de	  novo	  analysis	  identified	  several	  possibly	  pathogenic	  novel	  genes	  such	   as	   ZMYM2	   and	   ARHGAP35,	   that	   harbor	   de	   novo	   loss-­‐of-­‐function	   variants	  (frameshift	  and	  stop	  gain,	  respectively).	  	  	  In	   the	   second	   stage	   of	   the	   study,	   I	   designed	   custom	   baits	   to	   capture	   122	  candidate	  genes	   for	  additional	   sequencing	  using	  NGS	   in	  a	   larger	  sample	  size	  of	  250	  parent-­‐offspring	  trios	  with	  isolated	  Tetralogy	  of	  Fallot	  and	  identified	  six	  de	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novo	   variants	   in	   four	   genes,	   half	   of	   them	   are	   loss-­‐of-­‐function	   variants.	   Both	   of	  
NOTCH1	  and	  its	  ligand	  JAG1	  harbor	  two	  additional	  de	  novo	  mutations	  (two	  stop	  gains	   in	  NOTCH1	   and	   one	  missense	   and	   a	   splice	   donor	   in	   JAG1).	   The	   analysis	  showed	   a	   strongly	   significant	   over-­‐representation	   of	   de	   novo	   loss-­‐of-­‐function	  variants	  in	  NOTCH1	  (P=3.8	  ×10-­‐9).	  	  Additionally,	   when	   compared	   with	   1,080	   control	   trios,	   NOTCH1	   exhibit	  significant	  burden	  of	   inherited	  rare	  missense	  variant	   (minor	  allele	   frequency	  <	  1%	   in	   1000	   genomes)	   (Fisher	   exact	   test,	   P=	   8.8	   ×	   10-­‐05)	   in	   about	   10%	   of	   the	  isolated	   Tetralogy	   of	   Fallot	   patients.	   I	   also	   modified	   the	   transmission	  disequilibrium	   test	   (TDT)	   to	   detect	   any	   distortion	   of	   rare	   coding	   allele	  transmission	   from	  healthy	  parent	   to	   their	  affected	  children.	  This	  modified	  TDT	  test	   identified	   ARHGAP35	   gene,	   which	   exhibits	   an	   over-­‐transmission	   of	   rare	  missense	  variants	  in	  children	  (P=0.025).	  Although,	  the	  p	  value	  does	  not	  reach	  a	  genome-­‐wide	  significant	  level	  after	  correcting	  for	  multiple	  tests,	  ARHGAP35	  gene	  has	   also	   a	   de	   novo	   stop	   gain	   variant	   in	   one	   trio	   from	   the	   primary	   cohort	   and	  recently	  shown	  to	  play	  a	  role	  in	  cardiomyocyte	  fate	  which	  make	  it	  an	  interesting	  novel	  ToF	  candidate	  gene	  for	  future	  studies.	  	  To	  assess	  alternative	  family-­‐based	  study	  design	  in	  CHD,	  I	  combined	  the	  analysis	  from	   13	   isolated	   parent-­‐offspring	   trios	   with	   112	   unrelated	   index	   cases	   of	  isolated	  atrioventricular	  septal	  defects	  (AVSD)	   in	  chapter	   4.	   	   Initially,	   I	  started	  with	  a	  case/control	  analysis	  to	  test	  the	  burden	  of	  rare	  missense	  variants	  in	  cases	  compared	  with	  5,194	  ethnically	  matching	  controls	  and	  identified	  the	  gene	  NR2F2	  (Fisher	  exact	  test	  P=7.7×10-­‐07,	  odds	  ratio=54).	  The	  de	  novo	  analysis	  in	  the	  AVSD	  trios	   identified	   two	   de	   novo	   missense	   variants	   in	   this	   gene.	  NR2F2	   encodes	   a	  pleiotropic	  developmental	   transcription	   factor,	  and	  decreased	  dosage	  of	  NR2F2	  in	  mice	  has	  been	   shown	   to	   result	   in	  abnormal	  development	  of	   atrioventricular	  septa.	  The	  results	  from	  luciferase	  assays	  show	  that	  all	  coding	  sequence	  variants	  observed	  in	  patients	  significantly	  alter	  the	  activity	  of	  NR2F2	  target	  promoters.	  	  	  My	   work	   has	   identified	   both	   known	   and	   novel	   CHD	   genes	   enriched	   for	   rare	  coding	  variants	  using	  next-­‐generation	  sequencing	  data.	  I	  was	  able	  to	  show	  how	  using	   single	   or	   combined	   family-­‐based	   study	   designs	   can	   be	   an	   effective	  approach	   to	   study	   the	   genetic	   causes	   of	   isolated	   CHD	   subtypes.	   Despite	   the	  extreme	  heterogeneity	  of	  CHD,	  combining	  NGS	  data	  with	  the	  proper	  study	  design	  has	  proved	  to	  be	  an	  effective	  approach	  to	  identify	  novel	  and	  known	  CHD	  genes.	  Future	   studies	   with	   considerably	   larger	   sample	   sizes	   are	   required	   to	   yield	  deeper	  insights	  into	  the	  genetic	  causes	  of	  isolated	  CHD.	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1.1.1	  Historical	  overview	  	  
	   1	  
1 |	  Introduction	  	  
1.1 Congenital	  Heart	  Defects	  	  
1.1.1 Historical	  overview	  	  The	  chronicle	  of	  congenital	  heart	  defects	   (CHD)	  begins	   thousands	  of	  years	  ago.	  The	   earliest	  written	   records	   of	   CHD	   are	   clay	   tables	   dating	   back	   to	   BC	   4000	   in	  which	   the	   Babylonian	   listed	   62	   human	   malformations	   and	   their	   prophetic	  implications.	   One	   these	   CHD	   malformations	   is	   ectopia	   cordis,	   a	   very	   rare	  congenital	  malformation	  in	  which	  the	  heart	  is	  abnormally	  located	  either	  partially	  or	  totally	  outside	  of	  the	  thorax	  (Figure	  1-­‐1-­‐a),	  was	  referred	  to	  as	  follows	  “when	  a	  
woman	  gives	  birth	  to	  an	  infant	  that	  has	  the	  heart	  open	  and	  that	  has	  no	  skin	  over	  it,	  
the	  country	  will	  suffer	  from	  calamities”	  [1].	  	  	  Generally,	  one	  can	  divide	  the	  evolution	  of	  our	  understanding	  of	  CHD	  over	  the	  last	  300	  years	  to	  four	  major	  eras	  [2].	  The	  first	  era	  extended	  until	  the	  early	  decades	  of	  the	   20th	   century	   (before	   the	   1940s)	   and	   primarily	   consisted	   of	   descriptive	  
efforts	   of	   the	   pathological	   anatomy	   in	   the	   heart	   (Figure	   1-­‐1-­‐b and c).	   These	  descriptive	  efforts	  culminated	  when	  Maude	  Abbott	   (Figure	  1-­‐1-­‐d)	  at	   the	  McGill	  University	   published	   the	   first	   atlas	   of	   congenital	   heart	   defect	   in	   1936,	   with	  detailed	  clinical	  and	  anatomical	  descriptions	  of	  1,000	  malformed	  hearts	  [3].	  	  The	  second	  era	  was	  of	  clinicophysiology	  and	  surgery	  (1940s	  to	  1970s).	  	  The	  era	   started	   when	   Dr	   John	   Streider	   at	   the	   Massachusetts	   General	   hospital	  successfully	   interrupted	  a	  ductus	  for	  the	  first	  time	  on	  March	  6,	  1937.	  However,	  he	  selected	  a	  septic	  patient	  who	  died	  on	  the	  fourth	  postoperative	  day	  of	  severe	  pulmonary	   valve	   infection	   (bacterial	   endocarditis).	   Because	   of	   this	   regrettable	  event,	  Dr	   Streider	  halted	  his	   regular	   surgical	   practice	   [3].	   	   A	   year	   later,	   on	   the	  16th	  August	  1938,	  Dr	  Robert	  Gross	  was	  able	  to	  ligate	  the	  patent	  arterial	  duct	  in	  a	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7-­‐year	   old	   patient	   who	   recovered	   from	   the	   surgery	   and	   become	   the	   first	  successful	   patient	   to	   undergo	   heart	   surgery	   [4].	   	   In	   the	   subsequent	   couple	   of	  years,	   the	   work	   of	   a	   team	   at	   the	   Johns	   Hopkins	   University	   revolutionized	  pediatric	  cardiology	  using	  the	  opposite	  operation:	  instead	  of	  closing	  the	  ducts	  as	  Gross	   did,	   they	   created	   an	   artificial	   duct	   to	   rescue	   cyanotic	   CHD	   babies	   (blue	  babies)	  [2].	  Although	  this	  operation	  is	  no	  longer	  performed	  routinely,	  the	  whole	  field	  of	  vascular	  bypass	  surgery	  grew	  from	  the	  tools	  and	  concepts	  of	  their	  work	  [2].	   	  
	  Figure	   1-­‐1	   (a)	  A	   patient	  with	   ectopia	  cordis,	   a	  malformation	  mentioned	   in	   the	  Babylonian	   clay	  tablets	  (b,c)	  An	  example	  of	  anatomical	  description	  by	  Leonardo	  da	  Vinci	  and	  his	  drawing	  of	  an	  	  atrial	  septal	  defect	  in	  his	  	  book,	  Quaderni	  de	  Anatomia	  II.	  The	  text	  read	  right	  to	  left:	  “I	  have	  found	  
that	   a,	   left	   auricle,	   to	   b,	   right	   auricle,	   a	   perforating	   channel	   from	  a	   to	   b,	  which	   I	   not	   here	   to	   see	  
whether	  this	  occurs	  in	  other	  auricles	  of	  other	  hearts”	  [5,	  6].	  (d)	  Maude	  Abbott	  in	  1869	  (image	  from	  McCord	  Museum	  collection).	  	  	  
The	  infant	  era	  (1970s	  to	  1990s)	  witnessed	  the	  introduction	  of	  prostaglandins	  and	  the	  rise	  of	  echocardiography	  [2].	  Prostaglandins	  offered	  cardiologists	  a	  new	  medical	  option	  to	  keep	  the	  ductus	  open	  in	  neonates	  with	  various	  heart	  defects.	  The	  idea	  was	  to	  keep	  the	  shunt	  open	  to	  allow	  the	  blood	  to	  continue	  circulating	  until	  surgery	  (see	  fetal	  circulation	  section	  1.1.9)	  [7].	  	  The	  imaging	  of	  the	  heart	  by	  ultrasound	  was	  another	  major	  breakthrough	  that	  enabled	  cardiologists	  to	  have	  a	  more	  detailed	  view	  of	  the	  heart	  for	  precise	  and	  earlier	  diagnosis	  [8].	  	  	  
a"
b" c" d"
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Researchers	  in	  the	  current	  era	  of	  cardiac	  development	  (1990s	  and	  beyond)	  have	   been	   trying	   to	   tackle	   CHD	   from	  different	   angles.	  Deep	   insights	   into	   heart	  development	   have	   emerged	   from	   multidisciplinary	   fields	   such	   as	   cellular	   and	  molecular	   biology,	   human	   genetics	   and	   animal	   model	   studies.	   Methods	   like	  linkage,	   positional	   cloning,	   candidate	   gene	   sequencing	   and	   karyotyping	   have	  been	  used	  to	  discover	  the	  genetic	  causes	  of	  many	  syndromic	  CHD.	  The	  results	  of	  these	   studies	   proved	   the	   existence	   of	   a	   clear	   genetic	   component	   in	   a	   small	  proportion	  of	  CHD	  by	   linking	  some	  of	   the	  cases	  to	  monogenic	   factors	  (see	  CHD	  genetic	  causes	  section	  1.1.11.2).	  	  	  However,	   epidemiological	   studies	   have	   emphasized	   a	   multifactorial	   (genetic	  variants	  interacting	  with	  environmental	  factors)	  model	  of	  CHD	  causation.	  Many	  environmental	   factors	  have	  been	   found	   to	   increase	   the	   risk	  of	  CHD.	  One	  of	   the	  most	  influential	  studies	  in	  this	  regard	  is	  the	  Baltimore-­‐Washington	  Infant	  Study	  (BWIS)	   study	   [9].	   This	   study	  was	   a	   case–control	   study	   evaluating	   genetic	   and	  environmental	   risk	   factors	   in	   live-­‐born	   infants	  with	  CHD	   in	   comparison	  with	   a	  control	   population	   over	   a	   9-­‐year	   period.	   BWIS	   paints	   a	   picture	   of	   a	   wide	  spectrum	  of	  CHD	  that	  ranges	  from	  monogenic	  at	  one	  end	  to	  multifactorial	  at	  the	  other	  end	  of	  the	  spectrum	  (see	  Non-­‐genetic	  risk	  factors	  section	  1.1.11.1).	  	  	  Functional	   studies	   have	   also	   proven	   to	   be	   an	   invaluable	   source	   of	   knowledge	  about	   heart	   development.	   Many	   ingenious	   cellular	   and	   molecular	   techniques	  have	   been	   used	   to	   dissect	   the	   events	   and	   processes	   that	   take	   place	   in	   heart	  development.	  One	  of	  these	  methods	  is	  lineage	  tracing	  (Figure	  1-­‐2)	  used	  to	  follow	  individual	  cells	  at	  an	  early	  stage	  of	  the	  heart	  development	  and	  trace	  the	  course	  of	  their	   proliferation	   and	   contribution	   to	   different	   heart	   components.	   	   	   Another	  method	   is	   gene	   knockdown	   in	   zebrafish	   and	  mouse	   knockout	  models	   to	   study	  how	   genes	   and	   different	   mutations	   relate	   to	   heart	   development	   (see	   section	  1.1.11.2.3).	  	  
In	   the	   last	   few	   years,	   massively	   parallel	   sequencing,	   also	   known	   as	   next-­‐generation	   sequencing	   (NGS),	  was	   introduced	   as	   a	   new	   tool	   to	   study	   different	  genetic	   traits	   in	  biology	  and	  medicine.	   	   In	   this	  dissertation,	   I	  have	  used	  NGS	   to	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study	  some	  of	  the	  non-­‐syndromic	  CHD	  that	  are	  poorly	  understood	  at	  the	  genetic	  level.	  	  	  This	  chapter	  presents	  an	  overview	  of	  our	  current	  understanding	  of	  congenital	  heart	  defects	  from	  the	  clinical,	  embryological	  and	  genetic	  perspectives	  and	  then	  describes	  next	  generation	  sequencing	  methods	  and	  their	  applications.	  	  	  
	  
Figure 1-2 Using	  the	  Brainbow	  method	  [10],	  a	  multicolour	  strategy	  for	  following	  the	  progeny	  of	  numerous	  individual	  cells	  simultaneously,	  Gupta	  and	  Poss	  	  [11]	  show	  the	  patterns	  of	  cell	  growth	  in	   the	   zebrafish	   heart	   at	   different	   stages	   (a)	   The	   embryonic	   cardiomyocytes	   that	   build	   the	  juvenile	  ventricular	  wall	  are	  displayed	  in	  clonal	  patches	  of	  variable	  shapes	  and	  sizes	  [11].	  (b)	  A	  section	   through	   the	   ventricle	   of	   a	   zebrafish	   embryo	   reveals	   a	   thin	   outer	   wall	   and	   an	   internal	  meshwork	   of	  muscle.	   Different	   colours	   represent	   different	   cell	   lineages.	   (c)	   The	   surface	   of	   the	  juvenile	   ventricle	   is	   an	   irregular	   patchwork	   of	   multiple	   lineages.	   (d)	   The	   surface	   of	   the	   adult	  ventricle	  is	  encased	  by	  a	  thick	  cortical	  layer	  that	  is	  built	  by	  the	  proliferation	  of	  a	  few	  founder	  cells	  derived	   from	  the	  muscle	  meshwork	  (Image	   ‘a’	  adapted	   from	  [11]	   	  while	   the	  rest	  were	  adapted	  from	  [12]). 	  
of ventricular muscle had emerged externally to t e wall of single-
cardiomyocyte thickness present at earlier stages (Fig. 3c, g). As indi-
cated by whole-mount imaging, this external layer typically displayed
substantial regions of clonally related cardiomyocytes. We will refer
subsequently to the inner wall muscle as the ‘primordial layer’, as it
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Figure 3 | Clonally dominant cortical cardiomyocytes. a–c, 6 wpf ventricular
surface (a, b) and confocal slice (c), indicating cortical (Cor; arrow), primordial
(Pr; arrowhead) and trabecular (Tr) muscle. d–g, 8 wpf ventricular surface
indicating a large green basal clone (d–f), and section indicating 3muscle types
(g). Dashed boxes in a and e are shown in higher magnification in b and f,
respectively. h, 90 dpf ventricular surface, showing only a few large cortical
clones. i, 90 dpf ventricular section. j, Percentage surface area (SA) occupied by
90 dpf clones (56 clones, 10 ventricles); basal clones representing each ventricle
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Figure 2 | Several dozen embryonic cardiomyocytes build the juvenile
ventricular wall. a, Surface myocardium of h lf f a 30 dpf ve tricular side,
displaying clonal patches of varied shapes and sizes. b, c, Cardiomyocyte clones
near the apex or chambermidpoint formingwedge/stripe shapes (arrowheads).
d, Single-cell clone (green, arrowhead) positioned near a large clone (yellow,
a r w). e, 30 dpf ventricular confocal slice, depicting a wall of single-
cardiomyocyte thickness (Com) surrounding trabecular muscle (Tr).
f, Percentage surface area (SA) occupied by 30 dpf clones (146 clones, 5
ventricles). g, Surface clones per ventricle (n5 10). Scale bars, 50mm.
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1.1.2 Importance	  of	  CHD	  	  Congenital	  heart	  defects	  are	  considered	  one	  of	  the	  major	  health	  challenges	  in	  the	  21st	  century.	  	  Collectively,	  CHD	  are	  the	  most	  common	  birth	  defect	  with	  8-­‐9	  new	  cases	  in	  1000	  live	  births	  [13]	  and	  1.3	  million	  new	  cases	  annually	  worldwide	  [14].	  Although	   some	   heart	   defects,	   such	   as	   patent	   ductus	   arteriosus	   (PDA),	   have	   a	  minor	   impact	  on	   the	  patients’	   life	  and	  do	  not	  usually	  require	   immediate	  health	  care,	  other	  defects	  diminish	  the	  heart	  function	  severely	  and	  necessitate	  intensive	  medical	  care	  and	  may	  require	  multiple	  surgical	  interventions.	  	  The	  prevalence	  of	  CHD	   in	  adults	  has	  been	  estimated	  recently	  at	  approximately	  3000	   cases	  per	  one	  million	   [15]	   and	   the	   size	  of	   this	  population	   is	   growing	  5%	  every	  year	  [16],	  in	  part	  due	  to	  successful	  surgical	  intervention	  during	  childhood.	  These	   figures	   paint	   a	   picture	   of	   a	   major	   health	   problem	   that	   needs	   careful	  planning	   to	  accommodate	   the	  special	  medical	  needs	  of	   the	  CHD	  patients	   in	   the	  upcoming	  years.	  	  The	  impact	  of	  a	  CHD	  extends	  beyond	  the	  affected	  child	  to	  his	  family	  and	  can	  lead	  to	   catastrophic	   effects	   on	   their	   psychological	   and	   financial	   welfare.	   	   The	  psychological	  effect	  ranges	  from	  increased	  parental	  stress	  to	  severe	  depression	  and	  these	  complications	  are	  usually	  overlooked	  [17].	   	  The	  financial	  situation	  of	  the	   families	   may	   adversely	   be	   affected	   especially	   in	   the	   underdeveloped	  countries.	   In	   one	   study,	   a	   third	   of	   the	   families	   spend	   16%	   of	   their	   monthly	  limited	   income	   on	   basic	   medical	   care	   and	   medications	   to	   treat	   chronic	   heart	  failure	  in	  their	  CHD	  child	  [18].	  	  	  The	  causes	  of	   the	  heart	  defects	  are	   largely	  unknown	  despite	  some	  successes	   in	  defining	   environmental	   risk	   factors	   and	   genetic	   causes.	   	   The	   majority	   of	   CHD	  cases	   remain	   without	   definitive	   diagnosis	   at	   the	   genetic	   level	   which	   hinders	  medical	  practitioners	   from	  providing	  optimal	  health	  service	  especially	   in	  terms	  of	  genetic	  counselling,	  family	  planning,	  pre-­‐implantation	  and	  prenatal	  diagnosis.	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1.1.3 Prevalence	  of	  CHD	  	  Since	  some	  of	  the	  CHD	  subtypes	  require	  an	  advanced	  health	  care	  infrastructure,	  planners	   and	   policy	   makers	   need	   an	   accurate	   estimation	   of	   the	   CHD	  epidemiological	  parameters	  to	  maintain	  and	  expand	  the	  medical	   infrastructure.	  Towards	   this	   end,	   an	   extensive	   body	   of	   knowledge	   has	   documented	   the	   birth	  prevalence,	  mortality	  and	  complication	  of	  CHD	  (reviewed	  in	  [15]).	  Despite	  these	  efforts,	   most	   epidemiological	   studies	   have	   been	   impeded	   by	   the	   variability	   of	  CHD	   definitions,	   classifications,	   birth	   prevalence	   estimates	   and	   survival	   rates	  which	  all	  led	  to	  varied	  estimates	  of	  these	  parameters.	  Epidemiological	  studies	  tend	  to	  focus	  on	  birth	  prevalence	  rather	  than	  incidence	  as	  CHD	  are	  congenital	  defects	  [15].	  The	  birth	  prevalence	  has	  been	  estimated	  as	  low	  as	  four	  cases	  up	  to	  50	  per	  1000	  live	  births	  [19,	  20].	  In	  a	  country	  like	  the	  USA,	  the	  overall	  estimate	  of	  CHD	  birth	  prevalence	  regardless	  of	  the	  subtype	  is	  10	  per	  1000	  live	  births	  but	  if	  only	  more	  severe	  CHD	  subtypes	  are	  considered,	  it	  drops	  to	  1.5	  in	  1000	  live	  births	  [19].	  On	   the	   other	   hand,	   the	   overall	   prevalence	   (defined	   as	   the	   number	   of	   living	  patients	  with	  the	  disease	  in	  a	  certain	  period	  of	  time)	  is	  more	  difficult	  to	  estimate	  given	  the	  rapid	  changes	  in	  surgical	  efficacy	  and	  survival	  rates.	  The	  estimates	  in	  USA	  and	  Canada	  (Quebec)	  were	  3.5	  and	  4.09	  per	  1000	  adults,	  respectively,	  while	  the	  prevalence	  of	   severe	  CHD	  was	  0.52	  and	  0.38	   for	   the	  same	  populations	   [21,	  22].	  The	  advances	  in	  surgical	  treatment	  can	  change	  the	  prevalence	  as	  well.	  The	  CONCOR	  registry	   showed	  a	  dramatic	   improvement	  of	   the	  median	  age	  of	  death,	  increasing	  from	  37	  in	  2002	  to	  57	  in	  2007	  [15,	  23].	  Currently	  96%	  of	  newborns	  with	  CHD	  reach	  an	  age	  of	  16	  because	  of	  the	  improvement	  in	  surgical	  treatment.	  	  
1.1.4 Recurrence	  rate	  in	  CHD	  	  The	  early	  studies	  of	  CHD	  inheritance	  in	  families	  [24-­‐28],	  siblings	  [29]	  and	  twins	  [30]	   have	   supported	   a	   polygenic	   or	   multifactorial	   model	   for	   CHD	   inheritance.	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These	   studies	   reported	   the	   incidence	   of	   CHD	   in	   first-­‐degree	   relatives	   to	   be	  between	  1	  and	  5%	  [31].	  	  	  However,	  the	  polygenic	  mode	  of	  inheritance	  was	  challenged	  when	  other	  studies	  reported	  higher	  recurrence	  risk	  (RR)	  for	  offspring	  of	  patients	  with	  CHD.	  The	  RR	  varies	  considerably	  among	  different	  CHD	  phenotypes	  and	  also	  varies	  according	  to	  the	  member	  of	  the	  family	  who	  is	  affected	  (i.e.	  sibs,	  mother	  or	  father)	  (Figure	  1-­‐3	  and	  Table	  1-­‐1)	  	  For	   example,	   when	   only	   one	   child	   is	   affected,	   heterotaxy	   and	   TGA	   show	   the	  highest	  RR	  (5-­‐6%).	  Having	  more	  than	  two	  affected	  children	  increases	  sibling	  RR	  up	   to	   10%	   in	   ventricular	   septal	   defects	   (VSD)	   and	   in	   hypoplastic	   left	   heart	  syndrome	  (HLHS).	  The	  RR	  is	  even	  more	  prominent	   in	  same	  sex	  twins	  (12	  fold)	  compared	   to	   twins	   with	   unlike	   sex	   [32,	   33].	   A	   general	   observed	   trend	   is	   that	  hypoplastic	   left	   heart	   syndrome,	   aortic	   valve	   stenosis	   and	   coarctation	   of	   the	  aorta	   	   (all	   are	  obstructive	   left	  heart	   lesions)	   exhibit	  higher	  RR	   than	  other	  CHD	  phenotypes	  [34]	  	  Affected	   parents	   increase	   the	   RR	   more	   than	   having	   affected	   sibs	   but,	  interestingly,	   affected	   mothers	   result	   in	   significantly	   higher	   RR	   compared	   to	  affected	   fathers	   (2-­‐20%	   and	   1-­‐5%	   respectively).	   The	   reason	   behind	   this	  difference	   is	   unknown	   but	   epigenetics,	   imprinting	   and	   environmental	   factors	  have	  all	  been	  suggested	  as	  having	  a	  role	  to	  play.	  	  The	   phenotypic	   concordance	   of	   recurrent	   CHD	   phenotypes	   (the	   same	   CHD	  subtype	  in	  patients	  from	  the	  same	  family)	  is	  37%	  but	  can	  be	  as	  high	  as	  64%	  in	  laterality	  lesions	  and	  80%	  in	  isolated	  atrioventricular	  septal	  defects	  (AVSD)	  [35].	  	  In	  one	  of	  the	  largest	  population-­‐based	  studies,	  Øyen	  et	  al.	  examined	  the	  familial	  aggregation	  of	  CHD	  subtypes	  in	  a	  well-­‐defined	  Danish	  population	  that	  has	  been	  annotated	   in	   multiple	   registries.	   [32].	   This	   study	   captured	   all	   residents	   of	  Denmark	   (~1.7	   million)	   over	   a	   28-­‐year	   period	   (1977-­‐2005)	   and	   identified	  ~18,000	  individuals	  with	  CHD	  and	  linked	  affected	  individuals	  with	  first-­‐,	  second-­‐
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,	   and	   third-­‐degree	   relatives	   to	   estimate	   the	   contribution	   of	   a	   family	   history	   of	  CHD	   to	   an	   individual’s	   risk	   of	   CHD.	   	   The	   authors	   found	   the	   relative	   risk	   of	  recurrence	   for	  all	   types	  of	  CHD	   to	  be	  ~3	  when	  a	   first-­‐degree	   relative	  had	  CHD	  and	  diminished	  when	  the	   family	  history	  of	  CHD	  was	   in	  only	  second-­‐	  and	  third-­‐degree	   relatives	  which	   are	   consistent	  with	   the	   commonly	   used	   empirical	   risks	  provided	   to	   families	   faced	  with	   a	   potential	   recurrence	   of	   CHD	   [36].	   The	   same	  group	  used	  the	  same	  data	  to	  evaluate	  the	  general	  aggregation	  of	  dissimilar	  CHDs	  in	   families	   (by	   examining	   all	   pairwise	   combinations	   of	   discordant	   14	   CHD	  phenotypes)	   and	   found	   no	   evidence	   that	   specific	   combination	   of	   the	   14	   CHD	  phenotypes	  aggregated	  in	  families	  [37].	  This	  observation	  might	  be	  explained	  by	  the	   pleiotropic	   effect	   of	   a	   single	   gene	   interacting	   with	   external	   factors	   (e.g.	  environmental	  factors	  such	  as	  pregestational	  diabetes)	  and	  /	  or	  interacting	  with	  modifier	  gene(s),	  which	  lead	  to	  discordant	  CHDs.	  	  Although	  Øyen	   et	  al.	  have	   found	   variable	   recurrence	   rate	   risk	   for	   specific	   CHD	  (for	  example	  the	  recurrence	  risk	  ratio	  ranged	  from	  ~3	  in	   isolated	  VSD	  cases	  to	  ~80	   in	   heterotaxia),	   they	   found	   that	   only	   ~2-­‐4%	   of	   heart	   defect	   cases	   in	   the	  population	  were	  attributed	   to	  CHD	   family	  history	   in	   first-­‐degree	  relatives.	  This	  observation	   suggests	   multiple	   factors,	   including	   multiple	   genetic	   loci,	   de	   novo	  mutations,	   non-­‐coding	   factors	   (e.g.	   epigenetic),	   environmental	   influences,	   or	   a	  combination	   of	   these	   factors	   are	   involved	   in	   CHD	   pathogenicity.	   However,	   a	  major	   limitation	  of	   this	   study,	   and	  other	   similar	   studies,	   is	   that	  parents	  with	   a	  previous	  child	  or	  other	  family	  member	  with	  a	  CHD	  might	  be	  more	  inclined	  to	  opt	  for	   prenatal	   screening	   and	   termination	   of	   pregnancy	   if	   the	   fetus	   is	   affected,	  which	  would	  reduce	  the	  observed	  number	  of	  within-­‐family	  recurrences	  of	  CHD	  and	  deflate	  risk	  ratio	  estimates	  accordingly	  [37].	  	  It	  has	  been	  estimated	  that	  10%	  of	  stillbirths	  exhibit	  CHD	  and	  it	  is	  presumed	  to	  be	  a	  major	  cause	  of	  early	  fetal	  loss	  [14,	  38].	  RR	  estimates	  are	  thus	  subject	  to	  being	  biased	   toward	  milder	   forms	   of	   CHD	   since	  more	   complex	   forms	   of	   CHD	   can	   be	  incompatible	  with	  life.	  Nonetheless,	  increased	  RR	  in	  CHD	  indicates	  the	  presence	  of	  more	  familial	  forms	  of	  CHD.	  The	  ongoing	  genetic	  and	  molecular	  studies	  have	  indeed	  confirmed	  this	  when	  rare	  variants	  with	  large	  effect	  size	  have	  been	  found	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in	   syndromic	   and	   non-­‐syndromic	   CHD	   (see	   section	   1.1.11.2	   Genetic	   causes	  below).	  	  
	  Figure	  1-­‐3	  Recurrence	  rate	  (RR)	   in	  selected	  CHD	  subtypes.	  RR	  value	   is	  assigned	  to	  0	  when	  it	   is	  not	  reported	  [15].	  	  Table	  1-­‐1	  Recurrence	  risk	  (RR)	  of	  different	  CHD	  subtypes	  [15,	  39]	  
Cardiac	  lesion	  
RR	  in	  siblings	  with	  unaffected	  parents	   RR	  in	  children	  of	  affected	  parents	  
1	  child	  	  
affected	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1.1.5 Clinical	  presentation	  and	  screening	  for	  critical	  cases	  About	   25%	   of	   CHD	   are	   considered	   life	   threatening	   and	   require	   immediate	  surgical	  and	  palliative	  intervention	  in	  the	  first	  year	  of	  life	  [40].	  These	  are	  usually	  structural	   heart	   defects	   in	   which	   patients	   are	   likely	   to	   collapse	   clinically	   and	  include	   transposition	   of	   the	   great	   arteries,	   coarctation/interrupted	   aortic	   arch,	  aortic	  stenosis,	  pulmonary	  atresia,	  and	  hypoplastic	  left	  heart/mitral	  atresia.	  It	  is	  very	   important	   to	   diagnose	   these	   cases	   as	   early	   as	   possible	   to	   provide	   proper	  medical	  care	  and	  minimize	  the	  life-­‐threating	  complications.	  	  	  The	   early	   clinical	   signs	   of	   life	   threating	   CHD	   are	   usually	   non-­‐specific	   such	   as	  cyanosis	   (bluish	   discoloration	   of	   the	   skin),	   difficulty	   in	   breathing	   and	   feeding,	  poor	   weight	   gain,	   and	   excessive	   sweating.	   A	   cardiovascular	   examination	   may	  reveal	   abnormal	   findings	   such	   as	   abnormal	   heart	   rate,	   precordial	   activity,	   and	  heart	   sounds;	   pathologic	   murmurs;	   and	   diminished/absent	   peripheral	   pulse.	  	  The	   early	   diagnosis	   of	   critical	   CHD	   is	   very	   important	   to	   enhance	   the	   survival	  chances	  of	   the	   affected	   children.	  However,	   it	   is	  not	   always	   feasible	   since	  many	  critical	  CHD,	  especially	  the	  ductal-­‐dependent	  defects,	  may	  develop	  the	  signs	  after	  the	  initial	  evaluation	  and	  can	  be	  easily	  overlooked	  [41,	  42].	  	  	  	  Many	  newborn	  screening	  programs	  aim	   to	  detect	  pre-­‐symptomatic	  and	  critical	  CHD	   cases	   before	   collapse	   or	   death	   events	   [43].	   Echocardiography	   is	   the	  most	  sensitive	   newborn	   screening	   method	   for	   CHD	   but	   it	   is	   not	   cost-­‐effective.	   A	  promising	  alternative	  is	  pulse	  oximetry	  in	  the	  first	  day,	  which	  has	  been	  found	  to	  improve	  the	  early	  detection	  of	  life-­‐threatening	  CHD	  [44].	  	  
1.1.6 Major	  health	  complications	  of	  CHD	  In	  infants	  with	  untreated	  complex	  CHD,	  most	  cases	  of	  heart	  failure	  occur	  before	  the	   end	   of	   the	   first	   year	   of	   life	   due	   to	   volume	   overload	   caused	   by	   shunts	   and	  obstructive	   lesions	  of	   the	  heart	   [15].	  Heart	   failure	   can	  also	  occur	  after	   surgical	  treatment	  such	  as	  atrial	  switch	  or	  Fontan	  procedures	  in	  10–20%	  of	  children	  [45].	  Other	   important	   late	   complications	   of	   CHD	   include	   arrhythmias,	   endocarditis,	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and	  pulmonary	  hypertension	  [46].	  Arrhythmias	  are	  a	  leading	  cause	  of	  mortality	  and	  morbidity	  in	  adults	  with	  CHD	  [47,	  48].	  Its	  incidence	  increases	  with	  age	  and	  correlates	   with	   the	   severity	   of	   CHD	   [15].	   Surgical	   interventions	   such	   as	   the	  Fontan	  procedure	  can	  lead	  to	  arrhythmias	  in	  half	  of	  the	  patients	  and	  are	  thought	  to	   arise	   from	   trauma	   to	   the	   sinus	   node	   and	   atrial	   muscle	   during	   the	   surgical	  procedure	  [49,	  50].	  	  	  Endocarditis	  usually	  arises	  as	  a	  result	  of	  the	  surgical	  shunts	  or	  grafts	  [51]	  and	  its	  incidence	   in	   CHD	   patients	   (1.4-­‐11.5	   in	   1000)	   is	   higher	   than	   in	   the	   normal	  population	   (5-­‐7	   in	   100,000	   persons	   per	   year).	   It	   can	   lead	   to	   serious	  complications	   such	   as	   valvular	   regurgitation	   (30%),	   cardiac	   failure	   (23%),	   and	  systemic	   emboli	   (20%)	   [52].	   However,	   earlier	   surgical	   treatment	   and	   effective	  use	  of	  antibiotics	  has	  caused	  a	  noticeable	  decrease	  in	  the	  mortality	  rate	  caused	  by	  infectious	  endocarditis	  to	  6-­‐7%	  [53].	  	  A	   less	  common	  CHD	  complication	   is	  pulmonary	  hypertension	  (PH)	  seen	   in	  4.2-­‐10%	  of	  CHD	  cases	  [54,	  55]	  which	  can	  cause	  irreversible	  lung	  damage	  if	  untreated	  at	  an	  early	  stage.	  Pulmonary	  hypertension	  arises	  from	  left-­‐to-­‐right	  shunting	  and	  pulmonary	   blood	   volume	   overload	   [56].	   The	   high	   arterial	   pulmonary	   blood	  pressure	   leads	   to	   endothelial	   dysfunction	   and	   increases	   pulmonary	   vascular	  resistance,	  which	  leads	  to	  central	  cyanosis	  (Eisenmenger’s	  syndrome)	  [57].	  The	  presence	  of	  pulmonary	  hypertension	  is	  usually	  associated	  with	  ventricular	  septal	  defects	  [54]	  and	  increases	  the	  risk	  of	  death	  compared	  to	  other	  CHD	  patients	  [58].	  Early	   surgical	   closure	   of	   these	   shunts	   helps	   to	   decrease	   the	   incidence	   of	  pulmonary	  hypertension	  [15].	  	  
1.1.7 CHD	  classification	  Many	   CHD	   classifications	   have	   been	   proposed,	   on	   the	   basis	   of	   heart	   structure	  (anatomical),	   embryological/developmental,	   physiological,	   clinical	   presentation	  and/or	  surgical	   features.	  Researchers	  and	  clinicians	  use	   these	  classifications	   to	  communicate	   more	   precisely	   in	   different	   settings.	   However,	   there	   is	   no	  
1.1.7	  CHD	  classification	  	  
	   12	  
consensus	  among	  them	  on	  a	  single	  CHD	  classification	  that	  is	  able	  to	  capture	  the	  complex	  and	  multiple	  facets	  of	  congenital	  heart	  defects.	  	  	  One	  of	  the	  most	  widely	  used	  CHD	  classifications	  is	  structure-­‐based	  (anatomical)	  and	   is	  used	   in	   the	  clinical	  setting	  as	  well	  as	   in	  CHD	  registries.	   It	  also	   forms	  the	  basis	  of	  the	  CHD	  section	  in	  the	  International	  Classification	  of	  Diseases	  (ICD	  10)	  [59].	  Although	  a	  pure	  anatomical	  classification	  is	  not	  able	  to	  reflect	  the	  severity	  of	  the	  diseases,	  it	  is	  very	  useful	  when	  comparing	  different	  studies	  or	  registries.	  	  	  A	  developmental	  classification	  of	  heart	  defects	  was	  used	  by	  Leung	  et	  al	   [60]	   to	  provide	   an	   alternative	   to	   the	   anatomical	   classifications	   for	   obstetricians	   and	  ultrasonographers	  attempting	  early	  detection	  of	  CHD.	  This	  classification	  is	  based	  on	  detecting	  deviation	  from	  the	  four-­‐chamber	  norm	  and,	  although	  it	  lacks	  many	  details	  captured	  by	  the	  anatomical	  classification,	  it	  is	  able	  to	  provide	  the	  correct	  diagnosis	   in	   97%	   of	   CHD	   cases	   compared	   to	   other	   methods	   (post-­‐natal	  examination,	  surgery	  and	  autopsies)	  [60].	  However,	  this	  type	  of	  classification	  is	  more	  useful	  for	  antenatal	  diagnosis	  or	  to	  test	  predictive	  tools	  or	  models	  of	  CHD	  but	  may	  change	  as	  our	  understanding	  of	  the	  development	  of	  the	  heart	  improves	  [61].	  	  Physiological	   classifications	   group	   CHD	   by	   its	   most	   significant	   physiological	  consequences	  [62].	  For	  example,	  cyanotic	  CHD	  are	  characterized	  by	  low	  oxygen	  levels	   in	   arterial	   blood	   compared	   to	   non-­‐cyanotic	   heart	   defects.	   Such	  classification	   is	   useful	   for	   clinical	   training	   for	   simplicity	   but	   it	   overlooks	  important	  anatomical	  features	  and	  /	  or	  clinical	  implications	  [61].	  	  A	   more	   useful	   classification	   in	   clinical	   settings	   is	   based	   on	   disease	   severity,	  suggested	   by	   Connelly	   et	   al	   [63]	   and	   modified	   later	   during	   the	   Bethesda	  conference	  on	  congenital	  heart	  disease	  in	  2001	  [21].	  This	  classification	  includes	  three	  groups	  –	  severe,	  moderate,	  or	  simple	  defects–	  based	  on	  the	  frequency	  of	  an	  adult	   CHD	   patient’s	   visits	   to	   a	   specialized	   center	   [15].	   This	   classification	   was	  applied	   to	   more	   than	   seven	   thousand	   CHD	   cases	   from	   the	   PAN	   registry	   in	  Germany	   (Table	   1-­‐2).	   The	  majority	   of	   cases	  were	  mild	   CHD	   (~60%)	   including	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small	   or	   muscular	   ventricular	   septal	   defects,	   all	   types	   of	   atrial	   septal	   defects,	  pulmonary	  stenosis,	  and	  patent	  ductus	  arteriosus	  [64].	  	  	  	  	  	  	  Table	  1-­‐2	  Frequency	  of	  CHD	  cases	  based	  on	  clinical	  severity	  in	  7,245	  in	  newborns	  (Germany	  July	  2006	  to	  June	  2007)	  
CHD	  severity	   Number	  of	  cases	   Parentage	  Mild	  CHD	   4,372	   60.3	  Moderate	  CHD	   1,988	   27.4	  Severe	  CHD	   866	   12.0	  No	  classification	   19	   0.3	  Mild	  CHD	  include:	  VSD	  (small	  or	  muscular),	  ASD	  (all	  forms),	  PDA,	  PS;	  moderate	  CHD	  include:	  VSD	  (others	  than	  small	  or	  muscular),	  AVSD,	  AS,	  CoA,	  PAPVC;	  severe	  CHD	  include:	  UVH	  (all	  types),	  ToF,	  PA/VSD,	  PA/IVS,	  DORV,	  D-­‐TGA,	  L-­‐TGA,	  TAC,	  IAA,	  TAPVC,	  Ebstein’s	  anomaly.	  VSD:	  ventricular	  septal	  defects,	  ASD:	  atrial	  septal	  defects,	  AVSD:	  atrioventricular	  septal	  defects,	  AS:	   aortic	   stenosis,	   CoA:	   coarctation	   of	   aorta,	   PAPVC:	   partial	   anomalous	   pulmonary	   venous	  connection,	   	  UVH:	  univentricular	  heart,	  ToF:	   tetralogy	  of	  Fallot,	  PA:	  pulmonary	  atresia,	  PA/IVS:	  pulmonary	  atresia	  with	   intact	  ventricular	  septum,	  DORV:	  double	  outlet	   right	  ventricle,	   	  D-­‐TGA:	  dextro-­‐transposition	  of	   the	  great	  arteries,	  L-­‐TGA:	   levo-­‐transposition	  of	   the	  great	  arteries	   ,	  TAC:	  transverse	  aortic	  constriction,	   IAA:	  Interrupted	  aortic	  arch,	  TAPVC:	  total	  anomalous	  pulmonary	  venous	  connection	  	  	  Although	   anatomical	   and	   clinical	   classifications	   are	   useful,	   they	   may	   obscure	  developmental	   relationships	   in	  CHD	  [65].	  To	  address	   this	   issue,	  a	  pathogenetic	  classification	   proposed	   by	   Clark	   [66]	   was	   thought	   be	   more	   intuitive	   	   when	  identifying	   the	   causes	   and	   mechanisms	   of	   CHD.	   Clark’s	   pathogenetic	  classification	  includes	  six	  mechanisms	  (Table	  1-­‐3).	  However,	  a	  newer	  version	  of	  this	   classification	   is	  needed	   to	   reflect	   the	   recent	   insights	  of	  heart	  development	  research	  since	  its	  last	  update	  17	  years	  ago.	  	  Other	   classification	   and	   coding	   systems	   include	   OPCS	   4	   (Office	   for	   Population	  Censuses	   and	   Surveys)	   Classification	   of	   Surgical	   Operations	   and	   Procedures,	  Fourth	   Revision	   [67]	   and	   the	   European	   Paediatric	   Cardiac	   Code	   (EPCC)	   [68]	  commonly	  used	   to	   code	   surgical	  procedures	   in	  hospitals	   in	   the	  UK.	  However,	   I	  will	   adopt	   the	   structure-­‐based	   classification,	   ICD-­‐10	   [59],	   throughout	   this	  dissertation	  as	  it	  is	  widely	  adopted	  	  and	  used	  in	  clinical	  practice.	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Table	  1-­‐3	  Clark’s	  Pathogenetic	  Classification	  of	  Congenital	  Cardiovascular	  Malformations	  [66]	  
Group	   CHD	  
I.	  Ectomesenchymal	  tissue	  migration	  abnormalities	  
Conotruncal	  septation	  defects	  Increased	  mitral	  aortic	  separation	  	  Subarterial,	  type	  I	  ventricular	  septal	  defect	  	  Double-­‐outlet	  fight	  ventricle	  Tetralogy	  of	  Fallot	  Pulmonary	  atresia	  with	  ventricular	  septal	  defect	  Aorticopulmonary	  window	  Truncus	  arteriosus	  communis	  
Abnormal	  conotruncal	  cushion	  position	  	  Transposition	  of	  the	  great	  arteries	  (-­‐d)	  
Pharyngeal	  arch	  defects	  Interrupted	  aortic	  arch	  type	  B	  Double	  aortic	  arch	  Right	  aortic	  arch	  with	  mirror	  image	  branching	  
II.	  Abnormal	  intracardiac	  blood	  flow	  
Perimembranous	  ventricular	  septal	  defect	  
Left	  heart	  defects	  Bicuspid	  aortic	  valve	  Aortic	  valve	  stenosis	  Coarctation	  of	  the	  aorta	  Interrupted	  aortic	  arch	  type	  A	  	  Hypoplastic	  left	  heart,	  aortic	  atresia/mitral	  atresia	  
Right	  heart	  defects	  Bicuspid	  pulmonary	  valve	  Secundum	  atrial	  septal	  defect	  Pulmonary	  valve	  stenosis	  Pulmonary	  valve	  atresia	  with	  intact	  ventricular	  septum	  III.	  Cell	  death	  abnormalities	   Muscular	  ventricular	  septal	  defect	  Ebstein's	  malformation	  of	  the	  tricuspid	  valve	  Group	  IV.	  Extracellular	  matrix	  abnormalities	   Endocardial	  cushion	  defects	  Ostium	  primum	  atrial	  septal	  defect	  	  Type	  III,	  inflow	  ventricular	  septal	  defect	  Atrioventricular	  canal	  defect	  
Dysplastic	  pulmonary	  or	  aortic	  valve	  Group	  V.	  Abnormal	  targeted	  growth	   Anomalous	  pulmonary	  venous	  return	  Partial	  anomalous	  pulmonary	  venous	  return	  	  Total	  anomalous	  pulmonary	  venous	  return	  	  and	  Cor	  triatriatum	  VI.	  Abnormal	  situs	  and	  looping	   Heterotaxia	  L-­‐loop	  	  
1.1.8 Heart	  development	  	  The	  heart	  is	  the	  first	  organ	  to	  develop	  in	  the	  embryo	  to	  help	  circulate	  nutrients	  and	  remove	  waste.	  Its	  development	  starts	  as	  soon	  as	  the	  number	  of	  cells	  reaches	  a	   point	   where	   diffusion	   is	   no	   longer	   efficient	   [69].	   Recently,	   a	   few	   techniques	  have	  transformed	  our	  understanding	  of	  how	  the	  heart	  develops.	  Fate	  mapping,	  a	  method	  used	  to	  determine	  the	  cellular	  derivatives	  of	  a	  cell	  or	  population	  of	  cells,	  and	   lineage	   analysis	   in	   mammalian	   embryos	   have	   documented	   how	   different	  regions	   in	  the	  embryos	  are	   involved	  in	  cardiac	  development	  [70].	  This	  detailed	  knowledge	  is	  likely	  to	  improve	  our	  understanding	  of	  congenital	  heart	  defects.	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  There	  are	  four	  major	  steps	  in	  the	  development	  of	  the	  heart:	  formation	  of	  cardiac	  crescent,	   formation	   of	   the	   heart	   tube,	   looping	   of	   the	   heart	   tube	   followed	   by	  ballooning	  and	  finally	  septation	  and	  valve	  development	  [70].	  These	  steps	  result	  in	  a	  four-­‐chambered	  heart	  with	  parallel	  systemic	  and	  pulmonary	  circulations.	  	  	  The	  mature	   heart	   consists	   of	   different	   cell	   types	   that	   contribute	   to	   structural,	  biochemical,	  mechanical	   and	   electrical	   properties	   of	   the	   functional	   heart.	  With	  the	  help	  of	  cell	   lineage	  tracing	  and	  descriptive	  embryology	  of	  the	  origins	  of	  the	  heart,	   researchers	   have	   detected	   four	   different	   populations	   of	   cells	   that	  contribute	  to	  different	  parts	  of	  the	  heart	  [71]	  (Figure	  1-­‐4	  and	  Figure	  1-­‐5).	  	  	  	  
The	   primary	   heart	   field	   (PHF)	   forms	  a	   cardiac	   crescent	   in	   the	  most	  anterior	  region	  of	  the	  embryo	  at	  the	  second	  week	  of	  human	  gestation	  (Figure	  1-­‐5-­‐B)	  [72].	  The	  PHF	  cells	  contribute	  exclusively	  to	  the	  left	  ventricle	  and	  all	  other	  parts	  of	  the	  heart,	  except	  the	  outflow	  tract	  [73,	  74].	  	  	  
The	   second	   heart	   field	   (SHF)	   lies	  medially	   to	   the	   cardiac	   crescent	   and	   then	  behind	   the	   forming	   heart	   tube,	   extending	   into	   the	   mesodermal	   layer	   of	   the	  pharyngeal	  arches	  (Figure	  1-­‐5-­‐B).	  The	  cells	  in	  the	  SHF	  contribute	  exclusively	  to	  the	   outflow	   tract	   and	   all	   other	   parts	   of	   the	   heart;	   except	   the	   embryonic	   left	  ventricle	   [71,	   73,	   75].	   It	   has	   been	   suggested	   that	   the	   PHF	   provides	   a	   scaffold	  upon	  which	  cells	  from	  SHF	  migrate	  into	  both	  ends	  of	  the	  heart	  tube,	  where	  they	  eventually	  contribute	  to	  different	  cardiac	  complements	  [71].	  	  	  The	  third	  source	  of	  heart	  progenitor	  cells	  comes	  from	  the	  cardiac	  neural	  crest	  
cells	   (cNCC)	   that	   migrate	   as	   mesenchymal	   cells	   into	   the	   third	   and	   fourth	  pharyngeal	  arches	  and	  the	  cardiac	  outflow	  (conotruncus)	  (Figure	  1-­‐5-­‐D,E)	  [76].	  	  The	  cardiac	  cNCC	  cells	  are	  necessary	  for	  septation	  of	  the	  truncus	  arteriosus	  into	  the	   aorta	   and	   the	   pulmonary	   trunk	   as	   well	   as	   the	   formation	   of	   a	   part	   of	   the	  ventricular	  septum	  [77,	  78].	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The	   fourth	   lineage	   of	   cardiac	   precursor	   cells	   is	   derived	   from	   proepicardium	  
(PE),	   which	   in	   turn	   develops	   from	   the	   coelomic	  mesothelium	   that	   overlay	   the	  liver	   bud	   (Figure	   1-­‐5-­‐E).	   These	   cells	   contribute	   to	   the	   coronary	   vessels	   and	  cardiac	  connective	  tissue	  [71,	  79].	  	  	  The	  most	  important	  events	  taking	  place	  in	  human	  cardiac	  development	  are	  listed	  in	   (Table	   1-­‐4)	  More	  details	   about	   the	  development	   of	   specific	   heart	   structures	  involved	  in	  Tetralogy	  of	  Fallot	  (ToF)	  and	  Atrioventricular	  Septal	  Defects	  (AVSD)	  are	  discussed	  in	  the	  chapters	  3	  and	  4	  of	  this	  thesis,	  respectively.	  	  
	  Figure	   1-­‐4	   Multiple	   cell	   lineages	   contribute	   to	   cardiovascular	   development.	   A	   lateral	   view	   of	  embryo	  at	   the	  heart	   looping	  stage	   ,	  around	  embryonic	  day	   (E)	  9	   in	  mice,	  4	  weeks	   in	  human,	   is	  shown	  (the	  image	  is	  adapted	  from	  [71]).	  	   	  
LIM-homeodomain transcription factor Islet1 (Isl1) and
comprises the dorsal–medial aspect of the cardiogenic
plate, whereas the FHF comprises the ventral aspect of the
cardiogenic plate (Cai et al. 2003). As the heart tube forms,
SHF cells migrate into the midline and position themselves
dorsal to the heart tube in the pharyngeal mesoderm
(Fig. 2). Upon rightward looping of the heart tube, SHF
cells cross the pharyngeal mesoderm into the anterior and
posterior portions, populating a large portion of the outflow
tract, future right ventricle, and atria (Cai et al. 2003). Once
within the heart, FHF and SHF cells appear to proliferate in
response to endocardial-derived signals, such as neuregu-
lin, and epicardial signals dependent on retinoic acid,
although our understanding of these mechanisms remains
as yet incomplete (reviewed in Olson 2004).
Neural crest cells (NCC) are multipotential cells that
delaminate from the dorsal neural tube that is derived from
the ectoderm and migrate widely throughout the body as
mesenchymal cells. A subregion of the cranial NCC orig-
inating between the otocyst and somite 3 has been called
the ‘‘cardiac NCC’’ as the NCC of this region migrate into
third and fourth pharyngeal arches and the cardiac outflow
tract, or conotruncus (reviewed in Hutson and Kirby 2007).
These cells contribute to the remodeling of the six pairs of
bilaterally symmetric pharyngeal arch arteries that even-
tually results in the formation of the ascending aorta and
proximal subclavian, carotid, and pulmonary arteries.
Cardiac NCC are also necessary for septation of the truncus
arteriosus into the aorta and the pulmonary trunk as well as
the formation of a part of the ventricular septum. Results
from recent studies have suggested that reciprocal signal-
ing between NCC and SHF is required for aortic arch and
outflow tract development (Waldo et al. 2005; Ward et al.
2005).
The fourth lineage of cardiac precursor cells is
derived from proepicardium (PE). The PE develops from
the coelomic mesothelium that overlays the liver bud,
and the expression of PE-specific genes are induced in
naı¨ve mesothelial cells in response to a localized liver-
derived signal. All of the cells of the epicardium and the
coronary vessels arise from the PE, which develops as
multiple epithelial villi protruding from the pericardial
mesothelium immediately posterior to sinoatrium of the
looping stage mbryon c heart (Fig. 2) (Mikawa and
Gourdie 1996). The PE extends towards the primitive
heart, attaches, and spreads over the myocardial surface,
forming the epicardium. During PE growth and epicar-
dial formation, some PE/epicardial cells undergo an
epithelial–mesenchymal transformation (EMT) and are
related into the subepicardial space, giving rise to the
precursors of the coronary vessels and cardiac connective
tissue cells.
Tbx1 in the SHF is implicated in CHD
Tbx1, a member of the T-box family of transcription fac-
tors, is expressed in the SHF, but not in the FHF. This
factor is a major genetic determinant of the 22q11.2 dele-
tion syndrome (22q11DS) in humans (reviewed in
Yamagishi and Srivastava 2003). Outflow tract defects,
such as persistent truncus arteriosus and tetralogy of Fallot,
are characteristic cardiovascular features observed in
patients with 22q11DS along with craniofacial defects,
such as cleft palate (reviewed in Yamagishi 2002). Tbx1-
null mice phenocopy the 22q11DS phenotype (Jerome and
Papaioannou 2001; Lindsay et al. 2001; Merscher et al.
2001) and Tbx1-hypomorphic mice display a milder phe-
notype with cardiovascular defects but no cleft palate (Hu
et al. 2004; Xu et al. 2004). Tissue-specific disruption of
Tbx1 in the expression domain of cardiac-specific homeo-
box transcription factor Nkx2.5 developed the single
outflow tract with no evidence of aorto-pulmonary septum,
suggesting that loss of Tbx1 function in the SHF or pha-
ryngeal endoderm may result in outflow tract defects
(Xu et al. 2004).
Fig. 2 Multiple cell lineages contribute to cardiovascular develop-
ment. Schematic diagram of lateral view of embryo at the heart
looping stage [around embryonic day (E) 9 in mice, 4 weeks in
human] is shown. Cells derived from the lateral plate mesoderm, or
first/primary heart field (FHF/PHF), give rise to the heart tube (red).
Upon rightward looping of the heart tube, cells derived from the
pharyngeal mesoderm, or second heart field (blue), migrate into the
anterior and posterior portions of the heart tube, populating a large
portion of the outflow tract, future right ventricle, and atria. Cardiac
neural crest cells (yellow) delaminate from the dorsal neural tube and
migrate into the third and fourth pharyngeal arches and the outflow
tract. Cells of epicardium and the coronary vessels arise from the
proepicardium (green)
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  Figure	  1-­‐5	  (A)	  Migration	  of	  cells	  anteriorly	  from	  the	  primitive	  streak	  (PS).	  (B)	  Formation	  of	  the	  cardiac	  crescent	  (CC),	  with	  the	  second	  heart	  field	  (SHF)	  lying	  medial	  to	  it.	  (C–E)	  Front	  (left)	  and	  lateral	   (right)	   views	  of	   the	  heart	   tube	   as	   it	   begins	   to	   loop	  with	   contributions	  of	   cardiac	  neural	  crest	  cells	  (cNCC),	  which	  migrate	  from	  the	  pharyngeal	  arches	  (PA)	  to	  the	  arterial	  pole	  (AP).	  The	  proepicardial	   organ	   (PEO)	   forms	   in	   the	   vicinity	   of	   the	   venous	   pole	   (VP).	   (F)	   The	   looped	   heart	  tube,	  with	  the	  cardiac	  compartments—OFT,	  outflow	  tract;	  RA,	  right	  atrium;	  LA,	   left	  atrium;	  RV,	  right	   ventricle;	   LV,	   left	   ventricle.	   (G)	   The	   mature	   heart	   which	   has	   undergone	   septation—IVS,	  interventricular	   septum;	   AA,	   aortic	   arch;	   Ao,	   aorta;	   PT,	   pulmonary	   trunk;	   PV,	   pulmonary	   vein;	  SVC,	   superior	   caval	   vein;	   IVC,	   inferior	   caval	   vein.	   The	   primary	   heart	   field	   (PHF)	   and	   its	  myocardial	   contribution	   are	   shown	   in	   red,	   the	   SHF	   and	   its	   derivatives	   in	   dark	   green	  (myocardium)	   and	   pale	   green	   (vascular	   endothelial	   cells),	   cNCC	   in	   yellow	   (vascular	   smooth	  muscle	  of	  the	  AA,	  endocardial	  cushions),	  and	  PEO	  derivatives	  in	  blue.	  (The	  image	  and	  caption	  are	  adapted	  from	  [69])	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DPC	   Description	  CS8	   17-­‐19	   7	   The	  cardiac	  crescent	  forms	  
CS9	   19-­‐21	   7.5	   The	  embryo	  folds,	  the	  pericardiac	  cavity	  is	  placed	  in	  its	  final	  position,	  gully	  of	  myocardium	  forms,	  the	  endocardial	  plexus	  forms,	  cardiac	  jelly	  forms	  CS10	   22-­‐23	   8	   The	  heart	  beats,	  the	  endocardial	  tubes	  fuse,	  the	  mesocardium	  perforates,	  looping	  starts,	  the	  ventricle	  starts	  ballooning	  	  
CS11	   23-­‐26	   8.5	   The	  atria	  balloon,	  the	  pro-­‐epicardium	  forms	  
CS12	   26-­‐30	   9.5	   The	  septum	  premium	  appears,	  the	  right	  venous	  valve	  appears,	  the	  muscular	  part	  of	  the	  ventricular	  septum	  forms,	  cells	  appear	  in	  the	  cardiac	  jelly,	  the	  epicardial	  growth	  starts	  CS13	   28-­‐32	   10.5	   The	  atrioventricular-­‐cushions	  form,	  the	  pulmonary	  vein	  attaché	  to	  the	  atrium,	  the	  left	  venous	  valve	  appears,	  epicardial	  mesenchyme	  appears	  first	  in	  the	  atrioventricular	  sulcus	  CS14	   31-­‐35	   11.5	   The	  atrioventricular-­‐cushions	  approach	  one	  another,	  the	  outflow	  ridges	  become	  apparent,	  capillaries	  form	  in	  the	  epicardial	  mesenchyme	  
CS15	   35-­‐38	   12	   The	  atrioventricular	  cushions	  oppose	  one	  another,	  the	  secondary	  foramen	  forms,	  the	  distal	  outflow	  tract	  septates	  the	  outflow	  tract	  ridges	  reach	  the	  primary	  foramen	  CS16	   37-­‐42	   12.5	   The	  primary	  atrial	  septum	  closes,	  the	  outflow	  tract	  ridges	  approach	  the	  interventricular	  septum.	  The	  entire	  heart	  is	  covered	  in	  epicardium	  	  
CS17	   42-­‐44	   13.5	   Secondary	  atrial	  septum	  appears,	  the	  sinus	  node	  becomes	  discernable,	  the	  left	  and	  right	  atrioventricular	  connection	  becomes	  separate,	  the	  proximal	  outflow	  tract	  becomes	  septated,	  the	  semilunar	  valves	  develop	  CS18	   44-­‐48	   14.5	   Papillary	  muscles	  appear,	  the	  atrioventricular	  valves	  start	  to	  form	  
CS19	   48-­‐51	   15	   The	  left	  venous	  valve	  fuses	  with	  the	  secondary	  septum,	  the	  mural	  leaflets	  of	  the	  mitral	  and	  tricuspid	  valve	  are	  released	  
CS21	   53-­‐54	   16	   The	  main	  braches	  of	  the	  coronary	  artery	  become	  apparent	  
CS22	   54-­‐56	   16.5	   The	  chorda	  tendinae	  form	  
CS23	   56-­‐60	   17.5	   The	  septal	  leaflet	  of	  the	  tricuspid	  valve	  delaminates	  	  
1.1.9 Fetal	  circulation	  	  The	   fetal	   heart	   blood	   circulation	   relies	   on	   receiving	   oxygenated	   blood	   from	  maternal	  circulation	  via	  the	  umbilical	  veins	  (placenta-­‐based)	  and	  enters	  the	  right	  atrium	   of	   the	   heart	   via	   the	   inferior	   vena	   cava	   vein.	   This	   is	   facilitated	   by	   the	  presence	  of	  two	  naturally	  occurring	  fetal	  shunts	  (a	  connection	  that	  allow	  blood	  to	  flow	  directly	  from	  one	  side	  of	  the	  cardiac	  circulation	  to	  the	  other),	  the	  ductus	  arteriosus	   (PDA)	   and	   the	   foramen	   ovale	   (PFO)	   (Figure	   1-­‐6).	   	   The	   lungs	   at	   this	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stage	  are	  not	  developed	  and	  have	  very	  high	  pressure	  that	  makes	  the	  blood	  divert	  from	  the	  right	  atrium	  to	  the	  left	  atrium	  through	  PDA	  and	  then	  to	  the	  left	  ventricle	  and	  to	  the	  rest	  of	  the	  body.	  	  	  After	   birth,	   the	   first	   breath	   increases	   the	   O2	   levels	   in	   the	   lungs	   causing	  vasodilatation	  of	   the	   lung	  arteries	   leading	   to	  a	  sudden	  drop	   in	   the	  right	  atrium	  pressure	   and	   an	   increase	   in	   left	   atrium.	   This	   change	   closes	   the	   foramen	   ovale	  (becomes	   fossa	   ovalis)	   and	   similarly,	   the	   ductus	   arteriosus	   (becomes	  ligamentum	   venosum)	   within	   10-­‐15	   hours	   after	   birth.	   Postnatally,	   in	   20%	   to	  25%,	  incomplete	  fusion	  leads	  to	  the	  persistence	  of	  the	  flap	  valve,	   leaving	  a	  PFO	  opened	   [84,	   85].	   Although	   technically	   PFO	   is	   not	   a	   “congenital”	   defect	   since	   it	  present	   in	   all	  newborns,	   they	  are	   the	  most	   common	   “hole	   in	   the	  heart”	   among	  structural	  heart	  defects	  that	  require	  catheter	  intervention	  [86].	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1.1.10 Anatomical	  features	  of	  CHD	  subtypes	  There	  are	  hundreds	  of	  subtle	  anatomical	   features	  that	  have	  been	  classified	  and	  described	   in	   the	   EPCC	   and	   ICD-­‐10	   classification	   systems	   [59,	   68].	   This	   section	  provides	  short	  descriptions	  of	  a	  few	  selected	  CHD	  subtypes	  because	  either	  they	  are	   among	   the	  most	   common	  CHD	   (e.g.	   ventricular	   septal	   defects,	   VSD)	   or	   are	  considered	  severe	  CHD	  (e.g.	  hypoplastic	  left	  heart	  syndrome,	  HLHS).	  	  
Shunts	  	  Shunts	  are	  openings	  between	  right	  and	  left	  sides	  of	  the	  heart	  and	  are	  considered	  the	  most	  common	  type	  of	  CHD	  (Figure	  1-­‐7-­‐a).	  The	  communication	  can	  take	  place	  between	   heart	   chambers,	   between	   a	   chamber	   and	   a	   vessel	   or	   between	   two	  vessels.	  They	  can	  occur	  in	  isolated	  forms	  or	  as	  part	  of	  other	  severe	  CHD.	  	  
Vessel-­‐vessel	  shunts	  Patent	   ductus	   arteriosus	   (PDA)	   (Figure	   1-­‐7-­‐a,	   2)	   is	   a	   naturally	   occurring	  communication	  between	  the	  aorta	  and	  pulmonary	  artery.	  The	  persistence	  of	  PDA	  is	   considered	   the	  most	   common	   form	  of	   the	  CHD	  but	   usually	   does	  not	   require	  surgical	   intervention	   when	   asymptomatic.	   In	   cyanotic	   CHD,	   the	   pulmonary	  circulation	   entirely	   depends	   on	   the	   presence	   of	   PDA	   and	   keeping	   it	   open	  with	  prostaglandin	  helps	  to	  alleviate	  the	  symptoms	  [88].	  Another	  example	  is	  the	  rare	  direct	   communication	   between	   the	   ascending	   part	   of	   the	   aorta	   and	   the	  pulmonary	   artery	   superior	   to	   the	   two	   semilunar	   valves	   called	   aortopulmonary	  defect	  (Figure	  1-­‐7-­‐a,	  1).	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Chamber-­‐chamber	  shunts	  
	  These	   shunts	   occur	   between	   the	   ventricles	   (VSD)	   or	   the	   atrium	   (ASD)	   (Figure	  1-­‐7-­‐a,	   5	   to	   8).	   The	   septum	   between	   the	   two	   atria	   contains	   another	   naturally	  occurring	  shunt	   in	  the	  fetal	  heart	  called	  the	  patent	   foramen	  ovale,	  PFO,	  (Figure	  1-­‐7-­‐a,	  4)	  and	  closes	  immediately	  after	  birth	  (see	  Fetal	  circulation	  section).	  	  PFO	  is	  a	  variant	  of	  secundum	  atrial	  septal	  defects	  (ASD)	  and	  occurs	  in	  the	  mid	  portion	  of	   the	   interatrial	   septum.	   20-­‐25%	   of	   PFO	   can	   persist	   into	   adulthood	   in	   the	  absence	  of	  other	  CHD	  (Figure	  1-­‐7-­‐a,	  5).	  	  On	   the	   other	   hand,	   the	   septum	   between	   the	   two	   ventricles	   may	   rarely	   have	  multiple	  shunts	  (called	  “Swiss	  Cheese	  VSD”).	  If	  it	  has	  a	  single	  defect	  at	  the	  top	  of	  the	   interventricular	   septum	   near	   the	   AV	   annulus	   it	   called	   “membranous	   VSD”	  	  (Figure	  1-­‐7-­‐a,	  6)	  or	  “muscular	  VSD”	  otherwise	  (Figure	  1-­‐7-­‐a,	  7	  and	  8).	  	  
Atrioventricular	  septal	  defects	  (AVSD)	  AVSD	  is	  known	  as	  endocardial	  cushion	  defects	  or	  common	  atrioventricular	  canal	  defect	  and	   is	   thought	   to	  be	  caused	  by	   the	  underdevelopment	  of	  heart	  cushions	  and	   failure	   to	  migrate	   properly	   during	   the	   development	   of	   the	   heart.	   ASD	   and	  VSD	  are	  commonly	  associated	  with	  AVSD	  along	  with	  the	  abnormal	  development	  of	  the	  mitral	  and	  tricuspid	  valves	  (Figure	  1-­‐7-­‐b).	  AVSD	  classification	  and	  further	  anatomical	  details	  are	  discussed	  in	  chapter	  4.	  	  	  	  
Hypoplastic	  Left	  Heart	  Syndrome	  (HLHS)	  This	   is	   a	   cyanotic	   heart	   defect	   caused	   by	   severe	   underdevelopment	   of	   the	   left	  ventricular,	   aortic	   and	  mitral	   valves	   and	   ascending	   aorta	   (Figure	   1-­‐7-­‐c).	   If	   left	  untreated,	  HLHS	  is	  responsible	  for	  25	  to	  40	  percent	  of	  all	  neonatal	  cardiac	  deaths	  [89].	  	  	  
Double	  Outlet	  Right	  Ventricle	  (DORV)	  DORV	   is	   another	   cyanotic	   heart	   defect	   characterized	   by	   an	   abnormal	   origin	   of	  both	   great	   vessels	   (aorta	   and	   pulmonary	   arteries)	   arising	   either	   complete	   or	  predominantly	   from	   the	   right	   ventricle.	   This	   is	   usually	   accompanied	   by	   a	   VSD	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that	   varies	   in	   the	   location	   and	   size	   (subaortic	   or	   subpulmonary	   VSD),	   which	  determines	  the	  severity	  of	  the	  defect	  (Figure	  1-­‐7-­‐d).	  	  	  
Tetralogy	  of	  Fallot	  (TOF)	  TOF	  is	  the	  most	  common	  cause	  of	  cyanotic	  complex	  CHD.	  It	  arises	  by	  the	  failure	  of	   the	   interventricular	   septum	   to	   properly	   attach	   to	   the	   fibrous	   rings	   of	   heart	  (anulus	   fibrosus	   cordis)	   and	   as	   a	   result,	   causes	   a	   misalignment	   of	   the	  infundibulum	   (the	   outlet	   portion	   of	   the	   right	   ventricular).	   Four	   congenital	  structural	   defects	   collectively	   define	   TOF:	   ventricular	   septal	   defect,	   pulmonary	  stenosis,	  overriding	  aorta	  and	  hypertrophy	  of	   the	  right	  ventricular	  (Figure	  1-­‐7-­‐e).	  TOF	  is	  discussed	  in	  more	  details	  in	  chapter	  3.	  	  
Coarctation	  of	  the	  aorta	  (CoA)	  	  CoA	  describes	  a	  narrowing	  of	  the	  descending	  aorta,	  which	  is	  typically	  located	  at	  the	   insertion	   of	   the	   ductus	   arteriosus	   just	   distal	   to	   the	   left	   subclavian	   artery	  (Figure	  1-­‐7-­‐f).	  CoA	  generally	  results	  in	  left	  ventricular	  pressure	  overload.	  	  
Transposition	  of	  the	  great	  arteries	  	  TGA	   is	   another	   complex	   cyanotic	   ventriculoarterial	   discordant	   lesion	   in	  which	  the	  aorta	  and	  pulmonary	  artery	  reverse	  their	  connections	  to	  the	  heart.	  Normally,	  the	  pulmonary	  artery	  is	  located	  anterior	  to	  the	  aorta	  and	  connected	  to	  the	  right	  ventricle	  but	  this	  is	  reversed	  in	  TGA	  (Figure	  1-­‐7-­‐g).	  The	  most	  common	  subtype	  of	  TGA	   is	   the	   dextro	   type	   (referred	   to	   as	   D-­‐TGA)	   in	   which	   the	   right	   ventricle	   is	  positioned	  to	  the	  right	  of	  the	  left	  ventricle	  and	  the	  origin	  of	  the	  aorta	  is	  anterior	  and	  rightward	  to	  the	  origin	  of	  the	  pulmonary	  artery.	  A	  surgical	  repair	  is	  usually	  required	  within	  the	  first	  or	  second	  week	  of	  life.	  	  	  
Ebstein’s	  malformation	  of	  the	  tricuspid	  valve	  	  	  This	  malformation	   is	  characterized	  by	  downward	  displacement	  of	   the	  tricuspid	  posterior	   and	   septal	   leaflets	   in	   to	   the	   right	   ventricular.	   This	   leads	   to	  “atrialization”	  of	  the	  right	  ventricular	  as	  the	  right	  atrium	  becomes	  enlarged	  and	  with	   a	   dysfunctional	   and	   underdeveloped	   right	   ventricular	   (Figure	   1-­‐7-­‐h).	   The	  infant’s	  blood	  circulation	  may	  solely	  depend	  on	  the	  presence	  of	  PDA.	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  Figure	  1-­‐7	  Anatomical	  and	  physiological	  features	  of	  selected	  CHD	  subtypes.	  	  AO:	   aorta,	   cAVSD:	   complete	   atrioventricular	   septal	   defects,	  D-­‐TGA:	  dextro-­‐Transposition	  of	   the	  great	  arteries,	  DORV:Double	  Outlet	  Right	  Ventricle,	  HLHS:	  Hypoplastic	  Left	  Heart	  Syndrome,	  LA:	  left	   atrium,	  LA:	   left	  ventricular,	  PA:	  pulmonary	  artery,	  PDA:	  patent	  ductus	  arteriosus,	  RA:	   right	  atrium,	   RPA:	   right	   pulmonary	   artery,	   RSA:	   right	   subclavian	   artery,	   RV:	   right	   ventricular,	   TOF:	  Tetralogy	   of	   Fallot.(Images	   adapted	   from	   Congenital	   Heart	   Defects,	   Simplified	   (2009)	   by	   Ken	  Heiden[87]).	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environmental	   factors,	   different	   maternal	   illnesses	   and	   certain	   drugs	   to	   the	  increased	  risk	  of	  CHD.	  	  Pregestational	  diabetes	  in	  particular	  has	  been	  shown	  to	  increase	  the	  risk	  of	  CHD	  by	   fivefold	   with	   an	   overrepresentation	   of	   transposition	   of	   the	   great	   arteries,	  truncus	  arteriosus,	  and	   tricuspid	  atresia	   [91].	  The	  exact	  mechanism	   is	  not	  well	  understood	  but	  several	  theories	  have	  been	  suggested.	  One	  theory	  suggested	  high	  levels	   of	   glucose	   can	   lead	   to	   a	   disturbance	   of	   expression	   of	   some	   master	  regulatory	  genes	  during	  early	  embryogenesis	  [92].	  	  	  Other	  factors	  have	  been	  shown	  to	  increase	  the	  risk	  of	  CHD	  but	  their	  impact	  has	  varied,	  and	  is	  sometimes	  contradictory,	  between	  different	  studies.	  Table	  1-­‐5	  lists	  some	  of	   the	  known	  non-­‐genetic	   risk	   factors	   for	  any	  CHD	  defect	  when	  possible;	  otherwise,	   I	   selected	   the	  CHD	  defect	   associated	  with	  highest	   risk.	  More	  details	  about	  the	  association	  between	  non-­‐inherited	  risk	  factors	  and	  specific	  CHD	  (TOF	  and	  AVSD)	  are	  discussed	  in	  the	  third	  and	  fourth	  chapter	  of	  this	  thesis.	  	  Table	  1-­‐5	  List	  of	  the	  most	  important	  non-­‐inherited	  CHD	  risk	  factors.	  
Risk	  




risk	   Reference	  
Maternal	  illness	  
Phenylketonuria	   Any	  defects	   >	  6	   [93,	  94]	  Pregestational	  diabetes	   AVSD	   10.6	   [9]	  Febrile	  illness	   Tricuspid	  atresia	   5.1-­‐5.2	   [9,	  95]	  Influenza	   Aortic	  coarctation	   3.8	   [96]	  Rubella	   Any	  defects	   -­‐	   [97]	  
Maternal	  drug	  exposure	  
Anticonvulsants	   Any	  defects	   4.2	   [98]	  Ibuprofen	   Bicuspid	  aortic	  valve	   4.1	   [99]	  Vitamin	  A	  /retinoids	   Any	  defects	   -­‐	   [100]	  Environmental	  (maternal)	   Organic	  solvents	   AVSD	   5.6	   [9]	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1.1.11.2 Genetic	  causes	  	  	  To	   cause	   a	   phenotype,	   the	   multifactorial	   polygenic	   model	   requires	  environmental	   factors	   to	   interact	   with	   multiple	   genetic	   variants	   each	   with	   a	  relatively	   small	   effect	   size.	   This	   model	   has	   been	   widely	   accepted	   as	   the	   main	  inheritance	  model	   in	  CHD	  [28,	  39].	  However,	   this	  view	  has	  been	  challenged	  by	  the	  results	  of	  recurrent	  risk	  rates	  in	  familial	  CHD,	  which	  were	  found	  to	  be	  higher	  than	  what	   the	  multifactorial	  model	   has	   predicted.	   One	   of	   the	   consequences	   of	  this	  discordance	  is	  that	  it	  has	  become	  better	  appreciated	  that	  some	  proportion	  of	  CHD	  could	  be	  explained	  by	  monogenic	  or	  oligogenic	  models.	  	  	  In	   the	   past	   few	   decades,	   researchers	   have	   utilized	   various	   approaches	   to	   test	  different	   hypotheses	   and	   models	   for	   genetic	   causation	   (Figure	   1-­‐8).	   Classical	  genetic	   approaches	   such	   as	   linkage	   analysis,	   positional	   cloning	   and	   candidate	  gene	   resequencing,	   that	   are	   not	   generally	   suitable	   for	   dissecting	   polygenic	  inheritance	   have	   successfully	   found	   a	   genetic	   cause	   in	   15-­‐20%	   of	   CHD	   cases;	  most	  of	  which	  have	  been	  syndromic	  CHD	  [14,	  101]	  (see	  below).	  	  Only	  in	  the	  last	  few	  years,	  when	  high-­‐throughput	  SNP	  genotyping	  array	  (e.g.	  SNP	  arrays)	  were	  developed,	  has	  the	  contribution	  of	  common	  genetic	  variants	  to	  the	  polygenic	   CHD	   model	   become	   amenable	   to	   study.	   Genome-­‐wide	   association	  studies	   have	   detected	   a	   few	   common	   variants	   associated	   with	   CHD	   and	   this	  support	  the	  continued	  relevance	  of	  the	  polygenic	  model	  (see	  below).	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  Figure	  1-­‐8	  Overview	  of	  the	  common	  DNA-­‐based	  strategies	  and	  methods	  used	  to	   investigate	  the	  underlying	  genetic	  causes	  of	  CHD.	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expression,	   which	   can	   be	   found	   to	   cause	   heart	   cushion	   development	   defects	  when	  its	  expression	  fluctuates	  [104,	  105].	  	  	  Another	   3-­‐5%	  of	   CHD	   cases	   are	   part	   of	   different	  Mendelian	   syndromes	  where	  underlying	   causes	   can	   be	   attributed	   to	   single	   point	  mutations,	   indels	   and	   /	   or	  microdeletions	  [20].	   	  For	  example,	  Alagille	  syndrome	  is	  an	  autosomal	  dominant	  syndrome	  defined	  by	  the	  presence	  of	  bile	  duct	  paucity	  on	  liver	  biopsy	  and	  three	  out	   of	   five	   traits:	   cholestasis;	   skeletal,	   ocular	   anomalies,	   characteristic	   facial	  features	  and	  CHD	   in	  90%	  of	   the	  patients	   [106].	  Coding	  mutations	   in	   JAG1	   gene	  have	  been	  detected	   in	  (94%)	  of	   the	  patients	   [107]	  while	  20p12	  deletions	  were	  detected	  in	  3-­‐7%	  [108].	  	  	  Other	   syndromes	   such	   as	   Noonan,	   Holt-­‐Oram,	   CHARGE	   and	   Kabuki	   have	   been	  reported	  with	  CHD	  phenotypes	  associated	  with	  single	  gene	  mutations	  in	  variable	  proportions	  of	  cases	  (Table	  1-­‐6).	  	  Table	  1-­‐6	  List	  of	  syndromic	  CHD	  and	  the	  underlying	  genetic	  lesions	  [39,	  101]	  
Causes	   Syndrome	   Genetic	  lesion	   Cardiac	  phenotypes	   Proportion	  of	  CHD	  
Chromosomal	  
lesions	  
Edwards	   Trisomy	  18	   VSD,	  ASD,	  DORV,	  TOF,	  CoA,	  HLHS	   90-­‐100%	  Velocardiofacial	   Del	  22q11.2	   IAA	  (B),	  TA,	  TOF,	  aortic	  arch	  anomalies	   75-­‐85%	  Williams	   Del	  7q11.23	   SVAS,	  PVS,	  PS,	  PPS	   50-­‐80%	  Patau	   Trisomy	  13	   ASD,	  VSD,	  DORV,	  HLHS,	  L-­‐TGA,	  AVSD,	  TAPVR,	  dextrocardia,	  PDA	   80%	  Down	   Trisomy	  21	   AVSD,	  ASD,	  VSD,	  TOF	   40-­‐50%	  Klinefelter	  	   47,XXY	   ASD,	  PDA,	  MVP	   50%	  Cat	  eye	   Tetrasomy	  22p	   TAPVR,	  PAPVR	   50%	  Turner	   Monosomy	  X	   CoA,	  AS,	  HLHS,	  PAPVR	   25-­‐35%	  Pallister-­‐Killan	   Tetrasomy	  12p	   VSD,	  CoA,	  PDA,	  ASD,	  AS	   25%	  
Microdeletions	  
and	  
	  Single	  gene	  
mutations	  
Hetrotaxy	   ZIC3	   Dextrocardia,	  L-­‐TGA,	  AVSD,	  90%–100%	  TAPVR	   90-­‐100%	  Alagille	   JAG1,	  NOTCH1,	  del20p12	   PPS,	  TOF,	  ASD,	  PS	   85-­‐95%	  Noonan	   PTPN11,	  SOS1,	  KRAS,	  RAF1	   PVS,	  ASD,	  CoA,	  HCM	   80-­‐90%	  Holt-­‐Oram	   TBX5	   ASD,	  VSD,	  AVSD,	  TOF	   80%	  CHARGE	   CHD7,	  SEMA3E	   ASD,	  VSD	   50-­‐80%	  Char	   TFAP2B	   PDA	   60%	  Ellis-­‐van	  Creveld	   EVC,	  EVC2	   Primum	  ASD,	  common	  atrium,	  AVSD	   60%	  Smith-­‐Lemli-­‐Opotz	   DHCR7	   AVSD,	  primum	  ASD,	  VSD,	  PAPVR	   45%	  Kabuki	   MLL2	   CoA,	  ASD,	  VSD	   40%	  ASD	  =	  atrial	  septal	  defect.	  AS	  =	  aortic	  stenosis.	  AVSD	  =	  atrioventricular	  septal	  defect.	  CoA	  =	  coarctation	  of	  the	  aorta.	  DORV	  =	  double	  outlet	  right	  ventricle.	  HLHS	  =	  hypoplastic	  left	  heart	  syndrome.	  IAA(B)	  =	  interrupted	  aortic	  arch	  (type	  B).	  L-­‐TGA	  =	  congenitally	  corrected	  transposition	  of	  the	  great	   arteries.	   MVP	   =	   mitral	   valve	   prolapse.	   PAPVR	   =	   partial	   anomalous	   pulmonary	   venous	   return.	   PDA	   =	   patent	   ductus	   arteriosus.	   PPS	   =	  peripheral	   pulmonary	   stenosis.	   PS	   =	   pulmonary	   stenosis.	   PVS	   =	   pulmonary	   valve	   stenosis.	   SVAS	   =	   supravalvular	   aortic	   stenosis.	   TA	   =	   truncus	  arteriosus.	  TAPVR	  =	  total	  anomalous	  pulmonary	  venous	  return.	  TOF	  =	  tetralogy	  of	  Fallot.	  VSD	  =	  ventricular	  septal	  defect.	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1.1.11.2.2 Non-­‐syndromic	  CHD	  	  Although	  isolated	  non-­‐syndromic	  CHD	  are	  the	  most	  prevalent	  form	  of	  CHD,	  they	  remain	   largely	   without	   known	   genetic	   causes.	   Linkage	   analysis	   and	   positional	  cloning	   have	   been	   successfully	   used	   in	   the	   past	   few	   decades	   to	   detect	   some	  causal	   genes	   [14].	   The	   first	   genes	   to	   be	   reported	   with	   autosomal	   dominant	  inherited	   mutations	   were	  NKX2.5	   and	   GATA4.	   Four	   families	   with	   atrial	   septal	  defect	   (ASD)	   and	   atrioventricular	   conduction	  delay	  without	   any	   apparent	  non-­‐cardiac	  features	  were	  found	  to	  have	  mutations	  in	  NKX2.5	   that	  were	  not	  seen	  in	  controls	   [109].	   Similarly,	  GATA4	  was	   found	   to	  be	  mutated	  with	  novel	  missense	  variants	  in	  two	  kindreds	  with	  non-­‐syndromic	  septal	  defects	  [110].	  	  	  Currently,	   there	   are	   30	   genes	   that	   have	   been	   reported	   to	   cause	   isolated	   CHD	  when	   mutated	   in	   humans.	   Some	   genes	   detected	   with	   the	   help	   of	   positional	  cloning	   include	  ZIC3,	  GATA4,	  NKX2.5,	  NKX2.6,	  MYH6,	  ACTC1,	   and	  NOTCH1	  while	  others	  identified	  through	  candidate	  gene	  approaches	  include	  TBX1,	  TBX20,	  CFC1,	  
CITED2,	   CRELD1,	   FOG2,	   LEFTY2,	   NODAL,	   GDF1,	   FOXH1,	   TDGF,	   MYOCD,	   TLL1,	  
THRAP2	  and	  ANKRD1.	  These	  genes	  can	  be	  arranged	  into	  three	  classes	  based	  on	  their	  functions:	  transcriptional	  factors,	  receptors/ligands	  and	  structural	  protein	  (Table	  1-­‐7)	  Most	  of	  the	  mutations	  detected	  were	  missense	  variants	  inherited	  in	  an	  autosomal	  dominant	  fashion	  with	  variable	  penetrance.	  	  	  	  One	   major	   limitation	   of	   some	   classical	   genetic	   approaches	   such	   as	   linkage	  analysis	   is	  that	   it	  requires	  large	  extended	  families	  with	  multiple	  affected	  family	  members.	   The	   rarity	   of	   such	   large	   CHD	   families	   limits	   the	   use	   of	   these	  approaches	   and	   has	   led	   researchers	   to	   look	   for	   alternative	   methods	   in	   their	  quest	  to	  discover	  the	  genetic	  causes	  of	  CHD.	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Table	  1-­‐7	  List	  of	  genetic	  models	  and	  genes	  associated	  with	  non-­‐syndromic	  CHD	  [111]	  





NOTCH1 BAV, AS 




ALK2 ASD, TGA, DORV, AVSD 
NODAL Heterotaxy 
TDGF1 TOF 
JAG1 PS, TOF 
Transcription factor 
GATA4 ASD, TOF, VSD, HRV, PAPVR 
GATA6 PTA, PS 
NKX2.5 ASD-AV block, TOF, HLHS, CoA, IAA, Heterotaxy, TGA, DORV, VSD, Ebstein 
NKX2.6 PTA 
TBX20 ASD, CoA, VSD, PDA, DCM, MS, HLV, ASD 
CITED2 VSD, ASD 
FOXH1 TOF, CHM 
ZIC3 Heterotaxy, TGA, ASD, PS 
TBX5 ASD, VSD, AVSD 
TBX1 VSD, IAA 
ANKRD1 TAPVR 
Contractile proteins  
MYH11 PDS, AA 
ACTC1 ASD, VSD 
MYH6 ASD 
MYH7 ASD, Ebstein 






(b) Common variants 
with low penetrance  
Methylation cycle 





Vasoactive proteins NPPA Conotruncal defects NOS3 Conotruncal defects 
Polypeptide mitogen VEGF VSD, PTA, IAA, TOF 
Transcription factor NFATC1 VSD MSX1  ASD  [112] 
(c) Somatic mutations 
Gap junction protein GJA1 HLHS 
Transcription factors 
NKX2.5 VSD, ASD, AVSD 
GATA4 VSD, AVSD 
TBX5 ASD, AVSD 
HEY2 AVSD 
HAND1 HLV, HRV 
(d) Copy Number 
Variations (CNVs)  
De novo and / or 
inherited gain or loss 




9q34.3 TOF, CoA, HLHS 
19p13.3 TOF 
 
 One	   alternative	  method	   is	   to	   detect	   association	   between	   CHD	   phenotypes	   and	  specific	   loci	   or	   common	   variants.	   For	   example,	   by	   searching	   for	   association	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between	  common	  variants	   in	  23	  candidate	  genes	  and	  non-­‐syndromic	  Tetralogy	  of	  Fallot	   (TOF),	  Goodship	  et	  al.	   found	  a	  single	  variant	  (rs11066320)	   in	  PTPN11	  that	   increases	   the	   risk	   by	   5%	   [113].	   Rare	  mutations	   in	  PTPN11	   are	   known	   to	  cause	   Noonan	   syndrome,	   which	   includes	   congenital	   heart	   disease,	   by	   up	  regulating	  Ras/mitogen-­‐activated	  protein	  kinase	  (MAPK)	  signaling.	  A	  few	  other	  common	  variants	  were	  found	  to	  be	  associated	  with	  the	  increased	  risks	  of	  certain	  types	  of	  CHD	  in	  (Table	  1-­‐7,	  b).	  	  A	   more	   powerful	   approach	   is	   to	   perform	   genome-­‐wide	   association	   studies	  (GWAS)	  using	  SNP	  arrays.	  GWAS	  have	  been	  very	  successful	  in	  general;	  they	  have	  found	  more	   than	  8,500	  genome-­‐wide	   significant	  associations	  across	  more	   than	  350	  human	  complex	   traits	   such	  as	  Diabetes	  Mellitus	  Type	  2	  and	  obesity	   [114].	  Unfortunately,	  this	  level	  of	  success	  has	  not	  been	  matched	  thusfar	  in	  CHD,	  except	  for	   two	  published	   examples	   [112,	   115].	   Cordell	   et	  al.	   	   [112]	   found	   a	  moderate	  signal	  of	  association	  with	  the	  risk	  of	  ostium	  secundum	  atrial	  septal	  defect	  (340	  cases)	  with	  p-­‐value	  of	  (P	  =	  9.5	  ×	  10−7)	  near	  the	  MSX1	  gene.	  Although	  this	  study	  had	  a	  relatively	  larger	  number	  of	  CHD	  cases	  of	  various	  types	  (1,995	  in	  total)	  and	  has	  the	  power	  to	  detect	  moderate-­‐sized	  effects;	  it	  failed	  to	  find	  a	  globally	  strong	  signal	   when	   combining	   all	   CHD	   types.	   Only	   after	   the	   team	   analyzed	   the	  phenotypes	   separately,	   did	   the	   signal	   reached	   a	   genome-­‐wide	   significant	   level	  and	  accounted	  for	  9%	  of	  the	  population-­‐attributable	  risk	  of	  ASD	  and	  suggested	  that	   genetic	   associations	   with	   CHD	   may	   exhibit	   considerable	   phenotypic	  specificity.	  	  Zhibin	  Hu	   et	  al.	   published	   the	   second	   example	   of	   GWAS	   in	   CHD	   patients	   from	  Han	   Chinese	   population	   [112,	   115].	   Their	   multi-­‐stage	   GWAS	   study	   included	  4,225	  CHD	  cases	  and	  5,112	  controls	   in	   total	  and	   found	  two	  strong	  signals	  near	  
TBX15	  and	  MAML3	  genes.	  	  	  This	   modest	   performance	   of	   GWAS	   in	   CHD	   is	   not	   unexpected	   due	   of	   the	  heterogeneity	   of	   CHD	   phenotypes.	   Large	   collaborations	   between	   national	   CHD	  registries	  and	  large	  cohorts	  of	  homogeneous	  clinical	  CHD	  cases	  are	  expected	  to	  improve	  the	  discovery	  rate	  of	  associations	  [14].	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Non-­‐Mendelian	   inheritance	  mechanisms	  have	  also	  been	   suggested	   to	  explain	  some	   isolated	  CHD.	  The	  somatic	  mutations	   and	   two-­‐hit	   hypothesis	   suggested	  by	  Knudson	  has	  been	  widely	  accepted	  in	  tumor	  neology	  and	  skin	  diseases.	  Later	  studies	   by	   Reamon-­‐Buettner	   and	   Borlak	   show	   somatic	   mutations	   in	   NKX2.5,	  
TBX5,	   GATA4,	   HEY2	   and	   HAND1	   from	   the	   human	   heart	   tissue	   [116,	   117].	  	  However,	   subsequent	  work	   by	  Draus	   et	  al.	   failed	   to	   replicate	   these	   findings	   in	  fresh	  frozen	  tissues	  from	  28	  septal	  defect	  patients.	  They	  suggested	  that	  the	  poor	  DNA	  quality	  from	  the	  formalin-­‐fixed	  tissues	  in	  the	  work	  of	  Reamon-­‐Buettner	  and	  Borlak	  was	  the	  source	  for	  these	  somatic	  mutations	  [118].	  However,	  this	  doesn’t	  eliminate	   a	   possible	   role	   for	   somatic	  mutations	   in	   CHD,	   but	   their	   involvement	  remains	  to	  be	  confirmed	  by	  additional	  larger	  studies.	  	  	  
Small	  noncoding	  microRNAs	  (miRNAs)	  have	  also	  emerged	  lately	  as	  important	  players	   in	   cardiogenesis	   [119,	   120].	   	   These	   are	   short	   20	   to	   26	   nucleotides,	  evolutionary	   conserved	   RNAs	   that	   usually	   interact	   with	   the	   3’	   untranslated	  region	   (UTR)	   of	   specific	   target	   mRNAs	   to	   control	   their	   expression.	   Their	  involvement	   in	   heart	   development	   processes,	   such	   as	   cardiac	   pattering,	  angiogenesis,	   and	   cardiac	   cell	   fate	   decisions	   have	   been	   documented	   by	   many	  studies	   (reviewed	   by	   [119]).	   The	   upregulation	   of	   four	   maternal	   miRNA	   (miR-­‐19b,	  miR-­‐22,	  miR-­‐29c	  and	  miR-­‐375)	  were	  found	  to	  be	  associated	  with	  congenital	  heart	   defects	   in	   the	   fetus	   and	   thus	   have	   been	   suggested	   as	   non-­‐invasive	  biomarkers	  for	  the	  prenatal	  detection	  of	  fetal	  CHD	  [121].	  	  Most	   recently,	   de	   novo	   variants	   of	   different	   classes	   have	   been	   shown	   to	  contribute	  to	  as	  much	  as	  10-­‐15%	  of	  CHD	  cases.	  Soemedi	  et	  al.	  	  observed	  rare	  de	  
novo	   CNVs	   in	   5%	   CHD-­‐affected	   families	   [122].	   Additionally,	   whole	   exome	  sequencing	  of	  362	   trios	  detect	  recurrent	  de	  novo	  mutations	  (base	  substitutions	  and	   indels)	   in	   several	   genes	   including	   SMAD2	   [123].	   	   Although	   this	   cohort	  include	   both	   syndromic	   and	   isolated	   CHD,	   based	   on	   the	   expression	   of	   the	  mutated	   genes	   in	   the	   developing	   heart	   compared	   to	   genes	  mutated	   in	   control	  trios,	   the	   authors	   estimated	   that	   in	   10%	   of	   patients	   the	   de	   novo	   mutations	  contributed	  to	  the	  CHD.	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1.1.11.2.3 Known	  CHD	  genes	  in	  mouse	  	  In	  addition	  to	  the	  human	  genetic	  approaches	  described	  above,	  studying	  the	  effect	  of	  knocking	  out	  genes	  in	  mouse	  models	  and	  how	  it	  affects	  the	  heart	  development	  has	   identified	   300	   genes	   that	   when	   homozygously	   knocked	   out	   result	   in	  abnormal	   cardiac	   development	   [124].	   	   Additionally,	   a	   combination	   of	   high-­‐throughput	  imaging	  systems	  (MRI)	  and	  ENU	  mutagenesis	  workflow	  has	  enabled	  researchers	   to	   screen	   thousands	   of	   mice	   per	   year	   and	   to	   generate	   a	   list	   of	  candidate	   genes	   for	   resequencing	   in	   humans.	   Extrapolating	   from	   the	   mouse	  knockout	  data,	  based	  on	  the	  current	  incomplete	  coverage	  of	  mammalian	  genes,	  it	  has	   been	   estimated	   that	   the	   total	   number	   of	   genes	   that	   when	   homozygously	  knocked	  out	  cause	  CHD	  in	  the	  mice	  may	  be	  1,500-­‐2,000[124].	  	  
1.2 Next	  generation	  sequencing	  (NGS)	  	  Before	   2004,	   the	   DNA	   sequencing	   field	   was	   dominated	   by	   automated	   Sanger	  sequencing,	  also	  known	  as	  ‘capillary	  sequencing’,	  which	  has	  been	  considered	  the	  first	  generation	  of	  sequencing	  [125].	  Capillary	  sequencing	  helped	  to	  generate	  the	  first	   human	   genome	   (2.8Gb	   with	   99%	   completion	   and	   1	   in	   100,000	   error	  rate)[126].	   Despite	   its	   great	   success,	   it	   is	   considered	   a	   low-­‐throughput	  technology,	  expensive,	  and	   labor-­‐intensive	   for	   large-­‐scale	  projects.	  A	  new	  wave	  of	   novel	   sequencing	   approaches	   started	   in	   2005	   when	   the	   first	   commercially	  available	   massively	   parallel	   sequencing	   platform	   was	   released	   by	   Roche/454	  [127]	   and	   the	   multiplex	   polony	   sequencing	   protocol	   of	   George	   Church’s	   lab	  [128].	  	  	  These	  new	  waves	  of	  high-­‐throughput	  approaches	  were	  labeled	  “next-­‐generation	  sequencing”,	   which	   refers	   to	   a	   combination	   of	   advancement	   in	   the	   chemistry,	  sequencing,	   signal	   detection,	   imaging	   and	   computation	   methods	   that	   allow	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researchers	   to	   generate	   a	   vast	   amount	   of	   biological	   data	   (DNA-­‐	   or	   RNA-­‐based	  sequencing	  data)	  in	  a	  short	  time	  and	  at	  a	  reasonable	  cost	  [129].	  	  	  Currently,	   there	   are	   several	   commercially	   available	   platforms:	   Roche/454,	  Illumina/Solexa,	   Life/SOLiD,	   Helicos	   BioSciences,	   Polonator	   instrument	   and	  Pacific	  Biosciences	  among	  many	  others.	  Each	  of	  these	  platforms	  adopts	  various	  methods	   to	   sequence	   the	   DNA	   such	   as	   pyrosequencing,	   reversible	   terminator,	  sequencing	  by	  ligation.	  Each	  has	  its	  own	  advantages	  and	  disadvantages	  in	  terms	  of	  the	  length	  of	  DNA	  fragments,	  ease	  of	  preparation,	  error	  rates,	  run	  time	  and	  the	  amount	   of	   data	   they	   produce	   per	   run	   in	   Giga-­‐bases.	   These	   methods	   can	   be	  grouped	   into	   a	   few	   categories:	   (i)	   microelectrophoretic	   methods	   [130],	   (ii)	  sequencing	  by	  hybridization	  [131],	  (iii)	  real-­‐time	  observation	  of	  single	  molecules	  [132,	  133]	  and	  (iv)	  cyclic-­‐array	  sequencing	  [134]	  (reviewed	  by	  Michael	  Metzker	  [135]	   and	   Shendure	   et	  al.	   in	   [136]).	  However,	   the	   sequencing	   itself	   represents	  the	  first	  few	  steps	  in	  a	  larger	  workflow.	  	  	  
1.2.1 A	  standard	  NGS	  workflow	  The	  standard	  NGS	  workflow	  is	  composed	  of	  multiple	  steps	  or	  tasks	  that	  can	  be	  arranged	   in	   two	  main	   categories:	   	   laboratory-­‐based	   and	   computational-­‐based.	  	  The	   laboratory	   steps	   include	   DNA	   preparation,	   library	   quality	   control	   and	  sequencing.	  The	  computation-­‐based	  tasks	  start	  with	  converting	  raw	  sequencing	  signals	   (e.g.	   images	   or	   electrical	   changes)	   to	   text-­‐based	   DNA	   sequence	   reads,	  mapping	  to	  the	  genome,	  calling	  variants,	  quality	  control,	  filtering,	  annotation	  and	  finally	   specialized	   down-­‐stream	   analysis	   based	   on	   the	   biological	   question	   and	  the	  study-­‐design	  (e.g.	  trios,	  case/control)	  (Figure	  1-­‐9).	  	  This	   workflow	   is	   commonly	   shared	   between	   different	   sequencing	   platforms	  [137].	  However,	  I	  will	  discuss	  this	  workflow	  with	  the	  Illumina/Solexa	  platform	  in	  mind	  since	  it	  is	  currently	  the	  most	  widely	  used	  platform	  [135]	  and	  was	  the	  only	  platform	  used	  to	  sequence	  the	  samples	  in	  this	  thesis.	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  Figure	   1-­‐9	   Basic	   workflow	   for	   whole-­‐exome	   and	   whole-­‐genome	   sequencing	   projects.	   After	  library	   preparation,	   samples	   are	   sequenced	   on	   a	   certain	   platform.	   The	   next	   steps	   are	   quality	  assessment	   and	   read	  alignment	   against	   a	   reference	  genome,	   followed	  by	  variant	   identification.	  Detected	   mutations	   are	   then	   annotated	   to	   infer	   the	   biological	   relevance	   and	   results	   can	   be	  displayed	   using	   dedicated	   tools.	   The	   found	   mutations	   can	   further	   be	   prioritized	   and	   filtered,	  followed	  by	  validation	  of	   the	  generated	   results	   in	   the	   lab.	   (The	   image	  and	  caption	  are	  adapted	  from	  [137])	  
	  
1.2.1.1 Laboratory-­‐based	  steps	  	  The	  laboratory	  based	  steps	  start	  with	  genomic	  DNA	  extracted	  from	  blood,	  saliva	  or	   tissue	   samples.	   The	   amount	   and	   concentration	   of	   DNA	   required	   for	  sequencing	  depends	  on	  the	  platform	  and	  the	  size	  of	  targeted	  regions	  (e.g.	  whole	  exome	   or	   whole	   genome).	   For	   example,	   for	   the	   work	   described	   in	   this	   thesis,	  targeted	  exome	  sequencing	  on	  HiSeq	  Illumina	  platform	  required	  2000	  ng	  of	  DNA.	  	  In	  addition	  to	  DNA	  volume	  and	  concentration,	  an	  electrophoretic	  gel	  is	  also	  used	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to	   check	   for	   DNA	   integrity.	   At	   the	   early	   stages,	   DNA	   contamination	   should	   be	  checked	   rigorously	   before	   proceeding	   any	   further.	   One	   approach	   to	   test	   for	  possible	  DNA	  contamination	  issues	  is	  to	  genotype	  a	  handful	  of	  autosomal	  and	  sex	  chromosomal	  SNPs	  to	  match	  gender	  and	  test	  relatedness.	  	  	  Library	   preparation	   is	   accomplished	   by	   DNA	   fragmentation	   using	   physical	  (ultrasonic)	   or	   chemical	   approaches	   [138]	   into	   smaller	   pieces	   of	   relatively	  homogenous	   length	   followed	   by	   ligation	   to	   common	   adaptor	   sequences.	   To	  empower	  signal	  detection	  during	  sequencing,	  clonally	  clustered	  amplicons	  need	  be	  generated	  using	   in	  situ	  polonies,	  emulsion	  PCR	  or	  bridge	  PCR	  among	  others	  methods	   [136].	   	   The	   goal	   of	   these	  methods	   is	   to	   generate	  multiple	   copies	   of	   a	  single	  DNA	  molecule	  arranged	  spatially	  on	  a	  planar	  substrate	  or	  bead	  surface.	  	  	  	  Sequencing	  specific	  parts	  of	  the	  genome	  (e.g.	  all	  coding	  regions	  as	  in	  the	  whole-­‐exome)	  requires	  capturing	  these	  regions	  with	  predefined	  baits	  of	  various	  lengths	  (90-­‐mer	  in	  the	  case	  of	  TruSeq	  Exome	  Enrichment	  Kit	  from	  Illumina	  and	  120-­‐mer	  in	   SureSelect	   Exome	   Enrichment	   Kit	   form	  Agilent).	   To	   increase	   the	   number	   of	  samples	  sequenced	  per	  run	  (8,	  16,	  24,	  48	  and	  96),	  some	  of	  the	  exome	  enrichment	  protocols	   add	   an	   indexing	   step	   to	   allow	   samples	   to	   be	   pooled	   but	   their	   data	  deconvoluted.	  	  Once	  a	  library	  is	  ready,	  massively	  parallel	  sequencing	  is	  based	  on	  enzyme-­‐driven	  biochemistry	   and	   imaging-­‐based	   (SOLiD,	   Solexa)	   or	   voltage-­‐based	   data	  acquisition	   (Ion	   Torrent)	   (see	   Table	   1-­‐8	   	   for	   more	   details	   about	   different	  platforms).	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Table	  1-­‐8	  Technical	   specifications	  of	   some	  commercially	   available	  Next	  Generation	  Sequencing	  platforms	  [139,	  140]	  
Platform	   MiSeq	  	   Ion	  Torrent	  PGM	   PacBio	  RS	   HiSeq	  2000	  




Company	  	   Illumina	   Life	  technologies	  	   Pacific	  Biosciences	   Illumina	   Life	  technologies	   Roche	  /	  454	  Instrument	  Cost	   $128K	   $80K	   $695	   $645K	   $251K	   $450K	  Amplification	  method	   Bridge	  	  PCR	   Emulsion	  PCR	   None	   Bridge	  	  PCR	   Emulsion	  PCR	   Emulsion	  PCR	  Sequencing	  method	  	   Sequencing	  by	  synthesis	  	   Sequencing	  by	  synthesis	  	  (H+	  detection)	   Sequencing	  by	  synthesis	  	   Sequencing	  by	  synthesis	  	  
Ligation	  and	  two-­‐base	  coding	   Pyrosequencing	  Data	  acquisition	  	   Image-­‐based	   Semiconductor-­‐based	   Image-­‐based	   Image-­‐based	   Image-­‐based	   Image-­‐based	  Sequence	  yield	  per	  run	   1.5-­‐2Gb	   1Gb	  	  (318	  chip)	   100	  Mb	   600Gb	   155	  Gb	   0.4	  Gb	  Sequencing	  cost	  per	  Mb*	   $0.07	   $1.20	   $2-­‐17	   $0.04	   $0.07	   $12.00	  Run	  Time	   27	  hours	   2	  hours	   2	  hours	   11	  days	   8	  days	   10	  hours	  Primary	  errors	   Substitution	   Indel	   Indel	   Substitution	   A-­‐T	  bias	   Indel	  Observed	  Raw	  Error	  Rate	   0.8%	   1.7%	   12.8%	   0.3%	   ≤	  0.1%	   1.0%	  Read	  length	   Up	  to	  150	  bases	   ~200	  bases	   Average	  1,500	  bases	   Up	  to	  150	  bases	   75+35	  bases	   Up	  to	  700	  bases	  Paired	  reads	   Yes	   Yes	   No	   Yes	   Yes	   No	  Insert	  size	   Up	  to	  700	  bases	   Up	  to	  250	  bases	   Up	  to	  10	  kb	   Up	  to	  700	  bases	   NA	   NA	  Typical	  DNA	  requirements	   50-­‐1000	  ng	   100-­‐1000ng	   ~1	  μg	   50-­‐1000	  ng	   NA	   NA	  *	  The	  prices	  are	  updated	  as	  of	  2013	  [139,	  141]	  	  	  
1.2.1.2 Computation-­‐based	  steps	  	  The	   first	   computational	   step	   starts	   by	   converting	   the	   raw	   signals	   detected	   by	  NGS	   platforms	   (e.g.	   the	   fluorescence	   in	   imaging-­‐based	   systems)	   to	   sequence	  reads,	   ‘base-­‐calling’.	  This	   step	  usually	   takes	  place	  on	  or	  next	   to	   the	   sequencing	  machine	  in	  real	  time.	  The	  output	  is	  composed	  of	  raw	  sequence	  reads	  in	  addition	  to	  the	  corresponding	  quality	  score	  for	  each	  base	  in	  a	  file	  format	  called	  “FASTQ”	  [142].	  	  Each	   sequencing	   platform	   suffers	   from	   different	   types	   of	   error	   during	   base-­‐calling	  [143].	  For	  example,	  the	  454	  platform	  infers	  the	  length	  of	  homopolymers	  from	   the	   observed	   fluorescence	   intensity,	   which	   varies	   and	   usually	   leads	   to	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higher	   error	   rate	   with	   indels	   (short	   DNA	   insertion	   or	   deletion	   variants).	   The	  Illumina	   platform	   on	   the	   other	   hand	   has	   a	   miscall	   rate	   around	   1%	   due	   to	  different	   errors.	   	   As	   the	   Illumina	   read	   sequence	   length	   increases,	   the	   DNA	  synthesis	  process	  desynchronizes	  between	  different	  copies	  of	  DNA	  templates	  in	  the	  same	  cluster	  and	  base-­‐calling	  becomes	  less	  accurate	  in	  later	  cycles.	  Because	  of	   these	   errors,	   reads	  with	   an	   excess	   of	   sequence	   artifacts,	   base	   calling	   errors	  and	   adaptor	   contamination	   need	   to	   be	   excluded	   before	   mapping	   them	   to	   the	  human	  genome	  reference[144].	  	  The	  remaining	  high	  quality	  reads	  are	  then	  mapped	  to	  one	  of	  the	  available	  human	  genome	  references	  such	  as	   the	  Genome	  Reference	  Consortium	  human	  build	  37	  (GRCh37).	  Many	   alignment	   tools	   have	   been	   developed	   in	   the	   last	   few	   years	   to	  map	  millions	  of	  DNA	  sequencing	  reads	  (reviewed	  by	  [145,	  146]).	  	  The	  majority	  of	  the	  fast	  aligners	  generate	  auxiliary	  data	  structure	  called	  indices	  for	  the	  reference	  sequence,	   the	   read	   sequences	   or	   both	   [145].	   Based	   on	   the	   indexing	   method,	  these	   aligners	   can	   be	   arranged	   into	   three	   groups:	   hash	   tables-­‐based	   aligners	  such	  as	  BALT	  [147]	  and	  SSAHA2	  [148],	  suffix	  trees-­‐based	  aligners	  such	  as	  BWA	  [149]	  and	  Bowtie	  [150],	  and	  merge	  sorting-­‐based	  aligners	  such	  as	  Slider	  [151]	  .	  	  BWA	  was	   used	   to	   align	   raw	   sequence	   reads	   from	   all	   samples	   discussed	   in	  my	  thesis.	  BWA	  generates	  Sequence	  Alignment/Map	  (SAM)	   files	   [152],	  a	   tab-­‐based	  format	  that	  describes	  the	  alignment	  of	  reads	  in	  rich	  detail.	  SAM	  files	  include	  two	  parts:	  a	  header	  for	  metadata	  (optional)	  and	  an	  alignment	  section.	  Each	  line	  in	  the	  alignment	  section	  describes	  one	  sequence	  read	  in	  details:	  where	  	  it	  maps	  on	  the	  reference	  genome,	   the	  quality	  scores	  at	  base	  and	  read	   levels,	  a	  CIGAR	  string	   to	  record	   the	  matching	  output	  between	   the	   read	  bases	  and	   the	   reference	  genome	  and	  many	   other	   additional	   pieces	   of	   information.	   A	   binary	   version	   of	   SAM	   file	  format,	  called	  BAM,	  is	  usually	  preferred	  over	  SAM	  format	  to	  save	  digital	  storage	  space	  and	  provide	  faster	  operations	  and	  queries.	  	  	  Before	   calling	   variants	   from	   sequencing	   reads	   in	   BAM	   files,	   a	   few	   additional	  quality	  control	  steps	  are	  usually	  applied	  to	  reduce	  the	  false	  positive	  rate	  (FPR).	  For	  example,	  base	  quality	  score	  recalibration	  attempts	  to	  correct	  the	  variation	  in	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quality	   with	   machine	   cycle	   and	   sequencing	   context,	   as	   implemented	   in	   GATK	  [153,	  154].	  Once	  this	  is	  done,	  the	  quality	  scores	  in	  the	  BAM	  files	  are	  closer	  to	  the	  actual	   probabilities	   of	   erroneously	   mismatching	   with	   the	   sequenced	   genome.	  Additionally,	   removing	  reads	  with	  excess	  mismatches	   to	   the	  reference	  genome,	  realignment	  around	  common	  insertion/deletions	  and	  discarding	  duplicate	  reads	  originating	  from	  a	  single	  progenitor	  template	  can	  enhance	  the	  FPR.	  	  These	  steps	  generate	  BAM	  files	  with	  high	  quality	  reads	  that	  are	  ready	  for	  variant	  calling	  and	  many	  of	  them	  have	  been	  developed	  as	  part	  of	  the	  1000	  genome	  project	  [155].	  	  Today,	   there	   are	   more	   than	   60	   variant	   callers	   available	   (reviewed	   by	   [137]).	  These	   callers	   can	   be	   arranged	   into	   four	   groups	   according	   to	   the	   type	   of	   DNA	  variant:	   (i)	   germline	   callers	   (discussed	   below),	   (ii)	   somatic	   mutation-­‐calling	  based	  on	  DNA	  from	  matched	  tumor-­‐normal	  patient	  samples	  are	  an	  essential	  part	  of	  many	  cancer	  genome	  projects	  (reviewed	  by	  Kim	  and	  Speed	  [156]),	  (iii)	  copy	  number	   variant	   callers	   from	   NGS	   (reviewed	   by	   Duan	   et	   al.	   [157]	   )	   	   ,	   and	   (iv)	  structural	  variants	  (SV)	  callers	  which	  are	  	  designed	  to	  call	  	  insertions,	  deletions,	  inversions,	   inter-­‐	  and	   intra-­‐chromosomal	   translocations	  (reviewed	  by	  Pabinger	  
et	  al.	  	  [137]).	  	  	  Germline	  callers	   include	  GATK	  [153,	  154],	  Samtools	  [152]	  and	  they	  are	  used	  to	  call	  single	  nucleotide	  and	  short	   indels.	  These	  programs	  call	  a	  variant	  at	  a	  given	  locus	  when	  it	  is	  sequence	  different	  from	  the	  reference	  genome	  and	  then	  they	  try	  to	  determine	  its	  genotype	  status	  based	  on	  the	  number	  of	  alleles	  (heterozygous,	  hemizygous	  or	  homozygous	  non-­‐reference	  in	  the	  case	  of	  human	  DNA).	  Initially,	  simple	  algorithms	  based	  on	  allele	  counts	  at	  each	  site	  were	  used	  to	  call	  a	  variant	  or	   genotype	   using	   simple	   cutoffs.	   Recently,	   uncertainty	   was	   incorporated	   in	  more	   sophisticated	   statistical	   frameworks	   for	   variant	   /	   genotype	   calling	   [143].	  Because	  indels	  suffer	  from	  higher	  false	  positive	  rates,	  additional	  Bayesian-­‐based	  (e.g.	  Dindel	  [158])	  or	  pattern-­‐growth	  based	  programs	  (e.g.	  Pindel	  [159])	  may	  be	  used	  to	  improve	  their	  calling	  and	  genotyping	  (reviewed	  by	  Neuman	  et	  al.	  [160]).	  	  The	  germline	  callers	  usually	  output	  variant	  and	  genotype	  calls	  in	  a	  standardized	  generic	  format	  for	  storing	  sequenced	  variants	  including	  single	  nucleotide,	  indels,	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larger	   structural	   variants	   and	   annotations	   called	   Variant	   Call	   Format	   (VCF)	  [161].	  	  The	  VCF	  format	  is	  easily	  extendable	  and	  is	  able	  to	  hold	  rich	  details	  about	  every	  variant	   in	   single	  or	  multi-­‐sample	   files.	   	  VCF	  can	  be	   compressed	  by	  up	   to	  20%	  of	  its	  original	  size	  to	  save	  storage	  space	  and	  also	  can	  be	  indexed	  (e.g.	  using	  Tabix	   [162])	   for	   fast	   random	   access	   which	   is	   essential	   for	   most	   downstream	  analyses.	  	  The	  number	  of	  variants	   in	  VCF	   files	  depends	  on	   the	   size	  of	   sequenced	   regions.	  The	   numbers	   can	   range	   from	   four	   million	   variants	   in	   deep	   whole	   genome	  sequences	   to	   about	   40-­‐80	   thousand	   variants	   in	  whole	   50Mb-­‐size	   exomes.	   This	  large	  number	  of	  variants	  represents	  a	  challenge	  when	  researchers	  try	  to	  look	  for	  genetic	  causes	  of	  disease.	  Additional	  filtering	  and	  annotation	  are	  usually	  applied	  to	   exclude	  unwanted	  variants.	   For	   example,	   population	   allele	   frequencies	   from	  public	   resources	   such	  as	   the	  1000	  genomes	  project	   [155]	  or	  NHLBI	  GO	  Exome	  Sequencing	   Project	   (ESP)	   [163]	   are	   useful	   to	   exclude	   common	   variants	   (e.g.	  minor	  allele	  frequency	  >	  1%).	  Comparative	  genomics	  provides	  a	  base-­‐resolution	  conservation	   score	   (e.g.	   GERP	   [164,	   165],	   phastCons	   [166]	   or	   phyloP	   [167]).	  These	   scores	   are	   useful	   when	   analyzing	   non-­‐coding	   variants	   since	   most	  important	  functional	  elements	  of	  the	  genome	  are	  expected	  to	  be	  more	  conserved.	  	  	  	  Since	  most	   high	   penetrance	   pathological	   variants	   occur	   in	   coding	   regions	   (i.e.	  exons)	   as	   reported	   by	   human	   genetic	   mutation	   database	   (HGMD)	   [168],	  predicting	   the	   variant	   effect	   on	   protein	   structure	   is	   an	   important	   part	   of	   any	  downstream	   analysis.	   SNPeff	   [169]	   as	   well	   as	   Variant	   Effect	   Predictor	   	   (VEP)	  from	  Ensembl	  [170]	  are	  two	  commonly	  used	  programs	  used	  for	  this	  task.	  More	  specialized	  tools	  are	  used	  to	  predict	  the	  damaging	  effect	  of	  missense	  mutations	  such	  as	  PolyPhen	  [171],	  SIFT	  [172]	  and	  Condel	  [173].	  	  	  These	  annotations	  and	   filters,	  along	  with	  computation	  approaches	  discussed	   in	  chapter	   2,	   can	   help	   to	  minimize	   the	   search	   space	   for	   plausible	   casual	   variants	  dramatically,	   by	   order	   of	   magnitudes,	   down	   to	   few	   tens	   or	   hundreds	   of	  candidates	  per	  sample.	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1.2.2 NGS	  applications	  NGS	   has	   revolutionized	   many	   fields	   such	   as	   microbiology,	   molecular	   biology,	  population	   genetics,	   cancer	   genetics	   and	   molecular	   diagnostic	   to	   name	   a few.	  	  Although	   NGS	   applications	   have	   been	   extended	   with	   greater	   success	   to	   non-­‐human	  organisms	  such	  viral,	  bacterial,	  plants,	  and	  animals,	   this	  section	   focuses	  on	  human-­‐related	  applications	  only.	  	  	  Broadly	  speaking,	  NGS	  applications	   in	  humans	  can	  be	  divided	   into	   two	  groups:	  medical-­‐based	   and	   research-­‐based	   applications	   (Figure	   1-­‐10).	   There	   is	   a	   thin-­‐line	  between	  these	  two	  groups	  as	  many	  of	  the	  studies	  or	  applications	  start	  out	  as	  a	   research-­‐based,	   but	   once	   a	   solid	   foundation	   is	   established,	   they	   are	   usually	  translated	  into	  clinical	  practice.	  	  	  	  
	  Figure	  1-­‐10	  Examples	  of	  NGS	  applications	  in	  human	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causes	   of	   tens	   of	   rare	   Mendelian	   disorders	   have	   been	   deciphered	   under	  autosomal	  recessive,	  dominant	  inherited,	  dominant	  de	  novo	  and	  X-­‐linked	  models	  (see	  Table	  1-­‐9	  for	  more	  examples).	  	  Table	   1-­‐9	   Selected	   studies	   using	   exome	   and	   whole	   genome	   sequencing	   for	   disease	   gene	  identification	  [175]	  
Sequencing	   Inheritance	  Model	   Disease	   Putative	  Loci	  Identified	   Reference	  
Exome	  
Autosomal	  dominant	  Familial	  amyotrophic	  lateral	  sclerosis	   VCP	   [176]	  Neonatal	  diabetes	  mellitus	   ABCC8	   [177]	  Primary	  lymphedema	   GJC2	   [178]	  Spinocerebellar	  ataxia	   TGM6	   [179]	  
Autosomal	  	  recessive	  
Carnevale,	  Malpuech,	  Michels,	  and	  oculoskeletal-­‐abdominal	  syndromes	   MASP1	   [180]	  Charcot-­‐Marie-­‐Tooth	  neuropathy	   GJB1	   [181]	  Congenital	  chloride	  losing	  diarrhea	   SLC26A3	   [182]	  FADD	  deficiency	   FADD	   [183]	  Familial	  combined	  hypolipidemia	   ANGPTL3	   [184]	  Fowler	  syndrome	   FLVCR2	   [185]	  Joubert	  syndrome	  2	   TMEM216	   [186]	  Mental	  retardation	   TECR	   [187]	  Miller	  syndrome	   DHODH	   [174]	  Nonsyndromic	  hearing	  loss	  (DFNB82)	   GPSM2	   [188]	  Seckel	  syndrome	   CEP152	   [189]	  Sporadic	   Mental	  retardation	   Several	  genes	   [190]	  Schinzel-­‐Giedion	  syndrome	   SETBP1	   [191]	  X-­‐linked	  	  recessive	   Intractable	  inflammatory	  bowel	  disease	   XIAP	   [192]	  
Genome	  
Autosomal	  	  dominant	   Metachondromatosis	   PTPN11	   [193]	  
Autosomal	  	  recessive	   Charcot-­‐Marie-­‐Tooth	  neuropathy	   SH3TC2	   [194]	  Miller	  syndrome	   DHODH,	  DNAH5,	  and	  KIAA0556	   [195]	  Sitosterolemia	   ABCG5	   [196]	  	  Whole	  exome	  sequencing	  (WES)	  is	  the	  preferred	  method	  in	  most	  of	  these	  studies	  for	   its	   low	   cost	   and	   smaller	  number	  of	   variants	   compared	  with	  whole	   genome	  sequencing	   (WGS).	   Unlike	   WGS,	   where	   non-­‐coding	   variants	   are	   the	   dominant	  variant	   type,	   WES	   targets	   coding	   regions	   of	   the	   genome	   (~1-­‐2%),	   which	  enhances	  interpretability	  of	  the	  variants	  and	  can	  be	  subjected	  to	  further	  analysis	  with	  functional	  experiments.	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Researchers	   have	   used	   a	   common	   strategy	   to	   find	   the	   causal	   genes	   in	   these	  studies.	  This	   strategy	  usually	   starts	  by	   comparing	   the	  WES/WGS	  variants	  with	  public	  databases	  such	  as	  the	  1000	  Genomes	  Project	  [197,	  198],	  the	  NHLBI	  Exome	  Variant	  Server[199],	   International	  HapMap	  Project	   [200],	  and	  single-­‐nucleotide	  polymorphism	  (SNP)	  database	  (dbSNP)	  [201],	  as	  well	  as	  internal	  controls	  [202].	  By	   focusing	   on	   rare	   variants	   (typically	   with	   minor	   allele	   frequency	   <	   1%	   in	  controls),	  this	  usually	  excludes	  most	  of	  the	  variants	  in	  WES,	  down	  from	  ~20,000	  coding	  variants	  to	  a	  few	  hundreds.	  	  	  The	  detection	  of	  rare	  coding	  variants	   in	  the	  same	  gene	  in	  unrelated	  individuals	  or	   families	   with	   the	   same	   monogenic	   disorder	   is	   usually	   considered	   strong	  evidence	   to	   support	   the	   causality.	   However,	   additional	   functional	   studies	   are	  usually	  needed	   to	   support	   the	  pathogenicity	   if	   the	   candidate	  mutation	  appears	  only	  in	  a	  single-­‐family	  [202].	  	  To	  date,	  more	   than	  180	  novel	   genes	   have	  been	   linked	   to	  monogenic	   disorders	  using	  next-­‐generation	  sequencing	  where	  the	  causal	  mutations	  were	  either	  occur	  
de	   novo	   or	   inherited	   [202].	   	   Different	   family	   designs	   ranging	   from	   unrelated	  cases,	   affected	   sib-­‐pairs	   and	   trios	   have	   been	   used	   to	   investigate	   different	  inheritance	   models	   (Table	   1-­‐10).	   Autosomal	   recessive	   disorders	   were	   over-­‐represented	   during	   the	   first	   few	   years	   (2009-­‐2011)	   of	   using	  NGS	   platforms	   to	  elucidate	   causes	   of	  monogenic	   disorders.	   This	   over-­‐representation	  was	  mainly	  due	  to	  the	   fact	   that	  a	  small	  number	  of	  affected	  sib-­‐pairs	  are	  enough	  to	   find	  the	  causal	   homozygous	   variants.	   In	   non-­‐consanguineous	   families	   that	   demonstrate	  an	  autosomal	  recessive	  inherence	  pattern,	  the	  exome	  data	  from	  one	  or	  two	  sib-­‐pairs	  were	  usually	  enough	  to	  find	  a	  few	  compound	  heterozygous	  variants	  to	  be	  the	   cause	   of	   the	   disease	   (see	   the	   example	   of	   DDHD2	   gene	   in	   Table	   1-­‐10).	   In	  consanguineous	   families,	   15-­‐20	   rare	   homozygous	   candidate	   variants	   are	  expected	  in	  affected	  sib	  pairs	  [202].	  	  Similarly,	   autosomal	   dominant	   disorders	   caused	   by	   de	   novo	   mutations	   are	  relatively	   easy	   to	   identify	   using	   a	   parent-­‐offspring	   trio	   design.	   This	   analysis	  requires	  exome	  data	  from	  the	  affected	  child	  and	  both	  parents	  and	  is	  usually	  less	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complex	   since	   few	   de	   novo	   variants	   are	   present	   in	   each	   sample	   (for	   example	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-­‐	  Shared	  homozygous	  or	  compound	  heterozygous	  in	  affected	  sibs	  and	  heterozygous	  in	  unaffected	  parents	  
Complex	  form	  of	  hereditary	  spastic	  paraparesis	  [203]	  





-­‐Shared	  homozygous	  variants	  and	  heterozygous	  in	  unaffected	  parents	  -­‐	  Identical	  By	  Decent	  (IBD)	  analysis	  (Autozygosity)	  
Postaxial	  polydactyly	  type	  A	  [204]	   ZNF141	  
Three	  affected	  sibs	  in	  one	  family	  of	  a	  Pakistani	  origin	  	  
X-­‐linked	  
recessive	  
Affected	  male	  child	  and	  healthy	  mother	  
-­‐	  Shared	  variants	  in	  affected	  males	  and	  carrier	  mothers.	   Diamond–	  Blackfan	  anaemia	  [205]	   GATA1	  
Two	  affected	  male	  children	  and	  a	  carrier	  healthy	  mother	  
Autosomal	  
dominant	  
Affected	  parent-­‐child	  or	  unrelated	  index	  cases	  
-­‐	  Co-­‐segregation	  of	  heterozygous	  in	  affected	  parent-­‐child.	  -­‐	  Variant	  in	  the	  same	  gene	  in	  unrelated	  families.	  	  	  -­‐	  NGS	  coupled	  with	  linkage	  analysis	  in	  large	  families	  
Familial	  Diarrhea	  Syndrome	  [206]	   GUCY2C	  
Captured	  a	  2.9	  Mb	  linked	  region	  in	  32	  members	  of	  a	  large	  Norwegian	  family	  	  
De	  novo	  dominant	  
mutations	   Complete	  trios	   -­‐	  De	  novo	  variant	  in	  child	  not	  seen	  in	  healthy	  parents	   Weaver	  syndrome	  [207]	   EZH2	   Two	  unrelated	  parent–child	  trios	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Cancer	  	  Many	  studies	  have	  utilized	  NGS	  platforms	  to	  detect	  genes	  with	  recurrent	  somatic	  mutations	   in	   different	   solid	   and	   hematological	   neoplasms	   [208],	   	   acquired	  somatic	  mutations	  in	  melanoma	  [209]	   ,	  substitution	  and	  rearrangement	  in	  lung	  cancer	  [210,	  211]	  and	  in	  breast	  cancer	  [212].	  	  	  Recurrent	   somatic	  mutations	   in	  DNMT2,	   for	   example,	  were	  detected	   in	  22%	  of	  patients	   with	   Acute	   Myeloid	   Leukemia	   (AML)	   [213].	   These	  mutations	   provide	  not	  only	  a	  deep	  insight	  into	  the	  tumor	  biology	  but	  also	  have	  a	  prognostic	  value.	  Patients	  with	  DNMT2	  mutations	  were	  found	  to	  have	  a	  worsened	  prognosis	  when	  they	   have	   a	   normal	   cytogenetic	   profile	   [213].	   Additionally,	   pilot	   studies	   have	  successfully	   adapted	   NGS	   to	   monitor	   the	   cancer	   progression	   by	   detecting	   the	  residual	  disease	   following	   treatment	   [214,	  215].	  This	  was	  based	  on	  sequencing	  of	   immunoglobulin	   VDJ	   gene	   rearrangements	   in	   lymphoma	   or	   lymphoid	  leukemia	  for	  minimal	  residual	  of	  disease	  (MRD)	  [214].	  	  
Multifactorial	  disease	  	  Very	   recently,	  Morrison	  et	  al..	   used	   low-­‐coverage	  whole-­‐genome	   sequencing	  of	  962	   cases	   to	   study	   the	   genetic	   architecture	   of	   a	   complex	   trait,	   levels	   of	   high-­‐density	  lipoprotein	  cholesterol	  (HDL-­‐C)	  [216].	  Their	  results	  showed	  61.8%	  of	  the	  heritability	   of	   HDL-­‐C	   levels	   could	   be	   attributable	   to	   common	   variations.	   This	  supported	   the	   hypothesis	   that	   common	   variants	   are	   likely	   to	   represent	   true	  polygenic	   variations	  with	   small	   effects.	   The	   use	   of	   NGS	   to	   find	   these	   common	  variants	   is	   expected	   to	   play	   an	   important	   role	   in	   identifying	   the	   biological	  pathways	  involved	  in	  the	  complex	  disease	  pathophysiology.	  	  	  
Infectious	  disease	  	  Identifying	   novel	   infectious	   organisms	   and	   tracking	   outbreaks	   or	   epidemics	   of	  disease	   requires	   a	   fast	   and	   thorough	   response	   before	   they	   become	   a	   major	  health	   problem.	   NGS	   platforms	   fit	   the	   bill	   perfectly	   and	   have	   proved	   their	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tremendous	   value	   in	   such	   situations.	   	   The	   2010	  Haitian	   cholera	   outbreak	  was	  traced	   to	   have	   originated	   in	   Bangladesh	   using	   NGS	   [217].	   Similarly,	   the	  Escherichia	   coli	   O104:H4	   break	   in	   Germany	   were	   found	   to	   be	   a	   Shiga	   toxin-­‐producing	   strain	   [218].	   The	   underlying	   mechanism	   behind	   its	   virulence	   was	  thought	   to	   arise	   by	   horizontal	   transfer	   of	   a	   prophage	   carrying	   genes	   for	   Shiga	  toxin	  2	  and	  other	  virulence	  factors	  [218].	  	  	  More	   recently,	   NGS	   enabled	   the	   discovery	   of	   a	   novel	   Middle	   East	   Respiratory	  Syndrome	   (MERS)	   coronavirus	   that	   can	   spread	   between	   people	   in	   healthcare	  settings	  [219].	  This	  detailed	  clinical	  work	  accompanied	  with	  the	  identification	  of	  the	   virus	   clusters	   using	   NGS	   helped	   to	   identify	   the	   source	   of	   infection	   in	   the	  eastern	   region	   of	   Saudi	   Arabia.	   This	   discovery	   aided	  with	   NGS	   had	   immediate	  implications	  in	  terms	  of	  preventive	  infection	  control	  measures	  to	  halt	  the	  spread	  of	  the	  virus	  to	  other	  regions	  of	  the	  world.	  	  
Non-­‐invasive	  diagnosis	  and	  monitoring	  	  Detecting	  foreign	  DNA	  from	  the	  blood	  is	  an	  example	  of	  a	  novel	  NGS	  application.	  NGS	   platforms	   have	   been	   used	   to	   monitor	   solid-­‐organ	   transplant	   rejection	   by	  detecting	  cell-­‐free	  DNA	  from	  the	  blood	  [220].	  The	  ratio	  of	  recipient	  genomic	  DNA	  to	  graft-­‐derived	  donor	  DNA	  is	  used	  to	  measure	  the	  number	  of	  graft	  cells	  that	  are	  dying	  and	  releasing	  their	  DNA	  into	  the	  blood.	  This	  method	  has	  a	  big	  advantage	  of	  being	   less	   invasive	   compared	   with	   traditional	   methods	   requiring	   periodic	  biopsies	  of	  the	  graft	  tissue.	  	  Similarly,	   prenatal	   diagnosis	   of	   several	   trisomies	   is	   now	   possible	   with	   NGS	  without	   the	  need	   for	   traditional	   invasive	  amniocentesis.	  Here,	  NGS	  are	  used	   to	  sequence	  cell-­‐free	  DNA	  from	  the	  maternal	  blood	  in	  order	  to	  detect	  fetal	  trisomies	  by	   comparing	   the	   ratios	   of	   the	   number	   of	   DNA	   fragments	   derived	   from	   each	  chromosome	  [221].	  This	  technique	  showed	  impressive	  records	  of	  sensitivity	  and	  specificity	  of	  detection	  of	  fetal	  trisomy	  21,	  100%	  and	  97.9%	  respectively	  [222].	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Population	  genetics	  
	  The	   1000	   genomes	   project	   	   (1KG)	   is	   probably	   one	   of	   the	   most	   notable	   NGS	  applications	   [155,	   197].	   	   The	   1KG	   used	   both	   low-­‐coverage	   whole	   genome	  sequencing	  and	  exome	  sequencing	  of	  1,092	   individuals	   from	  14	  populations	   to	  provide	   a	   haplotype	   map	   of	   38	   million	   single	   nucleotide	   polymorphisms,	   1.4	  million	   short	   insertions	   and	   deletions,	   and	  more	   than	   14,000	   larger	   deletions.	  The	  1KG	  captures	  up	  to	  98%	  of	  accessible	  single	  nucleotide	  polymorphisms	  at	  a	  frequency	   of	   1%	   and	   provides	   a	   valuable	   resource	   in	  many	   projects	   including	  population	   frequency-­‐based	   filters	   used	   in	   the	   exome	   sequencing	   projects	  analyzed	  in	  this	  thesis.	  	  	  Another	   influential	   study	   entailed	   high-­‐coverage	   exome	   sequencing	   of	   6,515	  individuals	   [199].	   The	   study	   shows	   that	   73%	   of	   all	   protein-­‐coding	   SNVs	   and	  approximately	   86%	   of	   SNVs	   that	   are	   predicted	   to	   be	   deleterious,	   arose	   in	   the	  past	   5,000–10,000	   years.	   Additionally,	   it	   identified	   an	   excess	   of	   rare	   coding	  mutations	   in	  essential	  and	  Mendelian	  disease	  genes	   in	  Europeans	  compared	   to	  African	  Americans,	   a	   finding	   consistent	  with	  weaker	  purifying	   selection	  due	   to	  the	  smaller	  effective	  population	  sizes	  resulting	  from	  the	  Out–of	  –Africa	  dispersal.	  	  
Forensics	  	  
	  DNA-­‐based	  methods	  for	  human	  identification	  are	  generally	  based	  on	  genotyping	  of	  short	  tandem	  repeat	  (STR)	  loci	  using	  electrophoresis,	  which	  is	  relatively	  low	  throughput	  and	  does	  not	  yield	  nucleotide	  sequence	  information.	  NGS	  platforms	  have	   been	   used	   as	   high-­‐throughput	   genotyping	   analysis	   for	   the	   13	   Combined	  DNA	  Index	  System	  (CODIS)	  STR	  loci	  and	  amelogenin	  (AMEL)	  locus	  using	  as	  few	  as	  18,500	  reads	  (>99%	  confidence)	  [223].	  	  STRait	  Razor	  is	  a	  program	  developed	  to	   detect	   forensically	   relevant	   STR	   alleles	   in	   FASTQ	   sequence	   data,	   based	   on	  allelic	   length.	   Currently,	   it	   detects	   alleles	   for	   44	   autosomal	   and	  Y-­‐chromosome	  STR	  from	  Illumina	  sequencing	  instruments	  with	  100%	  concordance	  [224].	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Functional	  applications	  	  NGS	  has	  many	  applications	  that	  extend	  outside	  the	  scope	  of	  genome	  sequencing.	  The	   ENCODE	   project	   demonstrates	   the	   breadth	   of	   various	   non-­‐genome-­‐based	  NGS	  experiments	  (Table	  1-­‐11).	  	  In	  this	  project,	  a	  total	  of	  ~1659	  high-­‐throughput	  experiments	   were	   performed	   to	   analyze	   transcriptomes	   and	   identify	  methylation	  patterns	  in	  human	  genome	  [225].	  This	  is	  a	  large	  multicenter	  project	  has	   assigned	   biochemical	   activities	   to	   80%	   of	   the	   genome,	   particularly	   the	  annotation	  of	  non-­‐coding	  portions	  in	  the	  genome	  [226].	  This	  finding	  may	  help	  to	  improve	  the	  prioritization	  and	   interpretation	  of	  non-­‐coding	  variants	   frequently	  found	  in	  whole	  genome	  sequencing	  project.	  	  	  Table	   1-­‐11	   The	   various	   NGS	   assays	   employed	   in	   the	   ENCODE	   project	   to	   annotate	   the	   human	  genome	  [226].	  HT:	  high-­‐throughput	  	  
Feature	   Method	   Description	   Reference	  
Transcripts,	  small	  RNA	  and	  
transcribed	  regions	  




ChIP-­‐seq	   Antibody-­‐based	  pull	  down	  of	  DNA	  bound	  to	  protein	  followed	  by	  HT	  sequencing	   [234]	  DNAse	  footprinting	   HT	  sequencing	  of	  regions	  protected	  from	  DNAse1	  by	  presence	  of	  proteins	  on	  the	  DNA	   [235]	  DNAse-­‐seq	   HT	  sequencing	  of	  hypersensitive	  non-­‐methylated	  regions	  cut	  by	  DNAse1	   [236]	  FAIRE	   Open	  regions	  of	  chromatin	  that	  is	  sensitive	  to	  formaldehyde	  is	  isolated	  and	  sequenced	   [237]	  Histone	  modification	   ChIP-­‐seq	  to	  identify	  various	  methylation	  marks	   [238]	  
DNA	  methylation	   RRBS	   Bisulfite	  treatment	  creates	  C	  to	  U	  modification	  that	  is	  a	  marker	  for	  methylation	   [239]	  
Chromosome-­‐interacting	  
sites	  
5C	   HT	  sequencing	  of	  ligated	  chromosomal	  regions	   [240]	  ChIA-­‐PET	   Chromatin-­‐IP	  of	  formaldehyde	  cross-­‐linked	  chromosomal	  regions,	  followed	  by	  HT	  sequencing	   [241]1	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1.2.3 NGS	  challenges	  	  Recent	   advances	   in	   NGS	   technologies	   have	   brought	   a	   paradigm	   shift	   in	   how	  researchers	   investigate	   human	   disorders.	   The	   key	   advantage	   of	   NGS	   is	   their	  ability	  to	  generate	  vast	  amount	  of	  biological	  data	  in	  a	  short	  time	  frame	  and	  in	  a	  cost-­‐effective	  way.	  Despite	   their	  huge	  success,	   they	  are	  not	  without	   challenges.	  These	  challenges	  include	   in	  silico	  analysis,	  data	  privacy,	  data	  interpretation	  and	  ethical	  considerations.	  	  The	  amount	  of	  data	  that	  NGS	  platforms	  generate	  can	  be	  unmanageable	  in	  terms	  of	  data	  storage	  and	  processing.	  The	  cost	  of	  sequencing	  a	  base	  is	  dropping	  faster	  than	  the	  cost	  of	  storing	  a	  byte	  [242].	  Another	  issue	  caused	  by	  this	  large	  amount	  of	  data	   is	   that	   statistical	   analysis	   and	  data	  processing	   	   (e.g.	   imputation)	  of	   few	  hundreds	   to	   thousands	   of	   exomes	   or	   genomes	   can	   be	   very	   computationally	  intensive	   and	   almost	   always	   requires	   a	   large	   infrastructure	   of	   distributed	  servers,	  which	  may	  not	  be	  affordable	  for	  many	  researchers.	  	  	  There	  are	  growing	  concerns	  with	  data	  privacy	  and	  whether	  current	  measures	  of	  sample	   anonymization	   are	   sufficient.	   It	   has	   been	   reported	   that	   a	   minimum	  number	  of	  75	  independent	  SNPs,	  or	  fewer,	  will	  uniquely	  identify	  a	  person	  [243].	  It	   is	   even	   possible	   to	   re-­‐identify	   genotyped	   individuals	   or	   even	   individuals	   in	  pooled	  mixtures	   of	   DNA	   [244].	   This	   prompted	   the	  National	   Institute	   of	  Health	  (NIH),	   the	   Broad	   Institute	   in	   the	   US,	   and	   the	   Wellcome	   Trust	   in	   the	   United	  Kingdom	   to	   further	   restrict	   public	   access	   to	   the	   data	   from	   genome-­‐wide	  association	  studies	  [245].	  	  The	  biological	  and	  clinical	  interpretation	  of	  genetic	  variation	  is	  probably	  one	  of	  the	  remarkable	  challenges	  in	  the	  era	  of	  NGS.	  Most	  of	  the	  variants	  found	  in	  whole-­‐genome	  sequencing	  are	  non-­‐coding	  and	  many	  of	  the	  coding	  ones	  are	  of	  variants	  of	   uncertain	   significance	   (VUSs)	   [246].	   Functional	   studies	   are	   required	   to	  evaluate	   these	   VUSs	   properly	   but	   with	   tens	   or	   hundreds	   of	   coding	   VUSs	   per	  individual,	  this	  is	  clearly	  is	  not	  a	  scalable	  solution.	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At	  the	  ethical	  level,	  NGS	  raises	  many	  important	  questions.	  For	  example,	  when	  to	  return	  results	   to	  participants,	  and	  what	  are	   the	  researcher’s	  obligations,	   if	  any,	  towards	   the	   participants’	   relatives.	   Such	   ethical	   dilemmas	   are	   the	   subject	   of	  heated	  debate	  between	  researchers,	  clinicians	  and	  policy	  makers	  [247]	  and	  are	  being	  actively	  addressed.	  	  
1.3 Overview	  of	  the	  thesis	  	  In	  this	  thesis	  I	  establish	  an	  analytical	  infrastructure	  for	  exome	  sequence	  analysis	  and	  apply	  it	  to	  some	  simple	  monogenic	  scenarios	  where	  linkage	  analysis	  is	  used	  to	   guide	   the	   targeted	  NGS	   sequencing.	   I	   then	   apply	   it	   to	   two	   subtypes	   of	   CHD	  exploring	  the	  power	  of	  different	  study	  designs.	  	  
Chapter	   2	   describes	   the	   development	   of	   an	   analytical	   infrastructure	   and	   the	  workflow	   used	   to	   analyze	   exome	   data	   in	   family-­‐based	   study	   designs.	   First,	   I	  describe	  two	  pipelines	  used	  to	  call	  variants	  in	  all	  samples	  analyzed	  in	  this	  thesis	  in	  addition	   to	  a	   third	  pipeline	   that	   I	  designed	  and	   implemented	   to	   call	  de	  novo	  variants.	   Variants	   called	   by	   these	   pipeline	   were	   subjected	   to	   various	   quality	  control	   tests	   and	   additional	   filters	   to	   improve	   the	   sensitivity	   and	   specificity	   of	  the	  variant	  calling.	  	  I	  then	  explain	  how	  the	  number	  of	  candidate	  genes	  per	  exome	  varies	  in	  different	  family	  designs	  and	  also	  by	  utilizing	  different	  public	  resources	  of	  minor	  allele	   frequency	   (MAF).	  To	  automate	  many	  of	   these	  analytical	   steps,	   I	  developed	   a	   suite	   of	   tools	   called	   Family-­‐based	   Exome	   Variants	   Analysis	   or	  (FEVA)	   to	   report	   candidate	   genes	   in	   different	   study	   designs.	   FEVA	   has	   two	  interfaces:	   one	   is	   aimed	   to	   users	   without	   bioinformatics	   training	   (with	   a	  graphical	  user	  interface)	  while	  the	  other	  is	  a	  command-­‐line	  interface	  suitable	  for	  high-­‐throughput	   settings	   in	   large-­‐scale	   projects.	   Finally,	   I	   present	   several	  applications	  on	  how	  I	  used	  FEVA	   to	   identify	  candidate	  genes	   in	  different	  study	  designs	  that	  include	  linkage	  regions	  in	  index	  cases,	  affected	  sib-­‐pairs,	  trios,	  and	  affected	  parent-­‐child	  pairs.	   	  The	  tools	  and	  analytical	  strategies	  described	  in	  this	  chapter	  were	  used	   to	  explore	   the	  power	  of	  different	  study	  designs	   in	   two	  CHD	  subtypes	  in	  the	  subsequent	  chapters.	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Chapter	  3	  describes	  how	  exome	  sequencing	  combined	  with	  tools	  developed	  in	  chapter	  2	  were	  used	   to	   report	  de	  novo	  and	  recessively	   inherited	  variants	   in	  30	  trios	   with	   Tetralogy	   of	   Fallot	   (ToF).	   This	   is	   followed	   by	   custom	   targeted	  sequencing	  of	  122	  genes	  in	  a	  replication	  cohort	  of	  250	  additional	  ToF	  trios.	  	  This	  chapter	  also	  describes	  three	  additional	  analyses	  that	   I	  designed	  and	  performed	  that	  are	  not	  described	  in	  chapter	  2:	  a	  modified	  transmission	  disequilibrium	  test	  (TDT)	   to	  explore	   incomplete	  penetrance	  of	   rare	   coding	  variants,	   an	  analysis	  of	  digenic	  inheritance,	  and	  finally	  a	  pathway	  burden	  analysis.	  	  
Chapter	  4	  discusses	  an	  alternative	  study	  design	  where	  I	  combined	  the	  analysis	  from	  13	  trios	  and	  112	  index	  cases	  to	  discover	  a	  novel	  CHD	  gene	  in	  patients	  with	  Atrioventricular	  Septal	  Defects	  (AVSD).	  Beside	  de	  novo	  and	  recessively	  inherited	  coding	  variants,	  this	  chapter	  descries	  a	  new	  analysis	  not	  described	  in	  chapter	  2	  that	  aims	  to	  test	  for	  the	  burden	  of	  rare	  coding	  variants	  in	  case/control	  samples.	  	  	  Concluding	  remarks	  and	  future	  directions	  are	  detailed	  in	  Chapter	  5.	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2 |	  Developing,	  testing	  and	  applying	  analysis	  pipelines	  for	  
family-­‐based	  exome	  studies	  
2.1 Introduction	  	  	  Although	   a	   rare	   genetic	   disorder,	   by	   definition	   (according	   to	   the	   European	  Commission),	   has	   a	   frequency	   of	   1	   in	   2000,	   collectively	   rare	   diseases	   affect	   6-­‐10%	   of	   the	   population	   [248].	   Rare	   genetic	   disorders	   are	   associated	   with	   high	  mortality	  rates,	  may	  account	   for	  51%	  of	  deaths	   in	  children	  under	  1	  year	  [249],	  add	  a	  significant	  burden	  to	  the	  health	  care	  system	  in	  terms	  of	  cost	  (accounted	  for	  184%	   more	   hospital	   charges	   than	   children	   who	   were	   hospitalized	   for	   other	  reasons	  [250])	  and	  often	  under	  diagnosed	  	  [251].	  	  Studying	  rare	  genetic	  disorders	  is	  essential	  to	  improve	  the	  quality	  of	  health	  care	  services	   and	   to	   obtain	   a	   precise	   and	   early	   diagnosis	   to	   these	   patients.	  Additionally,	  the	  insights	  from	  rare	  genetic	  disorders	  have	  helped	  to	  improve	  our	  understanding	   of	   many	   novel	   genes	   and	   molecular	   phenomena	   such	   as	  uniparental	   disomy,	   parental	   imprinting	   and	   epistatic	   interactions.	   These	  insights	   have	   also	   improved	   our	   understanding	   of	   the	   etiology	   of	   the	   risk	   and	  pathology	   of	   complex	   disease.	   	   For	   example,	   studying	   severe	   forms	   of	   familial	  insulin	  resistance	  has	  revealed	  important	  key	  genes	  when	  studying	  the	  common	  form	  of	  Diabetes	  Mellitus	  Type	  II	  [252].	  	  	  In	   the	   last	   few	  decades,	  researchers	  have	  used	  different	  approaches	   to	   find	  the	  underlying	   genetic	   causes	  of	   rare	  disorders,	   such	   as	  positional	   cloning,	   linkage	  analysis	  and	  candidate	  gene	  resequencing	  among	  other	  methods.	  Despite	   these	  great	   efforts,	   the	  Online	  Mendelian	   Inheritance	   in	  Man	   (OMIM)	   [253]	  database	  lists	  3,675	  suspected	  Mendelian	  phenotypes	  without	  any	  known	  molecular	  basis	  ,	  as	  of	   January	  7th	  2013.	  This	   large	  number	  of	  unidentified	  disorders	  shows	  the	  limitation	  of	  the	  traditional	  tools	  in	  identifying	  their	  genetic	  causes.	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Next	  Generation	  Sequencing	  (NGS)	  platforms	  promise	  to	  accelerate	  this	  process.	  In	  2005,	   the	  454	  Roche	   sequencer	  was	   introduced	   to	   the	   scientific	   community	  and	   soon	  other	   similar	   platforms	   followed,	   such	   as	   the	  Genome	  Analyzer	   from	  Illumina,	   SOLiD	   from	  Life	  Technologies	   and	  many	  others	   (discussed	   in	   chapter	  1).	   These	   NGS	   platforms	   are	   able	   to	   generate	   unprecedented	   high-­‐throughput	  DNA	   sequencing	   from	   whole	   genome	   or	   targeted	   sequences	   (e.g.	   exome	   or	  linkage	   regions)	   in	   a	   very	   short	   time	   and	   at	   an	   affordable	   cost.	   The	   first	  successful	   example	  of	   finding	   causal	   variants	   in	   a	  novel	   gene	  was	  published	   in	  2010	  when	  Sarah	  Ng	  et	  al.	  	  [174]	  used	  NGS	  to	  sequence	  the	  whole	  exome	  of	  four	  patients	  with	  Miller	  syndrome	  (OMIM	  #263750)	  and	  showed	  that	  mutations	   in	  the	  DHODH	   gene	   cause	   this	   recessive	   disorder.	   Soon	   afterwards,	   other	   groups	  around	   the	  world	   started	   using	   NGS	   to	   discover	   the	   causes	   of	  more	   than	   100	  novel	  genes	  in	  less	  than	  3	  years	  (Figure	  2-­‐1).	  This	  number	  is	  expected	  to	  grow	  as	  more	   researchers	   adopt	  NGS	  platforms	   for	   gene	  discovery	   in	   other	  monogenic	  disorders	  [202,	  254]	  (discussed	  in	  monogenic	  disorder	  section	  in	  chapter	  1).	  	  	  
	  Figure	  2-­‐1	  Number	  of	  Mendelian	  disease	  genes	  identified	  by	  NGS	  2010	  to	  mid	  of	  2012	  [254]	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Congenital	   heart	  defects	   (CHD)	   are	   considered	   the	  most	   common	  birth	  defects	  worldwide	   when	   taken	   collectively	   [14].	   However,	   they	   are	   considered	   rare	  disorders	  when	  considered	  separately	  (CHD	  prevalence	  is	  review	  in	  chapter	  1).	  	  Inspired	   by	   the	   success	   of	   NGS	   in	   finding	   the	   genetic	   causes	   in	   other	   rare	  disorders,	   I	   approached	   CHD	   using	   family-­‐based	   study	   designs	   combined	  with	  NGS.	  	  	  However,	   since	   the	   genetic	   architecture	   of	   CHD	   is	   not	   currently	   clear,	   I	   have	  considered	   both	   Mendelian	   and	   non-­‐Mendelian	   contributions	   to	   CHD.	   Not	   all	  pathogenic	   mechanisms	   can	   be	   evaluated	   using	   exome	   sequencing	   since	   it	  targets	  a	  small	  proportion	  of	  the	  genome	  (only	  coding	  DNA	  regions	  or	  <	  ~1-­‐2%	  of	  the	  human	  genome	  size	  (Table	  2-­‐1).	  Cryptic	  splice	  sites,	   intragenic	  and	  long-­‐range	   promoter	   variants	   that	   affect	   gene	   regulation	   cannot	   be	   studied	   using	  exome	  sequencing	  alone,	  and	  as	  such	  as	  they	  do	  not	  fall	  within	  the	  scope	  of	  this	  thesis.	   The	   existing	   examples	   of	   genetic	   causation	   of	   CHD	   are	   diverse,	   with	  respect	   to	   both	   their	  modes	   of	   inheritance	   and	  molecular	  mechanisms,	   and	   so	  investigation	   of	   CHD	  by	   exome	   sequencing	   requires	   a	   suite	   of	   tools	   capable	   of	  exploring	  different	  scenarios.	  	  Table	  2-­‐1	  lists	  the	  major	  inheritance	  patterns	  with	  syndromic	  or	  /	  and	  isolated	  CHD	   examples	   from	   literature,	   and	   whether	   they	   are	   amenable	   to	   analysis	   in	  whole	   exome	   sequence	   data	   (WES)	   or	   not,	   using	   tools	   I	   developed	   or	  implemented	  to	  scrutinize	  the	  candidate	  variants.	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Table	  2-­‐1	  Selected	  patterns	  of	  Mendelian	  and	  non-­‐Mendelian	   inheritance	  and	  whether	  they	  are	  amenable	  to	  analysis	  using	  whole	  exome	  data.	  *	  Indicates	  mechanisms	  that	  have	  been	  evaluated	  in	  this	  thesis.	  	   Inheritance	  pattern	  	   Example	  of	  syndromic	  and/or	  isolated	  CHD	   Can	  be	  evaluated	  with	  WES?	   Software	   Explored	  in	  this	  thesis?	  
Mendelian	  
Autosomal	  recessive	  *	   Adams-­‐Oliver	  syndrome	  OMIM	  #	  100300	   Yes	  	   FEVA	  
Chapter	  2,	  3	  and	  4	  
Autosomal	  Recessive	  	  (compound	  heterozygous)	  *	  
five	  affected	  children	  	  with	  right	  atrial	  isomerism	  were	  compound	  heterozygotes	  for	  truncating	  mutations	  in	  
GDF1	  gene	  [255]	  
Yes	  	   FEVA	  
Autosomal	  dominant	  *	   Alagille	  syndrome	  OMIM	  #	  118450	   Yes	  	  	   FEVA	  X-­‐linked	  	  dominant	  *	   Opitz	  GBBB	  syndrome	  OMIM	  #	  300000	   Yes	  	  	   FEVA	  X-­‐linked	  	  recessive	  *	   X-­‐linked	  heterotaxy	  OMIM	  #	  306955	   Yes	  	  	   FEVA	  
Y-­‐linked	   No	  reported	  CHD	  cases.	  Unlikely	  to	  harbor	  heart	  developmental	  genes	   Yes	  	   FEVA	   Not	  explored	  
Non-­‐
Mendelian*	  
Recurrent	  de	  novo	  mutations	  *	  
De	  novo	  mutations	  in	  histone-­‐modifying	  genes	  in	  isolated	  and	  syndromic	  CHD	  cases	  using	  exome	  data	  [256]	   Yes,	  if	  in	  coding	  regions	  	   DenovoGear	  
Chapter	  3	  and	  4	  
Digenic	  	  inheritance	  *	  	   No	  reported	  CHD	  cases.	  But	  as	  an	  example:	  long	  QT	  syndrome	  	   Yes	  	   Digenic	  module	  	   Chapter	  3	  Polygenic	  inheritance	  	   Tetralogy	  of	  Fallot	  [257]	  	   Only	  with	  large	  sample	  size	  (in	  thousands),	  case/control	  analysis	   Case/Control	  analysis	   Not	  explored	  
Imprinting	  	   Prader-­‐Willi	  syndrome	  OMIM	  #	  176270	  [258]	   Yes,	  if	  large	  segment.	   Uniparental	  Disomy	  	  (UPD)	  caller	  by	  Dan	  King,	   Not	  explored	  Excess	  affected	  cases	  	  (segregation	  distortion)	  *	  
MTHFR	  C677T	  polymorphisms	  may	  contribute	  to	  the	  risk	  of	  CHDs	  [259]	   Yes,	  in	  trio	  based	  studies	  	  
Rare	  collapsed	  TDT	  module	  	   Chapter	  3	  	  
	  
2.1.1 Chapter	  overview	  The	  main	  goal	  of	   this	   chapter	   is	   to	  describe	   the	  pipelines	  and	  analytical	   tools	   I	  developed	   and	   then	   applied	   to	   evaluate	   the	   utility	   of	   four	   family-­‐based	   study	  designs	  (index	  cases	  with	   linkage	  analysis,	  affected	  sib-­‐pairs,	   trios	  and	  affected	  parent-­‐child).	  The	  lessons	  learnt	  from	  these	  analyses	  were	  subsequently	  applied	  to	  two	  CHD	  subtypes	  (Tetralogy	  of	  Fallot	  and	  Atrioventricular	  Septal	  Defects)	  in	  chapters	  3	  and	  4,	  respectively.	  	  Figure	  2-­‐1	  shows	  the	  main	  analytical	  components	  required	  for	  family-­‐based	  exome	  studies.	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In	   this	   chapter,	   first,	   I	   describe	   the	   three	   pipelines	   used	   to	   call	   SNVs	   and	  
indels	   from	   all	   CHD	   samples	   included	   in	   this	   thesis.	   My	   colleagues	   at	   the	  Wellcome	   Trust	   Sanger	   Institute	   implemented	   two	   of	   the	   three	   pipelines	   (the	  Genome	   Analysis	   Production	   Informatics	   (GAPI)	   and	   the	   (UK10K)	   pipelines	  whilst	   I	   implemented	   the	   third	   one	   to	   call	   de	   novo	   variants,	   which	   was	   later	  adapted	   by	   Ray	   Miller	   for	   the	   Deciphering	   Developmental	   Disorders	   (DDD)	  project	  [260].	  	  	  Each	  pipeline	  outputs	  a	   large	  number	  of	  variants	   including	  many	   false	  positive	  variants	  that	  would	  adversely	  affect	  any	  downstream	  analysis.	  At	  the	  beginning	  of	  my	  work	   on	   exome	   sequencing	   three	   years	   ago,	   it	   was	   not	   clear	  what	   best	  practices	   I	   should	   use	   to	   improve	   the	   sensitivity	   and	   specificity	   of	   variant	  calling.	  	  	  In	  the	  second	  part	  of	  the	  results,	  I	  describe	  how	  I	  chose	  various	  filters	  such	  as	  strand	  bias,	  phred-­‐like	  quality	  scores	  among	  other	  filters	  to	  improve	  the	  sensitivity	   and	   specificity	   of	   the	   variant	   calls.	   Choosing	   the	   right	   filters	   is	   a	  dynamic	  research	  area	  and	   the	  best	  practices	  are	  expected	   to	  change	   to	  reflect	  new	  statistical	  models	   for	  variant	  calling.	  Many	  of	   the	  results	   I	  describe	   in	   this	  section	  do	  not	  reflect	  the	  current	  best	  practices	  but	  they	  represent	  examples	  of	  how	   to	   approach	   and	   set	   proper	   filter	   thresholds	   in	   exome-­‐based	   studies.	   	   	   In	  addition	  to	  these	  filters,	  I	  discuss	  how	  I	  merged	  the	  variant	  calls	  from	  multiple	  
callers	   to	   enhance	   sensitivity.	   I	   show	   that	   the	   precise	   manner	   in	   which	   the	  outputs	   from	  these	  callers	  are	  combined	  can	  have	  an	  unexpectedly	   large	  effect	  on	  the	  number	  of	  candidate	  variants	  	  Once	  I	  have	  obtained	  a	  high	  quality	  set	  of	  variants	  for	  each	  sample,	  I	  describe	  in	  the	   third	  part	   of	   the	   results,	   how	   I	   used	  minor	   allele	   frequency	   and	   additional	  family	   data	   to	  minimize	   the	   search	   space	   for	   causal	   variants.	   These	   combined	  steps	   reduce	   the	   search	   space	   for	   causal	   variants	   to	   a	   few	   tens	   or	   hundreds	  instead	  of	  tens	  of	  thousands	  of	  variants.	  	  	  Finally,	   I	  describe	  a	  suite	  of	   tools	   that	   I	  have	  designed	  to	  automate	  many	  steps	  discussed	  above.	  Although	  similar	  software,	  such	  as	  SVA,	  EVA	  and	  VarSift	  [261-­‐263],	  have	  been	  published	  during	  my	  PhD,	  none	  of	  them	  were	  able	  to	  fulfill	  the	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needs	  for	  my	  studies.	  One	  of	  the	  main	  drawbacks	  of	  these	  tools	  is	  that	  they	  are	  not	   suitable	   for	   high-­‐throughput	   analysis.	   Additionally,	  most	   of	   them	  use	   hard	  coded	   filters,	  which	   is	   not	  practical	   to	   explore	  new	   filters.	   For	   these	   reasons,	   I	  developed	   a	   suite	   of	   tools	   called	   Family-­‐based	   Exome	   Variants	   Analysis	  
(FEVA)	   that	   reports	   candidate	   variants	   under	   different	   modes	   of	   inheritance	  (autosomal	   recessive,	   autosomal	   dominant	   and	   X-­‐linked)	   for	   different	   study	  designs	  (index	  cases,	  affected	  sib-­‐pairs,	  affected	  parent-­‐child,	  and	  trios).	   	   In	  the	  last	   part	   of	   this	   chapter,	   I	   show	   how	   I	   used	   FEVA	   to	   identify	   pathogenic	   and	  candidate	  pathogenic	  genes	  under	  different	  study	  designs	  using	  real	  examples.	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Table	  2-­‐2	  A	  list	  of	  main	  analytical	  tasks	  described	  in	  this	  chapter	  with	  a	  short	  description	  of	  each	  section.	  	  	  
Task	   Section	   Description	  	  
Variant	  calling	  
pipelines	  
Genome	  Analysis	  Production	  Informatics	  (GAPI)	  pipeline	   To	   call	   single	   nucleotide	   (SNVs)	   and	  insertion/deletion	   variants	   (INDELs)	   using	  three	   callers	   (Samtools,	   GATK	   and	   Dindel)	   in	  381	  CHD	  samples	  
UK10K	  pipeline	   Used	   to	   call	   SNVs	   and	   INDELs	   variants	   using	  two	   callers	   (Samtools	   and	   GATK)	   in	   125	   CHD	  samples.	  




Sample-­‐based	  DNA	  quality	  test	  (DNA	  samples)	   Various	  tests	  to	  detect	  the	  quantity	  and	  quality	  of	   the	   DNA	   samples	   and	   any	   possible	   sample	  contamination	  and	  swapping	  issues.	  Sample-­‐based	  data	  quality	  test	  (Sequencing	  data)	   Quality	   of	   NGS	   sequencing	   data	   in	   terms	   of	  depth,	  coverage	  and	  other	  parameters.	  	  
Variant-­‐based	  quality	  tests	   Quality	  of	  variant	  calling	  based	  on	  the	  number	  of	  variants,	  genotypes,	  variants	  predicted	  effect	  on	  the	  protein	  and	  other	  quality	  ratios.	  Filtering	  low	  quality	  variants	  	   Multiple	   filters	   based	   on	   thresholds	   of	   quality	  metrics	  used	  to	  exclude	  low	  quality	  variants	  	  
Using	  multiple	  callers	   Combining	   multiple	   variant	   callers	   (e.g.	  Samtools,	   GATK	   and	   Dindel)	   to	   overcome	   the	  deficiencies	  of	  individual	  callers	  	  	  
Minimizing	  the	  
search	  space	  for	  
causal	  variants	  
Minor	  allele	  frequency	  (MAF)	   Using	   different	   population-­‐based	   MAF	  resources	   to	   exclude	   common	   variants	   (>1%)	  and	  the	  effect	  of	  allele	  matching	  algorithm.	  
Family-­‐based	  designs	   The	   effect	   of	   considering	   additional	   members	  of	  the	  family	  (either	  healthy	  or	  affected)	  on	  the	  final	  number	  of	  candidate	  variants	  and	  genes	  
Applications	  	  
FEVA	  suite	  
An	  easy	  to	  use	  suite	  of	  programs	  I	  developed	  to	  automate	   many	   of	   the	   steps	   discussed	   above	  (minimize	   the	  search	  space	   for	  causal	  variants	  and	   prioritization).	   These	   tools	   are	   available	  for	   small	   scale	   use	   with	   a	   graphical	   user	  interface	   and	   as	   common-­‐line	   tools	   for	   high-­‐throughput	  analysis.	  Simple	  monogenic	  diseases	  combined	  with	  linkage	  analysis	   Use	   of	   FEVA	   to	   find	   pathogenic	   variants	   from	  four	   different	   index	   cases	   within	   linkage	  intervals	   for	   different	   neurodevelopmental	  monogenic	  disorders	  	  Affected	  sib-­‐pairs	   Use	   of	   FEVA	   to	   analyze	   CHD	   in	   affected	   sib-­‐pairs	   from	   eight	   non-­‐consanguineous	   and	   two	  consanguineous	  families.	  Affected	  parent-­‐child	   Using	   FEVA	   to	   analyze	   CHD	   in	   three	   affected	  parent-­‐child	  pairs.	  Example	  of	  affected	  trios	  combined	  with	  candidate	  gene	  screening	  	   Use	   of	   FEVA	   to	   analyze	   1,080	   trios	   from	  Deciphering	   Developmental	   Disorders	   (DDD)	  project	  trios	  and	  screen	  1,142	  candidate	  genes.	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2.2 Methods	  
2.2.1 Samples	  and	  phenotypes	  	  Table	  2-­‐3	  summarises	  the	  different	  sample	  collections	  that	  I	  analyzed	  to	  evaluate	  the	   utility	   of	   different	   study	   designs.	   These	   sample	   collections	   were	   accessed	  through	   collaboration	   with	   various	   researchers	   and	   clinicians	   from	   the	   UK,	  Europe	  and	  Canada.	  All	  samples	  were	  collected	  from	  the	  families	  after	  obtaining	  informed	   consents	   and	   approved	   by	   the	   Ethical	   Review	   Boards	   of	   their	  respective	   organizations.	   Not	   all	   of	   the	   analyses	   of	   these	   sample	   sets	   are	  described	  in	  detail	  in	  this	  thesis.	  	  Table	  2-­‐3	  Samples	  and	  family-­‐based	  study	  designs	  included	  in	  this	  thesis.	  	  *	  	  Sample	  cohorts	  discussed	  in	  this	  chapter.	  GO-­‐CHD:	  Genetic	  Origins	  of	  Congenital	  Heart	  Disease	  Study,	  DDD:	  Deciphering	  Developmental	  Disorders	  project,	  AVSD:	  atrioventricular	  septal	  defects.	  TOF:	  tetralogy	  of	  Fallot.	  
Design	   Targeted	  Region	   Cohort	   Origin	  
Consangui






Whole	  exome	   GO-­‐CHD	   UK	   No	   Various	  CHD	   110	  Toronto	   Canada	   No	   AVSD	   78	  Linkage	  region	   Amish*	   USA	   No	   Various	  Neurodevelopmental	   4	  
Trios	  
Whole	  exome	  








Whole	  exome	   GO-­‐CHD*	   UK	   No	   Various	  CHD	   3	  
2.2	  Methods	  	  
	   60	  
2.2.2 DNA	  preparation	  and	  Quality	  Control	  Our	  collaborators	  extracted	  the	  DNA	  from	  the	  patients’	  blood	  and	  /	  or	  saliva	  and	  sent	   the	   samples	   to	   the	   Sanger	   Institute	   for	   quality	   control	   before	   they	   were	  submitted	  for	  sequencing.	  The	  DNA	  sample	  quality	  control	  included	  three	  tests.	  The	   first	   was	   to	   determine	   the	   amount	   and	   concentration	   of	   DNA,	   which	  was	  analyzed	  by	   gel	   or	   picogram.	  The	   second	   test	   detected	   the	   sample’s	   gender	  by	  genotyping	  SNPs	  on	  the	  sex	  chromosomes	  and	  compared	  it	  to	  the	  supplier	  sheet	  in	  order	  to	  detect	  any	  potential	  gender	  mismatches.	  The	  third	  test	  was	  to	  check	  for	  the	  possibility	  of	  sample	  contamination	  or	  swapping	  by	  genotyping	  another	  30	  SNPs.	   	  The	  genotyping	  was	  done	  using	  Sequenom	  platform	  and	  any	  sample,	  which	   failed	  one	  of	   these	   tests,	  was	   flagged	   for	   replacement	  or	   exclusion.	   	  The	  Sample	   Logistic	   Team	   at	   the	   Sanger	   Institute	   performed	   these	   quality	   control	  tests.	  	  
2.2.3 Target	  capturing	  and	  sequencing	  	  DNA	  (1-­‐3μg)	  was	  sheared	  to	  100-­‐400	  bp	  using	  a	  Covaris	  E210	  or	  LE220	  (Covaris,	  Woburn,	   MA,	   USA).	   Sheared	   DNA	   was	   subjected	   to	   Illumina	   paired-­‐end	   DNA	  library	   preparation	   and	   enriched	   for	   target	   sequences	   (Agilent	   Technologies;	  Human	   All	   Exon	   50	   Mb	   -­‐	   ELID	   S02972011)	   according	   to	   manufacturer's	  recommendations	   (Agilent	   Technologies;	   SureSelectXT	   Automated	   Target	  Enrichment	  for	  Illumina	  Paired-­‐End	  Multiplexed	  Sequencing).	  Enriched	  libraries	  were	  sequenced	  using	  the	  HiSeq	  platform	  (Illumina)	  as	  paired-­‐end	  75	  base	  reads	  according	  to	  manufacturer's	  protocol.	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2.3 Results	  
2.3.1 Assessing	  variant	  calling	  pipelines	  	  
2.3.1.1 Genome	  Analysis	  Production	  Informatics	  (GAPI)	  and	  UK10K	  pipelines	  	  	  There	   are	   several	   pipelines	   deployed	   at	   the	   Wellcome	   Trust	   Sanger	   Institute	  (WTSI)	  to	  call	  variants	  from	  human	  whole	  genome	  and	  /	  or	  whole	  exome	  data.	  	  	  The	   majority	   of	   samples	   analyzed	   in	   this	   thesis	   were	   processed	   through	   the	  Genome	   Analysis	   Production	   Informatics	   (GAPI)	   pipeline	   (managed	   by	   Carol	  Scott	   et	  al.)	   except	   125	   samples	   that	   formed	   part	   of	   the	   UK10K	  RARE	   project,	  which	   were	   processed	   through	   the	   UK10K	   pipeline	   (managed	   by	   Shane	  McCarthy	  et	  al.)	  [264].	  Both	  pipelines	  are	  used	  to	  call	  single	  nucleotide	  variants	  (SNVs)	   as	   well	   as	   insertion/deletion	   variants	   (INDELs).	   The	   GAPI	   pipeline	  provided	  single-­‐sample	  calling	  only	  while	  UK10K	  pipeline	  provided	  both	  single	  and	  multi-­‐sample	   calling.	  Although,	   the	   latter	   has	   some	  potential	   advantages,	   I	  decided	  to	  use	  single-­‐sample	  calling	  only	  in	  order	  to	  be	  able	  to	  compare	  variants	  from	  both	  pipelines.	  	  	  However,	  differences	  between	   these	  pipelines	   led	   to	  variability	   in	   the	   type	  and	  numbers	   of	   variants	   (Table	   2-­‐4,	   Table	   2-­‐5	   and	   Figure	   2-­‐5).	   Data	   that	   were	  processed	  through	  the	  GAPI	  pipeline	  tend	  to	  have	  a	  larger	  number	  of	  SNVs	  and	  INDELs	  compared	  to	  UK10K	  pipeline.	  GAPI	  sequence	  data	  had	  60%	  more	  SNVs	  compared	  with	  UK10K	  data	  although	  most	  of	  these	  differences	  can	  be	  attributed	  to	  non-­‐coding	  variants	  which	  include	  intronic,	  intragenic,	  downstream,	  upstream	  and	  variants	  in	  untranslated	  regions	  UTRs).	  	  	  To	  see	  if	  using	  different	  filters	  and	  thresholds	  in	  Table	  2-­‐5	  caused	  the	  difference	  seen	   in	   SNVs	   counts	   between	   the	   two	   pipelines,	   I	   applied	   UK10K’s	   filters	   on	  samples	  from	  the	  GAPI	  pipeline.	  First,	  I	  created	  a	  new	  set	  of	  samples	  called	  GAPI-­‐II	  by	  merging	  variants	  from	  GATK	  and	  Samtools	  only	  and	  excluding	  Dindel	  calls	  since	  it	  is	  not	  part	  of	  the	  UK10K	  pipeline.	  	  This	  set	  of	  samples	  showed	  a	  similar	  number	  of	  coding	  and	  non-­‐coding	  variants	  between	  both	  pipelines	  (Figure	  2-­‐4)	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except	  for	  loss-­‐of-­‐function	  variants	  (LOF)	  where	  the	  UK10K	  pipeline	  has	  almost	  double	   the	   number	   of	   LOF	   variants	   compared	   with	   GAPI	   or	   GAPI-­‐II	   (t	   test,	   P	  value	  <	  2.2	  ×	  10-­‐16).	  	  A	  difference	  in	  a	  caller	  version	  and	  its	  underlying	  statistical	  model	   is	   likely	   to	   cause	   this	   variation.	   This	   is	   more	   readily	   observed	   in	   LOF	  counts	  since	  they	  are	  fewer	  than	  missense	  variants	  and	  have	  a	  lower	  number	  of	  true	  variants	  and	  so	  are	  more	  sensitive	  to	  calling	  errors.	  	  On	   the	   other	   hand,	   INDELs	   show	   larger	   differences	   between	   GAPI	   and	  UK10K	  pipelines	  (Figure	  2-­‐5).	   	  GAPI	  calls	  almost	  two	  to	  three	  times	  more	  INDELs	  than	  UK10K	   or	   GAPI-­‐II	   (Figure	   2-­‐5-­‐A).	   This	   is	   true	   regardless	   of	   the	   location	   of	   the	  indel	  with	  respect	  to	  coding	  sequences	  (Figure	  2-­‐5	  B,	  C	  and	  D).	  	  One	  explanation	  for	  this	  observation	  would	  be	  the	  use	  of	  an	  additional	  caller	  specifically	  designed	  to	   call	   INDELs,	   called	   as	   Dindel,	   in	   the	   GAPI	   pipeline	   but	   not	   in	   the	   UK10K	  pipeline.	   Dindel	   is	   a	   dedicated	   caller	   for	   INDELs	   that	   uses	   a	   probabilistic	  realignment	  model	   to	   account	   for	   base-­‐calling	   errors,	  mapping	   errors,	   and	   for	  increased	   sequencing	   error	   INDEL	   rates	   in	   long	   homopolymer	   runs	   [158].	  	  Dindel’s	   superior	  performance	   comes	   at	   a	  price	  of	   high	   computation	  demands,	  and	   the	   same	   underlying	   model	   has	   been	   incorporated	   into	   later	   versions	   of	  SAMtools,	  which	  is	  why	  the	  UK10K	  informatics	  team	  has	  refrained	  from	  using	  it	  on	  large	  numbers	  of	  samples.	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Table	  2-­‐4	  Similarities	  and	  differences	  between	  the	  components	  of	  Genome	  Analysis	  Production	  Informatics	  (GAPI)	  pipeline	  and	  the	  UK10K	  pipeline.	  Multiple	  factors	  are	  likely	  contribute	  to	  the	  differences	  in	  the	  number	  of	  variants	  generated	  by	  GAPI	  compared	  with	  UK10K	  pipeline	  such	  as	  the	  number	  of	  used	   callers,	   different	   software	  versions	  which	  usually	   reflect	   subtle	   changes	   in	  the	  underlying	  statistical	  models,	  filters	  and	  thresholds	  and	  how	  the	  output	  from	  different	  callers	  is	  merged	  (i.e.	  the	  order	  of	  callers	  from	  the	  most	  to	  least	  preferred,	  see	  section	  2.3.2.2	  for	  details)	  
Step	   Goal	  /	  Description	  	   GAPI	   UK10K	  
Reference	  genome	   Which	  version	  of	  the	  human	  reference	  genome	  used	  	   GRCh37	  (hs37d3)	  1000	  genome	  phase	  II	  reference	  
GRh37	  (human_g1k_b37)	  1000	  Genomes	  Phase	  1	  reference	  Align	  sequence	  reads	  to	  reference	  genome	   Generate	  SAM/BAM	  files	   BWA	  (v0.5.9-­‐r16)	   BWA	  (v0.5.9-­‐r16)	  Mark	  duplicates	   To	  mitigate	  the	  effects	  of	  PCR	  amplification	  bias	  introduced	  during	  library	  construction.	   Picard	  tools	  (v1.46)	   Picard	  tools	  (v1.46)	  Realignment	  around	  indels	   Enhance	  variant	  calling	   GATK	  (v1.4-­‐15)	   GATK	  (v1.1-­‐5-­‐g6f432841)	  Base	  quality	  score	  recalibration	   Recalibrate	  base	  quality	  scores	  of	  reads	  according	  to	  the	  base	  features	  (e.g.,	  reported	  quality	  score,	  the	  position	  within	  the	  read)	   GATK	  (v1.4-­‐15)	   GATK	  (v1.1-­‐5-­‐g6f43284)	  Calling	  target	  region	   Calling	  variants	  is	  limited	  to	  the	  coding	  regions	  plus	  variable	  flanking	  region	   Exon	  bait	  regions	  plus	  or	  minus	  a	  100bp	  window	   Exon	  bait	  regions	  plus	  or	  minus	  a	  100bp	  window	  SNV	  calling	   Single	  nucleotide	  variants	  calling	  programs	  	   Samtools	  (v0.1.16)	  GATK	  (v1.0.15777)	   Samtools	  (v0.1.17)	  GATK	  (v1.3-­‐21)	  INDEL	  calling	   Insertion	  and	  deletion	  variants	  calling	  programs	   Samtools	  (v0.1.16)	  Dindel	  (v1.01)	   Samtools	  (v0.1.17)	  GATK	  (v1.3-­‐21)	  Variant	  predicted	  effect	   The	  effect	  of	  variant	  on	  the	  protein	  is	  predicted	  by	  VEP	  	   VEP	  2.2	  to	  2.4	   VEP	  2.6	  to	  2.8	  Caller	  merging	  	   The	  order	  of	  which	  variants	  called	  by	  different	  callers	  are	  merged	   Dindel	  >	  GATK	  	  >	  Samtools	   GATK	  >	  Samtools	  General	  filters	   Filters	  applied	  during	  variant	  calling	  	   See	  	  Table	  2-­‐5	  for	  details	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  Figure	  2-­‐3	  A	  workflow	  diagram	  to	  describe	  how	  I	  generated	  VCF	  files	   for	  GAPI-­‐II	  set.	  The	  main	  goal	  is	  to	  use	  files	  from	  GAPI	  pipeline	  and	  apply	  similar	  workflow	  to	  UK10K	  and	  see	  if	  this	  would	  be	  enough	  to	  explain	  the	  differences	  between	  the	  pipelines.	  	  Each	   sample	   from	   the	   original	   GAPI	   pipeline	   has	   three	   VCF	   files	   of	   variants	   called	   by	   GATK,	  Samtools	   and	  Dindel.	   I	  merged	  VCF	   files	   from	  GATK	  and	  Samtools	  but	  not	   from	  Dindel.	  Next,	   I	  applied	  the	  same	  filters	  used	  by	  UK10K	  to	  exclude	  low	  quality	  variants	  (filters	  were	  supplied	  by	  Shane	  McCarthy).	  A	  list	  of	  UK10K	  filters	  is	  available	  in	  Table	  2-­‐5.	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Table	  2-­‐5	  Filters	  and	  thresholds	  applied	  on	  variants	  from	  UK10K	  and	  GAPI	  pipelines.	  	  
Variant	  
callers	   Filters	   Variant	  type	  
Pipelines	  
GAPI	   UK10K	  
Samtools	  
Depth	  at	  locus	  (DP)	   SNVs	   4	  <	  DP	  and	  DP	  >	  1200	   4	  <	  DP	  and	  DP	  >	  2000	  INDELs	   4	  <	  DP	  and	  DP	  >	  1200	   4	  <	  DP	  and	  DP	  >	  2000	  Mapping	  quality	  (MQ)	   SNVs	   MQ	  <=10	   MQ	  <=	  25	  INDELs	   MQ	  <=	  10	   MQ	  <=	  25	  Genotype	  quality	  (GQ)	   SNVs	   NA	   GQ	  <=	  25	  INDELs	   NA	   GQ	  <=	  60	  Variant	  quality	  (QUAL)	   SNVs	   NA	   QUAL	  <=	  30	  INDELs	   NA	   QUAL	  <=	  60	  StrandBiasPval	   SNVs	   StrandBiasPval	  <	  0.0001	   NA	  INDELs	   StrandBiasPval	  <	  0.0001	   NA	  BaseqBiasPval	  	   SNVs	   BaseqBiasPval	  <	  1e-­‐100	  	   NA	  INDELs	   BaseqBiasPval	  <	  1e-­‐100	  	   NA	  MapqBiasPval	   SNVs	   MapqBiasPval	  <	  0	   NA	  INDELs	   MapqBiasPval	  <	  0	   NA	  EndDistBiasPval	   SNVs	   EndDistBiasPval	  <	  0.0001	   NA	  INDELs	   EndDistBiasPval	  <	  0.0001	   NA	  MinbpfromGap	   SNVs	   MinbpfromGap	  <	  10	   NA	  INDELs	   MinbpfromGap	  <	  10	   NA	  
GATK	  
Variant	  quality	  (QUAL)	   SNVs	   QUAL	  <	  30	   QUAL	  <	  30	  INDELs	   NA	   NA	  Quality	  by	  Depth	  (QD)	   SNVs	   QD	  <	  5.0	   QD	  <	  5	  INDELs	   NA	   QD	  <	  2	  Homopolymer	  run	  length	  (Hrun)	   SNVs	   HRun	  >	  5	   Hrun	  >	  5	  INDELs	   NA	   NA	  Strand	  bias	  (SB)	   SNVs	   SB	  >	  10	   SB	  >	  -­‐0.1	  INDELs	   NA	   NA	  	  Fishers	  p-­‐value	  (FS)	   SNVs	   NA	   FS	  >	  60	  INDELs	   NA	   FS	  >	  200	  ReadPosRankSum	   SNVs	   NA	   NA	  INDELs	   NA	   <	  -­‐20	  InbreedingCoeff	   SNVs	   NA	   NA	  INDELs	   NA	   <	  -­‐0.8	  InDel	   SNVs	   Filtered	  if	  site	  covered	  by	  known	  indel	  mask	  file	   Filtered	  if	  site	  covered	  by	  known	  indel	  mask	  file	  INDELs	   NA	   NA	  LowQual	   SNVs	   Repeat	  of	  QUAL	  <	  30	  (applied	  at	  calling)	   NA	  INDELs	   NA	   NA	  SnpCluster	   SNVs	   Filtered	  if	  3	  SNPs	  within	  a	  10bp	  window	   NA	  INDELs	   NA	   NA	  Depth	  at	  locus	  (DP)	   SNVs	   4	  <	  DP	  and	  DP	  >	  1200	   NA	  INDELs	   4	  <	  DP	  and	  DP	  >	  1200	   NA	  Hard	  to	  validate	   SNVs	   MQ0	  >=	  4	  and	  (MQ0/(1.0*DP))	   MQ0	  >=	  4	  and	  (MQ0/(1.0*DP))	  INDELs	   NA	   NA	  
Dindel	  
Homopolymer	  run	  length	  (hp10)	   INDELs	   HRun	  >	  10	   NA	  Variant	  quality	  (q20)	   INDELs	   QUAL	  <	  20	   NA	  Non-­‐reference	  allele	  (fr0)	   INDELs	   Not	  covered	  by	  at	  least	  one	  read	  on	  both	  strands	   NA	  Multiple	  indels	  in	  the	  same	  window	  (wv)	   INDELs	   Other	  indel	  in	  window	  had	  higher	  likelihood	   NA	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(F) SNVs (rare coding) Het/Hom ratio
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  Figure	   2-­‐5	   Differences	   of	   insertion-­‐deletion	   variant	   	   (INDELs)	   counts	   between	   GAPI,	   UK10K	  pipeline	  and	  GAPI_II	  which	  are	  the	  same	  sample	  in	  GAPI	  but	  subjected	  to	  UK10K’s	  filters).	  	  	  	  






















































(B) INDELs (common coding) MAF > 1%
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subtypes	  (about	  a	  quarter	  of	  these	  samples	  are	  from	  consanguineous	  families	  of	  a	   Pakistani	   origin).	   	   I	   found	   the	   variant	   counts	  were	   consistent	   between	   these	  cohorts	   even	   though	   they	  were	  generated	  at	  different	   times	  and	  with	  different	  versions	  of	  the	  GAPI	  pipeline.	  	  Small	  variations	  may	  occur	  as	  a	  result	  of	  systemic	  differences	  caused	  by	  the	  depth	  of	  the	  sequencing,	  or	  the	  population	  ancestry	  of	  the	   samples	   (e.g.	   samples	   with	   African	   ancestry	   are	   expected	   to	   have	   more	  variants	  than	  non-­‐African	  samples).	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(F) SNVs (rare coding) Het/Hom ratio
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  Figure	   2-­‐7	   Differences	   of	   insertion-­‐deletion	   variant	   (INDELs)	   counts	   between	   GAPI	   studies.	  	  CHDT:	   Congenital	   heart	   defect	   samples	   from	   Toronto	   (discussed	   in	   chapter	   4).	   CHDUK:	  Congenital	  heart	  defect	  samples	  from	  UK	  (discussed	  in	  application	  section	  in	  this	  chapter),	  TOF	  (Tetralogy	  of	  Fallot	  samples	  discussed	  in	  chapter	  3).	  






















































(B) INDELs (common coding) MAF > 1%
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2.3.1.3 Implementing	  a	  de	  novo	  variant	  calling	  pipeline	  	  Initially,	  I	  tried	  to	  identify	  potential	  de	  novo	  variants	  based	  on	  the	  variants	  called	  by	  either	  GAPI	  or	  UK10K	  pipelines	  in	  the	  child	  and	  not	  in	  parents.	  However,	  this	  approach	  yields	  a	   large	  number	  of	   candidate	  de	  novo	   variants	  per	   trio.	  A	  more	  efficient	  approach	  is	  to	  discover	  potential	  de	  novo	  variants	  from	  the	  child	  and	  his	  parents	   in	   a	   unified	   statistical	   framework.	   	   I	   designed	   and	   implemented	   a	  pipeline	   to	   call,	   filter,	   annotate	   and	   visualize	   de	  novo	   variants	   from	   trio-­‐based	  studies	  based	  on	  DenovoGear	  program	  [265,	  266].	  This	  software	  was	  developed	  by	   Don	   Conrad	   and	   adopts	   a	   Bayesian	   approach	   to	   calculate	   the	   posterior	  probability	  of	  a	  de	  novo	  mutation	  at	  a	  single	  locus	  using	  the	  joint	  likelihood	  of	  the	  read-­‐level	  data	   for	  all	   three	   trio	  members.	  DenovoGear	  outputs	  ~170	  plausible	  
de	  novo	  variants	  (with	  a	  posterior	  probability	  of	  greater	  than	  0.001)	  per	  trio	  on	  average.	  However,	  most	  of	   these	  candidate	  variants	  are	   false	  positive	  since	   the	  expected	  number	  of	  de	  novo	  coding	  variants	  is	  ~1	  according	  to	  published	  studies	  [190,	  267-­‐271].	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In	   order	   to	   keep	   the	   number	   of	   false	   positive	   variants	   as	   small	   as	   possible,	   I	  applied	   five	   filters	   to	   exclude:	   (i)	   variants	   in	   tandem	   repeat	   or	   segmental	  duplication	   regions,	   (ii)	   common	  variants	  with	  minor	   allele	   frequency	  >	  1%	   in	  the	  1000	  genomes	  [155],	  NHLBI-­‐ESP	  exome	  project	  [199]	  and	  the	  UK10K	  Twins	  cohort	   [264],	   	   (iii)	   when	   >	   10%	   of	   the	   reads	   in	   either	   parent	   support	   the	  alternate	  allele	  (i.e.	  the	  variant	  is	  more	  likely	  to	  be	  inherited	  from	  a	  parent),	  (iv)	  variants	  not	  called	  by	  an	  independent	  caller	  such	  as	  SamTools,	  Dindel	  or	  GATK,	  and	  (v)	  variants	  predicted	  	  to	  be	  non-­‐coding	  by	  the	  VEP	  tool	  [170].	  	  Collectively,	  these	  filters	  effectively	  remove	  ~98.8%	  of	  the	  original	  candidate	  de	  novo	  variants	  (leaving	  ~1.8	  coding	  plausible	  de	  novo	  candidate	  per	  exome).	  	  	  	  This	  pipeline	  was	  used	  to	  automate	  several	  tasks	  designed	  to	  obtain	  high	  quality	  sets	  of	  candidate	  de	  novo	  variants	  from	  trios.	  This	  first	  step	  is	  calling	  candidate	  
de	  novo	  variants	  from	  whole	  genome	  or	  whole	  exome	  data	  from	  human	  or	  mouse	  trio	  samples,	  followed	  by	  applying	  various	  filters	  to	  improve	  the	  specificity	  of	  the	  calls.	  	  The	  pipeline	  was	  designed	  in	  a	  modular	  fashion	  where	  each	  step	  generates	  intermediate	  files	  that	  are	  used	  as	  input	  for	  subsequent	  steps	  (steps	  are	  listed	  in	  Figure	  2-­‐9).	  This	  design	  allows	  the	  end	  user	  to	  change	  the	  pipeline	  by	  modifying	  steps	   and	   files	   or	   add	  new	   steps	   in	  order	   to	   customize	   the	  pipeline	   to	   suit	   the	  need	  of	  different	  studies.	  	  One	  of	  the	  challenges	  faced	  by	  this	  pipeline	  is	  the	  run	  time	  per	  trio	  (~12	  hours	  for	  whole	  exome	  data	  and	  up	  to	  36	  hours	  for	  whole	  genome	  data).	  To	  make	  the	  pipeline	  run	  faster,	  especially	  for	  large-­‐scale	  project,	  I	  modified	  the	  code	  (which	  I	  wrote	   in	  Python	  programming	   language)	   to	  split	  sequence	  data	   in	  each	  sample	  into	   24	   segments	   (by	   the	   chromosome)	   and	   run	   them	   in	   parallel.	   This	   has	  shortened	  the	  run	  time	  to	  2-­‐3	  hours	  for	  whole	  exome	  data	  and	  10-­‐12	  hours	  for	  whole	   genome	   data.	   Moreover,	   another	   layer	   of	   parallelism	   is	   achievable	   by	  running	  multiple	  trios	  at	  the	  same	  time,	  which	  is	  suitable	  for	  large-­‐scale	  projects	  such	  as	  the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project	  with	  thousands	  of	  trios.	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I	  used	  this	  pipeline	  to	  call	  de	  novo	  variants	  in	  238	  trios	  affected	  with	  Tetralogy	  of	  Fallot	   in	   the	   third	  chapter	  and	   in	  13	   trios	  with	  atrioventricular	  septal	  defect	   in	  the	  fourth	  chapter.	  	  Moreover,	  this	  pipeline	  has	  been	  used	  successfully	  in	  several	  whole	   genome	   sequencing	   projects	   in	   human	   and	   mouse	   pedigrees	   that	   are	  investigating	  the	  factors	  influencing	  rates	  of	  germline	  mutation.	  	  
	  Figure	  2-­‐9	  The	  workflow	  of	  the	  DenovoGear	  pipeline.	  	  PED:	   pedigree	   files.	   BCF	   are	   binary	   files	   of	   VCF	   (variant	   call	   format)	   that	   are	   generated	   by	  Samtools	   mpileup	   with	   genotype	   likelihoods	   required	   by	   DenovoGear	   [272].	   DNMs:	   de	   novo	  mutations.	  VEP:	  variant	  effect	  predictor	  [170].	  1KG-­‐MAF:	  1000	  genomes	  minor	  allele	  frequency.	  	  GERP:	  Genomic	  Evolutionary	  Rate	  Profiling	  scores	  [164].	  HI:	  haploinsufficiency	  scores	  [273].	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2.3.2 Minimizing	  the	  rate	  of	  false	  positive	  variants	  
2.3.2.1 Variant-­‐based	  filters	  	  At	  the	  beginning	  of	  my	  PhD	  studies,	  it	  was	  not	  clear	  what	  were	  the	  best	  practices	  I	   should	   use	   to	   improve	   the	   sensitivity	   and	   specificity	   of	   variant	   calling	   from	  exome	  data.	  To	  investigate	  this	  aspect	  of	  data	  analysis,	  I	  tested	  different	  filters	  in	  order	   to	   determine	   the	   best	   callset	   possible	   from	   CHD	   samples	   called	   by	   the	  UK10K	  pipeline.	   These	   callsets	   include	   raw	  unfiltered	   variants	   called	   by	  GATK	  (G),	  Samtools	  (S),	  or	  both	  callers	  (GS).	  In	  this	  analysis,	  I	  focused	  mainly	  on	  SNVs	  since	   they	  are	   the	  most	  abundant	  variants	  and	   represent	  a	   large	  proportion	  of	  the	   known	   pathogenic	   variants	   [274].	   More	   importantly,	   there	   are	   many	   high	  quality	   training	   SNVs	   data	   sets	   available	   to	   improve	   variant	   quality	   (e.g.	  HapMap).	  	  On	  the	  other	  hand,	  indels	  were,	  and	  still	  are,	  more	  difficult	  to	  call	  and	  tend	  to	  have	  a	  higher	  false	  positive	  rate	  [155].	  	  	  SNVs	  are	  thought	  to	  be	  among	  the	  easiest	  variant	  classes	  to	  call	   from	  NGS	  data	  but	  nonetheless	  sequencing	  errors	  can	  generate	   false	  positive	  calls.	  Sequencing	  error	  rates	  depend	  on	  factors	  such	  as	  the	  context	  of	  the	  DNA	  sequence,	  depth	  of	  sequencing,	   and	   the	   type	   of	   substituted	   bases	   among	   other	   factors	   [143].	   To	  control	   for	   these	   biases	   in	   the	   exome	   NGS	   data,	   I	   examined	   the	   relationship	  between	   strand	   bias	   (SB),	   quality	   by	   depth	   (QD),	   genotype	   quality	   (GQ)	   and	  variant	  quality	  (QUAL)	  with	  transition/transversion	  ratio	  (Ts/Tv).	  This	  ratio	  has	  been	   used	   by	   different	   groups	   in	   the	   1000	   genomes	   consortium	   as	   a	   quality	  control	   test	   and	   typically	   ranged	   between	   2.9-­‐3.3	   in	   coding	   regions	   based	   on	  sequence	  data	  from	  different	  NGS	  platforms.	  I	  used	  the	  Ts/Tv	  ratio	  as	  the	  truth	  measurement	  to	  determine	  the	  proper	  thresholds	  values	  for	  each	  one	  of	  the	  four	  filters.	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Variant	  quality	  (QUAL)	  	  The	   QUAL	   parameter	   is	   the	   phred-­‐scaled	   quality	   score	   probability	   of	   the	  alternative	   allele	   at	   a	   given	   site	   in	   sequencing	   data	   being	  wrong.	   This	   scale	   is	  calculated	  as:	   QUAL	  =	  -­‐10	  *	  log	  (1-­‐p)	  	  where	   p	   is	   a	   base-­‐calling	   error	   probability.	   A	   value	   of	   10	   indicates	   one	   in	   10	  chance	  of	  error,	  while	  a	  value	  of	  100	  indicates	  one	  in	  100	  chance.	  Higher	  QUAL	  values	  indicate	  higher	  confident	  in	  the	  variant	  calls.	  I	  plotted	  the	  QUAL	  scores	  for	  eight	  different	  callsets	  based	  on	   filtered	  and	  unfiltered	  variants	   from	  Samtools,	  GATK	  or	  both	  against	  the	  Ts/Tv	  ratio	  (Figure	  2-­‐10).	   	  The	  Ts/Tv	  ratio	  was	  at	  its	  highest	  when	  variants	  are	  called	  by	  both	  GATK	  and	  Samtools	  and	  pass	  the	  callers	  internal	  filters	  (Figure	  2-­‐10,	  dashed	  red	  line)	  and	  dropped	  slightly	  below	  3	  when	  the	  QUAL	  was	  <	  30,	  which	  I	  used	  as	  the	  minimum	  accepted	  threshold.	  	  
	  Figure	   2-­‐10	   The	   relationship	   between	   variant	   calling	   quality	   (QUAL)	   and	   the	   transition/	  transversion	   ration	   (Ts/Tv)	   of	   coding	   SNVs.	   The	   plot	   shows	   eight	   different	   callsets	   based	   on	  variants	  called	  by	  a	  single	  caller	  or	  two	  callers	  and	  whether	  the	   internal	   filters	  of	  a	  caller	  were	  applied	  (filtered)	  or	  not	  (unfiltered).	  These	  internal	  filters	  are	  usually	  part	  of	  the	  pipeline	  itself.	  	  (S)	  is	  a	  variant	  callset	  called	  by	  Samtools	  alone,	  (G)	  variants	  called	  by	  GATK	  alone,	  (GS)	  variants	  called	  by	  both	  Samtools	  and	  GATK,	  and	  (All)	  is	  a	  callset	  composed	  of	  variants	  	  from	  the	  previous	  three	  callsets.	  The	  GS	  filtered	  callset	  (dashed	  red	  line)	  is	  the	  only	  callset	  that	  shows	  a	  Ts/Tv	  ratio	  close	  to	  the	  expected	  range	  (2.9-­‐3.3).	  However,	  since	  the	  Ts/Tv	  ratio	  of	  this	  callset	  drops	  below	  QUAL	  of	  30,	   I	   used	   this	   value	   as	   the	  minimum	   threshold	  of	   high	  quality	   variants.	  Any	  variants	  with	  QUAL	  <	  30	  were	  excluded	  from	  the	  downstream	  analyses.	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Quality	  by	  depth	  (QD)	  	  The	  QD	  is	  a	  simple	  statistic	   to	  quantify	   the	  variant	  confidence	  given	  as	   ‘variant	  confidence’	  (from	  the	  QUAL	  field)	  divided	  by	  	  ‘unfiltered	  depth	  of	  non-­‐reference	  samples’	  where	   low	  QD	  scores	  are	   indicative	  of	   false	  positive	  calls	   [275].	  QD	   is	  only	  available	   for	  variants	   called	  by	  GATK	  only	  and	   thus	   I	  was	  not	  able	   to	   test	  variants	  called	  by	  Samtools	  (Figure	  2-­‐11).	  Similar	  to	  the	  QUAL	  metric	  above,	  the	  variant	  callset	  closest	  to	  the	  expected	  Ts/Tv	  ratio	  is	  the	  one	  called	  by	  both	  GATK	  and	  Samtools	  and	  has	  passed	   their	   internal	   filters	   (dashed	  red	   line).	  Unfiltered	  variants	  with	  QD	  <	  5	  has	  significantly	  lower	  Ts/Tv	  ratio	  below	  2.0,	  which	  is	  the	  minimum	  accepted	  threshold	  I	  chose	  for	  QD	  (Figure	  2-­‐11).	  	  
	  Figure	   2-­‐11	   The	   relationship	   between	   quality	   by	   depth	   (QD)	   and	   the	   transition/	   transversion	  ration	  (Ts/Tv)	  of	  coding	  SNVs.	  	  (A)	  I	  plotted	  QD	  values	  from	  eight	  different	  callsets	  as	  described	  in	   the	   previous	   figure	   (Figure	   2-­‐10).	   QD	   values	   are	   available	   for	   GATK	   variants,	   thus	   variants	  called	   by	   Samtools	   alone	   are	   not	   shown.	   	   The	   GS	   filtered	   callset	   (dashed	   red	   line)	   the	   closest	  Ts/Tv	  ratio	  to	  the	  expected	  range	  (2.9-­‐3.1)	  is	  and	  was	  consentient	  along	  QD	  values	  on	  the	  X	  axis.	  (B)	   To	   choose	   the	   appropriate	  minimum	  QD	   threshold,	   I	   plotted	   the	  QD	   values	   of	   all	   variants,	  regardless	  of	   the	   caller,	   from	  unfiltered	   callset	   (All	   unfiltered,	   black	  dashed	   line	   in	  plot	  A)	   and	  restricted	  the	  QD	  to	  values	  between	  0-­‐15.	  This	  shows	  variants	  with	  QD	  <	  5	  are	  enriched	  for	  low	  quality	  variants	  (i.e.	  did	  not	  pass	  the	  internal	  filters).	  	  	  
	  
Strand	  bias	  (SB)	  	  The	  third	  filter	  I	  assessed	  was	  the	  strand	  bias	  (SB)	  metric,	  which	  quantifies	  the	  evidence	  of	  a	  variant	  being	  seen	  on	  only	  the	  forward	  or	  only	  the	  reverse	  strand	  in	  the	  sequencing	  reads.	  Higher	  SB	  values	  >	  0	  denote	  significant	  strand	  bias	  and	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are	  associated	  with	  lower	  values	  of	  Ts/Tv	  ratio,	  therefore	  they	  are	  more	  likely	  to	  indicate	  false	  positive	  calls	  (Figure	  2-­‐12).	  	  
	  Figure	  2-­‐12	  The	   relationship	  between	   strand	  bias	   (SB)	   and	   the	   transition/	   transversion	   ration	  (Ts/Tv)	   of	   coding	   SNVs.	   	   I	   plotted	   SB	   values	   from	   eight	   different	   callsets	   as	   described	   in	   the	  previous	  figure	  (Figure	  2-­‐10).	  At	  the	  time,	  SB	  values	  were	  available	  for	  GATK	  variants	  only	  and	  thus	   variants	   called	   by	   Samtools	   are	   not	   shown.	   	   The	   callset	   with	   closet	   Ts/Tv	   ratio	   to	   the	  expected	  range	  (2.9-­‐3.1)	  is	  the	  GS	  filtered	  callset	  (dashed	  red	  line)	  and	  was	  consentient	  along	  SB	  values	  (-­‐0.01	  to	  -­‐200).	  The	  Ts/Tv	  ratio	  values	  drop	  dramatically	  when	  SB	  >	  0	  (solid	  lines).	  	  	  
Genotype	  quality	  (GQ)	  	  Finally,	   the	  GQ	   is	  another	  phred-­‐scaled	  score	   that	   represents	   the	  confidence	  of	  the	   true	   genotype	   at	   a	   certain	   locus.	   In	   a	   diploid	   genome,	   the	   homozygous	  reference,	  heterozygous	  ,	  and	  homozygous	  non-­‐reference	  genotypes	  are	  denoted	  (‘0/0’	  ,	  ‘0/1’	  and	  ‘1/1’)	  respectively	  in	  the	  variant	  call	  format	  files	  (VCF	  files).	  	  For	  a	  heterozygous	  genotype	  (0/1),	  the	  genotype	  quality	  (GQ)	  is	  calculated	  as	  :	  	  	   	  	  where	  L	  is	  the	  likelihood	  of	  a	  genotype	  given	  the	  NGS	  sequence	  data	  at	  that	  locus.	  Variants	  with	  a	  GQ	  of	  	  <	  30	  tend	  to	  have	  lower	  Ts/Tv	  ration	  (~2.7)	  and	  hence	  I	  used	  this	  as	  the	  minimum	  cutoff	  (Figure	  2-­‐13)	  	  
L(0 /1) / L(0 / 0)
L(0 /1) / L(1 /1)
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  Figure	   2-­‐13	   The	   relationship	   between	   genotype	   quality	   (GQ)	   and	   the	   transition/	   transversion	  ration	  (Ts/Tv)	  of	  coding	  SNVs.	   	   I	  plotted	  GQ	  values	  from	  eight	  different	  callsets	  as	  described	  in	  the	  previous	  figure	  (Figure	  2-­‐10).	  	  The	  callset	  with	  closet	  Ts/Tv	  ratio	  to	  the	  expected	  range	  (2.9-­‐3.1)	  is	  the	  GS	  filtered	  callset	  (dashed	  red	  line)	  when	  GQ	  values	  >	  30.	  	  These	  four	  filters	  where	  used	  at	  the	  early	  stages	  of	  my	  analyses	  of	  UK10K	  data	  to	  improve	  the	  sensitivity	  and	  specificity	  of	  SNVs	  calling.	  It	   is	  important,	  however,	  to	   notice	   that	   choosing	   the	   best	   filters	   with	   highest	   sensitivity	   and	   specificity	  remains	  an	  active	  area	  of	  research.	  As	  the	  developers	  keep	  tuning	  the	  underlying	  statistical	   models	   in	   their	   variant	   calling	   programs,	   these	   filters	   need	   to	   be	  adjusted	   accordingly	   to	   reflect	   the	   current	   best	   practices.	   More	   importantly,	  reviewing	   the	   results	   of	   validation	   experiments	   using	   capillary	   sequencing	  periodically	  is	  essential	  to	  gain	  insights	  about	  the	  performance	  of	  each	  filter.	  	  
2.3.2.2 Merging	  caller	  sets	  and	  caller	  priority	  	  	  In	  order	   to	   increase	  the	  confidence	  of	  variant	  calls,	   the	  GAPI	  pipeline	  used	  two	  independent	  callers	  with	  different	  underlying	  probabilistic	  statistical	  models	  to	  detect	  SNVs	  and	  two	  callers	  for	  INDELs	  [152-­‐154,	  276].	  GATK	  and	  Samtools	  were	  used	  to	  call	  SNVs	  and	  while	  Samtools	  and	  Dindel	  are	  used	  to	  call	  INDELs.	  Since	  Samtools	  are	  used	  to	  call	  both	  SNVs	  and	  indels,	  the	  GAPI	  pipeline	  generates	  three	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files,	  one	  from	  each	  caller	  in	  a	  variant	  call	  format	  (known	  as	  VCF	  files)	  [161],	  per	  sample.	  	  	  Using	   three	   files	   separately	  would	   complicate	   downstream	   analyses	   since	   two	  callers	  do	  not	  agree	  on	  the	  total	  number	  of	  variants,	  genotypes,	  and	  alternative	  alleles.	  For	  example,	  two	  SNV	  callers	  may	  detect	  different	  alternative	  alleles	  at	  a	  given	   locus	   or	   report	   different	   genotypes	   (e.g	   heterozygous	   by	   one	   and	  homozygous	  non-­‐reference	  by	   the	   other).	   To	   overcome	   this	   issue,	   I	   decided	   to	  merge	  the	  three	  VCF	  files	  into	  a	  single	  file	  per	  sample.	  This	  would	  have	  been	  an	  easy	  task	  if	  the	  two	  callers	  agreed	  on	  all	  variants,	  but	  since	  this	  is	  not	  the	  case,	  I	  needed	   to	   decide	   on	  which	   caller	   of	   the	   two,	   generated	   a	  more	   reliable	   set	   of	  variants	  and	  thus	  should	  be	  used	  in	  the	  conflict	  cases.	  	  	  To	   answer	   this	   question,	   I	   generated	   seven	   different	   callsets,	   (Table	   2-­‐6	   first	  column)	  where	  each	  callset	   is	   composed	  of	  at	   least	  one	  group	  of	  variants	   from	  five	  scenarios	  (from	  1	  to	  5).	  These	  five	  scenarios	  are	  based	  on	  the	  variant’s	  status	  according	   to	   the	   two	   callers	   (A	   and	  B).	   A	   variant	   status	   can	   have	   one	   of	   three	  possible	   values:	   (PASS)	  when	   a	   variant	   is	   called	   and	   passes	   the	   caller’s	   filters,	  (Non-­‐PASS)	  when	   a	   variant	   is	   called	   but	   does	   not	   pass	   the	   caller’s	   filters	   (e.g.	  when	  a	  variant	  has	  a	  low	  genotype	  quality),	  and	  third	  status	  (Not	  called)	  is	  when	  a	  variant	   is	  missed	  completely	  by	   the	  caller.	  Based	  on	   the	  variant	   status	   in	   the	  two	   callers,	   there	   are	   five	   scenarios	   and	   each	   callset	   is	   composed	   of	   variants	  from	  one	  or	  more	  scenarios.	  	  	  One	   benefit	   of	   organizing	   variants	   in	   these	   callsets	   is	   to	   test	   various	   levels	   of	  stringency.	  For	  example,	  the	  callset	  named	  ‘Any	  PASS’	  includes	  variants	  from	  all	  five	   scenarios	   regardless	   of	   the	   variant	   status.	   On	   the	   other	   hand,	   the	   callset	  named	  “both	  PASS”	  includes	  only	  variants	  that	  pass	  the	  called	  and	  pass	  the	  filters	  of	  both	  callers.	  These	  different	  levels	  of	  stringency	  allowed	  some	  callsets	  to	  have	  more	   variants	   than	   other	   and	   thus	   reflected	   different	   levels	   sensitivity	   and	  specificity.	   Moreover,	   I	   generated	   these	   callsets	   for	   both	   SNVs	   and	   INDELs	  separately	  (Table	  2-­‐7)	  since	  SNVs	  are	  called	  by	  GATK	  (G)	  and	  Samtools	  (S)	  while	  INDELs	  are	  called	  by	  GATK	  (G)	  and	  Dindel	  (D).	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To	   decide	   which	   callset	   has	   the	   most	   desirable	   properties,	   I	   measured	   three	  different	   ratios.	   First,	   I	   used	   the	   Ts/Tv	   ratio	   for	   the	   SNVs	   the	   expected	   values	  ranges	  between	  (2.9-­‐3.3)	  based	  on	  different	  sequencing	  projects	  at	  the	  Wellcome	  Trust	   Sanger	   Institute	   and	   1000	   genomes	   consortium.	   For	   INDELs,	   I	   used	   the	  coding	   in-­‐frame/frameshift	   (n3/nn3)	   ratio,	  which	  was	   expected	   to	   be	   above	   1	  where	   the	   premise	   is	   coding	   frameshift	   variants	   are	   under	   much	   stronger	  negative	   selection.	   The	   third	   ratio	   I	   used	  was	   the	   rare/common	   ratio	   for	   both	  SNVs	  and	  INDELs	  (rare	  variants	  are	  defined	  as	  MAF	  <	  1%).	  	  	  Table	  2-­‐6	  The	  criteria	  of	  choosing	  different	  variant	  callsets	  in	  order	  to	  determine	  the	  closest	  set	  to	  the	  truth	  measurements	  (Ts/Tv,	  n3/nn3	  and	  rare/common	  ratios).	  	  	  	  
Scenarios	   Scenario	  1	   Scenario	  2	   Scenario	  3	   Scenario	  4	   Scenario	  5	  
Callset	  name	  
Caller	  A:	  	  PASS	   Caller	  A:	  	  PASS	   Caller	  A:	  	  	  Non	  PASS	   Caller	  A:	  	  PASS	  	   Caller	  A:	  	  Not	  Called	  Caller	  B:	  	  PASS	   Caller	  B:	  	  Non	  PASS	   Caller	  B:	  	  PASS	   Caller	  B:	  	  Not	  Called	   Caller	  B:	  	  PASS	  Both	  PASS	   Yes	   -­‐	   -­‐	   -­‐	   -­‐	  Any	  PASS	   Yes	   Yes	   Yes	   Yes	   Yes	  Priority	  PASS	  (single	  Caller)	   Yes	   Yes	   -­‐	   Yes	   -­‐	  Any	  PASS	  (stringent)	   Yes	   Yes	   Yes	   -­‐	   -­‐	  Priority	  PASS	  (stringent)	   Yes	   Yes	   -­‐	   -­‐	   -­‐	  Priority	  PASS	  (plus)	   Yes	   Yes	   -­‐	   Yes	   Yes	  No	  Conflicts	   Yes	   -­‐	   -­‐	   Yes	   Yes	  	  The	   total	   number	   of	   SNVs	   varies	   between	   the	   callsets	   (Figure	   2-­‐14-­‐A).	   The	  variation	   in	   coding	   SNVs	   was	   observed	   in	   the	   Ts/Tv	   ratio	   as	   well	   as	  rare/common	  ratio	  (Figure	  2-­‐14-­‐B	  and	  C).	  As	  expected,	  the	  most	  stringent	  callset	  (bothPASS),	  that	  includes	  a	  variant	  only	  if	  it	  is	  called	  by	  both	  callers	  (GATK	  and	  SamTools)	  and	  passes	  both	  of	  their	  filters	  (i.e.	  PASS),	  has	  the	  highest	  Ts/Tv	  ratio	  (~3.18)	  while	  (anyPass)	  callset	  has	  the	  lowest	  Ts/Tv	  ratio	  	  (~3.01).	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  Table	  2-­‐7	  A	  list	  of	  callsets	  in	  each	  call	  set	  based	  on	  the	  caller	  and	  if	  the	  pass	  the	  caller’s	  internal	  filters	  (i.e.	  PASS).	  
SNVs	   INDELs	  
Callset	  Name	   Callset	  included	   Callset	  Name	   Callset	  included	  Both	  PASS	  	   GS	   Both	  PASS	  	   DS	  Any	  PASS	  	   GS,	  Gs,	  gS,	  G.,	  .S	   Any	  PASS	  	   DS,	  Ds,	  dS,	  D.,	  .S	  G	  Priority	  PASS	  	   GS,	  Gs,	  G.	   D	  Priority	  PASS	  	   DS,	  Ds,	  D.	  S	  Priority	  PASS	  	   GS,	  gS,	  .S	   S	  Priority	  PASS	  	   DS,	  dS,	  .S	  Any	  PASS	  (stringent)	  	   	  GS,	  Gs,	  'gS'	   Any	  PASS	  stringent	  	   	  DS,	  Ds,	  'dS'	  G	  Priority	  PASS	  (stringent)	   	  GS,	  Gs	   D	  Priority	  PASS	  (stringent)	   	  DS,	  Ds	  S	  Priority	  PASS	  (stringent)	  	   	  GS,	  gS	   S	  Priority	  PASS	  (stringent)	  	   	  DS,	  dS	  G	  Priority	  PASS	  (plus)	  	   	  GS,	  Gs,	  G.,	  .S	   D	  Priority	  PASS	  (plus)	  	   	  DS,	  Ds,	  D.,	  .S	  S	  Priority	  PASS	  (plus)	  	   	  GS,	  gS,	  G.,	  .S	   S	  Priority	  PASS	  (plus)	  	   	  DS,	  dS,	  D.,	  .S	  No	  Conflicts	  	   	  GS,	  G.,	  .S	   No	  Conflicts	  	   	  DS,	  D.,	  .S	  
Keys:	  A	  single	  letter	  denotes	  each	  caller.	  For	  example	  “G”	  denotes	  GATK,	  “S”	  for	  Samtools	  and	  “D”	  for	  Dindel.	  Capital	  letter	  means	  the	  variant	  is	  a	  PASS	  (i.e.	  passed	  the	  caller	  internal	  filters)	  and	  a	  small	  letter	  if	  does	  not	  pass.	  The	   “.”	  means	   the	  variant	  was	  not	   called	  by	   the	  caller.	  As	  an	  example,	   the	  callset	  named	   “G	  Priority	  PASS	  (stringent)”	  under	  SNVs	  includes	  two	  types	  of	  variants	  (GS)	  and	  (Gs).	  The	  (GS)	  is	  all	  variants	  that	  are	  called	  as	  PASS	  in	  both	  GATK	  and	  Samtools	  while	  (Gs)	  includes	  all	  variants	  that	  are	  called	  by	  GATK	  as	  PASS	  but	  called	  as	  non-­‐PASS	  by	  Samtools.	  	  	  On	   the	   other	   hand,	   the	   rare/common	   ratio	   of	   loss-­‐of-­‐function	   (or	   functional	  variant)	   shows	   the	   opposite	   trend;	   “bothPass”	   callset	   has	   the	   lowest	  rare/common	   ratio	   (~0.09)	   and	   “anyPass”	   showed	   the	   highest	   (~0.15).	   The	  benefit	   of	   using	   rare/common	   ratio	   is	   that	   it	   can	   tell	   us	   if	   a	   certain	   callset	   is	  enriched	  for	  rare	  variant	  more	  than	  expected.	  Since	  single-­‐sample	  variant	  callers	  are	  not	  aware	  of	  the	  variant	  frequencies	  (i.e.	  whether	  it	  is	  common	  or	  rare)	  one	  would	   not	   expect	   the	   callers	   to	   be	   biased	   towards	   either	   rare	   or	   common	  variants.	  However,	  the	  variants	  called	  by	  Samtools	  seem	  to	  be	  enriched	  for	  rare	  variants	   mainly	   in	   three	   callsets	   that	   use	   Samtools	   as	   the	   dominant	   caller	  (S_Priority,	   S_	   PriorityPASSplus	   and	   S_PriorityPASSstringent).	   	   What	   is	   even	  more	   interesting	   is	   that	   the	   Ts/Tv	   and	   rare/common	   ratios	   are	   inversely	  correlated	   (Figure	   2-­‐14-­‐D).	   The	   higher	   Ts/Tv	   ratio	   gets,	   the	   lower	   the	  rare/common	  ratio	  becomes.	  Additionally,	   this	  correlation	   is	  also	  seen	   in	  other	  classes	   of	   variants	   such	   as	   functional	   (missense),	   silent	   (synonymous)	   and	  intronic	  variant	  (data	  not	  shown).	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Similarly	   for	   INDELs,	   I	   examined	   different	   callsets	   derived	   from	   two	   callers,	  Dindel	  and	  Samtools	   (Table	  2-­‐6	  and	  Table	  2-­‐7).	  The	   truth	  measurement	   I	  used	  for	  INDELs	  includes	  coding	  in-­‐frame/frameshift	  (n3/nn3)	  and	  the	  rare/common	  ratios.	  Not	  surprisingly,	  the	  most	  stringent	  callset	  is	  “bothPASS”	  which	  includes	  INDELs	   that	   are	   called	   both	   callers	   and	   pass	   their	   internal	   filters.	   This	   callset	  performs	  well	  on	  both	  matrices	  (the	  n3/3nn	  ratio	  is	  ~1.66	  and	  the	  rare/common	  ratio	   is	   ~0.10,	   see	   Figure	   2-­‐15	   A-­‐C).	   Here	   again,	   we	   see	   inverse	   correlation	  between	  these	  two	  ratios	  as	  we	  saw	  between	  the	  Ts/Tv	  and	  rare/common	  in	  the	  SNVs	  (Figure	  2-­‐15-­‐D).	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Although	   these	   analyses	   were	   very	   informative,	   they	   were	   not	   enough	   to	  determine	  which	  caller	  contributed	  the	  most	  to	  the	  false	  positive	  rate	  (in	  terms	  of	   low	   Ts/Tv,	   n3/nn3	   and	   /	   or	   rare/common	   ratios).	   The	   final	   piece	   of	  information	  was	  obtained	  by	  dissecting	  each	  callset	  to	  its	  basic	  five	  scenarios	  as	  defined	   in	   (Table	   2-­‐6).	   For	   example,	   SNVs	   variants	   can	   be	   grouped	   into	   five	  groups	  (GS,	  Gs,	  gS,	  G.	  and	  S.).	  Similarly,	  for	  INDELs,	  there	  are	  five	  classes	  (DS,	  Ds,	  dS,	  D.	  and	   .S)	  (see	  Figure	  2-­‐16).	  This	  analysis	  shows	  that	  Samtools	  tends	  to	  call	  more	  rare	  variants	   (in	  both	  SNVs	  and	   INDELs)	  and	  generally	  performed	  worse	  than	  other	  callers.	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This	   has	   a	   very	   important	   consequence	   on	   the	   downstream	   analysis	   since,	   on	  average,	  Samtools	  contributes	  2.5	  rare	  loss-­‐of-­‐function	  SNVs,	  four	  rare	  missense	  and	  two	  rare	  coding	  INDELs	  per	  sample.	  These	  might	  seem	  small	  for	  the	  number	  of	  candidates	  in	  one	  sample,	  but	  in	  a	  project	  with	  100	  or	  1000	  samples,	  this	  has	  a	  tremendous	  effect	  on	  the	  number	  of	  candidate	  variants	  needed	  to	  be	  validated	  or	  sent	  for	  functional	  studies.	  	  








































.S D. dS Ds DS











































.S G. gS Gs GS




























.S G. gS Gs GS

































.S D. dS Ds DS




2.3	  Results	  	  
	   85	  
Collectively,	  these	  results	  suggested	  the	  importance	  of	  discarding	  or	  flagging	  the	  rare	  coding	  variants	  called	  by	  Samtools	  alone	  (both	  SNVs	  and	  INDELs)	  in	  order	  to	  decrease	   the	   false	  positive	  rare	  candidate	  variants.	   	   It	   is	   important	   to	  notice	  that	  these	  observations	  are	  true	  for	  the	  specific	  older	  version	  of	  Samtools	  and	  for	  the	  filters	  used	  in	  the	  pipeline	  and	  may	  change	  accordingly.	  	  	  
2.3.2.3 Sample	  and	  data	  quality	  control	  tests	  	  	  Before	  obtaining	  a	  set	  of	  high	  quality	  DNA	  variants	  for	  any	  downstream	  analysis,	  several	   tests	   are	   required	   to	   detect	   any	   quality	   issues	   such	   as	   contamination,	  sample	  swapping	  or	  failed	  sequencing	  experiments	  at	  the	  level	  of	  DNA	  samples,	  sequence	  data	  (BAM	  files)	  and	  called	  variants	  (VCF	  files).	  	  	  
DNA	  sample	  quality	  tests	  The	  sample	  logistic	  team	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  tested	  the	  DNA	  quality	   of	   each	   sample	   using	   an	   electrophoretic	   gel	   to	   exclude	   samples	   with	  degraded	   DNA.	   The	   team	   also	   tested	   DNA	   volume	   and	   concentration	   using	  PicoGreen	   assay	   [277]	   to	   make	   sure	   every	   sample	   met	   the	   minimum	  requirements	   of	   exome	   sequencing.	   Additionally,	   26	   autosomal	   and	   four	   sex	  chromosomes	  SNPs	  were	  genotyped	  as	  part	  of	  the	  iPLEX	  assay	  from	  Sequenom	  (USA).	   This	   test	   helps	   to	   determine	   the	   gender	   discrepancies	   or	   possible	  contamination	   issues.	   Occasionally,	   the	   relatedness	   between	   sample	   and	   the	  family	  membership	  may	  need	  to	  be	  tested	  using	  the	  genotype	  of	  SNPs	  in	  iPLEX	  assay	   from	   the	   sample	   sequence	   data.	   An	   example	   of	   relatedness	   test	   from	  sequence	  data	  is	  discussed	  in	  chapter	  3	  (part	  of	  a	  replication	  study	  of	  250	  trios	  with	  tetralogy	  of	  Fallot).	  	  
Sequence	  data	  quality	  tests	  The	   second	   group	   of	   quality	   tests	   was	   performed	   on	   the	   sequence	   reads	  generated	   by	   the	   next-­‐generation	   sequencing	   platform.	   Carol	   Scott	   from	   the	  Genome	  Analysis	  Production	   Informatics	   (GAPI)	   team	  performed	   these	   tests	   to	  detect	  samples	  with	  low	  sequence	  coverage.	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Variant	  quality	  tests	  
	  The	  third	  group	  of	  quality	  control	  tests	  targets	  the	  called	  variants	  that	  are	  stored	  in	  the	  Variant	  Call	  Format	  (VCF)	  files	  [161].	  The	  aim	  of	  these	  tests	  is	  to	  detect	  the	  outlier	   samples	   based	   on	   the	   counts	   of	   single	   nucleotide	   variants	   (SNV)	   or	  insertion/	  deletion	  variants	  (INDEL)	  in	  comparison	  to	  other	  published	  and	  /	  or	  internal	  projects	  (Figure	  2-­‐17	   for	  SNV	  and	  for	  Figure	  2-­‐18	   for	   INDEL	  variants).	  These	  plots	  are	  based	  on	  94	  CHD	  samples	  generated	  by	  GAPI	  pipeline	  and	  these	  plots	   are	   generated	   for	   each	   CHD	   project	   in	   chapter	   3	   and	   4.	   These	   serve	   to	  monitor	   the	   consistency	   of	   variant	   calling	   between	   samples	   from	   the	   same	  project	  and	  also	  between	  different	  projects.	  Samples	   that	  show	  extreme	   low	  or	  high	   values	   above	   2-­‐3	   standard	   deviations	   of	   the	  mean	   values	   are	   flagged	   for	  further	   investigations	   to	   determine	   the	   possible	   causes	   (e.g.	   contamination	  issues,	  poor	  sequence	  data,	  etc.)	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  Figure	  2-­‐18	  Count	  of	  INDEL	  variants	  per	  sample	  (n=94	  selected	  CHD	  samples).	  (a)	  Total	  number	  of	  INDELs	  that	  pass	  caller	  internal	  filters	  (i.e.	  PASS).	  (b)	  Percentage	  of	  common	  variants	  (MAF	  ≥	  1%	   in	   1000	   genomes	   project).	   (c)	   Number	   of	   rare	   and	   common	   INDELs.	   (d)	   Coding	   In-­‐frame/frameshift	  ratio	  (n3/nn3).	  	  
2.3.3 Minimizing	  the	  search	  space	  for	  causal	  variants	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  It	   is	   generally	   accepted	   that	   rare	   variants	   are	   defined	   as	   the	   variants	   with	   a	  minor	   allele	   frequency	   of	   1%	   or	   less	   [278].	   	   Currently,	   there	   are	   three	   major	  projects	   from	   which	   the	   allele	   frequency	   is	   available	   in	   a	   large	   number	   of	  samples.	  The	  first	  is	  the	  1000	  genomes	  that	  include	  1,092	  samples	  from	  different	  populations	   and	   used	   low-­‐depth	   whole	   genome	   sequencing	   and	   high-­‐depth	  whole	   exome	   sequencing	   [155].	   The	   second	   is	   the	   NHLBI	   Exome	   Sequencing	  Project	   and	   includes	   6,015	   individuals	   of	   European	   American	   and	   African	  American	   ancestry	   and	   uses	   high-­‐depth	   whole	   exome	   sequencing	   [199].	   The	  third	  MAF	  resource	  is	  the	  UK10K	  cohort	  of	  low-­‐depth	  whole	  genome	  sequencing	  from	  ~4,000	  individuals	  of	  European	  ancestry	  [264].	  	  While	  the	  individuals	  from	  the	  1000	  genomes	  and	  UK10K	  Cohort	  are	  presumably	  healthy,	  the	  NHLBI	  Exome	  Sequencing	  Project	  includes	  affected	  patients	  with	  various	  different	  phenotypes.	  This	   led	  me	  to	  disregard	  the	  MAF	  from	  NHLBI-­‐ESP	  samples	  since	   I	  cannot	  rule	  out	   the	   possibility	   that	   some	   samples	   may	   have	   congenital	   heart	   defects.	  Additionally,	   the	   captured	   exome	   data	   in	   NHLBI-­‐ESP	   project	   is	   based	   on	   a	  smaller	  set	  of	  genes	  (~17,000	  genes	  compared	  with	  ~20,000	  genes	  captured	  in	  the	   exome	  data	   in	  my	   samples),	  which	   can	   adversely	   affect	  many	  downstream	  analyses	  such	  as	  the	  case/control	  analysis	  by	  generating	  spurious	  false	  positive	  signals.	  	  	  In	   addition	   to	   publicly	   available	   MAF	   resources,	   I	   generated	   an	   internal	   MAF	  based	   on	   576	   healthy	   parents	   from	   the	   Deciphering	   Developmental	   Disorders	  (DDD)	   project.	   The	  main	   goal	   of	   using	   the	   internal	  MAF	   is	   to	   exclude	   variants	  that	  appear	  as	  rare	  according	  to	  population	  MAF	  recourse	  but	  appear	  in	  >	  1%	  of	  the	  samples.	  These	  are	  expected	  to	  be	  novel	  ‘common’	  variants	  or,	  possibly	  more	  likely,	  sequencing	  /	  pipeline	  errors.	  	  At	   the	   time	   of	  writing	   this	   thesis,	   there	  was	   no	   general	   consensus	   on	   the	   best	  strategy	   to	   match	   the	   exome	   sequence	   variants	   with	   variants	   in	   population	  frequency	   resources,	   especially	   the	   indels,	   in	   our	   internal	   pipelines	   (GAPI	   and	  UK10K)	  nor	  in	  other	  external	  sequencing	  centers	  like	  the	  Broad	  institute	  in	  the	  USA	  (Shane	  McCarthy,	  personal	  communication).	  Some	  groups	  match	  variants	  in	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their	   projects	   with	   MAF	   from	   public	   resources	   if	   both	   have	   the	   same	  chromosome	   and	   position	   only	  while	   others	   expand	   this	  matching	   strategy	   by	  matching	  variants	  in	  a	  window	  of	  10-­‐30bp	  to	  the	  closest	  variant.	  	  	  
	  Figure	  2-­‐19	  The	  variant	  matching	  algorithm	  between	  alleles	  in	  exome	  data	  and	  alleles	  from	  MAF	  resources.	  	  I	   designed	   a	   hierarchical	   algorithm	   that	   matches	   between	   the	   source	   files	  (UK10K,	  1KG	  and	  ESP)	  and	  the	  target	   files	  (CHD	  samples	  or	  other	  samples	   like	  DDD)	  (see	  Figure	  2-­‐19).	  The	  goal	  of	   this	  algorithm	  is	   to	  make	  sure	   I	  match	   the	  right	   allele	   in	   my	   CHD	   samples	   with	   the	   corresponding	   alleles	   in	   the	   MAF	  resources.	  	  This	  algorithm	  generates	  two	  keys;	  one	  from	  the	  source	  file	  (e.g.	  CHD	  sample)	  and	  the	  second	  key	  is	  generated	  from	  the	  target	  file	  (1000	  genomes	  MAF	  file)	  and	  then	  tests	  if	  both	  keys	  match	  each	  other	  (see	  Figure	  2-­‐20	  for	  examples).	  	  	  In	   the	   case	   of	   SNVs,	   I	   constructed	   the	   key	   using	   four	   values	   (chromosome,	  position,	   reference	   allele	   and	   alternative	   allele)	   and	   called	   this	   an	   “exact	   I”	  matching.	  On	  other	  hand,	   INDELs	  are	  harder	   to	  annotate	  because	  callers	  might	  call	   the	   INDEL	  alleles	  differently	   especially	   in	   repeat	   regions.	  To	  accommodate	  these	  different	  scenarios,	  I	  tested	  three	  different	  matching	  definitions.	  The	  first	  is	  “exact	   I”	   which	   is	   similar	   to	   the	   SNVs	   and	   is	   considered	   the	   most	   stringent	  approach.	  The	  second	  strategy	   is	   called	   “exact	   II”	  where	   I	   construct	  a	  key,	  also	  using	  four	  values	  (chromosome,	  position,	  slice	  and	  direction).	  This	  key	  requires	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both	  INDELs	  in	  the	  target	  and	  source	  files	  to	  be	  at	  the	  same	  locus	  (chromosome	  and	   position)	  while	   ‘slice’	   is	   computed	   based	   on	   the	   DNA	   sequence	   difference	  between	  the	  reference	  and	  alternative	  alleles	  and	  ‘direction’	  is	  either	  deletion	  or	  insertion.	  	  Although	  “exact	  II”	  matching	  may	  look	  different	  to	  “exact	  I”,	  it	  is	  also	  a	  stringent	   matching	   that	   tries	   to	   accommodate	   the	   differences	   imposed	   by	  different	  callers	  when	  they	  call	  the	  same	  INDEL.	  	  	  When	   a	   matching	   algorithm	   fails	   to	   find	   any	   results	   using	   “exact	   I	   or	   II”	  strategies,	   it	   switches	   to	  a	   lenient	  matching	  mode	  where	   it	   expands	   the	   search	  for	  similar	  INDELs	  within	  10-­‐30bp	  flanking	  window.	  If	  the	  algorithm	  finds	  more	  than	  one	  INDEL	  that	  meet	  its	  criteria,	  it	  chooses	  the	  nearest	  matching	  INDEL	  to	  the	  target	  locus	  and	  if	  it	  finds	  multiple	  INDELs	  at	  the	  same	  distance,	  it	  picks	  the	  one	  with	  lower	  MAF	  value,	  to	  be	  conservative.	  	  	  	  







Chr$ Pos$ Ref$ Alt$$ Direc;on$ Slice$
chr1$ 866511$ CCCCT$ CCCCTCCCT$ ins$ CCCT$
Chr$ Pos$ Ref$ Alt$$ Direc;on$ Slice$ AF$
chr1$ 866505$ G$ A$ B$ B$ 0.00023$
chr1$ 866511$ CCCCT$ C$ del$ CCCT$ 0.00176$
chr1$ 866511$ CCCCT$ CCCCTCCCT$ ins$ CCCT$ 0.58993$
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  To	   test	   the	   algorithm	   performance	   under	   each	   mode	   (exact	   I,	   II	   and	   lenient),	   I	   tested	   the	  correlation	   between	   three	   MAF	   resources	   (1KG,	   UK10K	   and	   ESP)	   with	   DDD	   internal	   MAF	  described	  above	  (	  	  	  	  	  Table	   2-­‐8).	   My	   assumption	   is	   that	   the	   vast	   majority	   of	   variants	   should	   have	  similar	   allele	   frequency	   in	   the	   DDD	   samples	   as	   in	   the	   three	   MAF	   recourses	  (except	   for	   private	   or	   extremely	   rare	   variants	   and	   sequence	   errors).	   A	   proper	  matching	   algorithm	   should	   be	   able	   to	   match	   same	   alleles	   and	   thus	   the	   MAF	  values	  should	  show	  a	  strong	  correlation	  between	  the	  DDD	  samples	  and	  the	  other	  MAF	   resources.	   	   Both	   exact	   I	   and	   exact	   II	   strategies	   show	   a	   strong	   correlation	  between	   the	   allele	   frequencies	   in	   1KG,	  UK10K	  or	  ESP	  with	  DDD	   internal	   allele	  frequencies	   (correlation	   coefficient	   >	   0.8)	   but	   not	   the	   lenient	   strategy	   for	  declaring	  a	  match	  (correlation	  coefficient	  -­‐0.03	  to	  0.008).	  	  After	  I	  showed	  that	  both	   ‘exact	  I	  and	  II’	  algorithms	  are	  well	  suited	  for	  matching	  alleles	   in	  samples	  sequenced	   locally	  with	  alleles	  available	   in	  public	  resources,	   I	  decided	  to	  test	  the	  effect	  of	  using	  MAF	  from	  different	  resources	  on	  the	  number	  of	  rare	  coding	  variants	  per	  sample.	  To	  evaluate	  the	  effect	  of	  these	  MAF	  recourses,	  I	  selected	   288	   samples	   from	   DDD	   project	   and	   annotated	   them	   with	   allele	  frequency	  from	  four	  MAF	  recourses	  (1KG,	  UK10K,	  ESP	  and	  DDD’s	  internal	  MAF)	  (Figure	  2-­‐21)	  in	  order	  to	  eliminate	  common	  variants	  (MAF	  >	  1%).	  The	  number	  of	  variants	   left	   after	   excluding	   common	   variants	   based	   on	   MAF	   from	   the	   1000	  genomes	   project	   or	   the	   UK10K	   project	   was	   comparable	   (616	   and	   631	  respectively).	   The	  MAF	   from	   ESP	   on	   the	   other	   hand	   do	   not	   appear	   to	   be	   very	  effective	   for	   filtering.	   This	   is	   not	   unexpected	   since	   the	   ESP	   sequence	   data	   are	  based	  on	  a	  smaller	  version	  of	  the	  exome	  compared	  with	  the	  whole	  genome	  data	  in	   the	   1000	   genomes	   and	   UK10K	   projects.	   However,	   using	   all	   three	   MAF	  resources	   together	   was	  more	   effective	   than	   using	   each	   separately	   (~428	   rare	  variants	  per	  sample).	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Exact	  type	  I	   Exact	  type	  II	   Lenient	  
1KG	   0.80	   0.83	   -­‐0.03	  
COHROT	   0.92	   0.73	   0.01	  
ESP	   0.89	   0.88	   0.01	  	  Surprisingly,	   using	   the	   internal	  MAF	   from	  healthy	   parents	   in	  DDD	  project	  was	  even	  more	  effective	  than	  using	  all	  three	  public	  MAF	  together	  (~419	  rare	  variants	  per	  sample	  when	  used	  alone	  and	  327	  when	  used	  in	  addition	  to	  the	  other	  three	  MAF	   resources).	   A	   possible	   explanation	   is	   that	   alleles	   with	   MAF	   >	   1%	   and	  specific	  to	  a	  given	  project	  are	  likely	  to	  be	  sequence	  or	  pipeline	  errors,	  otherwise	  they	   would	   have	   been	   identified	   in	   large-­‐scale	   projects	   such	   as	   the	   1000	  genomes,	  which	  aims	  to	  discover	  alleles	  with	  low	  allele	  frequency	  of	  at	  least	  1%	  in	  the	  populations	  studied	  [155].	  	  
	  Figure	  2-­‐21	  average	  number	  of	  autosomal	  rare	  variant	  when	  filtering	  based	  on	  <	  1%	  minor	  allele	  frequencies	  from	  different	  resources.	  The	  data	  are	  based	  on	  288	  samples	  from	  the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project.	  	  1KG:	  1000	  genomes,	  UK10K:	  4,000	  healthy	  twins	  from	  UK10K	  cohort,	  ESP:	  6,015	  samples	   from	  NHLBI	  Exome	  Sequencing	  Project.	  3	  AFs	   includes	  rare	  
1KG$ UK10K$ ESP$ 3$AFs$ DDD$ 4AFs$
Heterozygous$ 518.4$ 572.7$ 994.8$ 401.1$ 408.7$ 322.2$
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variants	   in	   (1KG,	  UK10K	  and	  ESP).	  DDD	   is	   an	   internal	   allele	   frequencies	  based	  on	  576	  healthy	  parents	  from	  DDD	  project.	  4	  AFs	  includes	  rare	  variants	  in	  1KG,	  UK10K,	  ESP	  and	  DDD.	  
2.3.4 Family-­‐based	  study	  designs	  in	  CHD	  There	  are	  many	  family-­‐based	  designs	  one	  can	  consider	  when	  studying	  CHD,	  such	  as	  singletons,	  affected	  sib-­‐pairs,	  parent-­‐offspring	  trios,	  affected	  parent-­‐child	  and	  multiplex	   families.	   However,	   since	   the	   mode	   of	   inheritance	   in	   CHD	   is	   poorly	  understood	  in	  general,	  there	  is	  no	  obviously	  optimal	  study	  design.	  	  	  	  Each	   design	   has	   advantages	   and	   disadvantages,	   for	   example,	   in	   terms	   of	   the	  feasibility	   of	   the	   sample	   collection	   and	   the	   availability	   of	   suitable	   analytical	  approaches	  (Table	  2-­‐9).	  Singletons	  (or	  index	  cases)	  are	  the	  easiest	  to	  collect	  but	  each	  sample	  has	  several	  hundreds	  of	  rare	  coding	  variants	  if	  analyzed	  separately,	  which	  makes	  the	  task	  of	  finding	  likely	  pathogenic	  variants	  difficult.	  On	  the	  other	  hand,	   trio	   family	   designs	   are	   usually	   more	   difficult	   to	   collect	   but	   they	   offer	   a	  chance	  to	  detect	  de	  novo	  and	  definitive	  compound	  heterozygous	  variants	   in	  the	  affected	  child,	  which	  are	  not	  feasible	  in	  singleton	  or	  affected-­‐sib	  pair	  designs.	  	  	  	  To	   see	   how	   different	   study	   designs	   may	   affect	   the	   final	   number	   of	   candidate	  genes,	  I	  selected	  one	  family	  of	  healthy	  parents	  and	  three	  affected	  children	  (two	  females	   and	  one	  male,	   Figure	  2-­‐22)	   to	   estimate	   the	  number	  of	   rare,	   functional	  coding	  variants	  under	  different	  designs	  and	  inheritance	  scenarios.	  Variants	  were	  defined	  as	  rare	  if	  they	  have	  a	  minor	  allele	  frequency	  <	  1%	  in	  the	  1000	  genomes	  [155]	   and	   in	   2,172	   parents	   from	   the	   Deciphering	   Developmental	   Disorders	  (DDD)	  project	   [260]	   (this	   analysis	  was	  performed	  more	   recently	  with	   a	  newer	  version	  of	  the	  DDD	  project	  which	  include	  a	  larger	  number	  of	  parents	  compared	  with	  analysis	  described	  in	  previous	  sections	  where	  I	  included	  576	  parents	  only).	  Functional	  coding	  variants	  are	  defined	  as	  variants	  predicted	  by	  VEP	  tool	  [170]	  to	  be	   either	   loss	   of	   function	   (stop	   gain,	   frameshift	   or	   variants	   affected	   donor	   or	  acceptor	   splice	   sites)	   or	   functional	   (missense	   or	   stop	   lost).	   I	   excluded	   silent	  (synonymous)	  variants	  from	  the	  analysis.	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Table	  2-­‐9	  Overview	  of	  study	  designs	  and	  analytical	  approaches	  
	  	  	  
	  Figure	   2-­‐22	   Pedigree	   chart	   of	   a	   multiplex	   family	   (three	   affected	   children	   and	   their	   healthy	  parents)	   used	   to	   count	   the	   number	   of	   candidate	   genes	   with	   rare	   coding	   under	   different	  inheritance	  scenarios.	  	  AS:	  aortic	  stenosis,	  PS:	  pulmonary	  stenosis.	  	  
III"II"I"
AS" PS" PS"
Study	  Design	   Advantages	   Disadvantages	   Analytical	  approaches	  
Index	  cases	   -­‐Easy	  to	  collect	   -­‐Lack	  of	  family	  genotype	  information	  means	  larger	  search	  space	  for	  causal	  variant(s).	  
-­‐Case/control	  (collapsed,	  weighted,	  etc.)	  
Extended	  
families	  
-­‐	  Co-­‐segregated	  variants	  that	  are	  absent	  from	  control	  provide	  strong	  evidence	  for	  causality.	  	  
-­‐	  Rare	  to	  find	  and	  collect	  samples.	   -­‐	  Linkage	  analysis	  and	  then	  targeted	  sequencing.	  
Trios	   -­‐	  Utilize	  parental	  genotype	  to	  detected	  de	  novo	  variants	  -­‐	  Compound	  heterozygous	  mutations	  can	  be	  detected	  -­‐	  Avoid	  population	  stratification	  bias	  (e.g.	  TDT	  tests)	  
-­‐	  More	  difficult	  to	  collect	   -­‐	  De	  novo	  -­‐	  Co-­‐segregation	  -­‐	  Transmission	  disequilibrium	  test	  (TDT)	  	  
Affected-­‐sib	  
pairs	  
-­‐	  Suggestive	  of	  autosomal	  recessive	  disorders.	  -­‐	  Small	  search	  space	  due	  to	  few	  autosomal	  recessive	  candidates	  and	  siblings	  share	  only	  half	  of	  the	  variants.	  
-­‐	  The	  lack	  of	  parental	  genotype	  information	  inflates	  the	  number	  of	  homozygous	  variant	  candidates.	  	  




(parents	  plus	  >	  
1	  affected	  
child)	  
-­‐Combine	  the	  power	  both	  trios	  and	  affected	  sib-­‐pairs	  -­‐	  Smaller	  search	  space	  for	  variant	  with	  more	  affected	  children.	  
-­‐	  Difficult	  to	  analyze	  when	  affected	  members	  have	  heterogeneous	  phenotypes	  -­‐	  Less	  common	  families	  than	  the	  trios.	  	  
Same	  as	  trios	  in	  addition	  to	  the	  affected	  sib-­‐pairs	  
Affected	  
parent-­‐child	  
-­‐	  Suggestive	  of	  autosomal	  dominant	  disorders.	  	   -­‐	  The	  variant	  search	  space	  is	  larger	  than	  in	  trios.	  	   -­‐	  Co-­‐segregation	  of	  heterozygous	  variants	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Initially,	  I	  analyzed	  each	  affected	  child	  separately	  to	  test	  the	  singleton	  design	  and	  found	   two	   rare	   coding	   homozygous,	   10	   compound	   heterozygous	   and	   381	  heterozygous	  variants	  on	  average	  (Table	  2-­‐10).	  If	   I	  consider	  two	  children	  as	  an	  affected	   sib-­‐pair	   and	   look	   for	   shared	   rare	   coding	   variants,	   the	   number	   of	   rare	  coding	  heterozygous	  variants	  drops	   to	   less	   than	  half	  and	   less	   than	  a	  quarter	  of	  recessive	   variants	   (both	   homozygous	   and	   compound	   heterozygous)	   compared	  with	   the	   singleton	   design.	   Combining	   all	   three	   affected	   sibs	   at	   the	   same	   time	  shows	   only	   75	   rare	   coding	   heterozygous	   variants	   shared	   among	   them,	   which	  represents	  80%	  less	  than	  singleton	  and	  50%	  less	  than	  two	  affected	  sib-­‐pairs	  but	  no	  recessive	  variants	  are	  shared	  between	  all	  three	  sibs.	  	  On	   the	   other	   hand,	   the	   number	   of	   candidate	   genes	   with	   rare	   coding	   variants	  drops	  dramatically	  to	  just	  a	  handful	  of	  genes	  in	  the	  trio	  design	  when	  I	  consider	  the	   parents	   and	   assume	   complete	   penetrance.	   	   This	   is	   mainly	   because	   the	  parents’	  exome	  data	  provides	  additional	  genotype	   information	   to	  exclude	  most	  heterozygous	  variants	  (see	  Table	  2-­‐11	  for	  details).	  	  	  These	   empirical	   numbers	   of	   rare	   coding	   variants	   shared	   between	   different	  family	   members	   are	   in	   general	   agreement	   with	   what	   I	   would	   predict	   from	  Mendelian	   inheritance.	   For	   example,	   since	   the	   number	   of	   rare	   coding	  heterozygous	  variants	  observed	   in	  each	  child	   is	  ~381	  on	  average,	   two	  affected	  sibs	   should	   share	   50%	   (IBD=1)	   or	   190	   variants	   which	   is	   not	   far	   from	  what	   I	  observed	   in	   the	   three	  affected	   sib-­‐pairs	   in	   this	   family	   (~153).	   Similarly	   for	   the	  rare	  coding	  homozygous	  variants,	  the	  observed	  average	  in	  each	  child	  is	  ~10	  and	  each	   sib-­‐pair	   is	   expected	   to	   share	   25%	   (IBD=2)	   or	   2.5	   homozygous	   variants,	  which	  is	  very	  close	  to	  the	  observed	  value	  (~2.67).	  	  The	   variation	   between	   the	   observed	   and	   the	   expected	   numbers	   of	   shared	  variants	  under	  Mendelian	  inheritance	  laws	  is	  likely	  caused	  by	  under-­‐calling	  the	  same	  variant	  in	  one	  more	  member.	  	  I	  found	  the	  same	  broad	  agreement	  between	  the	   average	   numbers	   of	   variants	   in	   the	   affected	   parent-­‐child	   pairs	   (~157)	  compared	   with	   the	   expected	   numbers	   under	   Mendielian	   inheritance	   laws	  (~190).	  	  
2.3	  Results	  	  
	   97	  
	  Table	  2-­‐10	  Number	  of	  rare	  coding	  variants	  in	  affected	  children	  under	  different	  study	  designs	  (see	  family	  pedigree	  Figure	  2-­‐22).	  	  Singleton:	   each	   affected	   case	   is	   analyzed	   independently.	   Affected	   sib-­‐pairs:	   shared	   variants	  between	   two	  or	  more	   affected	   sibs	  without	   parental	   information.	   Trios:	   each	   child	   is	   analyzed	  with	  his/her	  healthy	  parents	  and	  assuming	  complete	  penetrance	  (see	  Table	  2-­‐11	  for	  the	  full	  list	  of	  allowed	  genotypes).	  Multiple:	  analysis	  of	  two	  or	  more	  children	  with	  their	  healthy	  parents	  and	  assuming	  complete	  penetrance.	  *	   Indicates	   the	   average	  number	  of	   one	   affected	  parent	   (father	  or	  mother)	   and	  any	   child	  of	   the	  three.	   NA:	   not	   applicable	   (e.g.	   no	   autosomal	   recessive	   variants	   are	   allowed	   in	   affected	   parent-­‐child	  design).	  
Family	  study	  
design	   Samples	  
Number	  of	  candidate	  genes	  	  




(compound)	   Dominant	  	  
Singleton	  
Child	  I	   1	   11	   373	  Child	  II	   1	   12	   413	  Child	  III	   4	   8	   357	  
Affected	  sibs	  
Shared	  between	  sibs	  	  (I	  and	  II)	   0	   5	   162	  Shared	  between	  sibs	  (I	  and	  III)	   1	   1	   171	  Shared	  between	  sibs	  	  (II	  and	  III)	   0	   2	   126	  Shared	  between	  sibs	  (I,	  II	  and	  III)	   0	   0	   75	  
Affected	  
parent-­‐child	  
One	  affected	  parent	  and	  	  one	  affected	  child	   NA	   NA	   157*	  One	  affected	  parent	  	  and	  two	  affected	  children	   NA	   NA	   74*	  One	  affected	  parent	  	  and	  three	  affected	  children	   NA	   NA	   37*	  
Trios	  
Trio	  (child	  I)	   0	   3	   1	  Trio	  (child	  II)	   0	   5	   0	  Trio	  (child	  III)	   0	   5	   0	  
Multiplex	  
Shared	  between	  trios	  	  (I	  and	  II)	   0	   4	   0	  Shared	  between	  trios	  	  (I	  and	  III)	   0	   0	   0	  Shared	  between	  trios	  	  (II	  and	  III)	   0	   4	   0	  Shared	  between	  trios	  	  (I,	  II,	  III)	   0	   0	   0	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Finally,	  I	  consider	  the	  shared	  rare	  coding	  variants	  between	  two	  or	  more	  trios	  (i.e.	  multiplex	   family	  design).	  This	   study	  design	  has	   identified	   four	  genes	  only	  with	  compound	   heterozygous	   that	   are	   shared	   between	   child-­‐I	   and	   child-­‐II	   and	  another	  four	  genes	  between	  child-­‐II	  and	  child-­‐III.	  No	  rare	  coding	  variants	  were	  detected	  when	  all	   three	  sibs	  and	  their	  parents	  were	  analysed	  at	  the	  same	  time.	  This	   may	   suggest	   either	   a	   possible	   under-­‐calling	   of	   a	   monogenic	   variant	   (i.e.	  missed	  by	  the	  callers)	  or	  an	  oligogenic	  nature	  of	  the	  disease	  (i.e.	  multiple	  genes	  with	   different	   rare	   causal	   variants).	   	   Nonetheless,	   the	   trio	   design	   is	   clearly	  superior	   to	   the	   affected-­‐sib	   pairs	   or	   singleton	   designs	   since	   it	   identifies	   very	  small	  number	  of	  candidate	  genes.	  	  	  Table	  2-­‐11	  The	   accepted	   genotype	   combinations	   in	   a	   complete	   trio	   are	   the	   genotypes	   that	   are	  compatible	   with	   Mendialin	   inherence	   laws	   and	   also	   in	   agreement	   with	   the	   assumption	   of	  complete	   penetrance.	   Each	   trio	   includes	   an	   affected	   child	   (male	   or	   female)	   and	   two	   healthy	  parents.	   Each	   cell	   in	   the	   first	   column	   “genotype	   combinations”	   represents	   three	   genotypes	   in	  child,	  mother	  and	  father.	   “0”	   indicates	  a	  homozygous	  reference	  genotype,	  “1”	   is	  a	  heterozygous	  genotype,	  and	  “2”	  is	  a	  homozygous	  genotype	  in	  diploid	  chromosome	  (autosomal)	  or	  hemizygous	  in	  a	  haploid	  chromosome	  (e.g.	  X-­‐chromosome	  in	  a	  male	  child).	  Y-­‐chromosome	  and	  mitochondrial	  DNA	   are	   omitted	   from	   the	   table.	   Empty	   cells	   indicate	   that	   a	   given	   genotype	   combination	   is	  incompatible	   with	   Mendelian	   laws	   (e.g.	   1,0,0	   is	   de	   novo)	   or	   not	   expected	   under	   complete	  penetrance	   assumption	   (e.g.	   1,1,1	   is	   heterozygous	   in	   both	   the	   affected	   child	   and	   his	   parents).	  Only	   three	   genotype	   combinations	   were	   considered	   when	   I	   performed	   trios	   or	   multiplex	  analysis.	  	  
Genotype	  
combinations	   Autosomal	  
X-­‐	  chromosome	  
in	  an	  affected	  male	  child	  
X-­‐	  chromosome	  
in	  an	  affected	  female	  
child	  (1,	  0,	  0)	   	   	   	  (1,	  0,	  1)	   	   	   	  (1,	  0,	  2)	   	   	   	  (1,	  1,	  0)	   	   	   	  (1,	  1,	  1)	   	   	   	  (1,	  1,	  2)	   	   	   	  (1,	  2,	  0)	   	   	   	  (1,	  2,	  1)	   	   	   	  (1,	  2,	  2)	   	   	   	  (2,	  0,	  0)	   	   	   	  (2,	  0,	  1)	   	   	   	  (2,	  0,	  2)	   	   	   	  (2,	  1,	  0)	   	   Hemizygous	  inherited	  from	  a	  carrier	  mother	   	  (2,	  1,	  1)	   Homozygous	  in	  child	  and	  inherited	  from	  carrier	  parents	   	   	  (2,	  1,	  2)	   	   	   	  (2,	  2,	  0)	   	   	   	  (2,	  2,	  1)	   	   	   	  (2,	  2,	  2)	   	   	   	  (1,0,1)	  and	  (1,1,0)	   Compound	  heterozygous	  in	  the	  child	  in	  a	  given	  gene	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2.3.5 Family-­‐based	  Exome	  Variant	  Analysis	  (FEVA)	  suite	  	  To	  generate	  a	  list	  of	  candidate	  genes	  from	  exome	  data	  of	  a	  given	  rare,	  putatively	  monogenic,	   disorder,	   one	   needs	   to	   go	   through	   multiple	   steps	   that	   include	  excluding	   low	  quality	   variants	   based	  on	   various	   filters,	   excluding	   incompatible	  genotype	  combinations	  with	  either	  the	  study	  design	  or	  the	  plausible	  inheritance	  models	   (see	   Table	   2-­‐11	   for	   an	   example	   of	   incompatible	   genotypes	  with	   a	   trio	  design)	   and	   filtering	   common	   variants	   (MAF	   >	   1%)	   as	   well	   as	   non-­‐coding	  variants	   since	   rare	   coding	   variants	   (except	   silent)	   are	   more	   likely	   to	   have	   a	  measurable	   effect	   on	   the	   phenotype.	   Performing	   these	   steps	  manually	   in	   non-­‐specialized	  software,	  such	  as	  Microsoft	  Excel,	  is	  time	  consuming	  and	  error	  prone	  due	   to	   the	   large	  number	  of	   variants.	   This	   is	   clearly	  not	   suitable	   for	   large-­‐scale	  projects	  of	  hundreds	  of	  samples	  with	  different	  family	  structures.	  	  To	   automate	   the	   analysis	   and	   variant	   reporting	   under	   different	   Mendelian	  inheritance	   models	   I	   designed	   a	   ‘Family-­‐based	   Exome	   Variant	   Analysis’	   tool.	  FEVA	   is	   a	   suite	   of	   tools	   that	   enable	  users	   to	   generate	   a	   list	   of	   candidate	   genes	  under	   various	   study	   designs.	   FEVA	   offers	   two	   interfaces	   for	   the	   end	   user.	   The	  first	   interface	   is	   a	   Command	   Line	   Interface	   (CLI)	   suitable	   for	   high-­‐throughput	  analysis,	  which	  can	  be	  incorporated	  into	  automated	  data	  analysis	  pipelines.	  The	  second	   interface	   is	   a	   graphical	   user	   interface	   (GUI)	   aimed	   for	   low-­‐throughput	  analysis	  that	  is	  easy	  to	  use	  with	  minimal	  training	  (Figure	  2-­‐23).	   	   I	  designed	  the	  GUI	  version	  of	  FEVA	  three	  years	  ago	  when	  many	  sequencing	  projects,	  such	  as	  the	  UK10K	  RARE	  project,	  was	  just	  starting	  at	  the	  Wellcome	  Trust	  Sanger	  Institute.	  At	  that	   time,	   there	  was	  no	  GUI	   available	   for	   our	   collaborators	   to	   explore	   variants	  files	   (VCF	   files)	   with	   ease.	   	   I	   coded	   most	   FEVA	   components	   in	   the	   Python	  programing	   language,	   which	   I	   chose	   for	   its	   readability	   and	   agility	   for	  prototyping.	  	  Since	  Python	  is	  a	  high-­‐level	  programming	  language;	  it	  can	  be	  slow	  when	  performing	  computer	  intensive	  tasks	  (such	  as	  parsing	  large	  files	  which	  are	  commonly	   used	   in	   the	   next-­‐generation	   sequencing	   era).	   However,	   Python	   is	  easily	   extendable	   by	   other	   low-­‐level	   statically	   typed,	   and	   thus	   quite	   fast,	  programming	   languages	   to	  overcome	   this	   limitation.	   	  For	  example,	   I	  have	  used	  many	  C	  and	  C++	   libraries	   to	  parse	   large	  exome/genome	   files.	  Moreover,	   I	  used	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graphical	  user	   interface	  components,	  which	  are	  written	   in	  C++	  (QT	   library)	   for	  fast	  viewing.	  	  
	  Figure	  2-­‐23	  Screen	  print	  of	  FEVA	  graphical	  user	  interface	  (GUI).	  	  This	   simple	   interface	   shows	   three	  parts.	  The	  green	   rectangle	   shows	  a	   list	  of	  variants	  and	   their	  annotations.	   Each	   row	   represents	   one	   variant	   along	   with	   its	   quality	   scores	   and	   biological	  information	  such	  as	  gene,	  variant	  type,	  effect	  on	  protein,	  etc.	  The	  red	  rectangle	  is	  where	  the	  user	  can	   enter	   filter	   conditions	   to	   exclude	   or	   include	   rows.	   	   The	   blue	   rectangle	   includes	   additional	  functions	  such	  as	  applying	  a	  set	  of	  pre-­‐defined	  filters	  or	  to	  export	  a	  list	  of	  candidate	  variants	  to	  other	  programs.	  	  Although	   other	   tools	   have	   been	   published	   during	   my	   work	   with	   similar	  functionality,	  such	  as	  SVA,	  EVA	  and	  VarSift	  [261-­‐263],	  none	  of	  them	  were	  able	  to	  fulfill	  the	  needs	  for	  my	  projects.	  One	  limitation	  common	  to	  these	  tools	  it	  that	  they	  are	  not	  suitable	  for	  both	  interactive	  and	  high-­‐throughput	  analysis.	  Additionally,	  many	  of	  them	  have	  hard	  coded	  filters,	  and	  so	  lack	  flexibility,	  or	  require	  a	  certain	  formatting	  that	  is	  not	  necessarily	  compatible	  with	  the	  VCF	  files	  generated	  by	  the	  GAPI	  or	  UK10K	  pipelines	  (see	  Table	  2-­‐12	  for	  comparisons	  with	  FEVA).	  	  	  	  
	  The	   family-­‐based	   analyses	   in	   FEVA	   go	   through	   three	   steps	   (Figure	   2-­‐24):	   (1)	  reduce	   the	   search	   space	   by	   applying	   quality	   and	   MAF	   filters	   (e.g.	   exclude	  common	  variants,	  low	  quality,	  etc.),	  (2)	  identify	  co-­‐segregating	  variants	  in	  family	  members	   (e.g.	   exclude	   variants	   in	   healthy	   sib	   or	   shared	   variants	   between	  affected	   parent-­‐child),	   (3)	   Group	   the	   possibly	   pathogenic	   variants	   by	   the	  inheritance	  model	  (e.g.	  recessive	  or	  dominant).	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Table	  2-­‐12	  Comparison	  of	  four	  freely	  available	  graphical	  user	  interface	  applications	  for	  genome	  or	  exome	  analysis.	  N/A:	  not	  available.	  
Features	   FEVA	   EVA	  [262]	   SVA	  [261]	   VarSifter	  [263]	  
Desktop	  application	   Yes	   No	   Yes	   Yes	  
User	  custom	  annotation	   Yes	   No	   Yes	   No	  
Visualization	   No	   Basic	   Advanced	   No	  
Custom	  filters	   Yes	   Hard-­‐coded	   Hard-­‐coded	   Hard-­‐coded	  
Whole	  genome	   Yes	   No	   Yes	   No	  
Accepts	  compressed	  files	   Yes	   No	   N/A	   No	  
Family	  Based	  analysis	   Yes	   Yes	   No	   No	  (Var-­‐MD)	  
Memory	  usage	  (RAM)	   Minimal	   N/A	   Large	   N/A	  
QC	  statistics	   External	  module	   Yes	   Yes	   No	  
Has	  command-­‐line	  tools	   Yes	   No	   No	   No	  
Input	  files	   VCF	   VCF	   VCF	  &	  bco	   VCF	  
Cross-­‐platform	   Yes	   N/A	   Yes	   Yes	  	  
	  Figure	  2-­‐24	  FEVA	  workflow.	  	  An	   example	   of	   one	   sib-­‐pair	   affected	   with	   Primary	   Ciliary	   Dyskinesia	   (PCD),	   which	   has	   been	  sequenced	   as	   part	   of	   the	   ciliopathies	   study	   in	   the	  UK10K	  RARE	  project.	   The	   user	   supplies	   the	  variants	   files	   and	   chooses	   which	   family	   design	   and	   FEVA	   performs	   three	   tasks	   automatically.	  First,	  FEVA	  excludes	  low	  quality	  variants	  and	  common	  variants	  using	  a	  MAF	  threshold	  supplied	  by	  the	  user.	   In	  the	  next	  step,	  FEVA	  applies	  the	  rules	  of	  co-­‐segregation	  designed	  for	  affected	  sib	  pairs	   (i.e.	   shared	   variants	   in	   both	   sibs).	   Finally,	   FEVA	   groups	   shared	   variants	   under	   recessive	  (homozygous	  or	  compound	  heterozygous)	  and	  dominant	  models.	  Furthermore,	  FEVA	  can	  divide	  the	  candidate	  variants	  into	  loss-­‐of-­‐function	  and	  functional	  classes	  according	  to	  the	  user	  settings.	  	  Almost	   all	   steps	   described	   here	   are	   adjustable	   by	   the	   end	   user,	   which	   enable	   FEVA	   to	  accommodate	  different	  needs	  and	  scenarios.	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The	   rules	   of	   co-­‐segregation	   vary	   according	   to	   the	   family	   design	   (e.g.	   singleton,	  trio	  of	  healthy	  parent	  or	  trio	  of	  affected	  father-­‐child,	  etc.)	  and	  can	  be	  made	  more	  or	   less	   stringent.	   These	   models	   are	   configurable	   by	   the	   user	   to	   suit	   a	   unique	  study	  design	  (only	  in	  the	  command-­‐line	  version	  of	  FEVA).	  	  In	  the	  next	  section,	  I	  will	   describe	   how	   I	   used	   FEVA	   with	   different	   study	   designs	   to	   identify	  pathogenic	  and	  candidate	  pathogenic	  genes	  for	  different	  disorders.	  	  	  
2.3.6 Application	  of	  FEVA	  in	  rare	  disease	  studies	  
Application	  1:	  Targeted	  sequencing	  of	  linkage	  regions	  (monogenic	  disease)	  	  
	  Dr.	   Andrew	   Crosby	   and	   his	   team	   at	   St.	   George’s	   University	   of	   London	   have	  previously	  detailed	  the	  clinical	  features	  of	  members	  of	  a	  large	  UK	  family	  affected	  by	  dominantly	   transmitted	  distal	  hereditary	  motor	  neuropathy	   type	  VII	   (OMIM	  158580).	   The	   team	   had	   previously	   mapped	   the	   gene	   responsible	   to	  chromosomal	  region	  2q14	  in	  a	  family	  of	  14	  affected	  and	  12	  unaffected	  members	  and	  I	  collaborated	  with	  them	  to	  analyze	  the	  exome	  sequence	  data	  of	  one	  affected	  family	  member.	  	  	  Coding	  regions	  were	  captured	  with	  SureSelect	  All	  Exons	  (50	  Mb)	  and	  sequenced	  by	   Illumina	  HiSeq	  at	   the	  Wellcome	  Trust	   Sanger	   Institute,	   yielding	  9.8	  Gb	  data	  (~130	  million	  reads)	  corresponding	  to	  91%	  target	  coverage	  with	  a	  mean	  depth	  of	   1,073	   and	   identifying	   52,806	   variants.	   Based	   on	   previous	   linkage	   analysis	  [279,	   280],	   I	   used	   the	   FEVA	   software	   to	   report	   rare	   coding	   variants	   in	   two	  regions	  (~13.5	  Mb)	  with	  high	  LOD	  scores	  (Table	  2-­‐13).	  	  Table	  2-­‐13	  Genome	  coordinates	  of	  microsatellite	  marker	  
Regions	   Size	   Marker	  ID	   Locus	  in	  human	  genome	  Region	  (1)	   9.2Mb	   AC084377	   Chr2:99560750	  D2S160	   Chr:2:112998734	  Region	  (2)	   4.3Mb	   D2S2970	   Chr2:118948333	  D2S2969	   Ch2:123237183	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After	   filtering	   common	   and	   non-­‐coding	   variants	   (Table	   2-­‐14),	   I	   identified	   only	  one	   loss	   of	   function	   variant	   within	   the	   critical	   region;	   this	   was	   a	   single	   base	  deletion	   (c.1497delG)	   in	   SLC5A7	   gene	   encoding	   the	   Na+/Cl-­‐	   dependent,	   high-­‐	  affinity	  choline	   transporter.	  This	  novel	  variant	  was	   found	   to	  co-­‐segregate	   in	  all	  affected	  members	  using	  capillary	  sequencing	  and	  this	  work	  was	  published	  in	  the	  American	  Journal	  of	  Human	  Genetics	  [281].	  	  
	  Figure	  2-­‐25	  Family	  pedigree	  and	  c.1497delG	  cosegregation	  in	  SLC5A7	  gene	  [281].	  The	  c.1497delG	  variant	   results	   in	   the	   creation	   of	   a	   novel	   SspI	   restriction	   site	   that	   facilitates	   cosegregation	  analysis	   by	   restriction	   digestion	   of	   exon	   9	   PCR	   products	   resolved	   by	   polyacrylamide	   gel	  electrophoresis.	  (Image	  and	  caption	  are	  adapted	  from	  [281])	  	  Table	  2-­‐14	  Number	  of	  variants	  in	  two	  linkage	  regions	  (~total	  size	  of	  13.5	  Mb).	  The	  variants	  are	  classified	  based	  on	  genotype	  (heterozygous	  or	  homozygous),	  by	  the	  predicted	  effect	  on	  protein	  to	  functional	   (missense)	  or	   loss-­‐of-­‐function	   (LOF	  class	   includes	   stop	  gain,	   frameshift	   and	  variants	  that	  disturb	  acceptor	  or	  donor	  splice	  sites).	  Only	  one	  rare	  LOF	  variant,	  a	  coding	  frameshift,	  found	  in	  SLC5A7	  gene	  that	  encodes	  for	  choline	  transporter	  protein.	  	  
Genotype	   All	  variants	  
Common	   Rare	  
Functional	   LOF	   Functional	   LOF	  Heterozygous	   134	   32	   2	   23	   1	  Homozygous	   77	   24	   1	   0	   0	  	  Similar	  to	  the	  analytical	  strategy	  I	  used	  to	  discover	  causal	  mutations	   in	  SLC5A7	  gene,	   I	   utilized	  FEVA	   to	   analyze	  data	   from	  other	  monogenic	  diseases	  under	   an	  autosomal	  recessive	  model	  in	  collaboration	  with	  Dr.	  Crosby	  and	  his	  team	  (Table	  2-­‐15).	  In	  all	  of	  these	  cases,	  I	  used	  the	  linkage	  analysis	  information	  to	  guide	  FEVA	  while	  filtering	  for	  rare	  coding	  homozygous	  or	  compound	  heterozygous	  variants.	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These	   analyses	  were	   usually	   straightforward	   since	   FEVA	   reported	   only	   one	   or	  two	  candidate	  variants	  per	  sample	  because	  of	  the	  small	  linkage	  intervals.	  
	  Table	  2-­‐15	  Results	  from	  other	  monogenic	  phenotypes	  where	  linkage	  analysis	  was	  used	  to	  guide	  the	  variant	  filtering	  of	  variants	  from	  whole	  exome	  or	  custom	  designed	  data	  (using	  FEVA).	  	  
Phenotype	   Hereditary	  spastic	  paraplegia	  	   Developmental	  delay	  with	  macrocephaly	   Microlissencephaly	  	  
Mendelian	  
model	   Autosomal	  recessive	  	   Autosomal	  recessive	  	   Autosomal	  recessive	  	  
Linkage	  
analysis	   14.3Mb	  (chr12)	   19q.13.32	   2.36Mb	  (chr19)	  	  
Sequencing	  
region	   Custom	  design	  	   Whole	  exome	   Custom	  design	  	  
Number	  of	  
samples	   1	   1	   1	  
Candidate	  
gene	   B4GALNT1	  	   KPTN	   WDR62	  	  
Casual	  variant	  	   c.1458insA	   c.776C>T	  	   c.1562T>A	  and	  	  	  c.4038-­‐4039delAA	  
Project	  status	   Published	  in	  [282]	   Published	  in	  [283]	   Manuscript	  is	  being	  prepared	  
	  
Application	  2:	  Affected	  trio	  families	  combined	  with	  candidate	  gene	  
screening	  	  The	  aim	  of	  the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project	  is	  to	  collect	  DNA	   and	   clinical	   information	   from	   undiagnosed	   children	   in	   the	   UK	   with	  developmental	   disorders	   and	   their	   parents	   [260].	   I	   used	   FEVA	   to	   test	   its	  performance	  in	  high-­‐throughput	  on	  1,080	  trios	  of	  affected	  children	  with	  various	  developmental	   disorders	   and	   also to	   estimate	   the	   number	   of	   candidate	   genes,	  assuming	   healthy	   parents	   and	   complete	   penetrance	   of	   rare	   coding	   variants	  (Table	  2-­‐16).	  	  FEVA	  was	  able	  to	  report	  rare	  coding	  variants	  according	  to	  the	  genotype	  rules	  in	  (Table	   2-­‐11)	   under	   	   	   autosomal	   recessive	   (homozygous	   or	   compound	  heterozygous)	   and	   X-­‐linked	  models	   (separately	   for	  male	   and	   female	   children).	  The	  rare	  variants	  are	  defined	  as	  variants	  with	  MAF	  <	  1%	  in	  the	  1000	  genomes	  project	   and	   in	   parental	   MAF	   from	   DDD	   (n=2,172).	   Regardless	   of	   gender,	   each	  child	  has,	  on	  average,	  four	  candidate	  genes	  with	  autosomal	  recessive	  rare	  coding	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variants	   (excluding	   silent)	   and	   another	   three	   candidate	   genes	   on	   the	   X	  chromosome.	  	  	  I	  also	  tested	  FEVA’s	  ability	  to	  screen	  candidate	  genes	  for	  the	  presence	  of	  rare	  or	  novel	   coding	   variants	   (Table	   2-­‐16,	   DDG2P	   genes).	   	   DDG2P	   is	   a	   list	   of	   1,148	  manually	   curated	   genes	   with	   strong	   evidence	   supporting	   involvement	   in	  development	  disorders	  (the	  DDG2P	  gene	  list	  was	  developed	  by	  the	  DDD	  team).	  The	   screening	   analysis	   revealed,	   on	   average,	   only	   one	   autosomal	   rare	   coding	  variant,	  one	  X-­‐linked	   in	   females	  and	  0.18	  X-­‐linked	   in	  males.	  However,	   the	  DDD	  team	   implements	   additional	   filtering	   steps	   for	   their	   clinical	   reporting	   pipeline.	  These	  steps	  involve	  matching	  the	  phenotype	  and	  family	  history	  to	  the	  genotype	  (i.e.	   compatibility	   with	   the	   Mendelian	   rules),	   which	   lowers	   the	   number	   of	  candidate	  genes	  per	  child	  still	  further.	  	  Table	  2-­‐16	  Number	  of	  candidate	  variants	  in	  1,080	  affected	  DDD	  trios	  assuming	  healthy	  parents	  and	  complete	  penetrance	  (558	  males	  and	  522	  females).	  	  LOF:	   loss-­‐of-­‐function	  (include	  strop	  gain,	  variants	  disturbing	  acceptor	  or	  donor	  splice	  sites	  and	  frameshift),	   functional	  (includes	  missense).	  DDG2P:	  a	   list	  of	  1,148	  manually	  curated	  genes	  with	  strong	   evidence	   supporting	   involvement	   in	   development	   disorders	   (the	   DDG2P	   gene	   list	   is	   a	  courtesy	  of	  DDD	  team).	  
Variant	   Chromosome	  	   Genotype	  




LOF	   Functional	   LOF	   Functional	  
SNVs	  
Autosomal	   Homozygous	   0.02	   1.01	   	  	   0.08	  Compound	  heterozygous	   0.13	   2.99	   0.01	   0.42	  X-­‐chromosome	  (male	  child)	   Homozygous	   0.1	   3.28	   0.02	   0.63	  
INDELs	  
Autosomal	   Homozygous	   0.03	   0.03	   	  	   0.08	  Compound	  heterozygous	   0.11	   0.07	   0.01	   0.43	  X-­‐chromosome	  (male	  child)	   Homozygous	   0.07	   0.12	   0.03	   0.66	  Total	  candidate	  genes	  in	  a	  female	  child	   0.29	   4.1	   0.02	   1.01	  Total	  candidate	  genes	  in	  a	  male	  child	   0.46	   7.5	   0.07	   2.3	  	  	  	  FEVA	  requires	  1-­‐3	  minutes	  to	  generate	  a	  report	  of	  candidate	  genes	  for	  one	  trio.	  When	   run	   in	   parallel,	   FEVA	   can	   generate	   reports	   of	   candidate	   genes	   for	  thousands	  of	  exomes	  in	  a	  few	  hours	  with	  minimum	  memory	  usage	  (<	  50	  Mb	  per	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trio).	  This	  feature	  makes	  FEVA	  suitable	  for	  large-­‐scale	  projects	  such	  as	  the	  DDD,	  which	   aims	   to	   analyze	   the	   exome	  data	   from	  12,000	   trios	   in	   the	  next	   couple	   of	  years.	  	  
	  
Application	  3:	  Affected	  sib-­‐pairs	  in	  UK	  CHD	  families	  	  In	   collaboration	   with	   Prof.	   Eamonn	  Maher	   at	   the	   University	   of	   Birmingham,	   I	  analyzed	  the	  exome	  data	  of	  10	  families	  with	  at	  least	  two	  CHD	  affected	  sibs.	  Two	  of	   these	   families	   are	   consanguineous	   (from	  Birmingham	  Pakistani	   population).	  All	   families	  have	   two	  affected	  sibs	  except	   family	  CHD1	  and	  CHD16	  where	  each	  has	  three	  affected	  sibs	  of	  various	  CHD	  phenotypes.	  	  	  I	  used	  FEVA	  software	  to	  generate	  reports	  of	  rare	  coding	  variants	  that	  are	  shared	  between	  at	  least	  two	  sibs	  (Table	  2-­‐17).	  The	  rare	  variants	  are	  defined	  as	  variants	  with	  MAF	  <	  1%	   in	  1000	  genomes	  and	   the	   internal	  MAF	  of	  2,172	  parents	   from	  DDD	   project.	   As	   expected,	   affected	   sib-­‐pairs	   from	   consanguineous	   families	  (CHD1	   and	   CHD4)	   have	   more	   candidate	   genes	   with	   autosomal	   recessive	   rare	  coding	   variants	   than	   non-­‐consanguineous	   families.	   On	   average,	   each	   family’s	  FEVA	   output	   lists	   3.5	   gene	   candidate	   genes	   with	   homozygous	   rare	   coding	  variants	   and	   25	   candidate	   genes	   with	   compound	   heterozygous	   rare	   coding	  variants.	  	  Initially,	  I	  focused	  my	  search	  for	  candidate	  genes	  with	  rare	  loss	  of	  function	  (stop	  gained,	   frameshift	  or	  variants	  disturbing	  acceptor	  or	  donor	   splice	   sites)	   (Table	  2-­‐18).	   	   The	   top	   recurrent	   five	   genes	   that	   appear	   in	   most	   of	   the	   families	  (ANKRD36C,	  LINC00955,	  CDC27,	  OR4C5,	  and	  MUC3A)	  are	  unlikely	  to	  be	  linked	  to	  the	  CHD	  phenotypes	  since	  they	  have	  compound	  heterozygous	  LOF	  in	  almost	  all	  families.	   Most	   of	   the	   remaining	   genes	   do	   not	   have	   knockout	   mouse	   models	  except	   three	   genes	   (TTN,	   PLA2G1B	   and	   RBMX)	   and	   TTN	   is	   the	   only	   gene	   that	  shows	  structural	  cardiac	  defects	   in	  the	  mouse	  models.	   	  Since	   it	  not	  expected	  to	  identify	   recurrent	   pathogenic	   genes	   in	   such	   a	   small	   study	   with	   variable	   CHD	  phenotypes,	   I	  only	  considered	  genes	  that	  appear	   in	  one	  affected	  sib-­‐pair	  only.	   I	  also	  excluded	  genes	  with	  frameshift	  variants	  (INDELs)	  since	  they	  tend	  to	  have	  a	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Number	  of	  candidate	  genes	  Homozygous	   Compound	  	  heterozygous	  CHD1	  	   Yes	   Child	  1:TOF	  Child	  2:VSD	  Child	  3:	  VSD,	  PA	  (TOF	  spectrum)	   3	   23	  (1)*	   36	  (29)*	  CHD4	  	   Child	  1:	  VSD,	  PA	  (TOF	  spectrum)	  Child	  2:	  AS	   2	   18	   24	  CHD5	  	  
No	  
Child	  1:	  VSD,	  RV	  hypoplasia	  Child	  2:	  ASD,	  RV	  hypoplasia	   2	   3	   21	  CHD6	  	   Child	  1:	  TOF	  Child	  2:	  TOF	   2	   6	   25	  CHD11	  	   Child	  1:	  VSD	  Child	  2:AS,	  BAV	   2	   1	   29	  CHD13	  	   Child	  1:	  TGA,	  VSD,	  PS	  Child	  2:	  TGA	   2	   0	   25	  CHD16	  	   Child	  1:	  TOF	  Child	  2:	  VSD,	  CoA,	  BAV	  Child	  3:	  ASD	   3	   39	  (1)*	   36	  (28)*	  CHD20	  	   Child	  1:	  Tricuspid	  Atresisa	  	  Child	  2:	  TGA,	  RV	  hypoplasia	   2	   1	   29	  CHD22	  	   Child	  1:	  HLHS	  Child	  2:	  VSD	   2	   4	   19	  CHD23	  	   Child	  1:	  AS,	  subaortic	  stenosis	  Child	  2:	  AS,	  subaortic	  stenosis	   2	   0	   23	  ASD:	  Atrial	  Septal	  Defects,	  AS:	  Aortic	  stenosis,	  BAV:	  Bicuspid	  Aortic	  Valve,	  CoA:	  Coarctation	  of	  Aorta,	  HLHS:	  Hypoplastic	   left	   heart	   syndrome,	   PA:	   Pulmonary	   Atresia,	   	   RV:	   Right	   Ventricle,	   TGA:	   Transposition	   of	   the	  Great	  Arteries,	  TOF:	  Tetralogy	  of	  Fallot,	  VSD:	  Ventricular	  Septal	  Defects.	  
	  
GMFG	   was	   initially	   identified	   as	   a	   growth	   and	   differentiation	   factor	   acting	   on	  neurons	  and	  glia	  in	  vertebrate	  brain	  [284].	  GMFG	  encodes	  a	  small	  protein	  of	  142	  amino	  acids	  an	  actin-­‐binding	  protein	  predominantly	  expressed	  in	  microvascular	  endothelial	  cells	  and	  inflammatory	  cells	  [285,	  286].	  	  The	  expression	  of	  GMFG	  was	  found	   to	   be	   unregulated	   at	   the	   site	   injury	   during	   the	   heart	   regeneration	   in	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zebrafish	  models[287].	  However,	  its	  role	  in	  the	  heart	  development	  in	  mammals	  has	  not	  been	   studied	  yet.	  A	  knockout	  mouse	  of	  GMGF	   is	   being	  modelled	  at	   the	  Wellcome	   Trust	   Sanger	   Institute	   to	   investigate	   further	   its	   role	   during	   the	  development	  of	  the	  heart.	  	  Table	  2-­‐18	  List	  of	  candidate	  genes	  with	  rare	  loss-­‐of-­‐function	  variants	  shared	  in	  between	  at	  least	  two	   affected	   sibs.	   	   Genes	   in	   red	   harbor	   stop	   gained	   (SNVs)	   variants	   while	   the	   rest	   have	  frameshift.	  The	  phenotypes	  in	  knockout	  mouse	  models	  from	  the	  Mouse	  Genome	  Database	  [288].	  
Gene	  
Number	  of	  families	  with	  
candidate	  genes	  carrying	   Phenotypes	  in	  mouse	  knockout	  
	  mouse	  models	  
	  Mouse	  Genome	  Database	  Homozygous	   Compound	  	  Heterozygous	  	  
ANKRD36C	   	  	   10	   NA	  
LINC00955	   	  	   10	   NA	  
CDC27	   	  	   10	   NA	  
OR4C5	   	  	   9	   NA	  
MUC3A	   	  	   9	   NA	  
RBMX	   	  	   5	   Decreased	  lean	  body	  mass	  
CCDC144NL	   	  	   4	   NA	  
FAM182A	   	  	   1	   NA	  
TTN	   	  	   1	   First	  branchial	  arch	  and	  somites,	  vascular,	  cardiac	  and	  skeletal	  muscle	  defects.	  
MUC4	   	  	   1	   NA	  
PLA2G1B	   	  	   1	   Abnormalities	  in	  lipid	  absorption	  and	  increased	  insulin	  sensitivity.	  
KLHL24	   	  	   1	   NA	  
ROPN1	   	  	   1	   NA	  
PITPNC1	   	  	   1	   NA	  
GMFG	   1	   	  	   NA	  
TAS2R43	   1	   	  	   NA	  
ZNF717	   1	   	  	   NA	  
	  	  Next,	   I	  performed	   the	  same	  analysis	  but	   for	  shared	  rare	  missense	  variants	  and	  identified	   119	   genes	   with	   homozygous	   and	   /	   or	   compound	   heterozygous	  variants	  in	  these	  families	  (Table	  2-­‐19).	  The	  majority	  of	  the	  genes	  appear	  only	  in	  one	  affected	  sib-­‐pair	  while	  a	   few	  appear	   in	  all	  of	   them	  (mainly	  genes	   from	   the	  Olfactory	  or	  Mucin	  gene	  families	  which	  are	  unlikely	  to	  be	  causal	  in	  CHD).	  	  	  Two	   of	   these	   genes	   are	   well	   known	   CHD	   genes	   such	   NOTCH2	   and	   TBX20	  although	   as	   dominant	   genes.	   Other	   genes	   knockout	   mouse	   models	   exhibit	  structural	  heart	  defects	  (UTY,	  HSPG2,	  CTBP2,	  and	  ADAM12).	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Table	  2-­‐19	  List	  of	  candidate	  genes	  with	  rare	  missense	  variants	  shared	  between	  at	  least	  two	  sibs.	  Genes	  in	  red	  have	  a	  knockout	  mouse	  models	  that	  exhibit	  structural	  heart	  defects	  [288].	  	  
Number	  of	  
	  Affected	  	  
sib-­‐pairs	  
Homozygous	   Compound	  heterozygous	  
1	  
ZC3H13,	  PGLYRP2,	  FAM182A,	  PLCH2,	  KIAA1683,	  ZFX,	  
NPIPB1P,	  PSG6,	  HR,	  SHROOM4,	  PSG11,	  GMIP,	  GUCY2F,	  
IKBKG,	  LPAR4,	  OR11H6,	  SPTBN4,	  UTY,	  FCGBP,	  TRGC2,	  
GPKOW,	  TAS2R43,	  SLITRK2,	  MUC16,	  CXorf61,	  CXorf64,	  
GPR112,	  LYNX1,	  ZNF431,	  MEGF6,	  IL12RB1,	  LRBA,	  
NADK,	  ZNF30,	  NKX2-­‐1,	  ASXL3,	  OR11H7,	  MCOLN1,	  
VCX2,	  OR4L1,	  TUBGCP5,	  NDUFA13,	  HSPG2,	  TRIT1,	  
OR4K13,	  PKN2,	  AQP12A,	  HNRNPA1L2	  	  
CTBP2,	  MYEOV,	  FILIP1L,	  FAM182A,	  TMC2,	  LRSAM1,	  
CMYA5,	  KANK1,	  FAT1,	  TYRO3,	  IGHV5-­‐51,	  MYOCD,	  
TBX20,	  STIL,	  SPTBN5,	  NRCAM,	  GPR108,	  MYO15A,	  
PITPNM1,	  ADAM12,	  MYO7B,	  GCOM1,	  FRAS1,	  
PLA2G1B,	  LAMB2,	  RANBP2,	  IQGAP1,	  AHRR,	  
PRRC2B,	  PTGFRN,	  ODZ4,	  TRIOBP,	  HNRNPCL1,	  
KIAA2022,	  IGHV3-­‐38,	  NOTCH2,	  FRG2B,	  PDHX,	  
AHNAK2	  2	   MUC4	  	   FRG1,	  SRRM2,	  FAM27E1,	  USP6,	  DNAH14	  3	   SLC9B1P1	   ATM,	  IGHV7-­‐81,	  MUC16,	  ARSD	  4	   	  	   PRSS1,	  CCDC144NL	  5	   	  	   TTN,	  TRGC2,	  LINC00273	  6	   	  	   IGHV2-­‐70,	  IGLV5-­‐45	  7	   	  	   CEP89,	  NCOR1,	  RBMX	  8	   	  	   TAS2R31	  9	   	  	   MUC4	  
10	   	  	   MUC6,	  TRBV6-­‐5,	  ANKRD36C,	  MUC3A,	  BCLAF1,	  OR9G1,	  CDC27,	  AQP7,	  LINC00955,	  KCNJ12,	  MUC3A,	  
OR4C5,	  OR4C3	  	  	  
	  Figure	  2-­‐26	  Pedigree	  chart	  of	  family	  CHD1.	  	  	  Four	  affected	  sibs	  from	  a	  consanguineous	  family	  of	  a	  Pakistani	  origin.	  Only	  three	  sibs	  had	  their	  exome	  sequenced	  in	  this	  study	  (IV:1,	  IV:2	  and	  IV:3).	  All	  sibs	  are	  diagnosed	  with	  tetralogy	  of	  Fallot	  except	   IV:3	   who	   is	   diagnosed	   with	   ventricle	   septal	   defect	   (VSD).	   The	   homozygous	   stop	   gain	  variant	  was	  detected	   in	   two	   sibs	  with	  TOF	   (IV:1,	   IV:2)	   and	   capillary	   sequencing	   confirmed	   the	  presence	  of	  the	  same	  homozygous	  stop	  gain	  variant	  in	  the	  third	  sib	  with	  TOF	  (IV:4).	  Both	  parents	  are	  heterozygous	   for	   this	   variant	   and	   in	  200	   ethnically	  matched	   control	   chromosomes	  but	  not	  see	  in	  the	  child	  with	  VSD	  (IV:3).	  (Dr.	  Chirag	  Patel	  at	  the	  University	  of	  Birmingham	  performed	  the	  validation	  work).	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Application	  4:	  	  Affected	  parent-­‐child	  pairs	  in	  UK10K	  CHD	  families	  
	  Most	   of	   the	   samples	   in	   UK10K	   (RARE	   CHD)	   are	   index	   cases	   (110	   out	   of	   124	  samples)	  except	  for	  a	  few	  related	  samples	  (three	  affected	  parent-­‐child	  pairs,	  one	  affected	  sib-­‐pair	  and	  two	  parent-­‐offspring	  trios).	  In	  this	  analysis,	  I	  focused	  on	  the	  affected	  parent-­‐child	  only	  as	  this	  family	  structure	  is	  not	  covered	  in	  the	  analyses	  described	  above.	  In	  such	  a	  family	  design,	  I	  only	  looked	  for	  inherited	  rare	  coding	  and	  heterozygous	  variants	  shared	  between	  the	  parent	  and	  the	  child.	  	  
 I	   used	   FEVA	   software	   to	   report	   rare	   coding	   heterozygous	   variants	   shared	  between	  the	  parent	  and	  the	  child.	   I	  defined	  rare	  as	  variants	  with	  MAF	  <	  1%	  in	  1000	   genomes	   and	   the	   internal	   MAF	   of	   2,172	   parents	   from	   DDD	   project.	   On	  average,	   each	   affected	   parent-­‐child	   pair	   shared	   230	   candidate	   genes	   (Table	  2-­‐20),	  which	  is	  much	  higher	  than	  the	  number	  of	  candidate	  genes	  in	  affected	  sib-­‐pairs	  or	  complete	  trios	  (28	  and	  7	  candidate	  genes,	  respectively).	  It	  is	  important	  to	  note	  that	  the	  number	  of	  candidate	  genes	  in	  these	  families	  is	  even	  larger	  (47%	  more)	   than	   the	   number	   of	   candidate	   genes	   from	   the	   simulated	   parent-­‐child	  family	   (see	  Table	  2-­‐10	   for	  details),	  which	  has	  157	  candidate	  genes	  on	  average.	  This	  is	   likely	  to	  be	  as	  a	  result	   in	  the	  differences	  in	  the	  calling	  pipelines	  (UK10K	  vs.	  GAPI).	  The	   internal	  MAF	   from	  the	  2,172	   is	  based	  on	  GAPI	  pipeline	  and	   it	   is	  likely	  to	  be	  less	  effective	  on	  samples	  that	  went	  through	  the	  UK10K	  pipeline	  and	  thus	  have	  more	  candidate	  genes	  per	  family.	  
 Table	  2-­‐20	  Number	  of	  candidate	  genes	  with	  rare	  coding	  heterozygous	  variants	  shared	  between	  affected	  parent	  and	  child	  in	  three	  CHD	  families	  form	  UK10K	  RARE	  CHD	  project.	  Loss	  of	  function	  class	   includes	   (stop	   gain,	   frameshift,	   variants	   that	   disturb	   acceptor	   or	   donor	   splice	   sites),	  functional	  class	  includes	  (missense,	  in-­‐frame	  deletion	  or	  insertion	  and	  stop	  lost).	  
Family	  Id	  
CHD	  phenotype	   Number	  of	  	  candidate	  genes	  
Child	   Parent	   Loss	  of	  function	   Functional	  UK10K_CHD_0015	  	   Atrial	  septal	  defect	   Atrial	  septal	  defect	   23	   219	  UK10K_CHD_0060	  	   Atrioventricular	  septal	  defects	   Ebstein's	  anomaly	   24	   208	  UK10K_CHD_0067	  	   Pulmonary	  stenosis	  and	  Atrial	  septal	  defect	   Pulmonary	  stenosis	   15	   201	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Since	  the	  number	  of	  genes	  with	  rare	  functional	  variants	  is	  large	  in	  each	  affected	  parent-­‐child	  pair	  (~200),	  I	  focused	  my	  search	  for	  genes	  with	  rare	  heterozygous	  loss	  of	  function	  variants	  (this	  class	  includes	  stop	  gain,	  frame-­‐shift,	  variants	  that	  disturb	   acceptor	   or	   donor	   splice	   sites)	   and	   are	   shared	   between	   the	   affected	  parent	   and	   the	   child	   (Table	   2-­‐21).	   The	   heart	   phenotypes	   observed	   in	   these	  families	   are	   varied	   from	   family	   to	   family	   and	   thus	   I	   did	   not	   expect	   to	   see	   the	  same	   gene	   appear	  more	   than	   once.	   There	   are	   29	   genes	  where	   each	   one	   has	   a	  single	  loss	  of	  function	  in	  a	  single	  family	  (first	  row	  in	  Table	  2-­‐21).	  Only	  one	  gene,	  
CCDC39,	  shows	  heart	  phenotypes	  in	  knockout	  mouse	  models.	  This	  gene	  harbors	  a	  rare	  frame-­‐shift	  (c.610_614delTTAGAinsA)	  in	  a	  parent	  with	  Ebstein's	  anomaly	  and	  a	  child	  with	  atrioventricular	  septal	  defect	  (family	  id:	  UK10K_CHD_0060).	  	  	  	  	  
CCDC39	  gene	  encodes	  a	  protein	  that	  localizes	  to	  ciliary	  axonemes	  and	  is	  essential	  for	  the	  assembly	  of	  inner	  dynein	  arms	  and	  the	  dynein	  regulatory	  complex	  [289].	  Recessive	  loss	  of	  function	  variants	  have	  been	  found	  to	  cause	  a	  large	  proportion	  of	  primary	   ciliary	  dyskinesia	   in	  human.	  However,	   the	  knockdown	  of	  Ccdc39	   in	  zebrafish	  embryos	  at	  the	  2-­‐cell	  stage	  caused	  a	  dose-­‐dependent	  increase	  in	  heart	  looping	   defects	   and	   other	   laterality	   defects	   may	   suggest	   a	   possible	   CCDC39	  haploinsufficiency	  [289].	   	  Moreover,	  a	  knockout	  mouse	  model	  submitted	  to	   the	  Mouse	   Genome	   Database	   (MGI:5445973)	   [288]	   shows	   double	   outlet	   right	  ventricle,	   atrial	   septal	   defect	   and	   dextrocardia	   but	   it	   has	   not	   been	   published.	  These	   findings	   suggest	   the	   involvement	   in	   CCDC39	   in	   the	   development	   of	   the	  heart	   but	   further	   work	   is	   required	   to	   confirm	   the	   role	   of	   this	   heterozygous	  frame-­‐shift	  variant	  in	  causing	  the	  heart	  phenotypes	  observed	  in	  this	  family.	  
	  Table	   2-­‐21	  List	   of	   genes	  with	   rare	   loss	   of	   function	   (stop	   gain,	   frameshift,	   variants	   that	   disturb	  acceptor	  or	  donor	  splice	  sites)	  variants	  shared	  between	  affected	  parent	  and	  child.	  	  
Number	  of	  affected	  	  
parent-­‐child	  pairs	   Genes	  
1	   ATXN3L,	  AXDND1,	  CCDC39,	  CCDC7,	  CCL8,	  CD5L,	  COL6A5,	  CYP2C8,	  AC061992.1,	  ERAP1,	  F5,	  FAM49A,	  FHAD1,	  FLG2,	  GPLD1,	  MUC19,	  NDUFA10,	  NLRP5,	  OR51E1,	  OR51T1,	  OR5AN1,	  POLR1A,	  SERGEF,	  SMYD4,	  
TAS1R3,	  TAS2R43,	  VNN2,	  VPS8,	  ZNF211	  2	   PRSS3,	  RBMX	  3	   CDC27,	  LINC00955,	  FRG1B,	  MUC3A,	  OR4C5	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2.4 Discussion	  	  	  NGS	  has	  accelerated	  gene	  discovery	  in	  rare	  monogenic	  disorders	  in	  the	  last	  few	  years.	  More	   than	  180	  novel	  genes	  have	  been	   identified	  using	  whole	  genome	  or	  whole	   exome	   sequence	   data	   generated	   by	   NGS	   platforms	   so	   far.	   Based	   on	   the	  current	  rate	  of	  novel	  gene	  discovery,	  it	  has	  been	  estimated	  recently	  that	  most	  of	  the	   disease-­‐causing	   genes	   of	   rare	  monogenic	   diseases	  will	   be	   identified	   by	   the	  year	  2020	  [202].	  	  	  The	   success	   of	   NGS	   with	   rare	   monogenic	   disorders	   inspired	   me	   to	   apply	   the	  exome	   sequencing	   strategy	   for	   studying	   congenital	   heart	   defects	   (CHD).	  	  However,	  applying	  NGS	  to	  CHD	  cases	  is	  not	  straightforward	  since	  the	  inheritance	  model	   for	   CHD	   is	   not	   well	   defined.	   	   Evidence	   from	   genetic	   epidemiology	   and	  genome-­‐wide	  association	  studies	  has	  supported	  the	  polygenic	  model	  [112,	  115]	  and	  at	  the	  same	  time	  several	  monogenic	  examples	  of	  isolated	  and	  familial	  forms	  of	  CHD	  have	  been	  reported	  in	  the	  literature	  [14].	  There	  is	  no	  general	  consensus	  on	  what	   is	   the	  most	  plausible	   inheritance	  model	   that	  can	  explain	  CHD.	  For	  this	  reason,	  I	  explored	  four	  different	  family-­‐based	  study	  designs	  in	  order	  to	  evaluate	  the	  power	  of	  each	  design	  to	  identify	  rare	  coding	  variants	  that	  might	  explain	  the	  monogenic	  CHD	  cases.	  	  	  This	   chapter	   describes	   the	   tools	   and	   pipelines	   used	   to	   call	   single	   nucleotide	  (SNVs)	   and	   insertion/deletion	   (INDELs)	   variants	   from	   exome	   data.	   One	  major	  challenge	  I	  addressed	  is	  how	  to	  improve	  the	  sensitivity	  and	  specificity	  of	  variant	  calling	   from	  exome	  data.	   The	   issue	   of	   sensitivity	   and	   specificity	   stem	   from	   the	  underlying	   probabilistic	   statistical	   models	   implemented	   by	   different	   variant	  callers.	  These	  models	  are	  being	  actively	  developed	  and	   thus	   it	   is	   expected	   that	  the	  best	  practices	  for	  filtering	  and	  cleaning	  up	  exome	  data	  will	  keep	  changing	  for	  the	  foreseeable	  future,	  especially	  for	  indels.	  	  	  In	   this	   thesis,	   two	   pipelines	   have	   been	   used	   to	   call	   variants	   from	   exome	   data:	  GAPI	   and	   UK10K	   pipelines.	   Both	   of	   these	   pipelines	   use	   different	   callers	   and	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filters	   to	   generate	   the	   variants.	   Although	   they	   have	   been	   able	   to	   detect	   a	  relatively	   comparable	  number	  of	   coding	  SNVs,	   the	  number	  and	   type	  of	   INDELs	  varied	  substantially	  in	  both	  pipelines.	  This	  is	  most	  likely	  caused	  by	  the	  use	  of	  an	  additional	   caller,	   Dindel,	   to	   detect	   INDELs	   in	   the	   GAPI	   pipeline.	   On	   the	   other	  hand,	  the	  intra-­‐pipeline	  comparisons	  between	  GAPI	  sample	  releases	  at	  different	  time	  points	  show	  minimal	  differences.	  These	   findings	  highlight	   the	  need	  to	  use	  only	  one	  pipeline	  for	  consistency	  and	  to	  avoid	  unnecessary	  complications	  for	  the	  downstream	   analysis	   (such	   as	   case/control	   analysis	   using	   the	   samples	   from	  different	  pipelines	  as	  discussed	  in	  chapter	  4).	  	  To	   improve	   the	   sensitivity	   and	   specificity	   of	   SNV	   calls	   generated	   by	   UK10K	  pipeline	   as	   an	   example,	   I	   tested	   the	   relationship	   between	   strand	   bias	   (SB),	  quality	   by	   depth	   (QD),	   genotype	   quality	   (GQ)	   and	   variant	   quality	   (QUAL)	  with	  transition/transversion	   ratio	   (Ts/Tv)	   to	   chose	   the	   proper	   filtering	   thresholds.	  Applying	   these	   filters	  has	  helped	  me	   to	   eliminate	   low	  quality	   variant	   calls	   in	   a	  systematic	  fashion.	  However,	  this	  method	  of	  variant	  filtering	  using	  hard	  cut-­‐offs	  is	   no	   longer	   considered	   the	   best	   practice	   and	   newer	   filters	   based	   on	  sophisticated	   statistical	   models	   that	   integrate	   several	   quality	   metrics	  simultaneously	  have	  now	  been	  used.	  One	   example	   is	   the	  Variant	  Quality	   Score	  Recalibration	  (VQSR)	  scores	  recently	   implemented	  in	  GATK,	  which	  seems	  to	  be	  superior	   to	   other	   filtering	   methods.	   	   However,	   VQSR	   is	   not	   so	   successful	   for	  filtering	  indel	  callsets	  since	  it	  is	  sutable	  for	  SNV	  callsets	  only.	  	  It	  is	  not	  uncommon	  to	  use	  more	  than	  one	  variant	  caller	  to	  detected	  SNVs	  and	  /	  or	  INDELs	  to	  improve	  the	  sensitivity	  and	  specificity	  of	  variant	  calling.	  Theoretically,	  callers	   that	  utilize	  different	  probabilistic	  models	   to	  call	  variants	   independently,	  are	  most	   appropriate.	   	  However,	   it	  was	   not	   clear	   how	   to	   resolve	   conflicts	   that	  arise	  when	  a	  variant	  passes	  the	  filters	  of	  one	  caller	  but	  not	  the	  other,	  or	  when	  a	  variant	   is	   missed	   by	   one	   of	   them.	   My	   analysis	   of	   14	   different	   datasets	   (seven	  INDELs	  and	  seven	  SNVs)	  based	  on	  different	  scenarios	  shows	  that	  INDELs	  called	  by	   Dindel	   were	   superior	   to	   Samtools	   calls,	   as	   they	   show	   in-­‐frame/frameshift	  (n3/nn3)	  ratio	  closer	  to	  the	  exacted	  ~1.5	  ratio.	  Similarly,	  GATK	  SNVs	  calls	  were	  superior	   to	   Samtools	   calls	   in	   terms	   of	   transition	   /transversion	   (Ts/Tv)	   and	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rare/common	   ratios.	   These	   results	   have	   led	   me	   to	   change	   the	   order	   of	   caller	  when	  I	  merge	  calls	  in	  the	  final	  variant	  call	  format	  files	  	  (i.e.	  I	  used	  Dindel	  as	  the	  default	  caller	  for	  INDELs	  and	  GATK	  as	  the	  default	  caller	  for	  SNVs).	  Such	  a	  small	  decision	   has	   a	   large	   effect	   on	   the	   final	   number	   of	   rare	   coding	   variants.	   For	  example,	  Samtools	  calls	  more	  rare	  loss	  of	  function	  variants	  than	  GATK	  or	  Dindel.	  Such	   that,	   in	   large-­‐scale	   projects,	   this	   could	   mean	   hundreds	   of	   false	   positive	  candidate	  variants	  that	  would	  slow	  down	  any	  downstream	  analysis	  or	  functional	  studies.	  	  	  	  	  	  	  	  Once	   an	   optimal	   callset	   of	   variants	   is	   obtained,	   it	   is	   important	   to	   exclude	  common	   variants	   based	   on	  minor	   allele	   frequencies	   (MAF)	   to	  minimize	   the	  number	  of	  candidate	  variants.	  There	  are	  many	  population-­‐based	  MAF	  recourses	  available	   to	   facilitate	   this	   step	   such	   as	   1000	   genomes	   (1KG),	   UK10K	   Twins	  cohort	  (UK10K)	  and	  the	  NHLBI	  Exome	  Sequencing	  Project	  (ESP).	  	  Additionally,	  I	  generated	   a	   fourth	  MAF	   resources	   (called	   internal	   DDD	  MAF)	   based	   on	   2,172	  parental	   samples	   generated	   by	  GAPI	   pipeline	   to	   target	   variants	   that	   appear	   as	  rare	  variants	  in	  the	  public	  MAF	  recourse	  but	  are	  common	  in	  the	  internal	  samples	  which	  likely	  indicate	  that	  they	  are	  sequence	  or	  calling	  errors.	  	  	  
Matching	   alleles	   between	   sequenced	   samples	   (e.g.	  DDD	  or	  CHD	   samples)	   and	  the	   population	   variation	   resources	   (e.g.	   1000	   genomes	   project)	   in	   order	   to	  obtain	  the	  correct	  minor	  allele	   frequency	   is	  straightforward	   for	  SNVs	  but	  more	  difficult	   for	   INDELs	   since	   they	   can	   be	   called	   differently	   due	   to	   the	   genomic	  context	   such	   as	   	   homopolymer	   runs	   for	   example.	   To	   assign	   the	   correct	  MAF,	   I	  tested	  three	  allele-­‐matching	  strategies	  (two	  exact	  matching	  algorithms	  and	  one	  lenient	   algorithm	   based	   on	   10-­‐30bp	   matching	   window)	   and	   I	   used	   the	  correlation	   between	   the	   observed	  minor	   allele	   frequency	   in	   DDD	   samples	   and	  the	   population	   allele	   frequency	   from	   all	   three	   MAF	   population	   resources	   as	   a	  metric	   to	   compare	   different	   matching	   strategies.	   I	   showed	   that	   the	   exact	  strategies	   have	   a	   stronger	   correlation	   between	   the	   observed	   minor	   allele	  frequency	  from	  DDD	  samples	  and	  population	  allele	  frequency	  from	  all	  three	  MAF	  population	  resources.	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Using	   the	  exact	  matching	   algorithm,	   I	  evaluated	   the	  consequence	  of	  applying	  each	   MAF	   resource	   independently	   and	   combined	   on	   the	   final	   number	   of	   rare	  candidate	  variants	   in	  288	  affected	  samples	   from	  the	  DDD	  project.	  This	  analysis	  showed	   that	   the	   internal	   frequency	   from	   the	   DDD	   project	   alone	   was	   able	   to	  eliminate	   most	   common	   variants	   compared	   with	   other	   combined	   public	   MAF	  recourses.	   Combining	   two	   or	   more	   MAF	   is	   more	   effective	   than	   using	   each	  individually.	  However,	   using	   allele	   frequencies	   from	  ESP	   and	  UK10K	  has	   some	  drawbacks.	   First,	   ESP	   includes	   many	   affected	   samples	   with	   unpublished	  phenotype,	   which	   may	   include	   CHDs	   and	   thus	   cannot	   be	   used	   as	   controls.	  Moreover,	   the	   targeted	  exome	   in	  ESP	   is	  smaller	   than	  the	  exome	  design	  used	  to	  sequence	   CHD	   samples	   in	   my	   thesis,	   	   (~16,000	   genes	   and	   ~20,000	   genes,	  respectively.	   	  Similarly,	   the	  MAF	  from	  the	  UK10K	  Twin	  cohort	  does	  not	   include	  variants	   on	   X-­‐chromosome.	   For	   these	   reasons,	   I	   decided	   on	   a	   MAF	   filtering	  strategy	  using	  the	  1000	  genomes	  project	  data	  combined	  with	  the	  internal	  allele	  frequencies	   from	   healthy	   parents	   in	   DDD	   project	   to	   exclude	   common	   variants	  and	  pipeline	  errors.	  	  	  Another	   factor	   that	   affects	   the	   final	   number	  of	   candidate	   variants/genes	   is	   the	  
family	   design.	   I	  performed	  a	  simulation	  analysis	  using	  one	  multiplex	   family	  of	  three	  affected	   sibs	   and	   two	  parents	   and	   showed	  how	   the	  number	  of	   candidate	  variants	   varied	   between	   singletons,	   sib-­‐pairs,	   parent-­‐child,	   and	   complete	   trios	  study	  designs	  within	  the	  same	  family.	  	  	  	  The	   Singleton	  study	  design	  generates	  the	  largest	  number	  of	  candidate	  variants	  per	   sample	   compared	   with	   other	   family-­‐based	   study	   designs,	   unless	   it	   is	  combined	   with	   linkage	   analysis	   to	   limit	   the	   search	   in	   a	   smaller	   region.	   The	  example	   of	   ‘distal	   hereditary	   motor	   neuropathies	   type	   VII’	   with	   two	   small	  linkage	  regions	  (9.2	  and	  4.3	  Mb)	  has	  identified	  only	  one	  candidate	  gene,	  SLC5A7.	  This	   example,	   in	   addition	   to	   another	   three	   genes	   identified	   using	   the	   same	  strategy	   (B4GALNT1,	  KPTN	   and	  WDR62),	   indicates	   that	   finding	  causal	  genes	  by	  combining	   NGS	   and	   linkage	   analysis	   can	   be	   powerful	   and	   relatively	  straightforward.	  Without	   linkage	   analysis,	   the	   number	   of	   candidate	   genes	   per	  sample	   is	   usually	   large	   especially	   for	   dominant	   disorders.	   In	   the	   absence	   of	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linkage	   analysis	   information,	   sequencing	  multiple	   unrelated	   cases	  may	   help	   to	  identify	   the	   causal	   gene	   in	   monogenic	   disorder,	   but	   can	   be	   challenging	   for	  extremely	   genetically	   heterogeneous	   disorders	   such	   as	   intellectual	   disabilities	  and	  CHD.	  	  In	  such	  disorders,	  a	  case/control	  analysis	  might	  be	  more	  suitable	  but	  requires	  a	  large	  number	  of	  samples.	  	  
The	  affected	  sib-­‐pairs	  design	  is	  helpful	  when	  looking	  for	  shared	  homozygous	  or	  compound	   heterozygous	   candidate	   genes	   in	   non-­‐consanguineous	   families	   or	  homozygous	   candidates	   in	   consanguineous	   families.	   This	   analysis	   has	  highlighted	  variants	  in	  a	  few	  known	  CHD	  genes	  such	  as	  NOTCH2	  and	  TBX20,	  but	  these	  genes	  are	  mostly	  known	  to	  cause	  CHD	  under	  a	  dominant	  model	  while	  they	  have	   been	   reported	   here	   to	   harbor	   rare	   and	   presumably	   recessive	   variants.	   It	  remains	   to	   be	   seen	   if	   these	   variants	   are	   pathogenic.	   Additionally,	   I	   identified	  novel	  genes	  such	  as	  GMFG	  with	  a	  homozygous	  stop	  gain	  shared	  between	   three	  affected	   sibs	   in	   the	   same	   consanguineous	   family	   of	   a	   Pakistani	   origin.	   These	  candidate	  genes	  were	  found	  in	  a	  single	  sib-­‐pair	  only	  and	  thus	  require	  additional	  families	   sharing	   the	   same	   candidate	   genes	   to	   be	   identified	   and	   /	   or	   to	   be	  confirmed	  by	  functional	  studies.	  Nonetheless,	  the	  number	  of	  recessive	  candidate	  genes	   in	   this	   design	   is	   manageable	   and	   provides	   a	   chance	   to	   investigate	   the	  recessive	  model	  in	  different	  CHD	  subtypes.	  	  	  	  The	   trio	   and	   multiplex	   designs	   identify	   far	   fewer	   candidate	   genes	   than	   the	  other	  designs	  because	  of	  the	  additional	  information	  from	  the	  parents.	  Assuming	  healthy	  parents	  and	  complete	  penetrance,	  each	  trio	  has,	  on	  average,	  seven	  rare	  inherited	  coding	  variants	  and	  a	  smaller	  number	  in	  multiplex	  families.	  The	  small	  number	  of	  candidate	  genes	  per	  trio	  makes	  most	  downstream	  analyses	  amenable	  to	   further	   investigations	   either	   in	   silico	   or	   by	   functional	   experiments	   (e.g.	  modeling	  in	  zebrafish).	  	  The	  design	  is	  also	  suitable	  for	  de	  novo	  analysis,	  as	  I	  will	  discuss	  in	  the	  next	  two	  chapters.	  	  	  Many	  of	   the	   steps	  described	   above	   are	   time	   consuming	   and	   error	  prone	  when	  performed	   manually	   in	   non-­‐specialized	   software	   such	   as	   Microsoft	   Excel.	   I	  designed	   the	   “Family-­‐based	   Exome	   Variant	   Analysis”	   (FEVA)	   tools	   to	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automate	   applying	   various	   quality	   filters	   and	   to	   report	   candidate	   genes	   from	  different	  study	  designs.	  FEVA	  reports	  candidate	  variants	  under	  different	  models	  of	   inheritance	   and	   can	   be	   customized	   by	   the	   end	   users	   to	   accommodate	   new	  family	   designs	   not	   covered	   by	   the	   program	   default	   settings.	   I	   used	   FEVA	  successfully	  to	  find	  causal	  genes	  in	  monogenic	  disorders	  from	  single	  cases	  such	  as	   the	  SLC5A7	  gene	   in	  distal	  hereditary	  motor	  neuropathy	  (type	  VII)	   [281]	  and	  another	   three	   genes	   (B4GALNT1,	   KPTN	   and	   WDR62)	   in	   various	  neurodevelopmental	   disorders	   (manuscripts	   were	   submitted	   or	   are	   being	  prepared).	   Other	   groups	   at	   the	   Wellcome	   Trust	   Sanger	   Institute	   as	   well	   as	  external	   groups	   from	   Cambridge	   University,	   University	   College	   London	   and	  other	  institutes,	  working	  with	  different	  rare	  disorders	  such	  as	  ciliopathies	  [290-­‐292],	   neuromuscular,	   thyroid	  disorders	   and	   familial	   hyperlipidemia,	   have	  used	  FEVA	   to	   identify	   mutations	   in	   novel	   or	   known	   genes.	   Moreover,	   FEVA	   is	   also	  being	   used	   in	   large-­‐scale	   projects	   with	   hundreds	   of	   families,	   such	   as	   in	   the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project	  [260].	  	  	  The	   results	   from	   this	   chapter	   show	   that	   at	   every	   step	   of	   the	   analysis	   pipeline	  small,	  seemingly	  insignificant,	  changes	  can	  have	  a	  big	  impact	  on	  the	  numbers	  of	  candidate	   variants	   being	   explored.	   Planning	   an	   upgrade	   of	   a	   pipeline,	  implementing	  a	  new	  version	  of	  a	  caller,	  modifying	  a	  filter	  threshold	  are	  some	  of	  the	   decisions	   that	   should	   not	   be	   taken	   lightly	  without	   careful	   consideration	   of	  how	   such	   a	   decision	  would	   affect	   the	   output.	   This	   is	   especially	   true	   in	   clinical	  settings	  where	  maximum	   levels	  of	   sensitivity	  and	  specificity	  are	   required	   for	  a	  definitive	  diagnosis.	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Collaboration	  note	  	  
Dr.	  Sebastian	  Gerety	  and	  Dr.	  Sarah	  Lindsay	  generated	  some	  of	  the	  data	  described	  
in	  this	  chapter.	  Sebastian	  performed	  the	  gene	  knockdown	  in	  zebrafish	  (appendix	  A)	  
while	   Sarah	   provided	   technical	   assistance	   for	   the	   validation	   experiments	   for	   de	  
novo	  mutations	  using	  PCR	  and	  capillary	  sequencing.	  	  
3.1 Introduction	  	  	  
3.1.1 Historical	  overview	  on	  Tetralogy	  of	  Fallot	  In	   1888,	   Étienne-­‐Louis	   Arthur	   Fallot,	   a	   French	   physician,	   described	   heart	  anatomical	  features	  and	  linked	  them	  to	  the	  clinical	  presentation	  of	  a	  “la	  maladie	  
bleue”	   or	   “the	   blue	   disease”	   [293].	   Fallot	   noticed	   an	   interventricular	  communication,	   sub	   pulmonary	   stenosis,	   biventricular	   origin	   of	   the	   aorta	   and	  hypertrophy	  of	  the	  right	  ventricle	   in	  three	  patients	  with	  cyanotic	  discoloration.	  	  Today,	  we	  are	  aware	  that	  others	  such	  as	  Stenonis	  (1672),	  Farre	  (1814),	  Peacock	  (1866)	  and	  von	  Rokitansky	  (1875)	  also	  observed	  these	  anatomical	  features	  prior	  to	  Arthur	  Fallot.	  However,	  Fallot	  was	  the	  first	  to	  correlate	  these	  findings	  to	  the	  clinical	   features	   [294].	   In	   1924,	   Maude	   Abbott	   coined	   the	   term	   “Tetralogy	   of	  Fallot”	   (ToF)	   as	   a	   convenient	   for	   of	   identification	   instead	   of	   listing	   all	   four	  anatomical	  features	  [295]	  in	  her	  “Atlas of Congenital Cardiac Disease”	  [2,	  296].	  	  
3.1.2 Epidemiology	  and	  recurrence	  risks	  of	  Tetralogy	  of	  Fallot	  Tetralogy	  of	  Fallot	  occurs	   in	  3	  out	  of	  every	  10,000	   live	  births,	  and	  accounts	   for	  10%	  of	  all	  CHD	  cases	  and	  is	  considered	  to	  be	  one	  of	  the	  most	  common	  cyanotic	  cardiac	   lesions	   beyond	   neonatal	   age	   [297].	   Both	   genders	   are	   equally	   affected	  [298],	  but	  a	  recent	  report	  from	  the	  PAN	  study,	  a	  nation-­‐wide	  study	  in	  Germany,	  showed	   that	   slightly	  more	  males	   are	   affected	   than	   females	   (1.4:1)	   [64].	   A	   few	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risk	  factors	  have	  been	  identified	  that	  increase	  the	  risk	  of	  ToF	  such	  as	  the	  age	  of	  father	   ≥	   25	   [299],	   race	   and	   ethnicity	  may	   also	   contribute	   to	   differences	   in	   the	  prevalence	  of	  ToF.	  Compared	  to	  black	  infants,	  white	  infants	  were	  found	  to	  have	  an	  increased	  prevalence	  of	  many	  CHD	  subtypes	  including	  ToF	  [300].	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non-­‐consanguineous,	  the	  RR	  when	  one	  child	  is	  already	  affected	  by	  CHD	  is	  low	  (2-­‐3%)	   but	   almost	   triples	   when	   two	   or	   more	   siblings	   are	   affected	   (8%).	   On	   the	  other	  hand,	  when	  the	  mother	  or	  the	  father	  is	  affected,	  the	  RR	  is	  around	  2-­‐5%	  and	  1-­‐2%,	  respectively	  [29,	  39,	  301].	  	  
3.1.3 Embryology	  and	  anatomy	  of	  Tetralogy	  of	  Fallot	  	  Tetralogy	  of	  Fallot	  has	  been	  classified	  as	  an	  obstructive	  lesion	  of	  the	  right	  side	  of	  the	   heart.	   To	   understand	   how	   the	   structural	   components	   of	   ToF	   arise,	   I	   will	  illustrate	   the	   normal	   anatomy	   of	   the	   right	   ventricle	   (RV)	   followed	   by	   the	  anatomical	   features	   of	   ToF	   and	   then	   describe	   the	   main	   embryological	   events	  related	  to	  ToF	  anatomical	  features.	  	  	  The	  main	  function	  of	  the	  right	  side	  of	  the	  heart	  is	  to	  pump	  deoxygenated	  blood	  to	  the	  lungs.	  The	  right	  ventricle	  (RV)	  forms	  a	  major	  portion	  of	  the	  anterior	  surface	  of	   the	   heart	   as	   it	   extends	   from	   the	   right	   atrium	   to	   the	   apex	   of	   the	   heart.	  	  Traditionally,	   the	  RV	  has	  been	  divided	  into	  two	  components:	   the	  sinus	  (inflow)	  and	   the	   conus	   (infundibulum).	   	   The	   inflow	   portion	   extends	   from	   the	   tricuspid	  valve	  (TV)	  to	  the	  trabeculated	  (apical)	  portion	  of	  the	  ventricle	  while	  the	  outflow	  portion	  starts	  and	  extends	  to	  the	  pulmonary	  valve	  (PV)	  (Figure	  3-­‐2).	  	  	  ToF	  is	  defined	  by	  four	  anatomical	  features:	  pulmonary	  stenosis,	  ventricle	  septal	  defect,	   overriding	   of	   the	   aorta,	   and	   hypertrophy	   of	   the	   right	   ventricle	   (Figure	  3-­‐3).	   These	   four	   features	   are	   thought	   to	   arise	   from	   a	   displacement	   of	   a	   single	  anatomical	  structure	  know	  as	  muscular	  outlet	  septum	  or	  the	  conal	  septum	  [302].	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  Figure	   3-­‐2	   The	   anatomy	   of	   the	   human	   right	   ventricle	   (image	   adapted	   from	   Netter's	   clinical	  anatomy	  [303])	   	  	  The	   misalignment	   of	   the	   conal	   septum	   narrows	   the	   right	   ventricular	   outflow	  tract,	  leading	  to	  subpulmonic	  obstruction	  (first	  ToF	  feature)	  and	  forms	  a	  typical	  misaligment	   type	   of	   ventricular	   septal	   defect	   (second	   ToF	   feature).	   The	   aortic	  wall	  is	  immediately	  behind	  the	  conal	  septum	  so	  that	  the	  left	  ventricular	  outflow	  tract	   always	   overrides	   the	  misaligned	   VSD	   (third	   ToF	   feature).	   Finally,	   the	   RV	  hypertrophy	  is	  considered	  a	  mechanical	  consequence	  of	  the	  RV	  obstruction.	  	  	  
	  Figure	  3-­‐3	  The	  main	  anatomical	  features	  in	  tetralogy	  of	  Fallot	  (image	  adapted	  from	  [304])	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During	   embryogenesis,	   these	   structural	   abnormalities	   arise	   as	   a	   result	   of	  abnormal	   development	   of	   the	   outflow	   tract	   (OFT)	   septation.	   As	   part	   of	   the	  transition	   from	   the	   heart	   tube	   stage	   to	   a	   four-­‐chambered	   heart,	   the	   heart	  requires	  proper	   septation	  of	   the	  outflow	   tract	   into	   the	   right	   and	   left	   ventricles	  that	   open	   into	   separate	   pulmonary	   and	   aorta	   trunks.	   OFT	   septation	   requires	  multiple	  cell	  lineages	  to	  participate	  in	  cushion	  growth.	  For	  example,	  neural	  crest	  cells	  (NCCs)	  migrate	  into	  the	  distal	  OFT	  (Figure	  3-­‐4-­‐A)	  and	  help	  to	  develop	  two	  groups	  of	  cushions:	  the	  conal	  and	  truncal	  cushions	  (Figure	  3-­‐4-­‐B,C).	  	  	  The	  distal	  (truncal)	  cushions	  fuse	  to	  form	  the	  aortopulmonary	  septum,	  dividing	  the	  distal	  part	  of	   the	  OFT	   into	  the	  aorta	  and	  pulmonary	  trunks	  [305]	  while	   the	  conal	  cushions	  merge	  to	  form	  the	  conal	  septum	  and	  separating	  the	  right	  and	  left	  ventricles	  [306].	  Misaligned	  or	  incomplete	  OFT	  septation	  (Figure	  3-­‐4-­‐D)	  leads	  to	  a	   number	   of	   congenital	   heart	   defects	   beside	   ToF	   such	   as	   double-­‐outlet	   right	  ventricle	  (DORV)	  and	  transposition	  of	  great	  arteries	  (TGA)	  [307].	  	  	  Up	  to	  16%	  of	  ToF	  cases	  are	  associated	  with	  other	  structural	  or	  vascular	  lesions	  that	  can	   influence	  the	  clinical	  presentation	  of	  ToF	  patients	  and	  may	  complicate	  surgical	   intervention	   [302].	   The	   most	   commonly	   associated	   structural	   lesions	  are	  aortic	  root	  dilation	  (40%),	  peripheral	  pulmonary	  stenosis	  (28%),	  aortic	  arch	  anomalies	   (25%)	   and	   secundum	   atrial	   septal	   defects	   (20%).	   Vascular	   lesions	  may	   also	   accompany	   ToF,	   most	   of	   which	   are	   coronary	   anomalies	   (15%),	   left	  superior	  vena	  cava	  (11%)	  or	  aortopulmonary	  collaterals	  (10%)	  [308].	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  Figure	  3-­‐4	  Septation	  of	  the	  cardiac	  outflow	  tract.	  (A)	  Left	  lateral	  view	  of	  an	  E10	  mouse	  embryo.	  The	  neural	  crest	  gives	  rise	  to	  cells	  (blue)	  that	  migrate	  to	  and	  colonize	  the	  distal	  cardiac	  outflow	  tract	   (OFT).	   (B)	   The	   cardiac	   OFT	   contains	   conal	   (proximal)	   and	   truncal	   (distal)	   cushions.	   The	  boundary	  between	   the	  conal	  and	   truncal	   cushions	   is	  marked	  by	  an	  outer	   curvature	  of	   the	  OFT	  (the	   conotruncal	   curvature).	   (C)	  The	   conotruncal	   cushions	   (CTCs)	   and	   intercalated	   cushions	  (ICCs)	   develop	   within	   the	   OFT.	   These	   cushions	   occupy	   four	   quadrants	   of	   the	   OFT	   (shown	   in	  cross-­‐section).	  The	  conotruncal	  cushions	  fuse	  to	  septate	  the	  OFT,	  as	  shown	  in	  D.	  (D)	  Fusion	  of	  the	  conotruncal	  cushions	  forms	  a	  spiral	  septum,	  the	  truncal	  part	  of	  which	  divides	  the	  OFT	  into	  aorta	  and	   pulmonary	   trunk,	   whereas	   the	   conal	   part	   septates	   the	   OFT	   into	   left	   and	   right	   ventricular	  outlets	  (LVOT,	  RVOT).	  The	  aortic	  valve	  (AV)	  and	  pulmonic	  valves	  (PV)	  develop	  at	  the	  conotruncal	  junction.	  (Image	  and	  caption	  adapted	  from	  [307])	  	  
3.1.4 Causes	  of	  Tetralogy	  of	  Fallot	  As	   for	   other	   CHD	   subtypes,	   both	   environmental	   and	   genetic	   causes	   have	   been	  proposed	  for	  ToF,	  and	  supporting	  evidence	  for	  both	  is	  discussed	  below.	  	  	  	  
Non-­‐genetic	  causes	  	  Many	  environmental	  factors	  have	  been	  found	  to	  increase	  the	  risk	  of	  the	  ToF.	  For	  example,	   maternal	   illnesses	   during	   pregnancy	   such	   as	   untreated	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phenylketonuria	   increases	   the	   risk	   of	   any	   CHD	   including	   ToF	   >	   6-­‐fold,	  pregestational	  diabetes	  (3.1-­‐18	  fold),	  and	  febrile	  illness	  (1.8-­‐2.9)	  fold	  [299].	  	  	  	  Besides	  maternal	   illness,	   external	   factors	  have	   also	  been	   found	   to	   increase	   the	  relative	   risk	   of	   ToF	   such	   as	   the	   exposure	   to	   organic	   solvents	   [9]	   or	   carbon	  monoxide	  in	  the	  first	  3-­‐8	  weeks	  of	  pregnancy	  [309].	  	  
Known	  genetic	  causes	  in	  syndromic	  ToF	  (Mendelian)	  
	  Almost	   32%	   of	   ToF	   cases	   occur	   as	   part	   of	   syndromes	   with	   extracardiac	  phenotypes	  [310].	  The	  underlying	  genetic	  causes	  of	  these	  syndromes	  range	  from	  whole	   chromosome	   lesions	   to	   single	   point	   mutations.	   	   Many	   chromosomal	  trisomies	   are	   associated	   with	   ToF.	   Down	   syndrome	   (trisomy	   21)	   has	   a	  prevalence	   of	   1	   in	   700	   live	   births	   where	   44%	   exhibits	   various	   CHD	   such	   as	  complete	  VSD	  in	  43%	  and	  ToF	  in	  6%	  of	  the	  cases	  [311].	  Other	  trisomies	  such	  as	  Patau	  syndrome	  (trisomy	  13)	  and	  Edwards	  syndrome	  (trisomy	  18)	  may	  present	  with	  ToF	  features	  [312,	  313].	  	  Submicroscopic	   chromosomal	   rearrangements	  may	   also	   cause	   syndromic	   ToF.	  The	   most	   common	   submicroscopic	   chromosomal	   lesion	   is	   22q11.2	   deletion	  syndrome	   (1	   in	   4000	   live	   births),	   which	   causes	   a	   spectrum	   of	   phenotypes	  ranging	  from	  DiGeorge	  to	  Shprintzen	  (velocardiofacial)	  syndrome	  wherein	  CHD	  are	  found	  in	  75%	  of	  cases	  [314,	  315].	  	  This	  microscopic	  deletion	  spans	  a	  1.5	  to	  3-­‐Mb	   region	   and	   includes	   30-­‐40	   genes.	   One	   of	   them	   is	   TBX1,	   a	   known	  haploinsufficient	   gene	   that	   is	   likely	   to	   be	   a	   major	   contributor	   to	   the	   heart	  phenotypes	  [316]. 	  Other	  genes	  such	  as	  JAG1	  and	  NOTCH2	  cause	  Alagille	  syndrome	  when	  they	  carry	  point	  mutations	   or	   small	   insertion/deletion	   (indel)	   and	   exhibit	   similar	   clinical	  symptoms	   to	   the	   22q11.2	   deletion	   [317].	   Alagille	   syndrome	   is	   an	   autosomal	  dominant	   heterogeneous	   hepato-­‐caridac	   syndrome	   where	   90-­‐96%	   of	   the	  patients	   exhibit	   various	   CHD	   [317,	   318].	   The	   most	   common	   heart	   defect	   is	  pulmonary	   stenosis	   (67%)	   while	   ToF	   occurs	   in	   7-­‐16%	   of	   the	   patients	   [318].	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About	  89%	  of	  the	  cases	  are	  associated	  with	  point	  mutations	  in	  the	  JAG1	  gene,	  a	  ligand	   for	  NOTCH	   receptors,	  while	  mutations	   in	  NOTCH2	   are	   found	   in	  1-­‐2%	  of	  the	  cases	  [319].	   	  50-­‐70%	  of	   the	  mutations	   in	  Alagille	  cases	  arise	  de	  novo	   [319].	  The	   majority	   of	   these	   mutations	   (~80%)	   are	   protein-­‐truncating	   mutations	  (frameshift,	  nonsense,	  splice	  site),	  7%	  are	  whole	  gene	  deleting	  and	  the	  remaining	  are	  missense	  mutations	   [320].	  However,	   some	   individuals	  with	   JAG1	  mutations	  may	   express	   only	   some	   of	   the	   features	   of	   Alagille	   syndrome,	   mainly	   isolated	  cardiac	  defects	   [321-­‐324].	  The	  molecular	  analysis	  performed	  by	  Fengmin	  Lu	  et	  
al.	  	  [325]	  in	  a	  family	  with	  JAG1	  missense	  mutation	  that	  co-­‐segregates	  with	  heart	  defect	   in	   absence	   of	   liver	   disease	   demonstrated	   a	   'leaky'	   mutation.	   The	   leaky	  mutation	   affects	   the	   amount	   of	   Jagged1	   protein	   produced	   to	   fall	   between	   that	  seen	  in	  an	  individual	  with	  haploinsufficiency	  and	  an	  individual	  with	  two	  normal	  copies	   of	   JAG1.	   The	   authors	   suggested	   that	   the	   heart	   is	  more	   sensitive	   to	   JAG1	  dosage	  than	  the	  liver.	  	  More	  recently,	  specific	  mutations	  in	  the	  last	  exon	  of	  NOTCH2	  has	  been	  shown	  to	  cause	  Hajdu-­‐Cheney	   syndrome,	   an	   autosomal	   dominant	   disorder	  which	   causes	  focal	   bone	   destruction,	   osteoporosis,	   craniofacial	   dysmorphology,	   renal	   cysts,	  cleft	  palate,	  and	  cardiac	  defects	  [326].	  	  These	  mutations	  are	  predicted	  to	  disrupt	  the	   intracellular	   PEST	   (proline-­‐glutamate-­‐serine-­‐threonine-­‐rich)	   domain	   and	  decrease	   clearance	   of	   the	   notch	   intracellular	   domain,	   thus	   increasing	   Notch	  signalling	   [326-­‐328].	   These	   findings	   suggest	   a	   complex	   genotype-­‐phenotype	  relationship	  may	  exist	  by	  which	  different	  mutations	  in	  the	  same	  gene	  can	  cause	  completely	  different	  monogenic	  syndromes.	  	  	  CHARGE	   syndrome	   (which	   stands	   for	   coloboma,	   heart	   defect,	   atresia	   choanae,	  retarded	   growth	   and	   development,	   genital	   hypoplasia	   and	   ear	   anomalies)	   is	  another	  example	  of	  a	  syndrome	  where	  84%	  of	  the	  cases	  have	  CHD	  phenotypes,	  including	  ToF	  in	  33%	  of	  the	  patients,	  and	  is	  usually	  caused	  by	  point	  mutations	  in	  the	  CHD7	  gene	  [305,	  329].	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Known	  genetic	  causes	  in	  non-­‐syndromic	  ToF	  	  Few	  genes	  have	  been	  associated	  with	  isolated	  ToF	  (Table	  3-­‐1).	  Most	  are	  based	  on	  candidate	   gene	   re-­‐sequencing	   studies.	   These	   studies	   are	   usually	   small	   (<	   200	  patients)	   and	   can	   explain	   a	   small	   percentage	   of	   the	   cases	   (~4%	   on	   average).	  	  Among	   these	   candidate	   genes	   is	   NKX2.5	   gene;	   a	   transcription	   factor	   that	   is	  expressed	   in	   cardiac	   mesoderm	   and	   its	   null	   knockout	   mouse	   model	   halts	   the	  heart	  development	  at	  the	  linear	  tube	  stage	  [330].	  Mutations	  in	  NKX2.5	  have	  been	  found	   in	   1-­‐4%	   of	   ToF	   cases	   [331,	   332]	   but	   these	   two	   studies	   did	   not	   provide	  functional	   evidence	   to	   support	   the	   effect	   of	   these	   mutations.	   Other	   studies	  confirmed	   the	   effect	   of	   mutations	   found	   in	   isolated	   ToF	   cases	   by	   functional	  studies	   such	   as	   luciferase	   assays,	   gene	   expression	   and	   protein	   localization,	  modelling	   mutations	   in	   zebrafish	   (Table	   3-­‐1).	   The	   strength	   of	   evidence	   from	  supporting	   functional	   experiments	   varies	   between	   studies,	   which	   makes	  establishing	  genotype-­‐phenotype	  correlation	  more	  difficult.	  	  	  Table	  3-­‐1	  Gene	  mutations	  in	  selected	  candidate	  genes	  in	  isolated	  ToF	  from	  resequencing	  studies	  [294]	  
Gene	   Mutated	  patients	  /	  analyzed	  patients	   %	   Functional	  studies	   Reference	  
NKX2.5	  
6/150	   4	   N/A	   Goldmuntz	  et	  al.	  [332]	  	  9/201	   4.5	   N/A	   McElhinney	  et	  al.[331]	  
FOG2	   2/47	   4	   Repression	  assay	   Pizzuti	  et	  al.[333]	  
CITED2	   3/46	   6	   Transcriptional	  assay	   Sperling	  et	  al.	  [334]	  NODAL	  pathway	   15/121	   12	   Zebraﬁsh	  rescue	  assay	   Roessler	  et	  al.[335]	  
JAG1	  
3/94	   3	   Notch	  activation	  assay	   Bauer	  et	  al.[321]	  2/112	   2.7	   N/A	   Guida	  et	  al.[336]	  
TBX1	   3/93	   3	   Luciferase	  assay	   Griffin	  et	  al.	  [337]	  
FOXA2	   4/93	   4	   N/A	   Topf	  et	  al.[338]	  
GJA5	   2/178	   1	   Zebrafish	  modeling	  and	  dye	  transfer	  studies	   Guida	  et	  al.	  [339]	  
FOXC1	   1/93	   1	   N/A	   Topf	  et	  al.[338]	  
HAND2	   1/93	   1	   N/A	   Topf	  et	  al.[338]	  	  	  Beside	   point	  mutations	   as	   a	   cause	   of	   isolated	  ToF,	   several	   recent	   studies	   have	  demonstrated	  an	  excess	  of	  rare	  and	  de	  novo	  copy	  number	  variants	  (CNV)	  in	  non-­‐
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syndromic	  ToF	  [122,	  340,	  341].	  Greenway	  et	  al.	  [341]	  detected	  11	  de	  novo	  CNVs	  in	   114	   isolated	   ToF	   cases	   that	   are	   novel	   or	   extremely	   rare	   in	   2,265	   controls.	  Some	  of	   these	  CNVs	  overlap	  with	   genes	   known	   to	   cause	  CHD	   such	   as	  NOTCH1	  and	   JAG1.	   Based	   on	   these	   findings,	   the	   authors	   predicted	   that	   10%	   of	   non-­‐syndromic	  ToF	  cases	  result	  from	  de	  novo	  CNVs.	  A	  more	  recent	  work	  by	  Soemedi	  
et	  al	   [122]	  confirmed	  the	  burden	  of	   large	  rare	  genic	  CNVs	  in	  isolated	  ToF	  cases	  but	  reported	  a	  lower	  rate	  of	  de	  novo	  CNVs	  in	  ToF	  (5%)	  compared	  with	  Greenway	  
et	   al.	   Silversides	   et	   al	   [340]	   were	   able	   to	   replicate	   previous	   locus-­‐specific	  findings,	   such	   as	   1q21.1	   deletion	   CNVs	   in	   ~1%,	   but	   they	   also	   detected	   CNVs	  overlapping	   PLXNA2	   and	   highlighted	   the	   possible	   involvement	   of	   PLXNA2-­‐semaphorin	   signaling	   in	   the	   development	   of	   ToF.	   The	   results	   from	   the	   CNV	  analyses	  suggest	   the	   involvement	  of	  novel	  and	  multiple	  genes	  and	  pathways	   in	  the	  development	  of	  the	  heart.	  	  At	  the	  other	  end	  of	  the	  spectrum,	  the	  “common	  variant	  common	  disease”	  (CVCD)	  hypothesis	  proposes	  that	  co-­‐occurrence	  of	  multiple	  common	  variants,	  each	  with	  a	   small	   effect	   size,	   is	   required	   to	  cause	  a	   complex	  disease	   [342,	  343].	  Genome-­‐wide	   association	   studies	   (GWAS)	   using	   SNP	   arrays	   have	   detected	   hundreds	   of	  common	   variants	   associated	   with	   many	   complex	   diseases	   (a	   full-­‐catalogue	   of	  these	  studies	  is	  available	  in	  [114]).	  Because	  GWAS	  requires	  large	  sample	  sizes	  to	  detect	   strongly	   significant	   modest	   effect	   sizes	   at	   the	   genome-­‐wide	   level,	   few	  studies	   have	   detected	   such	   signals	   in	   CHD.	   Very	   recently,	   Cordell	   et	   al.	   [344]	  published	   the	   first	   example	   of	   a	   GWAS	   of	   a	   CHD	   subtype	   (ToF).	   The	   authors	  detected	  a	  region	  on	  chromosome	  12q24	  in	  a	  northern	  European	  discovery	  set	  of	   835	   ToF	   cases	   and	   5,159	   controls	   (P=1.4	   ×	   10-­‐7)	   and	   were	   also	   able	   to	  replicate	  the	  signal	  in	  798	  cases	  and	  2,931	  controls	  (P=3.9	  ×	  10-­‐5).	  The	  strongest	  signal	   detected	   was	   for	   rs11065987,	   a	   marker	   located	   on	   12q24	   that	   had	  previously	   been	   associated	   with	   other	   complex	   conditions	   including	   celiac	  disease	  [345],	  coronary	  artery	  disease	  [346]	  and	  rheumatoid	  arthritis	  [347].	  The	  strongest	   candidate	   gene	   within	   the	   12q24	   region	   is	   PTPN11,	   a	   regulator	   of	  Ras/mitogen-­‐associated	   protein	   kinase	   signaling.	   Mutations	   in	   PTPN11	   are	   a	  known	   cause	   of	   Noonan’s	   syndrome	   in	   which	   malformation	   of	   the	   cardiac	  outﬂow	   tract	   is	   a	   typical	   feature	   [348].	   This	   study	   also	   identified	   a	   few	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interesting	   signals	   in	   other	   genes	   such	   as	   GPC5,	   a	   gene	   encoding	   glypican	   5,	  which	   belongs	   to	   a	   family	   of	   genes	   known	   to	   work	   as	   regulators	   in	   many	  developmental	   signaling	   pathways,	   including	   the	   Wnt,	   Hedgehog,	   fibroblast	  growth	  factor	  and	  bone	  morphogenetic	  protein	  pathways	  [349].	  
3.1.5 Aim	  of	  the	  study	  The	  aim	  of	  this	  project	  is	  to	  detect	  genes	  significantly	  enriched	  for	  rare	  and	  /	  or	  
de	   novo	   coding	   variants	   in	   isolated	   ToF	   cases	   using	   a	   trio-­‐based	   study	   design	  based	  on	  exome	  sequencing.	  
3.1.6 Overview	  of	  the	  ToF	  analyses	  	  The	  molecular	  genetic	  studies	  of	  ToF,	  described	  above,	  paint	  a	  picture	  of	  a	  broad	  spectrum	  of	  aetiologies	   that	  range	   from	  monogenic	   forms	  of	  ToF	  at	  one	  end	   to	  environmental	   risk	   factors	   and	   common	   susceptibility	   variants	   (multifactorial)	  at	   the	   other.	   I	   decided	   to	   use	   exome	   sequencing	   to	   identify	   highly	   penetrant	  coding	  variants.	  I	  used	  a	  two-­‐stage	  study	  design,	  with	  an	  initial	  discovery	  phase	  using	   exome	   sequencing	   of	   parent-­‐offspring	   trios	   to	   identify	   candidate	   genes,	  and	  then	  a	  second	  phase	  of	  custom	  targeted	  sequencing	  of	  these	  candidate	  genes	  in	  a	  much	  larger	  set	  of	  patient-­‐offspring	  trios	  (n=250).	  	  In	  analyzing	  these	  data,	  first	  I	  tried	  to	  identify	  genes	  with	  plausibly	  pathogenic	  de	  
novo	  mutations	   	   or	   inherited	   variants	   under	   autosomal	   recessive	   and	   X-­‐linked	  models.	   I	   also	   tried	   to	   identify	   genes	   enriched	   for	   inherited	   variants	   of	  incomplete	   penetrance	   using	   a	   modified	   version	   of	   the	   transmission	  disequilibrium	  test	  (TDT)	  that	  I	  developed	  and	  implemented.	  	  	  I	   also	   investigated	  whether	   it	   might	   be	   possible	   to	   identify	   a	   digenic	  mode	   of	  causation	  whereby	  rare	  coding	  variants	  in	  two	  functionally	  related	  genes	  would	  be	  pathogenic.	  Digenic	  inheritance	  (DI)	  is	  the	  simplest	  form	  of	  inheritance	  when	  we	   consider	   polygenic	   disorders.	   Five	   decades	   ago,	   Defrise–Gussenhoven	  discussed	   the	   subject	   of	   reduced	   penetrance	   under	   the	  monogenic	  model	   and	  suggested	  that	  a	  two-­‐locus	  model	  could	  explain	  the	  inheritance	  more	  accurately	  [350].	  Currently,	  there	  are	  tens	  of	  syndromes	  that	  show	  DI	  but	  only	  a	  few	  have	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been	   successfully	   replicated	   with	   supporting	   evidence	   from	   functional	   studies	  and	   /	   or	   animal	  models	   [351].	  Alejandro	   Schäffer	   has	   provided	   an	   operational	  definition	   of	   DI:	   ‘inheritance	   is	   digenic	   when	   the	   variant	   genotypes	   at	   two	   loci	  
explain	   the	   phenotypes	   of	   some	   patients	   and	   their	   unaffected	   (or	   more	   mildly	  
affected)	  relatives	  more	  clearly	  than	  the	  genotypes	  at	  one	  locus	  alone’	  [351].	  	  	  The	  most	  well	  studied	  example	  of	  DI	  is	  retinitis	  pigmentosa,	  which	  was	  also	  the	  first	   example	   of	   DI	   in	   1994	   based	   on	   the	   analysis	   of	  multiple	   pedigrees	   [352].	  Most	   of	   the	   DI	   studies	   used	   either	   candidate	   genes	   design	   or	   genetic	   linkage	  design	   [351].	   The	   massively	   parallel	   sequencing	   (MPS)	   platforms	   have	   the	  potential	   to	   facilitate	  both	  DI	  study	  designs,	  because	  they	  are	  able	   to	  screen	  all	  known	  genes	   in	   every	   sample	   in	   the	   study.	   	   To	  date,	   only	   two	  DI	   studies	   used	  MPS:	  the	  first	  was	  facioscapulohumeral	  muscular	  dystrophy	  (FSHD)	  type	  2	  [353]	  and	   the	   second	   ataxia	   and	   hypogonadism	   [354].	   This	   analysis	   is	   discussed	   in	  section	  3.3.3	  in	  this	  chapter.	  	  	  Finally,	   I	   investigated	   whether	   I	   could	   detect	   an	   enrichment	   of	   rare	   coding	  variants	  in	  distinct	  pathways	  and	  this	  is	  discussed	  in	  section	  3.3.4.	  Additionally,	  next	   generation	   sequencing	   data	   can	   also	   be	   used	   to	   detect	   copy	   number	  variants,	  which	  I	  discuss	  in	  section	  3.3.1.4.	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  Figure	   3-­‐5	   A	   two-­‐stage	   study	   design	   was	   adapted	   in	   this	   chapter.	   The	   first	   stage	  included	  exome	  sequencing	  of	  30	  parent-­‐offspring	  trios	  isolated	  ToF	  while	  the	  second	  stage	  included	  an	  additional	  250	  trios	  as	  a	  replication	  cohort	  (red	  dashed	  box).	  	  Quality	  control	   (QC)	   tests	   (blue	  boxes)	   helped	   to	   exclude	   trios	   that	   performed	  poorly	   on	  QC	  test	  at	  the	  level	  of	  samples	  (DNA),	  data	  or	  variant	  calls.	  Various	  analytical	  approaches	  (orange	  boxes)	  are	  described	  in	  the	  results	  section.	  *Indicates	   tests	   performed	   after	   designing	   the	   custom	   baits	   and	   thus	   any	   identified	  candidate	   genes	   in	   those	   tests	   was	   not	   included	   in	   the	   replication	   cohort.	   	   FEVA:	  Family-­‐based	  Exome	  Variant	  Analysis.	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3.2 Methods	  
	  
Samples	  and	  inclusion	  criteria	  	  	  
	  The	   primary	   cohort	   includes	   30	   trios	   of	   Tetralogy	   of	   Fallot	   children	   and	   their	  healthy	  parents.	  These	  trios	  are	  part	  of	  the	  CHANGE	  cohort	  managed	  by	  Bernard	  Keavney	   and	   Judith	   Goodship	   at	   Newcastle	   University.	   The	   diagnosis	   was	  confirmed	   by	   echocardiography	   and	   only	   isolated	   non-­‐syndromic	   cases	   were	  included.	   	  The	  replication	  cohort	  of	  250	  trios	  of	  ToF	  was	  also	  selected	  from	  the	  CHANGE	  cohort	  using	  the	  same	  inclusion	  criteria.	  	  	  
Exome	  sequencing	  
	  Samples	  were	  sequenced	  at	  the	  Wellcome	  Trust	  Sanger	  Institute.	  Genomic	  DNA	  from	  venous	  blood	  or	  saliva	  was	  obtained	  and	  captured	  using	  SureSelect	  Target	  Enrichment	  V3	  (Agilent)	  and	  sequenced	  (HiSeq	  Illumina	  75	  bp	  pair-­‐end	  reads).	  Reads	   were	   mapped	   to	   the	   reference	   genome	   using	   BWA	   [149].	   Single-­‐nucleotide	  variants	  were	  called	  by	  SAMtools	  [272]	  and	  GATK	  [153]	  while	  indels	  were	  called	  using	  SAMtools	  and	  Dindel	  [158].	  	  Variants	  were	  annotated	  for	  allele	  frequency	   using	   1000	   Genomes	   (June	   2012	   release)	   [155]	   and	   2,172	   healthy	  parents	  from	  the	  Deciphering	  Developmental	  Disorders	  project	  (DDD)	  [260].	  The	  Ensembl	  Variant	  Effect	  Predictor	  [170]	  was	  used	  to	  annotate	  the	  impact	  on	  the	  protein	  structure.	  
	  
Validation	  with	  capillary	  sequencing	  	  For	  samples	  with	  limited	  DNA,	  my	  colleague,	  Sarah	  Lindsay,	  amplified	  the	  whole	  genome	  using	  illustra	  GenomiPhi	  V2	  DNA	  Amplification	  Kit	  (GE	  Healthcare,	  USA).	  I	   used	   BatchPrimer3	   server	   [355]	   to	   design	   the	   PCR	   primers	  with	   the	   default	  settings.	  Dr.	  Lindsay	  performed	  the	  variant	  validation	  using	  capillary	  sequencing	  (Genetic	  Analyzer	  from	  Life	  Technologies,	  USA).	  DNA	  sequences	  were	  aligned	  to	  the	  genome	  reference	  and	  analyzed	  using	  Geneious	  Pro	  (version	  5.4.6)	  [356].	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3.3 Results	  
3.3.1 DNA	  samples	  	  The	   primary	   dataset	   comprises	   exome	   sequences	   for	   30	   complete	   trios	   of	  children	   diagnosed	   with	   Tetralogy	   of	   Fallot	   and	   their	   healthy	   parents	   (all	  Caucasian).	  The	  DNA	  samples	  were	  provided	  by	  Professor	  Bernard	  Keavney	  and	  Judith	  Goodship	  from	  the	  University	  of	  Newcastle.	  None	  of	  the	  selected	  patients	  in	  this	  cohort	  have	  any	  other	  extra	  cardiac	  symptoms	  upon	  clinical	  examination.	  	  The	   definitive	   final	   diagnosis	   of	   the	   heart	   defect	   was	   confirmed	   by	  echocardiography.	  	  
3.3.1.1 Quality	  Control	  	  	  In	  order	  to	  obtain	  a	  high	  quality	  dataset	  for	  downstream	  analysis,	  several	  quality	  control	  assessments	  are	  required	  to	  detect	  issues	  such	  as	  contamination,	  sample	  swapping	  or	  failed	  sequencing	  experiments.	  DNA	  quality	  control	  is	  applied	  prior	  to	  exome	  sequencing	  and	  data	  quality	  control	  is	  applied	  after	  exome	  sequencing	  at	   the	   level	  of	  both	   the	  sequence	  data	   (BAM	  files)	  and	   the	  called	  variants	   (VCF	  files).	  	  	  
DNA	  quality	  control	  The	  sample	  logistics	  team	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  tested	  the	  DNA	  quality	   of	   each	   sample	   using	   an	   electrophoretic	   gel	   to	   exclude	   samples	   with	  degraded	  DNA.	  The	  team	  also	  assessed	  DNA	  volume	  and	  concentration	  using	  the	  PicoGreen	   assay	   [277]	   to	   make	   sure	   every	   sample	   met	   the	   minimum	  requirements	   for	   exome	   sequencing.	   Additionally,	   26	   autosomal	   and	   four	   sex	  chromosomal	  SNPs	  were	  genotyped	  as	  part	  of	   the	   iPLEX	  assay	   from	  Sequenom	  (USA).	   This	   test	   helps	   to	   determine	   the	   gender	   discrepancies,	   relatedness	   or	  possible	   contamination	   issues.	   All	   trios	   in	   the	   primary	   cohort	   for	   exome	  sequencing	  (30	  trios)	  passed	  these	  tests.	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Sequence	  data	  quality	  control	  	  The	   second	   group	   of	   quality	   control	   tests	   was	   performed	   once	   the	   sequence	  reads	   had	   been	   generated	   by	   the	   next-­‐generation	   sequencing	   platform.	   Carol	  Scott	   at	   the	   Genome	   Analysis	   Production	   Informatics	   (GAPI)	   team	   performed	  these	  tests	  to	  detect	  samples	  with	  too	  low	  sequence	  coverage.	  None	  of	  the	  trios	  in	   the	   primary	   cohort	   failed	   any	   of	   these	   assessments.	   The	   average	   sequence	  data	  generated	  per	  exome	  was	  6.2	  Gb	  with	  68-­‐fold	  mean	  depth	  and	  88%	  of	  the	  exome	  covered	  by	  at	  least	  10	  reads.	  	  	  
DNA	  variant	  quality	  control	  The	  third	  phase	  of	  quality	  control	  assessed	  the	  called	  variants	  in	  the	  Variant	  Call	  Format	  (VCF)	  files	  [161].	  The	  aim	  of	  these	  tests	  was	  to	  detect	  any	  outlier	  samples	  based	   on	   the	   counts	   of	   single	   nucleotide	   variants	   (SNV)	   or	   insertion/	   deletion	  variants	   (INDEL)	   in	   comparison	   to	   other	   published	   and/or	   internal	   projects	  (Table	  3-­‐2).	  All	  90	  samples	   in	   the	  primary	  cohort	   	   (30	  complete	   trios)	   showed	  comparable	   QC	   matrices	   to	   other	   internal	   projects	   except	   one	   sample	  (TOF5136022)	   that	   showed	   a	   high	   heterozygous–to-­‐homozygous	   ratio	   ~3.0	  instead	  of	  the	  average	  ratio	  of	  ~1.5.	  This	  is	  often	  a	  sign	  of	  possible	  contamination	  and	  was	  confirmed	  later	  by	  the	  sample	  logistic	  team.	  This	  sample	  was	  excluded	  from	   the	  downstream	  analysis	   along	  with	   its	  parents.	  The	   average	  numbers	  of	  rare	   and	   common	   variants	   in	   different	   classes	   such	   as	   loss-­‐of-­‐function,	  functional,	  silent	  are	  listed	  in	  Table	  3-­‐2	  and	  Figure	  3-­‐6	  and	  Figure	  3-­‐7.	  All	  of	  the	  QC	   parameters	   of	   the	   remaining	   samples	   are	   comparable	   to	   other	   internal	  projects.	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Table	  3-­‐2	  Average	  counts	  of	  various	  quality	  matrices	  and	  variants	  classes	  per	  sample.	  	  
Phase	   Goals	   Measures	  	   Average	  per	  sample	  
Exome	  
sequencing	  
Base-­‐level	  stats	   Raw	  output	   6.2	  billion	  High	  quality	  bases	  >	  Q30	   88%	  Average	  coverage	  per	  base	   68	  Read-­‐level	  stats	   Raw	  read	  count	   82	  million	  Duplication	  fraction	   11%	  High	  quality	  mapped	  reads	   62	  millions	  
Variant	  
calling	  	  
Single	  nucleotide	  variants	  (SNVs)	  stats	  
Total	  number	  of	  coding	  SNVs	  	   21,367	  Transition/Transversion	  ratio	  	   3.02	  Het/hom	  ratio	  (all	  coding	  variants)	   1.62	  %	  Of	  common	  coding	  SNVs	  (MAF	  >	  1%)	   95.4%	  Common	  loss-­‐of-­‐function	  variants	   80	  Common	  functional	  variants	   9,629	  Common	  silent	  variants	   10,271	  %	  Of	  rare	  coding	  SNVs	  (MAF<	  1%)*	   4.5%	  Rare	  loss-­‐of-­‐function	  variants	   15	  Rare	  functional	  variants	   608	  Rare	  silent	  variants	   325	  
Insertion	  and	  deletion	  (indels)	  stats	  
Total	  number	  of	  coding	  indels	  count	   436	  %	  Of	  common	  coding	  INDELs	  (MAF	  >	  1%)	   86%	  Coding	  in-­‐frame	  indels	   261	  Coding	  frameshift	  indels	   175	  Coding	  in-­‐frame	  /	  frameshift	  ratio	   1.49	  Rare	  coding	  indels	   60	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Figure	   3-­‐6	   Quality	   control	   plots	   including	   global	   counts	   and	   various	   single	   nucleotide	  variants	  stats	  (see	  main	  text	  for	  description)	  
3.3	  Results	  	  
	   136	  
	  
3.3.1.2 De	  novo	  analysis	  (primary	  cohort)	  	  The	  trio	  study	  design	  allows	  the	  detection	  of	  de	  novo	  variants.	  I	  submitted	  each	  trio	   in	   the	   primary	   ToF	   cohort	   to	   the	   DeNovoGear	   pipeline	   that	   I	   developed	  (described	  in	  chapter	  2)	  to	  detect	  and	  annotate	  candidate	  de	  novo	  variants.	  	  Before	   filtering	   the	  DeNovoGear	  output,	  each	   trio	  had	  176	  unfiltered	  candidate	  













































































































































































































































































Figure	  3-­‐7	  Quality	  control	  plots	  for	  insertion	  and	  deletion	  variants	  (indels)	  
3.3	  Results	  	  
	   137	  
inherited	  from	  a	  parent),	  (iv)	  variants	  not	  called	  by	  an	  independent	  caller	  such	  as	  SamTools,	   Dindel	   or	   GATK,	   and	   (v)	   variants	   predicted	   	   to	   be	   non-­‐coding	   and	  outside	  canonical	  splice	  sites	  by	  the	  VEP	  annotation	  tool	  [170].	  	  	  Table	  3-­‐3	  lists	  the	  number	  of	  filtered	  candidate	  de	  novo	  variants	  grouped	  by	  their	  predicted	  effect	  on	  the	  protein	  structure	  after	  applying	  the	  above	  five	  filters.	  	  	  Table	  3-­‐3	  Candidate	  coding	  de	  novo	  variants	  passed	  the	  five	  filters	  from	  29	  ToF	  trios	  
Variant	  predicted	  consequences	  	   Count	  Missense	   39	  Synonymous	   8	  Splice	  region	   7	  Stop	  gained	   6	  Frameshift	   2	  Splice	  acceptor	   2	  Splice	  donor	   1	  
Total	   65	  	  To	  see	  how	  these	  filtered	  candidate	  de	  novo	  variants	  are	  distributed	   in	  the	  ToF	  trios,	   I	  plotted	   the	  number	  of	  variants	   in	  each	  trio	   in	  (Figure	  3-­‐8).	  The	  average	  number	   of	   filtered	   candidate	   coding	   variants	   per	   trio	   is	   ~2.1.	   However,	   three	  trios	  did	  not	  have	  any	  filtered	  candidate	  de	  novo	  coding	  or	  splicing	  variants	  while	  only	   one	   trio,	   TOF5135947,	   showed	   an	   excess	   of	   filtered	   candidate	   de	   novo	  variants	  (7	  mutations:	  two	  loss	  of	  functions	  (stop	  gain	  and	  slice	  site	  donor)	  and	  five	  missense	  variants).	  The	  most	  frequent	  variant	  class	  was	  the	  missense	  (n=39)	  followed	  by	  synonymous	  (n=8).	  	  	  Upon	   validation	   using	   capillary	   sequencing,	   performed	   by	  my	   colleague	   Sarah	  Lindsay,	  only	  a	  third	  of	   these	  variants	  were	  found	  to	  be	  true	  positive	  while	  the	  remaining	  candidates	  are	  either	  inherited	  variants,	  false	  positive	  (i.e.	  reference)	  or	  failed	  sequencing	  after	  three	  attempts	  (Table	  3-­‐4).	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  Figure	  3-­‐8	  Filtered	  candidate	  de	  novo	  variants	  per	  trio	  by	  consequences.	  (B)	  Validated	  de	  novo	  variants	  by	  capillary	  sequencing.	  	  Table	  3-­‐4	  Summary	  of	  capillary	  sequencing	  validation	  experiment	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The	  21	  validated	  coding	  de	  novo	  variants	  are	  listed	  in	  Table	  3-­‐5	  along	  with	  their	  genome	   loci	   and	   the	   predicted	   consequences	   on	   the	   protein	   structure.	   The	  average	   numbers	   of	   SNVs	   or	   INDELs	   in	   this	   cohort	   are	   comparable	   to	   other	  published	  studies	  (Figure	  3-­‐9).	  Excluding	  INDELs,	  I	  observed	  a	  significant	  excess	  of	  loss-­‐of-­‐function	  mutations	  	  (~15%)	  compared	  to	  the	  rate	  previously	  reported	  in	  controls	  ~3.4%	  (exact	  binomial	  test	  P=	  0.025)	  [357]	  but	  not	  for	  missense	  (P=	  0.06)	  or	  splice	  sites	  (P	  =	  0.29).	  	  Among	  the	  genes	  with	  validated	  de	  novo	   coding	  variants,	   there	  are	   three	  genes	  known	   to	   cause	   structural	   heart	   defects	   in	   human	   and/or	   knockout	   mouse	  models	  	  (NOTCH1,	  DCHS1	  and	  SPEN).	  	  	  	  The	  NOTCH1	  is	  the	  only	  gene	  with	  recurrent	  de	  novo	  variants	  in	  the	  primary	  ToF	  cohort	  (a	  confirmed	  missense	  and	  a	  single-­‐base	  deletion	  predicted	  to	  disturb	  the	  acceptor	   splice	   site	   of	   the	   sixth	   exon	   waiting	   for	   additional	   DNA	   aliquote).	  
NOTCH1	  belongs	  to	  a	  family	  of	  four	  genes	  encoding	  single-­‐pass	  transmembrane	  receptors	   that	   regulate	   cell	   fate	   decisions	   during	   development	   and	   that	   are	  involved	  in	  many	  cellular	  processes	  (reviewed	  in	  [358]).	  Dominant	  mutations	  in	  
NOTCH1	  have	  been	  associated	  with	  left	  ventricular	  outflow	  tract	  abnormalities	  in	  human	   such	   as	   coarctation	   of	   the	   aorta,	   hypoplastic	   left	   heart	   syndrome,	  bicuspid	  aortic	  valve,	  and	  aortic	  valve	  stenosis	  [359-­‐361].	  	  	  The	  DCHS1	  gene	   is	   a	  member	  of	   the	   cadherin	   superfamily	   of	   cell-­‐cell	   adhesion	  molecules	  and	  its	  homozygous	  knockout	  mouse	  model	  exhibits	  defects	   in	  atrial	  septation	   [362].	  The	   third	  gene	  with	  a	  knockout	  mouse	  model	   showing	  CHD	   is	  
SPEN.	  The	  mouse	  model	  died	  around	  day	  14.5	  with	  morphological	  abnormalities	  in	   the	  pancreas	  and	  heart	   [363].	  However,	   the	  de	  novo	   variant	   in	  SPEN	   gene	   is	  predicted	  to	  be	  silent	  and	  thus	  unlikely	  to	  be	  causal.	  	  One	   novel	   gene	   in	   particular	   worth	   discussing	   here	   is	   ZMYM2,	   a	   transcription	  factor	   and	   part	   of	   a	   BHC	   histone	   deacetylase	   complex	   with	   a	   de	   novo	   coding	  frameshift	   [364].	   Translocation	   of	   this	   gene	   with	   the	   fibroblast	   growth	   factor	  receptor-­‐1	  gene	  (FGFR1)	  results	  in	  a	  fusion	  gene,	  which	  has	  been	  found	  to	  cause	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stem	  cell	  leukemia	  lymphoma	  syndrome	  (SCLL)	  [365].	  This	  fusion	  gene	  was	  also	  found	   to	   activate	   the	   Notch	   pathway	   in	  murine	   ZMYM2-­‐FGFR1–induced	   T-­‐cell	  lymphomas	   [366].	   Although	   this	   gene	   does	   not	   have	   any	   published	   knockout	  mouse	   model	   yet,	   its	   involvement	   in	   the	   Notch	   pathway	   made	   this	   gene	   an	  interesting	   candidate	   for	   modelling	   in	   zebrafish	   (see	   zebrafish	   morpholino	  knockdown	  experiments	  section).	  	  The	   remaining	  genes	  with	  validated	  de	  novo	   coding	  or	   splicing	  variants	  do	  not	  have	   clear	   biological	   links	   to	   the	   development	   of	   the	   heart.	   Nonetheless,	   I	  selected	  them	  for	  re-­‐sequencing	   in	  a	   larger	  number	  of	  samples	  (see	  replication	  study	  section)	  to	  detect	  any	  recurrent	  de	  novo	  variants	  in	  these	  genes.	  	  	  Table	  3-­‐5	  List	  of	  validate	  de	  novo	  variants	  from	  29	  ToF	  trios.	  *	  Pending	  validation.	  
Gene	   Trio	  Id	   Locus	   Reference/Alternative	   Consequences	  
ZMYM2	   334	   13:20567809	   TGG/TG	   Frameshift	  
IKZF1	   325	   7:50467964	   C/T	   Missense	  
TTC18	   352	   10:75037994	   G/A	   Missense	  
MYO7B	   367	   2:128393882	   G/A	   Missense	  
NOTCH1	   312	   9:139399497	   C/T	   Missense	  
DCHS1	   382	   11:6650724	   C/T	   Missense	  
OSBPL10	   352	   3:31918002	   C/A	   Missense	  
FAM178A	   333	   10:102698379	   C/G	   Missense	  
ANKRD11	   359	   16:89350711	   A/C	   Missense	  
ADCY5	   318	   3:123047511	   C/T	   Missense	  
PLCXD1	   318	   X:209880	   G/T	   Missense	  
ATP5G1	   330	   17:46970784	   A/G	   Missense	  
TPRA1	   402	   3:127298623	   C/T	   Missense	  
FLOT2	   318	   17:27209354	   C/T	   Disturb	  donor	  splice	  site	  
PLCG2	   319	   16:81925070	   CTTTT/CTT	   Near	  a	  splice	  site	  (<8bp)	  
ARHGAP35	   335	   19:47423379	   C/T	   Stop	  gained	  
SERAC1	   402	   6:158537270	   C/A	   Stop	  gained	  
ITGB4	   382	   17:73723777	   C/T	   Stop	  gained	  
SPEN	   328	   1:16256191	   A/G	   Synonymous	  
RREB1	   366	   6:7230783	   C/T	   Synonymous	  
PHRF1	   356	   11:582022	   A/G	   Missense	  
NOTCH1*	   549	   9:	  139396541	   CT/C	   Disturb	  an	  acceptor	  splice	  site	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  Figure	  3-­‐9	  The	  average	  number	  of	  validated	  de	  novo	  in	  the	  primary	  ToF	  cohort	  is	  comparable	  to	  other	   published	   studies	   [190,	   267-­‐271].	   (The	   literature	   survey	   is	   a	   courtesy	   of	   Dr.	   Matthew	  Hurles).	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when	  dealing	  with	  variants	  on	   the	  X	  chromosome.	  The	   first	  scenario	   is	  when	  a	  female	   child	   inherits	   an	   allele	   from	   the	  mother’s	   inactive	  X-­‐chromosome	  while	  the	  daughter	  have	  a	  skewed	  X	  inactivation	  (Table	  3-­‐6,	  B).	  The	  second	  scenario	  is	  when	  a	  male	  child	  inherits	  an	  allele	  from	  a	  carrier	  mother	  (Table	  3-­‐6,	  C).	  	  I	   used	   the	   Family-­‐based	   Exome	   Variant	   Analysis	   (FEVA)	   software	   that	   I	  developed	   in	   chapter	   2	   to	   output	   candidate	   variants	   for	   each	   trio	   under	   each	  scenario.	   Table	   3-­‐6	   lists	   the	   average	   number	   of	   loss	   of	   function	   (include	   stop	  gain,	   frameshift	  and	  variants	  that	  disturb	  either	  donor	  or	  acceptor	  splice	  sites),	  and	  functional	  variants	  (including	  missense	  and	  stop	  lost).	  	  FEVA	  reported	  total	  of	  	  ~6.0	  rare	  coding	  variants	  per	  trio	  regardless	  of	  gender.	  Half	  of	  these	  variants	  (~2.6	  per	  trio)	  are	  autosomally	   inherited	  while	  the	  rest	  are	   inherited	  on	  the	  X-­‐chromosome.	  	  	  Under	   these	   four	  Mendelian	   inheritance	   scenarios,	   this	   analysis	   picked	  up	  159	  unique	   genes	   with	   rare	   coding	   variants:	   51	   genes	   under	   autosomal	   recessive	  homozygous,	   58	   autosomal	   recessive	   compound	   heterozygous,	   and	   50	   genes	  were	  X-­‐linked	  model	  in	  either	  male	  or	  female	  probands.	  	  	  The	  vast	  majority	  of	  these	  candidate	  genes	  appear	  in	  one	  sample	  only	  except	  for	  five	   genes	   that	   appear	   to	   be	   recurrent.	   All	   of	   the	   five	   recurrent	   genes	   were	  detected	  under	  the	  compound	  heterozygous	  model	  suggesting	  that	  they	  may	  be	  highly	   variable	   genes.	   Based	   on	   their	   biological	   functions,	   two	   out	   of	   the	   five	  genes	  (FLG	  and	  MUC16)	  are	  less	  likely	  to	  be	  strong	  candidates	  for	  the	  ToF	  or	  CHD	  in	   general.	  FLG	  encodes	   a	   protein	   aggregates	   keratin	   intermediate	   filaments	   in	  the	  mammalian	  epidermis	  while	  MUC16	  encodes	  Mucin	  16	  at	  mucosal	  surfaces.	  The	  other	   three	  genes	  encode	   sarcomeric	  proteins	   (TTN,	  NEB	   and	  OBSCN)	   and	  are	  known	  to	  be	  very	  large	  genes,	  which	  may	  partially	  explain	  why	  they	  harbor	  multiple	  rare	  coding	  variants.	  	  Under	  the	  X-­‐linked	  model,	  four	  genes	  appear	  to	  be	  recurrent	  in	  female	  patients	  only	  (i.e.	  variants	  inherited	  from	  the	  mother).	  These	  are	  IL13RA1	  (interleukin	  13	  receptor,	  alpha1),	  IRAK1	  (interleukin-­‐1	  receptor-­‐associated	  kinase	  1),	  TLR7	  (toll-­‐
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like	   receptor	   7),	   and	   ZNF674.	   All	   of	   these	   genes,	   except	   for	   ZNF674,	   have	  knockout	  mouse	  models	  but	  none	   show	  any	  gross	   structural	  heart	  phenotypes	  and	  thus	  they	  are	  unlikely	  to	  be	  strong	  candidates	  for	  ToF	  [368-­‐370].	  ZNF674	  has	  been	  linked	  to	  nonsyndromic	  X-­‐linked	  mental	  retardation	  [371]	  and	  there	  is	  no	  obvious	  evidence	  to	  support	  its	  involvement	  in	  heart	  development.	  	  Table	  3-­‐6	  Average	  number	  of	  genes	  with	  coding	  variants	  (excluding	  silent	  variants)	  per	  offspring	  in	  the	  primary	  ToF	  cohort	  (males=11	  and	  females	  =18)	  under	  different	  mode	  of	  inheritance.	  The	  numbers	   in	   trio	   genotype	   combination	   column	   correspond	   to	   homozygous	   reference	   (0),	  heterozygous	  (1),	  and	  homozygous	  non-­‐reference	  or	  hemizygous	  on	  the	  X	  chromosome	  (2)	  and	  are	  ordered	  as	  the	  child,	  mother	  and	  father,	  respectively.	  
Chromosome	  





Loss	  of	  	  
function	   Functional	   Both	  
[A]	  Autosomal	   	  Homozygous	   (2,1,1)	  	   0.03	   0.34	   0.37	  Compound	  heterozygous	   Locus	  A	  (1,1,0)	  Locus	  B	  (1,0,1)	  	   0.07	   2.17	   2.24	  [B]	  X	  in	  females	   Heterozygous	   (1,1,0)	  	   0.22	   3.22	   3.44	  [C]	  X	  	  in	  males	   Hemizygous	   (2,1,0)	  	   0.09	   3.55	   3.64	  	  
3.3.1.4 Copy	  Number	  Variant	  analysis	  (primary	  cohort)	  	  Rare	   copy	   number	   variants	   are	   known	   to	   cause	   5-­‐10%	   of	   isolated	   ToF	   cases	  [122,	   340,	   341]	   based	   on	   array	   CGH	   and	   SNP	   array.	   Recently,	   several	   groups	  have	   published	   computation	   approaches	   to	   call	   CNVs	   from	   exome	   data	  (reviewed	   in	   [157]).	   Calling	   CNV	   from	   exome	   data	   is	   still	   in	   its	   infancy	   and	  consequently	   is	  associated	  with	  a	   relatively	  high	   false	  positive	  rate.	  However,	   I	  decided	   to	   investigate	   the	   possibility	   of	   de	   novo	   or	   rare	   inherited	   CNVs	   that	  overlap	  with	  known	  CHD	  genes.	  	  	  My	   colleague,	   Dr.	   Parthiban	   Vijayarangakannan,	   has	   developed	   a	   CNV-­‐calling	  algorithm	   and	   software	   called	   CoNVex	   [372]	   to	   detect	   copy	   number	   variation	  from	  exome	  and	   targeted-­‐resequencing	  data	  using	   comparative	   read-­‐depth.	  He	  generated	   the	   CNV	   calls	   from	   the	   primary	   ToF	   cohort	   and	   I	   performed	   the	  downstream	  analysis.	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Initially,	  I	  was	  able	  to	  detect	  two	  plausible	  de	  novo	  duplication	  events	  in	  two	  trios	  out	  of	  29.	  The	  first	   is	  a	  218Kb	  duplication	  on	  chromosome	  2	  and	  spans	  several	  genes	   including	  HDAC4	   (Histone	   deacetylase	   4).	   The	   second	   CNV	   event	   was	   a	  1.6Mb	   duplication	   overlapping	   with	   the	   PFKP,	   PITRM1,	   and	   ADARB2	   genes	  (Figure	  3-­‐10	  and	  Table 3-7).	  	  
	  
HDAC4	  encodes	  a	  protein	  with	  deacetylation	  activity	  against	  core	  histones	  [373]	  and	  HDAC4-­‐null	  mice	  display	  premature	  ossification	  of	  developing	  bones	  but	  did	  not	   exhibit	   heart	   phenotypes	   [374].	  However,	   the	   haploinsufficiency	   of	  HDAC4	  causes	  brachydactyly	  mental	   retardation	  syndrome,	  which	  has	  been	  associated	  with	  cardiac	  defects	  in	  20%	  of	  the	  patients	  [375,	  376].	  Moreover,	  overexpression	  of	  HDAC4	   inhibits	   cardiomyoblast	   formation	  and	  down-­‐regulate	   the	  expression	  of	  GATA4	  and	  Nkx2-­‐5	  [377].	  Further	  investigations	  are	  required	  to	  determine	  the	  dosage	  sensitivity	  of	  HDAC4	  and	  the	  nature	  of	  its	  role	  in	  heart	  development.	  	  	  	  On	   the	   other	   hand,	   none	   of	   the	   genes	   that	   overlap	   with	   the	   second	   de	   novo	  duplication	   have	   a	   knockout	   mouse	   model	   (PFKP,	   PITRM1,	   and	   ADARB2).	   The	  
PFKP	   gene	   encodes	   the	   platelet	   isoform	   of	   phosphofructokinase	   and	   a	   key	  metabolic	   regulator	   of	   glucose	   metabolism	   [378].	   PITRM1	   is	   a	   zinc	  metalloendopeptidase	   that	   has	   been	   implicated	   in	   Alzheimer’s	   disease	   and	  mitochondrial	  peptide	  degradation.	  More	  recently,	   the	  hedgehog	  signalling	  was	  found	   to	   regulate	   Pitrm1	   in	   the	   developing	   mouse	   limb	   [379].	   The	   last	   gene,	  
ADARB2,	   encodes	   a	   protein	   	   that	   is	   a	   member	   of	   the	   double-­‐stranded	   RNA	  (dsRNA)	   adenosine	   deaminase	   family	   of	   RNA-­‐editing	   enzymes	   [380].	   None	   of	  these	   genes	   have	   strong	   evidence	   to	   support	   a	   direct	   involvement	   in	   heart	  development.	  	  	  My	  aim	  in	  the	  second	  part	  of	  CNV	  analysis	  was	  to	   find	  recurrent	  rare	   inherited	  CNV	   that	  overlap	  with	  known	  CHD	  genes	   in	  human	  and/or	  animal	  models.	   	  To	  obtain	   this	   callset,	   I	   applied	   four	   filters	   on	   the	  original	  CNV	   calls	   from	  CoNVex	  pipeline	   :	   (i)	  CNV	  calls	  with	  CoNVex	  scores	  <	  10	  were	  excluded	   to	   remove	   low	  quality	   calls,	   (ii)	   CNV	   calls	   with	   >	   50%	   	   of	   their	   length	   overlapping	   known	  common	  CNV	  manually	  curated	  from	  multiple	  high-­‐quality	  publications	  and	  used	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as	  part	  of	  CoNVex	  pipeline,	  (iii)	  	  I	  excluded	  CNV	  calls	  with	  frequency	  >	  1%	  in	  CHD	  samples	  sequenced	  by	  our	  group	  (n=723)	  ,	  and	  (iv)	  I	  excluded	  CNV	  calls	  that	  do	  not	   overlap	  with	   candidate	   CHD	   genes	   (n=1,507	   genes	  manually	   curated	   from	  CHD	  studies	  in	  human	  and	  animal	  models,	  curtsey	  of	  Dr.	  Marc-­‐Phillip	  Hitz).	  	  
	  Figure	   3-­‐10:	   (A)	   A	   218Kb	   duplication	   event	   on	   chromosome	   2	   spanning	   the	   HDAC4	   gene	   in	  patient	  (TOF5135983).	  The	  blue	  line	  is	  the	  log2	  ratio	  in	  the	  patient	  while	  the	  grey	  lines	  represent	  the	   log2ratio	   scores	   for	   the	   same	   region	   in	   other	   samples	   in	   the	   cohort.	   (B)	   A	   1.6	   duplication	  event	  on	  chromosome	  10	  spanning	  the	  PFKP,	  PITRM1	  and	  ADARB2	  genes	  in	  patient	  TOF5136013.	  	  
	  
Table	   3-­‐7	   Plausible	   de	   novo	   duplications	   in	   the	   primary	   ToF	   cohort.	   DUP:	   duplication.	  	  Chr:	   chromosome,	   Number	   of	   probes:	   number	   of	   baits	   covering	   CNV.	   The	   CoNVex	   score	   is	   a	  confidence	  score	  based	  on	  the	  Smith-­‐Waterman	  score	  divided	  by	  the	  square	  root	  of	  the	  number	  of	  probes	  where	  higher	  values	  mean	  better	  and	  more	  confidant	  calls.	  




type	   Genes	  TOF5135983	   2	   239894438	   240112834	   27	   10.73	   DUP	   HDAC4,	  MIR4440,	  MIR4441	  TOF5136013	   10	   1568930	   3215096	   52	   52.23	   DUP	   PFKP,	  	  PITRM1,	  
	  ADARB2	  	  	  	  
A"
B"
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Only	  three	  trios	  were	  found	  to	  have	  two	  small	  inherited	  duplications	  (1.3	  Kb,	  and	  12.7Kb)	  that	  span	  FOXC1	  and	  FOXC2,	  respectively	  (Table	  3-­‐8).	  FOXC1	  and	  FOXC2	  are	  both	   forkhead	  box	   transcription	   factors	  crucial	   for	  development	  of	   the	  eye,	  cardiovascular	  network,	  and	  other	  physiological	  systems.	  The	  mice	  null	  models	  show	   various	   structural	   heart	   defects	   [381,	   382].	   Mutations	   in	   FOXC1	   in	  particular	   have	   been	   associated	  with	   aortic	   stenosis,	   pulmonary	   valve	   stenosis	  and	  atrial	   septal	  defect	   [383].	  However,	   it	   is	   unlikely	   to	   identify	   the	   same	   rare	  duplication	   in	   three	   unrelated	   trios	   in	   a	   small	   sample	   size	   and	   thus	   these	  duplications	   are	   likely	   to	   be	   false	   positive.	   Moreover,	   the	   number	   of	   probes	  overlapping	  these	  two	  duplications	  is	  small	  (one	  or	  two	  probes).	  Validation	  using	  an	  alternative	  CNV	  detection	  method	  (e.g.	  custom	  designed	  array	  or	  MLPA	  [384])	  is	  required	  before	  considering	  these	  interesting	  findings	  any	  further.	  	  Table	   3-­‐8	   List	   of	   recurrent	   rare	   inherited	   duplications	   overlapping	   known	   CHD	   genes.	   DUP:	  duplication	  




type	   Genes	   Inherited	  from	  
TOF5135968	   6	   1610536	   1611901	   1	   13.75	   DUP	   FOXC1,	  	   Paternal	  16	   86600787	   86613488	   2	   11.14	   DUP	   FOXC2,	  FOXL1,	  RP11-­‐463O9.5,	  	   Maternal	  
TOF5135971	   6	   1610536	   1611901	   1	   14.64	   DUP	   FOXC1,	  	   Both	  parents	  have	  this	  CNV	  16	   86600787	   86613488	   2	   13.83	   DUP	   FOXC2,	  FOXL1,	  RP11-­‐463O9.5,	  	   Father	  X	   153283293	   153285567	   1	   11.34	   DUP	   IRAK1,	  MIR718,	  	   Mother	  
TOF5135977	   6	   1610536	   1611901	   1	   13.22	   DUP	   FOXC1,	  	   Maternal	  16	   86600787	   86613488	   2	   10.56	   DUP	   FOXC2,	  FOXL1,	  RP11-­‐463O9.5,	  	   Maternal	  	  
3.3.2 Replication	  study	  In	   the	   second	   stage	   of	   the	   study	   I	   designed	   custom	   baits	   to	   capture	   coding	  regions	  of	  122	  candidate	  CHD	  genes	  for	  sequencing	  in	  whole	  genome	  amplified	  DNA	   from	   250	   parent-­‐offspring	   trios	   with	   isolated	   ToF.	   The	  main	   goal	   of	   this	  replication	   study	   is	   to	   identify	   additional	   ToF	   families	   with	   mutations	   in	   the	  same	  genes	   identified	   in	   the	  primary	  cohort	  analyses.	  Additionally,	   I	  wanted	  to	  test	   the	   burden	   of	   rare	   coding	   variants	   in	   other	   known	   candidate	   CHD	   genes	  from	   published	   studies	   that	   include	   linkage	   analysis,	   candidate	   genes,	   genome	  wide	  associations	  and	  copy	  number	  variant	  studies.	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3.3.2.1 Gene	  selection	  for	  replication	  study	  	  	  I	  selected	  122	  genes	  for	  the	  replication	  study	  using	  three	  different	  classes	  (Table	  3-­‐9).	  The	   first	   class	   includes	  genes	  with	  validated	  de	  novo	   coding	  variants	   (e.g.	  
NOTCH1,	  ZMYM2,	  and	  DCHS1)	  in	  the	  29	  trios	  described	  above	  or	  other	  candidate	  genes	   harbouring	   rare	   loss-­‐of-­‐function	   variants	   in	   other	   ToF	   samples	   (e.g.	   the	  
GMFG	   gene	   that	   I	   found	   to	   harbor	   a	   homozygous	   stop	   gain	   in	   three	   affected	  siblings	   with	   ToF	   in	   a	   different	   study	   (see	   section	   2.3.6	   FEVA	   applications	   in	  chapter	  2).	  The	  second	  group	  of	  candidate	  genes	  includes	  genes	  that	  have	  been	  linked	   to	   ToF	   in	   humans	   through	   genetic	   evidence	   from	   candidate	   gene	  sequencing,	  association,	  CNV	  and	  /	  or	   linkage	  studies.	  The	  third	  group	  includes	  genes	  that	  are	  involved	  in	  the	  WNT	  or	  NOTCH	  pathways	  and	  have	  been	  shown	  to	  have	  a	  clear	  structural	  heart	  phenotype	  in	  mouse	  knockout	  models.	  	  	  The	  WNT/NOTCH	  pathways	  have	  previously	  been	  shown	  to	  be	  enriched	  for	  rare	  and	  de	  novo	   CNVs	   in	  CHD	   in	  general	   and	   in	  TOF	   cases	   in	  particular	   [122,	  341]	  which	   make	   them	   good	   candidates	   for	   sequencing	   in	   replication	   studies.	  	  Because	   the	   total	  number	  of	  genes	   involved	   in	   the	  WNT	  and	  NOTCH	  pathways	  exceeds	  the	  available	  space	  within	  the	  custom	  bait	  design,	  I	  had	  to	  exclude	  many	  genes	   in	   a	   systematic	   fashion.	   First,	   I	   downloaded	   the	   mouse	   knockout	  phenotype	  data	  from	  the	  MGI	  database	  [288]	  and	  then	  assigned	  each	  gene	  to	  one	  of	  five	  different	  levels	  based	  on	  the	  type	  and	  severity	  of	  the	  CHD	  phenotype	  and	  associated	  GO	   terms	   in	   the	  mouse	  model	   (see	   the	   full	  workflow	  of	  mouse	  CHD	  genes	  selection	  in	  Figure	  3-­‐11).	  The	  complete	  list	  of	  selected	  genes	  is	  available	  in	  the	  Table	  3-­‐10.	  	  The	  bait	   length	   is	  120	  and	   I	  used	   the	   same	  baits	  used	   to	   cover	   the	  genes	   from	  Agilent	  Technologies;	  Human	  All	   Exon	  50	  Mb	   (SureSelectXT	  Automated	  Target	  Enrichment	   for	   Illumina	   Paired-­‐End	  Multiplexed	   Sequencing	  V4).	   	   The	   baits	   in	  this	   kit	   have	   been	   optimized	   for	   all	   candidate	   genes	   I	   have	   selected	   for	   the	  replication	  study,	  except	  for	  the	  CFC1	  gene.	  CFC1	  was	  not	  covered	  in	  the	  original	  SureSelectXT	  kit	  and	  I	  added	  2x	  tiling	  baits	  to	  cover	  it.	   I	  also	  visually	   inspected	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the	   bait	   coverage	   of	   the	   genes	   using	   the	   UCSC	   genome	   browser	   to	   ensure	   all	  coding	  regions	  were	  covered	  properly.	  	  	  Table	  3-­‐9	  The	  rationale	  and	  number	  of	  selected	  candidate	  genes	  in	  ToF	  replication.	  
Group	  of	  genes	   Rationale	  for	  selection	   Number	  of	  genes	  From	  primary	  cohort	  (exome)	   Candidate	  TOF	  genes	  	   12	  
Known	  ToF	  genes	   Published	  ToF	  candidate	  genes	  	   20	  Gene-­‐based	  and	  genome-­‐wide	  association	  studies	  	   11	  Candidate	  genes	  from	  linkage	  analysis	  studies	   4	  Candidate	  genes	  from	  CNV	  studies	   5	  NOTCH/WNT	  pathways	   Notch	  pathway	  (with	  heart	  phenotypes	  in	  MGI)	  	   41	  Wnt	  pathway	  (with	  heart	  phenotypes	  in	  MGI)	  	   36	  Total	   129	  (122	  unique)	  	  	  
	  
	   	  
Get all mammalian phenotypes (MP) 
that are children of abnormal 
cardiovascular system morphology 
term (MP:0002127)
(total 618 phenotypes) 
Note: Not all of these 618 MP terms are related 






Step (1) Get genes from netpath.org Step (2) Download Mammalian Phenotype from MGI database
Step (3) Annotate all genes in WNT/NOTCH pathways with MP from MGI database. 
Then manually assign the level of the CHD  phenotype  for each gene
level (3) Strong phenotype in the KO model (ex 
VSD, AVSD, cardia bifida, failure of heart looping 
etc.)
level (2) Unspecific or vague cardiac phenotypes 
(pericardial edema, decreased heart 
weight,  increased atrioventricular cushion 
size etc )
level (1) Phenotypes related to vasculature but no 
heart phenotype (e.g.  abnormal lung 
vasculature morphology ) 
level (0) The gene has no KO model in MGI
level (-1) The gene has a KO model in MGI but no 
cardiovascular phenotypes.
level$3$ level$2$ level$1$ level$0$$ level$)1$
NOTCH$ 24$ 17$ 5$ 11$ 27$



















Figure	   3-­‐11	   The	   workflow	   of	   gene	   selection	   from	   NOTCH/WNT	   pathway	   in	   the	   ToF	  replication	  study	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Table	  3-­‐10	  List	  of	  candidate	  gene	  selected	  for	  the	  replication	  study.	  Some	  of	  the	  candidate	  genes	  from	  primary	  cohort	  de	  novo	  analysis	  such	  as	  ITGB4	  were	  not	  included	  since	  they	  were	  identified	  after	  I	  designed	  the	  custom	  baits.	  	  *	  The	   candidate	  de	  novo	   variants	   in	  XXYLT2	   and	  MTUS2	  turned	  out	   to	  be	   false	  positive	  during	  capillary	  sequencing.	  
	  **CFC1	  has	  been	  covered	  using	  tiling	  probes	  (1x),	  while	  other	  genes	  have	  Agilent’s	  V4	  baits	  that	  overlap	  with	  GENCODE	  v12.	  
ADAM10	   ESR1	   MAP3K1	   PRKCQ	  
ADAM17	   FAT1	   MAP3K7	   PSEN1	  
ALDH1A2	   FBXW7	   MAPK1	   PSEN2	  
APC	   FN1	   MAPK3	   PTPN11	  
APH1A	   FOXH1	   MAPK8	   RAC1	  
ARHGAP35	   FURIN	   MEF2C	   RAF1	  
ATR	   FZD1	   MTHFR	   RAI1	  
AXIN1	   FZD10	   MTUS2*	   RBPJ	  
AXIN2	   FZD2	   NCOR2	   RELA	  
C2CD3	   GATA3	   NCSTN	   ROR1	  
CCND1	   GATA4	   NFATC1	   ROR2	  
CDH18	   GATA6	   NKX2-­‐5	   RPS6KB2	  
CDH2	   GDF1	   NODAL	   SALL4	  
CDK2	   GMFG	   NOTCH1	   SLC19A1	  
CFC1**	   GPC3	   NOTCH2	   SMAD1	  
CNOT6	   GPC5	   NRP1	   SMAD3	  
COL3A1	   HAND2	   NUMB	   SPEN	  
CRKL	   HDAC1	   PAX9	   STAT3	  
CSNK2A1	   HDAC2	   PCDH15	   TBX1	  
CTBP1	   HEY2	   PCDHB7	   TBX5	  
CTBP2	   IL6ST	   PCDHB8	   TCF3	  
CTNNB1	   ISL1	   PCSK5	   TDGF1	  
DAAM1	   JAG1	   PIK3R1	   TP53	  
DCHS1	   JUN	   PIK3R2	   VEGFA	  
DLL1	   JUP	   PLEC	   VEGFC	  
DLL4	   KL	   POFUT1	   WNT7B	  
DVL1	   LAMP2	   PPARG	   XXYLT1*	  
DVL2	   LPP	   PPM1K	   ZFPM2	  
DVL3	   LRP5L	   PRKACA	   ZMYM2	  
EDIL3	   MAML1	   PRKCA	   	  
EP300	   MAML3	   PRKCB	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3.3.2.2 Quality	  control	  (replication	  study)	  	  Similar	  to	  the	  primary	  exome	  sequencing	  of	  ToF	  trios	  to	  obtain	  high	  quality	  DNA	  variants	   for	   downstream	   analyses,	   different	   quality	   control	   steps	   were	  performed	  at	  the	  level	  of	  DNA	  samples,	  the	  sequencing	  data	  (BAM	  files)	  and	  the	  called	  variants	  (VCF	  files).	  	  The	  sample	  logistics	  team	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  tested	  the	  DNA	  quality	   of	   each	   sample	   using	   electrophoretic	   gel	   to	   exclude	   samples	   with	  degraded	  DNA.	  The	   team	  also	   tested	  DNA	  volume	  and	   concentration	  using	   the	  PicoGreen	   assay	   [277]	   to	   make	   sure	   every	   sample	   meets	   the	   minimum	  requirements	   for	   sequencing.	   Additionally,	   26	   autosomal	   and	   four	   sex	  chromosome	  SNPs	  were	  genotyped	  as	  part	  of	   the	   iPLEX	  assay	   from	  Sequenom	  (USA).	   These	   tests	   excluded	   41	   out	   of	   250	   complete	   trios	   submitted	   for	  sequencing.	   	   The	   custom	   sequencing	   generated	   0.35	   Gb	   per	   sample	   with	   an	  average	  267-­‐fold	  depth	  within	  the	  target	  regions.	  	  	  Since	   the	   targeted	   region	   is	   much	   smaller	   than	   the	   regular	   exome	   sequence	  study	  (122	  genes	  vs.	  ~20,000	  genes	  in	  an	  exome),	  the	  basic	  QC	  matrices	  such	  as	  the	  number	  of	  variants	  are	  expected	  to	  be	  different	  (Table	  3-­‐11,	  Figure	  3-­‐12	  and	  Figure	   3-­‐13).	   However,	   the	   transition/	   transversion	   ratio	   in	   the	   replication	  cohort	   (~3.3)	   is	   comparable	   to	   the	   primary	   exome-­‐based	   cohort	   (~3.1).	  Similarly,	  heterozygous	  /	  homozygous	  ratio	  is	  also	  comparable	  (1.4	  in	  the	  exome	  and	   1.5	   in	   replication	   design).	   On	   the	   other	   hand,	   the	   coding	   in-­‐frame	   /	  frameshift	   ratio	   is	   very	   different	   (1.5	   in	   the	   exome	   and	   5.1	   in	   the	   replication	  design).	  This	   is	  mainly	  due	   to	   the	  very	   low	  number	  of	   indels	   in	   the	   replication	  design,	  which	  is	  expected	  given	  its	  smaller	  number	  of	  genes.	  These	  analyses	  did	  not	  identify	  any	  further	  outlier	  samples	  that	  needed	  exclusion.	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Table	  3-­‐11	  Quality	  tests	  of	  the	  exome	  sequence	  data	  and	  called	  variants	  in	  replication	  ToF	  cohort	  
Phase	   Goals	   Tasks	   Average	  per	  sample	  
Exome	  
sequencing	  
Base-­‐level	  stats	   Raw	  output	   346	  million	  High	  quality	  bases	  >	  Q30	   87%	  Average	  coverage	  per	  base	   267	  Read-­‐level	  stats	   Raw	  read	  count	   4.6	  million	  Duplication	  fraction	   25%	  High	  quality	  mapped	  reads	   3.2	  million	  
Single	  nucleotide	  variants	  (SNVs)	  stats	  
Total	  number	  of	  coding	  SNVs	  	   230	  Transition/Transversion	  ratio	  	   3.34	  Het/hom	  ratio	  (all	  coding	  variants)	   1.72	  %	  Of	  common	  coding	  SNVs	  (MAF	  >	  1%)	   96%	  Common	  loss-­‐of-­‐function	  variants	   0.4	  Common	  functional	  variants	   99	  Common	  silent	  variants	   121	  %	  Of	  rare	  coding	  SNVs	  (MAF<	  1%)*	   4%	  Rare	  loss-­‐of-­‐function	  variants	   0.06	  Rare	  functional	  variants	   4.35	  Rare	  silent	  variants	   4.41	  
Insertion	  and	  deletion	  (indels)	  stats	  
Total	  number	  of	  coding	  indels	  count	   12.4	  %	  Of	  common	  coding	  INDELs	  (MAF	  >	  1%)	   86%	  Coding	  in-­‐frame	  indels	   10.5	  Coding	  frameshift	  indels	   1.82	  Coding	  in-­‐frame	  /	  frameshift	  ratio	   5.11	  Rare	  coding	  indels	   1.78	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3.3.2.3 Trio	  relatedness	  (replication	  cohort)	  	  After	   performing	   the	   sample-­‐by	   sample	   quality	   control	   tests,	   I	   checked	   trio	  relatedness	  in	  silico.	  My	  approach	  was	  based	  on	  examining	  the	  number	  of	  shared	  variants	  between	  each	  child	  and	  his	  parents.	  Most	  children	  shared	  ~71%	  of	  their	  variants	  on	  average	  with	  each	  parent	  (Figure	  3-­‐14,	  red	  points).	  To	  use	  a	  control	  set,	   I	   assigned	   each	   child	   to	   random	   parents	   and	   calculated	   the	   percentage	   of	  shared	  variants	  again	  (Figure	  3-­‐14,	  blue	  points)	  which	  show	  children	  assigned	  to	  random	   parents	   shared	   59%	   of	   their	   variants	   on	   average	   (they	   mostly	   share	  common	  variants).	  	  	  I	  found	  six	  outlier	  samples	  out	  of	  the	  209	  original	  trios	  where	  each	  child	  shared	  <	  62.5%	  with	  the	  father	  and	  65.5%	  with	  the	  mother.	  The	  low	  percentage	  of	  shared	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variants	   indicates	   either	   a	   contamination	   or	   sample	   swapping	   issue.	   These	   six	  samples	  have	  been	  flagged	  in	  the	  downstream	  analyses	  in	  order	  to	  spot	  possible	  unusual	  output,	  but	  were	  not	  excluded	  from	  the	  analysis.	  	  
	  Figure	  3-­‐14	  Percentage	  of	   shared	  variants	  between	  each	  child	  and	  his	  parents	   (red)	  and	  when	  children	  are	  assigned	  to	  random	  parent	  pairs	  (blue).	  Dashed	  black	  lines	  are	  used	  to	  separate	  the	  two	  groups	  and	  to	   flag	  six	   trios	  where	  children	  have	  shared	  <	  62.5%	  of	   their	  variants	  with	   the	  father	  and/or	  <	  65.5%	  with	  the	  mother.	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  I	  submitted	  all	  trios	  to	  the	  DenovoGear	  pipeline	  I	  designed	  (described	  in	  chapter	  2)	   and	   used	   the	   same	   five	   filters	   described	   in	   the	   primary	   ToF	   cohort	   to	   pick	  coding	   or	   splicing	   rare	   plausible	   de	   novo	   variants	   that	   were	   not	   seen	   in	   the	  parents	   and	   were	   called	   by	   independent	   programs	   (GATK,	   SamTools	   and/or	  Dindel).	  I	  was	  able	  to	  detect	  six	  plausible	  de	  novo	  variants	  in	  four	  genes,	  three	  of	  which	  are	  loss-­‐of-­‐function	  (Table	  3-­‐12).	  Two	  genes	  had	  de	  novo	  mutations	  in	  two	  unrelated	  trios.	  	  	  To	  assess	  whether	  the	  observed	  number	  of	  coding	  de	  novo	  variants	  is	  more	  than	  expected,	   I	   calculated	   the	   expected	   number	   of	   missense	   and	   putative	   loss	   of	  function	   variants	   given	   the	   cumulative	   length	   of	   coding	   regions	   in	   122	   genes	  selected	   for	   the	   replication	   study	   (329,562	  bp),	   the	   single	   nucleotide	  mutation	  rate	   (1.5	   ×10-­‐8),	   proportion	   of	   loss	   of	   function	   (0.052)	   and	   proportion	   of	  missense	  (0.663)	  [357].	  In	  122	  genes	  from	  209	  trios,	  this	  analysis	  estimates	  the	  expected	   number	   of	   de	   novo	   missense	   and	   loss	   of	   function	   to	   be	   1.3	   and	   0.1,	  respectively.	  	  	  
NOTCH1,	  which	  already	  had	   two	  de	  novo	   coding	  variants	   in	   the	  primary	  cohort	  (one	  missense	   and	  one	   insertion	  disturbing	   the	   acceptor	   splice	   site	   of	   the	  29th	  exon)	   had	   another	   two	   plausible	   de	   novo	   coding	   variants	   in	   the	   replication	  cohort,	  both	  of	  which	  were	  loss-­‐of-­‐function	  (nonsense).	  	  	  Interestingly,	   I	   also	  detected	   two	  plausible	  de	  novo	   coding	  variants	   in	   the	   JAG1	  gene	   (a	   missense	   and	   a	   variant	   predicted	   to	   disrupt	   a	   donor	   splice	   site)	   that	  encodes	  for	  jagged	  1	  protein,	  a	  known	  ligand	  for	  NOTCH1.	  	  Mutations	  that	  alter	  jagged	   1	   protein	   have	   been	   linked	   to	   Alagille	   syndrome,	   where	   90%	   of	   the	  patients	   have	   CHD,	   mostly	   right-­‐sided	   defects	   ranging	   from	   mild	   peripheral	  pulmonic	  stenosis	  to	  severe	  forms	  of	  tetralogy	  of	  Fallot	  [317,	  318].	  The	  knockout	  mouse	  model	  also	  showed	  similarities	  with	  Alagille	  syndrome	  including	  various	  heart	  defects	  [385].	  However,	  mutations	  in	  JAG1	  have	  been	  suggested	  as	  a	  cause	  for	  non-­‐syndromic	  CHD	  [386]	  and	  have	  also	  been	  reported	  in	  familial	  tetralogy	  of	  Fallot	  [323].	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  The	   fifth	   plausible	   missense	   de	   novo	   mutation	   was	   detected	   in	   VEGFA,	   which	  encodes	   for	   a	   growth	   factor	   that	   is	   active	   in	   angiogenesis,	   vasculogenesis	   and	  endothelial	   cell	   growth.	   The	  VEGFA	  mouse	   knockout	  model	   has	   a	   delayed	   and	  abnormal	   heart	   development,	   including	   the	   overriding	   of	   the	   aorta	   [387,	   388].	  Moreover,	   common	   SNPs	   in	  VEGFA	   have	   been	   reported	   to	   increase	   the	   risk	   of	  isolated	  ToF	  [389].	  	  	  The	  last	  plausible	  de	  novo	  missense	  variants	  was	  found	  in	  AXIN1,	  which	  encodes	  a	   protein	   that	   has	   both	   positive	   and	   negative	   regulatory	   roles	   in	   Wnt-­‐beta-­‐catenin	   signaling	   during	   embryonic	   development	   and	   in	   tissue	   homeostasis	   in	  adults	   [390].	   	  The	  homozygotic	  mouse	  null	  model	  died	  at	   embryonic	  day	  8-­‐10,	  exhibiting	  neuroectodermal	  defects	  and	  axial	  duplications.	  Heterozygotes	  exhibit	  underdeveloped	   trunk,	   kinky	   neural	   tube,	   enlarged	   pericardium,	   and	   cardia	  bifida	  [391].	  	  Moreover,	  the	  axin1	  zebrafish	  (mbl)	  mutants	  showed	  an	  absence	  of	  heart	  looping	  in	  13%	  of	  the	  embryos	  [392].	  	  	  	  Table	  3-­‐12	  List	  of	  plausible	  de	  novo	  coding	  variants	  that	  pass	  quality	  filters	  in	  209	  ToF	  trios.	  All	  variants	   are	  missense	   and	  predicted	  by	  PolyPhen	   [171]	   to	  have	   a	  probably	  damaging	   (PRD),	   a	  possibly	  damaging	  (PSD),	  or	  a	  benign	  (BEN)	   	  effect	  on	  the	  protein	   function.	  VEP:	  Variant	  Effect	  Predictor	   [170].	   GERP	   is	   Genomic	   Evolutionary	   Rate	   Profiling	   scores	   where	   higher	   values	  indicate	  conserved	  nucleotides)	  [164].	  chr:	  chromosome,	  	  na:	  not	  applicable.	  	  
Sample	  




allele	   Gene	   Type	  
Amino	  
acid	   PolyPhen	  
Capillary	  	  
Sequencing	  
Validation	  843	   9	   139399230	   C	   T	   NOTCH1	   Stop	  gained	   W/*	   Unknown	  	   Confirmed	  169	   9	   139412303	   G	   A	   NOTCH1	   Stop	  gained	   R/*	   Unknown	   Confirmed	  577	   20	   10630973	   C	   A	   JAG1	   Missense	   G/W	   PRD	  (0.999)	   Confirmed	  317	   20	   10625003	   A	   C	   JAG1	   Splice	  donor	   na	   Unknown	   Confirmed	  861	   16	   339545	   G	   A	   AXIN1	   Missense	   A/V	   PSD	  (0.679)	   Not	  validated	  	  780	   6	   43749703	   C	   T	   VEGFA	   Missense	   P/S	   PRD	  (1)	   Not	  validated	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I	  determined	  the	  probability	  of	  seeing	  multiple	  mutations	  in	  the	  same	  gene	  given	  the	  size	  of	   the	  gene	  and	   the	  number	  of	  patients	  evaluated	   in	  both	  primary	  and	  replication	   cohorts	   (Table	   3-­‐13).	   The	   number	   of	   de	  novo	   variants	   observed	   in	  
NOTCH1	   reached	   genome-­‐wide	   significant	   levels	   for	   putative	   loss	   of	   function	  variants	   (P=3.8	  ×10-­‐9)	   and	   for	  missense	   variants	   (P=9.4	  ×10-­‐8).	   The	  number	  of	  observed	   de	   novo	   mutations	   in	   JAG1	   is	   not	   significantly	   greater	   than	   the	   null	  expectation	  after	  applying	  a	  Bonferroni	  correction	  for	  multiple	  testing	  of	  20,000	  genes,	   but	   it	  would	   remain	   significant	   after	   applying	  Bonferroni	   correction	   for	  multiple	  testing	  in	  the	  122	  genes	  in	  the	  replication	  experiment.	  	  	  Table	  3-­‐13	  Probability	  of	  observing	  the	  reported	  number	  of	  de	  novo	  variant	  by	  chance	  in	  genes	  recurrently	  mutated	  in	  this	  study.	  The	  weighted	  mutation	  rate	  is	  calculated	  based	  on	  the	  coding	  gene	  length,	  single	  nucleotide	  mutation	  rate	  (1.5	  ×10-­‐8),	  proportion	  of	  loss	  of	  function	  (0.052)	  or	  proportion	   of	  missense	   (0.663)	   [357]	   and	   the	   number	   of	   autosomal	   chromosomes	   (number	   of	  samples	  ×	  2=476).	  The	  p	  value	  is	  bases	  on	  the	  Poisson	  distribution	  density	  function.	  
Gene	   Captured	  length	  (bp)	   Variant	  type	  
Weighted	  
mutation	  rate	  	  
De	  novo	  
mutation	  	   P	  value	  
†	  
NOTCH1	   7,668	   LoF	   0.0028	   3	   3.8	  ×10-­‐9	  ***	  Functional	   0.0362	   4‡	   9.4	  ×10-­‐8	  **	  
JAG1	   3,657	   LoF	   0.0013	   1	   0.00135	  Functional	   0.0173	   2‡	   0.00017	  †	  Adjusted	  α	  is	  equivalent	  to	  0.05/20,000	  =	  2.5	  ×10-­‐6	  (*),	  0.01/20,000	  =	  5.0	  ×10-­‐7	  (**)	  and	  0.001/20,000	  =	  5.0	  ×10-­‐8	  (***)	  ‡	  Functional	  de	  novo	  variant	  count	  include	  both	  loss	  of	  function	  and	  functional	  de	  novo	  variants.	  	  
3.3.2.5 Mendelian-­‐based	  variant	  analysis	  (replication	  cohort)	  	  Similar	   to	   the	   Mendelian-­‐based	   variant	   analysis	   in	   the	   primary	   cohort,	   I	  generated	  a	   list	  of	   rare	   inherited	  coding	  and	  splicing	  variants	  under	  autosomal	  recessive	   and	   X-­‐linked	  models	   assuming	   healthy	   parents	   (for	  more	   details	   see	  Mendelian-­‐based	  variant	  analysis	  in	  the	  primary	  cohort	  section	  above).	  	  	  I	  defined	  rare	  variants	  as	  having	  a	  minor	  allele	  frequency	  of	  less	  than	  1%	  in	  both	  the	  1000	  genomes	  project	  data	   [155]	  and	  also	   in	  ~2,172	  healthy	  parents	   from	  the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project	  [260].	  In	  these	  analyses	  I	  only	  included	  variants	  annotated	  by	  the	  VEP	  software	  [170]	  as	  being	  stop	  gain,	  frameshift,	  missense,	  stop	  lost	  or	  disrupting	  donor	  or	  acceptor	  splice	  sites.	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I	  used	  the	  family-­‐based	  variant	  analysis	  program	  (FEVA)	  to	  detect	  11	  candidate	  genes	  with	  rare	  coding	  variants	  under	  different	  inheritance	  models	  (Table	  3-­‐14).	  	  Three	  genes	  out	  of	  11	  appear	  in	  more	  than	  one	  trio.	  	  The	  first	  recurrent	  gene	  is	  
PCSK5	   (proprotein	   convertase	   subtilisin/kexin	   type	   5)	   wherein	   the	   same	  frameshift	   variant	   appears	   homozygously	   in	   three	   different	   samples	   under	   an	  autosomal	   recessive	   model	   (Table	   3-­‐15).	   PCSK5	   belongs	   to	   a	   proconvertase	  family,	   which	   cleave	   latent	   precursor	   proteins	   into	   their	   biologically	   active	  products	   and	   has	   been	   found	   to	   mediate	   post-­‐translational	   endoproteolytic	  processing	  for	  several	  integrin	  alpha	  subunits	  [393].	  The	  knockout	  mouse	  model	  exhibited	  multiple	  cardiac	  defects,	  including	  atrial	  and	  ventricular	  septal	  defects	  [394].	  	  
PLEC	  is	  the	  second	  gene	  with	  recurrent	  rare	  coding	  variants	  under	  the	  autosomal	  recessive	   compound	  heterozygous	  model.	  One	  of	   the	  patients	   carries	   four	   rare	  missense	   variants	   (one	   inherited	   from	   the	   father	   and	   the	   other	   thee	   from	   the	  mother	  (Table	  3-­‐16).	  	  PLEC	  encodes	  plectin-­‐1,	  an	  intermediate	  filament-­‐binding	  protein,	   to	   provide	   mechanical	   strength	   to	   cells	   and	   tissues	   by	   acting	   as	   a	  crosslinking	  element	  of	  the	  cytoskeleton	  [395].	  Plectin-­‐1	  is	  considered	  to	  be	  one	  of	   the	   largest	   polypeptides	   known	   (500-­‐kD).	  Mutations	   in	   this	   gene	  have	  been	  linked	   to	   epidermolysis	   bullosa	   simplex	   [396],	  while	   recessive	  mutations	  were	  found	   in	   three	   patients	   with	   limb-­‐girdle	   muscular	   dystrophy	   without	   skin	  abnormalities	   [397].	  The	  mouse	  knockout	  model	  did	  not	  show	  gross	  structural	  defects	  in	  the	  heart	  although	  the	  histological	  sections	  of	  the	  heart	  tissues	  showed	  cardiomyocyte	  degeneration	  and	  misaligned	  Z-­‐disks	  [398].	  	  	  	  The	   last	   recurrent	   gene	   is	   LAMP2	   with	   two	   samples	   showing	   X-­‐linked	   rare	  coding	   variants.	   	   One	   of	   the	   samples	   is	   from	   a	   male	   patient	   with	   a	   rare	  hemizygous	  missense	  variant	  inherited	  from	  the	  mother,	  while	  the	  other	  sample	  is	  from	  a	  female	  patient	  with	  heterozygous	  missense	  variant	  also	  inherited	  from	  the	  mother	   (Table	  3-­‐17).	  LAMP2	   belongs	   to	   the	  membrane	  glycoprotein	   family	  and	   constitutes	   a	   significant	   fraction	   of	   the	   total	   lysosomal	   membrane	  glycoproteins	   [399].	  Mutations	   in	   this	  gene	  have	  been	   linked	  to	  Danon	  disease,	  an	   X-­‐linked	   vacuolar	   cardiomyopathy	   and	   myopathy	   (OMIM	   300257)[400].	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Homozygous	  	   Compound	  
COL18A1	   	  	   1	   	  	  
CTBP2	   	  	   1	   	  	  
DCHS1	   	  	   1	   	  	  
LAMP2	   	   	  	   2	  MAML1	   	  	   1	   	  	  
PCDH15	   	  	   1	   	  	  
PCSK5	   3	   	  	   	  	  
PLEC	   	  	   2	   	  	  
RAI1	   	  	   1	   	  	  
ROR2	   	  	   1	   	  	  
TCF3	   	  	   1	   	  	  	  	  Table	  3-­‐15	  List	  of	  rare	  coding	  compound	  variants	  in	  gene.	  The	  trio	  genotypes	  are	  represented	  by	  0:homozygous	   references,	   1:	   heterozygous,	   2:	   homozygous	   non-­‐reference	  where	   the	   genotype	  order	  corresponds	  to	  child,	  mother	  and	  father,	  respectively.	  VEP:	  Variant	  Effect	  Predictor	  [170].	  1KG	  MAF	  is	  the	  minor	  allele	  frequency	  from	  the	  1000	  genome	  project.	  
Sample	  ID	   SC_RCTOF5364247	  	   SC_RCTOF5364472	  	   SC_RCTOF5363671	  	  
Gender	   Male	  	   Female	  	   Female	  	  
Chromosome	   9	   9	   9	  
Position	   78790207	   78790207	   78790207	  
Reference	   C	   C	   C	  
Alternative	   CGAATA	   CGAATA	   CGAATA	  
Gene	   PCSK5	   PCSK5	   PCSK5	  
VEP	  prediciton	  	   Frameshift	   Frameshift	   Frameshift	  
1KG	  MAF	   0	   0	   0	  
Trio	  genotypes	  	   2/1/1	   2/1/1	   2/1/1	  
Inherited	  from	   Both	  parents	   Both	  parents	   Both	  parents	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Table	  3-­‐16	  List	  of	  rare	  coding	  compound	  variants	  in	  the	  PLEC	  gene.	  All	  variants	  are	  missense	  and	  predicted	  by	  PolyPhen	  [171]	  to	  have	  a	  probably	  damaging	  (PRD),	  a	  possibly	  damaging	  (PSD),	  or	  a	  benign	  (BEN)	  	  effect	  on	  protein	  function.	  
Sample	  ID	   SC_RCTOF5364334	  	   SC_RCTOF5394511	  	  
Gender	   Female	  	   Female	  	  
Chromosome	   8	   8	   8	   8	   8	   8	  
Position	   144996830	   145003613	   144992962	   144997315	   144998052	   144998495	  
Reference	   C	   C	   G	   T	   T	   G	  
Alternative	   T	   T	   A	   C	   A	   A	  
Gene	   PLEC	   PLEC	   PLEC	   PLEC	   PLEC	   PLEC	  
VEP	  predication	  	   Missense	   Missense	   Missense	   Missense	   Missense	   Missense	  
PolyPhen	   PSD	  (0.856)	   Unknown	   BEN	  (0.005)	   PSD	  (0.917)	   Unknown	   Unknown	  
1KG	  MAF	   0.004604	   0	   0.000460	   0.00046	   0.000921	   0.001151	  
Trio	  genotypes	  	   1/0/1	   1/1/0	   1/1/0	   1/0/1	   1/1/0	   1/1/0	  
Inherited	  from	   Father	   Mother	   Mother	   Father	   Mother	   Mother	  	  Table	  3-­‐17	  List	  of	  rare	  coding	  compound	  variants	  in	  LAMP2	  gene.	  	  
Sample	  ID	   SC_RCTOF5394505	  	   SC_RCTOF5364097	  	  
Gender	   Female	  	   Male	  	  
Chromosome	   X	   X	  
Position	   119581776	   119581776	  
Reference	   C	   C	  
Alternative	   T	   T	  
Gene	   LAMP2	   LAMP2	  
VEP	  predication	  	   Missense	   Missense	  
PolyPhen	   PRD	  (1)	   PRD	  (1)	  
1KG	  MAF	   0.003223	   0.003223	  
Trio	  genotypes	  	   1/1/0	   2/1/0	  
Inherited	  from	   Mother	   Mother	  	  
3.3.2.6 Transmission	  disequilibrium	  test	  (replication	  cohort)	  	  Transmission	  Disequilibrium	  Tests	  comprise	  a	  group	  of	  family-­‐based	  association	  tests	   based	   on	   the	   observed	   transmissions	   from	   parents	   to	   affected	   offspring	  [404].	   The	   main	   idea	   behind	   a	   TDT	   is	   the	   ability	   to	   detect	   the	   distortion	   in	  transmission	   of	   alleles	   from	   a	   heterozygous	   parent	   to	   an	   affected	   offspring	  (Figure	  3-­‐15).	  The	  Mendelian	  analyses	  above	  assume	  complete	  penetrance	  and	  so	   will	   not	   detect	   inherited	   variants	   with	   incomplete	   penetrance,	   but	   over-­‐transmission	  of	  such	  variants	  may	  be	  picked	  up	  by	  the	  TDT	  test.	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three	   possible	   genotypes:	   homozygous	   reference,	   heterozygous,	   and	  homozygous	   non-­‐reference,	   which	   are	   denoted	   as	   0,	   1,	   and	   2	   respectively.	  Because	   each	   trio	   is	   composed	   of	   three	   members	   (child,	   mother	   and	   father),	  there	   are	   27	   possible	   genotype	   combinations	   (Table	   3-­‐18).	   	   Only	   13	   out	   of	   27	  genotype	   combinations	   are	   accepted	   as	   TDT	   informative	   genotypes	   and	   they	  contribute	   to	   the	   final	   2	   by	   2	   table	   of	   transmitted	   and	   un-­‐transmitted	   allele	  counts.	  The	   remaining	  genotype	  combinations	  were	  excluded	  because	   they	  are	  either	   not	   compatible	  with	  Mendelian	   inheritance	   laws	   or	   are	   non-­‐informative	  (e.g.	  when	  both	  parents	  carry	  homozygous	  non-­‐reference	  alleles).	  	  Table	   3-­‐18	   List	   of	   27	   possible	   genotype	   combinations	   in	   a	   trio	   family	   (homozygous	   reference,	  heterozygous,	   and	  homozygous	  non-­‐reference	   and	  denotes	  0,	   1,	   and	  2	   respectively).	  When	   the	  status	  of	  a	  genotype	  combination	  is	  non-­‐informative	  or	  not	  compatible	  with	  Mendelian	  laws	  (the	  latter	   is	   labeled	   as	   inheritance	   error)	   no	   rules	   are	   applied.	   However,	   when	   a	   genotype	  combination	  is	  informative	  (green	  cells),	  I	  add	  1	  or	  2	  (under	  rules)	  to	  either	  transmitted	  allele	  or	  non-­‐transmitted	  allele	  counts	  which	  both	  are	  going	  to	  be	  used	  in	  the	  T	  test.	  
Genotypes	   Rules	  
Status	  	  Child	   Mother	   Father	   Add	  to	  transmitted	  alleles	  count	   Add	  to	  non-­‐transmitted	  alleles	  count	  0	   0	   0	   	   	   Non-­‐informative	  	  0	   0	   1	   	   1	   TDT	  0	   0	   2	   	   	   Inheritance	  error	  0	   1	   0	   	   1	   TDT	  0	   1	   1	   	   2	   TDT	  0	   1	   2	   	   	   Inheritance	  error	  0	   2	   0	   	   	   Inheritance	  error	  0	   2	   1	   	   	   Inheritance	  error	  0	   2	   2	   	   	   Inheritance	  error	  1	   0	   0	   	   	   Inheritance	  error	  1	   0	   1	   1	   	   TDT	  1	   0	   2	   1	   1	   TDT	  1	   1	   0	   1	   	   TDT	  1	   1	   1	   1	   1	   TDT	  1	   1	   2	   1	   2	   TDT	  1	   2	   0	   1	   1	   TDT	  1	   2	   1	   1	   2	   TDT	  1	   2	   2	   	   	   Inheritance	  error	  2	   0	   0	   	   	   Inheritance	  error	  2	   0	   1	   	   	   Inheritance	  error	  2	   0	   2	   	   	   Inheritance	  error	  2	   1	   0	   	   	   Inheritance	  error	  2	   1	   1	   2	   0	   TDT	  2	   1	   2	   2	   1	   TDT	  2	   2	   0	   	   	   Inheritance	  error	  2	   2	   1	   2	   1	   TDT	  2	   2	   2	   	   	   Non-­‐informative	  	  	  Before	  running	  the	  modified	  TDT	  test,	  I	  made	  a	  separate	  count	  for	  each	  variant	  class	   (e.g.	   frameshift,	   missense,	   stop	   gained,	   etc.).	   Since	   very	   few	   silent	   (or	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synonymous)	  variants	  are	  expected	  to	  have	  a	  sizable	  effect	  on	  the	  phenotype,	   I	  used	  the	  transmission	  of	  silent	  variants	  as	  an	  addition	  control	  for	  the	  TDT	  tests	  for	  both	  loss-­‐of-­‐function	  and	  functional	  variants	  with	  the	  aim	  of	  identifying	  any	  technical	  biases	  associated	  with	  a	  given	  gene.	  	  Of	   the	   122	   genes	   selected	   for	   the	   replication	   study,	   only	   one	   gene,	  ARHGAP35,	  shows	   nominally	   significant	   over-­‐transmission	   of	   rare	   missense	   alleles	   from	  heterozygous	  parents	  to	  affected	  offspring	  (Table	  3-­‐19).	  	  The	  modified	  TDT	  test	  reported	  five	  rare	  missense	  alleles	  in	  the	  ARHGAP35	  gene	  in	  the	  parents	  (Table	  3-­‐20).	  All	  of	  them	  have	  been	  transmitted	  to	  the	  affected	  children.	  The	  rare	  silent	  variants	  in	  ARHGAP35	  on	  the	  other	  hand	  did	  do	  not	  show	  any	  signs	  of	  distorted	  transmission	   (six	   rare	   silent	   alleles	   transmitted	   and	   five	   non-­‐transmitted).	  However,	   the	   difference	   between	   missense	   and	   silent	   variants	   counts	   are	   not	  significant	  (P=	  0.1186,	  Fisher’s	  Exact	  test).	  Given	  the	  number	  of	  genes	  tested,	  the	  nominal	   significance	   of	   ARHGAP35	   would	   not	   survive	   correction	   for	   multiple	  testing.	  	  	  ARHGAP35,	   also	   known	   as	   GRLF1,	   is	   thought	   to	   repress	   transcription	   of	   the	  glucocorticoid	   receptor	   in	   response	   to	   glucocorticoids	   [407].	   This	   gene	   was	  selected	  in	  the	  replication	  study	  because	  I	  detected	  one	  validated	  de	  novo	  loss	  of	  function	   in	  the	  primary	  cohort	  (Table	  3-­‐5).	  The	  mouse	  knockout	  model	  usually	  dies	   within	   2	   days	   of	   birth	   and	   does	   not	   survive	   beyond	   3	   weeks	   with	  abnormalities	  seen	  in	  the	  retina	  and	  in	  the	  development	  of	  the	  brain	  and	  nervous	  system	  [408].	  Beckerle	  et	  al.	  showed	  how	  ARHGAP35	  inactivate	  RhoA,	  a	  member	  of	   the	  molecular	   switches	   called	   Rho	   family	   GTPases,	   in	   response	   to	   integrin-­‐mediated	   adhesion	   and	   argued	   that	   this	   inhibition	   enhances	   spreading	   and	  migration	  by	  regulating	  cell	  protrusion	  and	  polarity	  [409].	  More	  recently,	  Kshitiz	  
et	   al.	   [410]	   showed	   how	   ARHGAP35	   shaped	   the	   development	   of	   cardiac	   stem	  cells,	   inducing	   them	   to	   become	   the	   building	   blocks	   for	   either	   blood	   vessels	   or	  heart	   muscle	   by	   acting	   in	   RhoA-­‐dependent	   and	   -­‐independent	   fashion.	   These	  recent	   findings	  make	  ARHGAP35	  an	   interesting	   candidate	   for	   ToF	   and	   CHD	   in	  general.	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Table	   3-­‐19	   Transmitted	   and	   non-­‐transmitted	   alleles	   of	   rare	   coding	   variants	   in	   the	  ARHGAP35	  gene.	  TDT	  test	  were	  calculated	  as	  a	  McNemar’s	  test	  (see	  Figure	  3-­‐15).	  
Gene	   Variant	  class	   Transmitted	  AB	   Non	  transmitted	  AB	   TDT	  test	   P	  Value	  
ARHGAP35	   Functional	  (missense)	   5	   0	   5.00000	   0.02535	  
ARHGAP35	   Silent	  (synonymous)	   6	   5	   0.09091	   0.76302	  	  Table	   3-­‐20	   List	   of	   rare	   coding	   missense	   variants	   detected	   in	   the	   ARHGAP35	   gene	   and	   the	  genotypes	   in	   each	   trio	   (child,	   mother,	   father).	   Genotypes	   are	   homozygous	   reference	   (0)	   or	  heterozygous	  (1).	  





Genotypes	  Child	   Mother	  Father	  19	   47424846	   C	   G	   Missense	   1	   1	   0	  19	   47504580	   G	   A	   Missense	   1	   0	   1	  19	   47422911	   C	   T	   Missense	   1	   1	   0	  19	   47424531	   T	   A	   Missense	   1	   0	   1	  19	   47491295	   G	   A	   Missense	   1	   0	   1	  	  Based	  on	  the	  TDT	  findings	  in	  the	  replication	  cohort	  with	  only	  122	  genes,	  I	  did	  not	  perform	  similar	  analysis	  on	  the	  primary	  cohort	  samples	  (~20,000	  genes),	  since	  achieving	  significant	  P	  values	  is	  not	  likely	  after	  correcting	  for	  multiple	  testing.	  
 
3.3.3 Digenic	  inheritance	  analysis	  	  I	  wanted	  to	  explore	  the	  possibility	  of	  digenic	   inheritance	   in	  ToF	  samples	  based	  on	  two	  observations.	  First,	  there	  is	  a	  well-­‐known	  example	  of	  digenic	  inheritance	  with	   a	   cardiac	   phenotype,	   the	   long	   QT	   syndrome.	   Patients	   with	   long	   QT	  syndrome	   are	   predisposed	   to	   cardiac	   arrhythmias	   and	   sudden	  death	   [411].	   As	  with	  CHD	  in	  general,	  long	  QT	  syndrome	  exhibit	  locus	  heterogeneity	  and	  variable	  expressivity	   but	   several	   studies	   showed	   a	   statistically	   significant	   digenic	  inheritance	  in	  multiple	  genes	  (e.g.	  KCNQ1/KCNE1	  and	  SCN51/KCNE1)[412-­‐414].	  Secondly,	  the	  recurrent	  de	  novo	  variants	  I	  found	  in	  NOTCH1	  and	  its	  ligand	  JAG1,	  although	   they	   did	   not	   occur	   in	   the	   same	   patient,	   they	   pointed	   towards	   the	  possibility	   of	  mutation	   overload	   in	   the	   same	   pathway,	  which	   I	   consider	   in	   the	  next	  section.	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To	   explore	   this	   direction,	   I	   started	   by	   looking	   for	   rare	   coding	   variants	   in	   gene	  pairs.	  Because	  there	  are	  ~20,000	  genes	  in	  the	  exome	  data,	  the	  search	  space	  for	  gene-­‐pairs	   is	   very	   large	   (1.9	   ×	   108	  unique	   gene	   pairs).	   Even	  when	   all	   possible	  gene	  pairs	  are	  calculated,	  the	  lack	  of	  biological	  evidence	  to	  support	  most	  of	  these	  gene-­‐gene	   interactions	  makes	   it	   difficult	   to	   interpret	   the	   results.	   To	   overcome	  this	   issue,	   Schaffer	   has	   suggested	   using	   protein-­‐protein	   interactions	   (PPI)	   to	  limit	  the	  number	  of	  possible	  gene-­‐pairs	  [351].	  I	  used	  a	  list	  of	  68,085	  binary	  PPI	  integrated	  from	  a	  number	  of	  sources	  by	  Ni	  et	  al.	  [273].	  For	  each	  pair	  of	  genes	  in	  the	   PPI	   list,	   I	   tested	   two	   conditions:	   (i)	   both	   genes	   should	   include	   rare,	  functional,	   coding	   variants,	   and	   (ii)	   variant-­‐pairs	   in	   affected	   children	   are	  included	  only	  if	  the	  two	  variants	  are	  inherited	  from	  different	  parents	  (i.e.	  similar	  to	  the	  compound	  heterozygous	  concept).	  	  Rare	  functional	  variants	  are	  defined	  as	  variants	  with	  minor	  allele	  frequency	  <	  1%	  in	  the	  1000	  genomes	  project	  dataset	  or	  2,175	  healthy	  parents	   from	  the	  DDD	  project,	  which	   fall	   in	  coding	  regions	  or	  splice	  sites,	  and	  are	  not	  synonymous.	  	  This	   analysis	  was	  performed	  on	   samples	   from	   the	  primary	   and	   the	   replication	  cohorts	  separately.	  In	  the	  primary	  cohort	  (n=29	  trios),	  I	  detected	  four	  gene	  pairs	  under	  the	  DI	  model	  that	  appear	  in	  at	  least	  two	  or	  more	  trios	  (Table	  3-­‐21).	  These	  gene	  pairs	   include	  TTN,	  OBSCN	   and	  NEB	   genes,	  which	   all	   are	   giant	   sarcomeric	  proteins	   of	   striated	   muscles:	   titin	   (TTN),	   nebulette,	   a	   member	   of	   the	   nebulin	  subfamily	   (NEB),	   and	   obscurin	   (OBSCN).	   Mutations	   in	   these	   genes	   have	   been	  linked	   to	   cardiomyopathies	   [415]	  but	   the	   size	   of	   these	   genes	   is	   very	   large	   and	  thus	  it	  is	  not	  unexpected	  to	  see	  an	  accumulation	  of	  rare	  coding	  variants	  in	  these	  genes.	  	  	  	  Table	   3-­‐21	   List	   of	   interacting	   gene	   pairs	   that	   carry	   rare	   coding	   variants	   inherited	   from	   one	  parent	  in	  the	  primary	  ToF	  cohort	  (29	  trios).	  The	  list	  below	  only	  includes	  gene	  pairs	  that	  appear	  in	  at	  least	  two	  samples.	  	  
Gene	  A	   Gene	  B	   Number	  of	  trios	  
MYH2	   OBSCN	   2	  
GPR98	   MKI67	   2	  
TTN	   NEB	   2	  
TTN	   OBSCN	   3	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These	  four	  gene-­‐pairs	  are	  distributed	  across	  8	  trios	  (Table	  3-­‐22).	  	  	  Table	  3-­‐22	  Breakdown	  of	  digenic	  variant	  counts	  per	  sample	  in	  the	  primary	  ToF	  cohort	  (29	  trios)	  
Sample	  ID	   Gene	  pairs	   Total	  per	  sample	  
GPR98/MKI67	   MYH2/OBSCN	   TTN/NEB	   TTN/OBSCN	  TOF5136028	   	   1	   	   1	   2	  TOF5135944	   	   	   	   1	   1	  TOF5135947	   1	   	   	   	   1	  TOF5135980	   	   	   1	   	   1	  TOF5135989	   	   1	   	   	   1	  TOF5135998	   	   	   1	   	   1	  TOF5136004	   	   	   	   1	   1	  TOF5136019	   1	   	   	   	   1	  Total	  per	  	  gene	  pair	   2	   2	   2	   3	   9	  	  	  To	  test	  if	  these	  findings	  are	  statistically	  significant,	  I	  considered	  1,080	  trios	  from	  the	   Deciphering	   Developmental	   Disorders	   project	   (DDD)	   as	   controls.	   After	  performing	   the	   same	   DI	   analysis	   on	   1,080	   DDD	   trios,	   I	   tested	   each	   pair	   of	   DI	  genes	  for	  a	  difference	  in	  the	  number	  of	  samples	  between	  ToF	  and	  DDD	  trios	  with	  Fisher’s	  exact	  test	  to	  generate	  P	  values	  (Table	  3-­‐23).	  Although	  some	  of	  the	  DDD	  trios	   have	   heart	   phenotypes,	   these	   are	   a	   small	  minority	   and	   I	   did	   not	   exclude	  these	  samples	  from	  the	  controls,	  which	  makes	  this	  analysis	  more	  conservative.	  	  Table	  3-­‐23	  For	  each	  pair	  of	  genes	  found	  in	  at	  least	  two	  ToF	  trios	  (primary	  cohort),	  this	  table	  list	  the	  number	  of	   samples	   from	   the	  Deciphering	  Developmental	  Disorders	  project	   in	  a	  given	  gene	  pair.	  	  




	  (DDD	  n=1080)	  
Fisher's	  
	  Exact	  Test	  
Digenic	   No	   Digenic	   No	   P	  value	   Odds	  ratio	  
MYH2	   OBSCN	   2	   27	   6	   1074	   0.0168	   13.26	  
GPR98	   MKI67	   2	   27	   18	   1062	   0.0938	   4.37	  
TTN	   NEB	   2	   27	   72	   1008	   1	   1.04	  
TTN	   OBSCN	   3	   26	   138	   942	   1	   0.79	  	  None	  of	   the	  gene	  pairs	   that	   include	  either	  TTN	  or	  NEB	   appear	   to	  be	  significant	  when	  compared	  with	  DDD	  trios.	  This	  indicates	  that	  the	  large	  size	  of	  these	  genes	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is	  probably	  the	  reason	  why	  they	  frequently	  appear	  under	  the	  DI	  model	  and	  not	  necessarily	  because	  of	  a	  pathogenic	  association.	  	  Only	   one	   DI	   gene	   pair,	   (MYH2/OBSCN),	   in	   the	   primary	   ToF	   cohort	   showed	   a	  significant	   difference	   (P=	   0.016)	   (Table	   3-­‐23	   and	   Table	   3-­‐24).	   	  MYH2	   encodes	  myosin	  heavy	  chain	   IIa	  protein	  and	  mutations	   in	   this	  gene	  have	  been	   found	   to	  cause	   an	   autosomal	   dominant	   myopathy	   (inclusion	   body	   myopathy-­‐3)	   [416].	  	  There	  are	  six	  human	  skeletal	  MYH	  genes	  present	  as	  a	  cluster	  on	  chromosome	  17	  (MYH1,	  MYH2,	  MYH3,	  MYH4,	  MYH8	  and	  MYH13)	  but	  only	  MYH3	  was	  found	  to	  be	  expressed	   in	   the	   fetal	   heart	   and	   may	   be	   involved	   in	   the	   atrial	   septal	   defects	  [417].	  	  Obscurin	  on	  the	  other	  hand	  is	  a	  sarcomeric	  protein	  composed	  of	  adhesion	  modules	  and	  signalling	  domains	  and	  surrounds	  myofibrils	  [418]	  but	  the	  role	  of	  
OBSCN	  in	  cardiogenesis	  is	  not	  obvious	  [419].	  All	  variants	  that	  appear	  in	  this	  gene	  pair	   are	   missense	   and	   are	   predicted	   to	   have	   damaging	   effects	   on	   protein	  structure	  (Table	  3-­‐24).	  	  	  Table	  3-­‐24	  List	  of	  rare	  coding	  variants	  in	  (MYH2/OBSCN)	  DI	  gene	  pair.	  All	  variants	  are	  missense	  and	   predicted	   by	   PolyPhen	   [171]	   to	   have	   a	   probably	   damaging	   (PRD)	   or	   a	   possibly	   damaging	  (PSD)	  effect	  on	  protein	  function.	  The	  genotypes	  are	  represented	  by	  (0:homozygous	  references,	  1:	  heterozygous)	  where	   the	   order	   corresponds	   to	   (child/mother/father)	   genotypes.	   VEP:	   Variant	  Effect	  Predictor	  [170].	  
Sample	  ID	   TOF5136028	  	   TOF5135989	  	  
Chromosome	   17	   1	   17	   1	  
Position	  	   10438612	   228566387	   10433181	   228461504	  
dbSNP	   .	   .	   rs143872329	   .	  
Ref	   T	   G	   C	   G	  
Alt	   C	   A	   T	   A	  
Gene	   MYH2	   OBSCN	   MYH2	   OBSCN	  
VEP	   Missense	   Missense	   Missense	   Missense	  
PolyPhen	   PRD	  (0.971)	   PSD	  (0.317)	   PRD	  (0.915)	   PRD	  (0.993)	  
AF_MAX	   0.00023	   0	   0.007136	   0.002532	  
Genotypes	   1/1/0	   1/0/1	   1/0/1	   1/1/0	  
Inherited	  from	   Mother	   Father	   Father	   Mother	  	  	  Because	  the	  DI	  analysis	  was	  performed	  after	   I	  designed	  the	  replication	  study,	   I	  was	  not	  able	  to	  include	  the	  (MYH2	  /	  OBSCN)	  gene	  pair	  in	  the	  replication	  design.	  However,	  in	  my	  DI	  analysis	  in	  the	  replication	  cohort	  (209	  trios)	  I	  identified	  four	  recurrent	  DI	  candidate	  gene	  pairs	  across	  11	  trios	  out	  of	  219	  possible	  gene-­‐pairs	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available	   to	   the	   122	   genes	   selected	   for	   the	   replicating	   study	   (Table	   3-­‐25	  andTable	   3-­‐26).	   These	   four	   pairs	   are	   ZFPM2/CTBP2,	   NCOR2/ESR1,	  
PSEN2/NOTCH2,	  and	  SPEN/NCOR2.	  To	  investigate	  if	  any	  of	  these	  gene-­‐pairs	  were	  significantly	  enriched,	  I	  compared	  the	  number	  of	  trios	  DI	  variants	  in	  these	  gene	  pairs	  between	  209	  ToF	  trios	  and	  1,080	  DDD	  trios.	  Only	  two	  gene	  pairs,	  ZFPM2/	  
CTBP2	  and	  NCOR2/ESR1	  show	  P	  values	  <	  0.05	  (Fisher’s	  exact	  test,	  Table	  3-­‐27).	  	  
	  Table	   3-­‐25	   List	   of	   interacting	   gene	   pairs	   that	   carry	   rare	   coding	   variants	   inherited	   from	   one	  parent	   in	   the	   replication	   ToF	   cohort	   (209	   trios).	   The	   list	   below	   only	   includes	   gene	   pairs	   that	  appear	  in	  at	  least	  two	  samples.	  	  
Gene	  A	   Gene	  B	   Number	  of	  samples	  
NCOR2	  	   ESR1	  	   4	  
PSEN2	  	   NOTCH2	  	   2	  
SPEN	  	   NCOR2	  	   2	  
ZFPM2	  	   CTBP2	  	   3	  	  Table	  3-­‐26	  Breakdown	  of	  digenic	  variant	  counts	  per	  sample	   in	   the	  replication	  ToF	  cohort	  (209	  trios)	  
Sample	  Id	  
Gene	  pairs	  
Total	  per	  trio	  
NCOR2	  /	  ESR1	   PSEN2	  /	  NOTCH2	   SPEN	  /	  NCOR2	   ZFPM2	  /	  CTBP2	  SC_RCTOF5363452	   	   	   	   1	   1	  SC_RCTOF5363671	   	   	   1	   	   1	  SC_RCTOF5363674	   	   	   	   1	   1	  SC_RCTOF5364163	   1	   	   	   	   1	  SC_RCTOF5364172	   1	   	   	   	   1	  SC_RCTOF5364214	   	   	   	   1	   1	  SC_RCTOF5364247	   1	   	   	   	   1	  SC_RCTOF5364262	   	   1	   	   	   1	  SC_RCTOF5364430	   	   1	   	   	   1	  SC_RCTOF5364460	   1	   	   	   	   1	  SC_RCTOF5394511	   	   	   1	   	   1	  Total	  per	  	  
gene	  Pair	   4	   2	   2	   3	   11	  	  Table	  3-­‐27	  For	  each	  pair	  of	  genes	  found	  in	  at	  least	  two	  ToF	  trios	  (replication	  cohort),	  this	  table	  lists	   the	   number	   of	   samples	   from	   the	  Deciphering	  Developmental	  Disorders	   project	   in	   a	   given	  gene	  pair.	  





Fisher's	  Exact	  	  
Test	  
Digenic	   No	   Digenic	   No	   P	  value	   Odds	  ratio	  
ZFPM2	   CTBP2	   3	   206	   1	   1079	   0.0148	   15.71	  
NCOR2	   ESR1	   4	   205	   5	   1075	   0.0433	   4.2	  
PSEN2	   NOTCH2	   2	   207	   1	   1079	   0.0701	   10.43	  
SPEN	   NCOR2	   2	   207	   1	   1079	   0.0701	   10.43	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The	  ZFPM2/	  CTBP2	  gene	  pair	  was	  mutated	  in	  three	  ToF	  trios	  under	  DI.	  Whereas	  
ZFPM2	  carries	  three	  different	  missense	  variants	  (all	  predicted	  to	  be	  damaging	  by	  PolyPhen	  [171])	  in	  each	  trio,	  CTBP2	  carries	  the	  same	  rare	  in-­‐frame	  insertion	  in	  all	  of	  them	  (Table	  3-­‐28).	  	  	  
ZFPM2,	   is	   a	   known	   CHD	   gene	   and	   is	   also	   called	   FOG2.	   It	   is	   a	   zinc	   finger	  transcriptional	   factor	   that	   is	   known	   to	   regulate	   many	   GATA-­‐target	   genes	  including	  GATA4	   in	  cardiomyocytes	  [420].	  Heterozygous	  mutations	   in	  this	  gene	  have	   been	   linked	   to	   isolated	   ToF	   cases	   [333]	   and	   its	   knockout	   mouse	   model	  shows	  a	  spectrum	  of	  ToF’s	  structural	  heart	  defects	  [421,	  422].	  	  	  
CTBP2,	  on	  the	  other	  hand,	  belongs	  to	  the	  C-­‐terminal	  binding	  protein	  family	  that	  is	  linked	  to	  multiple	  biological	  processes	  through	  its	  association	  with	  numerous	  transcription	   factors	   [423].	  This	  gene	  was	  picked	  up	  during	   the	  design	  process	  because	   it	   is	   part	   of	   the	  WNT	   pathway	   and	   also	   because	   its	   knockout	   mouse	  model	  showed	  aberrant	  halting	  of	  heart	  morphogenesis	  at	   the	  heart	   tube	  stage	  [423].	  	  	  Table	   3-­‐28	   List	   of	   rare	   coding	   variants	   in	   the	   CTBP2/ZFPM2	   DI	   gene	   pair.	   All	   variants	   are	  missense	   and	   predicted	   by	   PolyPhen	   [171]	   to	   have	   a	   probably	   damaging	   (PRD),	   a	   possibly	  damaging	   (PSD),	   or	   a	   benign	   (BEN)	   	   effect	   on	   the	   protein	   function.	   The	   genotypes	   are	  represented	   by	   (0:homozygous	   references,	   1:	   heterozygous)	   where	   the	   order	   corresponds	   to	  (child/mother/father)	   genotypes.	   VEP:	   Variant	   Effect	   Predictor	   [170].	   1KG	   MAF	   is	   the	   minor	  allele	  frequency	  from	  the	  1000	  genome	  project.	  
Sample	  ID	   SC_RCTOF5364214	   SC_RCTOF5363452	   SC_RCTOF5363674	  
Chromosome	   10	   8	   10	   8	   10	   8	  
Position	  	   126715159	   106431420	   126715159	   106801092	   126715159	   106456600	  
dbSNP	   .	   rs121908601	   .	   rs202204708	   .	   rs202217256	  
Reference	   A	   A	   A	   A	   A	   G	  
Alternative	  
allele	  	  
AGCCGCAGGCTGGGGCTGCAGG	   G	   AGCCGCAGGCTGGGGCTGCAGG	   G	   AGCCGCAGGCTGGGGCTGCAGG	   A	  
Gene	   CTBP2	   ZFPM2	   CTBP2	   ZFPM2	   CTBP2	   ZFPM2	  
VEP	   In-­‐frame	  insertion	   Missense	  	   In-­‐frame	  insertion	   Missense	  	   In-­‐frame	  insertion	   Missense	  	  
PolyPhen	   NA	   PSD	  (0.572)	   NA	   PRD	  (0.987)	   NA	   PSD	  (0.456)	  
1KG	  MAF	   0.004374	   0.005525	   0.004374	   0.001381	   0.004374	   0.004374	  
Genotypes	   1/0/1	   1/1/0	   1/1/0	   1/0/1	   1/0/1	   1/1/0	  
Inherited	  
from	   Father	   Mother	   Father	   Mother	   Father	   Mother	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The	   second	   gene	   pair	   that	   carries	   rare	   coding	   variants	   under	   DI	   model	   is	  (NCOR2/ESR1)	   in	   four	  ToF	   trios.	  When	  compared	  with	   five	   trios	   from	  the	  DDD	  project	  it	  results	  in	  a	  marginally	  significant	  nominal	  P	  value	  of	  0.043.	  The	  NCOR2	  gene,	   also	   known	   as	   SMRT,	   encodes	   a	   silencing	   mediator	   (co-­‐repressor)	   for	  retinoid	   and	   thyroid	   hormone	   receptors	   [424].	   This	   gene	   was	   selected	   in	   the	  replication	   study	   because	   it	   is	   part	   of	   the	  NOTCH	   pathway	   and	   its	   null	  mouse	  model	  died	  before	  embryonic	  day	  16.5	  owing	  to	  a	  lethal	  heart	  defect	  [425].	  	  The	  second	  gene	  in	  this	  pair	  is	  ESR1	  gene,	  which	  encodes	  for	  estrogen	  receptor.	  Although	   the	  ESR1	   knockout	  mouse	  model	   showed	   no	   heart	   structural	   defects	  (only	  decreased	  heart	  weight	  [426]),	  ESR1	  was	  included	  in	  the	  replication	  study	  because	  of	  its	  role	  in	  the	  NOTCH	  pathway	  (reviewed	  in	  [427])	  (see	  gene	  selection	  in	  the	  replication	  cohort	   for	  details).	  The	   interaction	  between	  NCOR1	  and	  ESR1	  has	  been	  detected	  by	  yeast	  two-­‐hybrid	  screen	  assays	  [428].	  	  All	   variants	   in	   the	   NCOR2/ESR1	   pair	   are	   rare	   missense	   variants.	   With	   the	  exception	   of	   one	   variant	   (rs139960913)	   that	   appears	   in	   two	   trios,	   all	   other	  missense	   variants	   appear	   to	   be	   unique	   to	   each	   trio	   (Table	   3-­‐29).	  NCOR2	   also	  appears	   in	  another	  DI	  gene	  pair	  (SPEN/NCOR2),	  although	  when	  compared	  with	  DDD	  trios	  the	  difference	  was	  not	  significant	  (P	  =	  0.07).	  	  	  	  
	  Table	  3-­‐29	  List	  of	  rare	  coding	  variants	  in	  the	  NCOR2/ESR1	  DI	  gene	  pair.	  All	  variants	  are	  missense	  and	  predicted	  by	  PolyPhen	  [171]	  to	  have	  a	  probably	  damaging	  (PRD),	  a	  possibly	  damaging	  (PSD),	  or	   a	   benign	   (BEN)	   	   effect	   on	   the	   protein	   function.	   The	   genotypes	   are	   represented	   by	  (0:homozygous	   references,	   1:	   heterozygous)	   where	   the	   order	   corresponds	   to	  (child/mother/father)	  genotypes.	  VEP:	  Variant	  Effect	  Predictor	  [170].	  
Sample	  ID	   SC_RCTOF5364247	   SC_RCTOF5364163	   SC_RCTOF5364172	   SC_RCTOF5364460	  
Chromosome	   6	   12	   6	   12	   6	   12	   6	   12	  
Position	  	   152129063	   124819118	   152129063	   124835148	   152130253	   124835279	   152265443	   124817779	  
dbSNP	   rs139960913	   .	   rs139960913	   .	   rs201212952	  rs200297509	  rs77797873	  rs61754987	  
Ref	   C	   T	   C	   C	   A	   G	   A	   C	  
Alt	   T	   C	   T	   T	   G	   A	   G	   T	  
Gene	   ESR1	   NCOR2	   ESR1	   NCOR2	   ESR1	   NCOR2	   ESR1	   NCOR2	  
VEP	   Missense	   Missense	   Missense	   Missense	   Missense	   Missense	   Missense	   Missense	  
PolyPhen	   PRD	  (0.996)	   BEN	  (0.311)	   PRD	  (0.996)	   PSD	  (0.72)	   BEN	  (0.001)	   PRD	  (1)	   PRD	  (0.994)	  PSD	  (0.838)	  
AF_MAX	   0.004834	   0	   0.004834	   0	   0.005525	   0.001381	   0.002302	   0.003223	  
Genotypes	   1/0/1	   1/1/0	   1/0/1	   1/1/0	   1/0/1	   1/1/0	   1/1/0	   1/0/1	  
Inherited	  from	   Father	   Mother	   Father	   Mother	   Father	   Mother	   Mother	   Father	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3.3.4 Pathway-­‐based	  analysis	  	  	  The	  final	  analysis	  I	  performed	  was	  to	  test	  for	  a	  burden	  of	  rare	  coding	  variants	  in	  a	   set	   of	   genes	   linked	   by	   biological	   pathway.	   To	   define	   these	   pathways,	   I	  downloaded	   the	  Kyoto	  Encyclopedia	  of	  Genes	   and	  Genomes	   (KEGG)	   set,	  which	  integrates	  genomic,	  chemical	  and	  systemic	  functional	  information	  to	  define	  175	  different	  pathways	  [429].	  	  	  In	  this	  analysis,	  I	  examined	  the	  burden	  of	  rare	  inherited	  heterozygous	  missense	  variants	   where	   rare	   is	   defined	   as	   minor	   allele	   frequency	   <	   1%	   in	   the	   1000	  genomes	   [155]	   and	   in	   2,172	   healthy	   parents	   from	   the	   Deciphering	  Developmental	  Disorders	  project	  (DDD)	  [260].	  For	  each	  pathway,	  I	  counted	  the	  number	   of	   samples	   that	   carry	   rare	   missense	   variants	   in	   at	   least	   one	   or	   more	  genes	   from	   the	   same	   pathway.	   Then,	   I	   used	   Fisher’s	   exact	   test	   to	   detect	   if	   the	  difference	  between	  cases	  and	  controls	  is	  statistically	  significant.	  	  	  I	   applied	   this	  workflow	  on	   the	  29	  ToF	   trios	   from	   the	  primary	  cohort	  and	  used	  1,080	   trios	   from	   the	   DDD	   project	   as	   controls	   (Table	   3-­‐30).	   None	   of	   the	   KEGG	  pathways	  show	  a	  statistically	  significant	  burden	  of	  rare	  missense	  variants	  after	  correcting	  for	  multiple	  testing.	  	  Table	   3-­‐30	   The	   results	   of	   burden	   analysis	   from	   the	   29	   ToF	   trios	   (primary	   cohort)	   when	  considering	   all	   genes	   in	   the	   exome	   data.	   None	   of	   the	   KEGG	   pathways	   reach	   a	   significance	  threshold	  after	  correcting	  for	  multiple	  testing	  (n=175	  pathways,	  adjusted	  P	  value	  =0.00028).	  	  FET:	  Fisher’s	  exact	  test	  p-­‐value	  (right	  tail),	  OR:	  odds	  ratio	  
	  	  
Pathway	   #	  Of	  genes	  in	  pathway	  
Number	  of	  samples	  
FET	   OR	  Cases	   Controls	  




	  >	  1	  
genes	  
<	  1	  
genes	  KEGG_RENAL_CELL_CARCINOMA	   12	   6	   23	   100	   980	   0.05	   2.56	  KEGG_JAK_STAT_SIGNALING_PATHWAY	   7	   6	   23	   107	   973	   0.07	   2.37	  KEGG_LONG_TERM_POTENTIATION	   7	   5	   24	   94	   986	   0.11	   2.19	  KEGG_HUNTINGTONS_DISEASE	   5	   4	   25	   68	   1012	   0.11	   2.38	  KEGG_PROSTATE_CANCER	   11	   5	   24	   97	   983	   0.12	   2.11	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On	  the	  other	  hand,	   the	  baits	   in	   the	  replication	  cohort	   (n=209	  trios)	  only	   target	  122	  genes.	  By	  performing	   the	  same	  pathway-­‐analysis,	  but	   limited	   to	   these	  122	  genes,	   I	   was	   able	   to	   detect	   a	   burden	   of	   rare	   missense	   variants	   in	   the	  Dorsoventral	  axis	  formation	  pathway	  (P=3.4	  ×	  10-­‐4,	  Fisher’s	  exact	  test,	  right	  tail)	  and	  in	  prion	  diseases	  pathway	  (P	  =3.6	  ×	  10-­‐4,	  Fisher’s	  exact	  test,	  right	  tail)	  (Table	  3-­‐31).	  	  	  Table	   3-­‐31	   The	   results	   of	   burden	   analysis	   from	   the	   209	   ToF	   trios	   (replication	   cohort)	   when	  considering	  122	  genes	  that	  belong	  to	  73	  KEGG	  pathways.	  Only	  2	  of	  the	  KEGG	  pathways	  reach	  a	  significant	   threshold	   after	   correcting	   for	  multiple	   testing	   (n=73	   pathways	   that	   have	   at	   least	   1	  gene	  among	  the	  122	  genes,	  P-­‐value	  threshold=0.00041).	  The	  last	  two	  rows	  show	  the	  NOTCH	  and	  WNT	   pathways	   but	   both	   of	   their	   P-­‐values	   do	   not	   reach	   a	   statistically	   significant	   level.	   FET:	  Fisher’s	  exact	  test,	  OR:	  odds	  ratio	  
Pathway	   #	  Of	  genes	  considered	  
Number	  of	  samples	  





	  ≥	  1	  
genes	  
<	  1	  
genes	  KEGG_DORSO_VENTRAL_AXIS_FORMATION	   4	   41	   168	   114	   966	   0.00034	   2.06	  KEGG_PRION_DISEASES	   4	   24	   185	   51	   1029	   0.00036	   2.61	  KEGG_NOTCH_SIGNALING_PATHWAY	   23	   99	   110	   427	   653	   0.02149	   1.37	  KEGG_WNT_SIGNALING_PATHWAY	   28	   62	   147	   353	   727	   0.82521	   0.86	  	  Next,	  I	  tried	  to	  see	  which	  genes	  drive	  the	  signal	  of	  rare	  missense	  variants	  burden	  in	   the	   dorsoventral	   axis	   formation	   and	   prion	   diseases	   pathways.	   I	   found	   four	  genes	  (NOTCH1,	  TP53,	  DLL1,	  and	  PTPN11)	  that	  show	  the	  highest	  burden	  of	  rare	  missense	  (Table	  3-­‐32).	  However,	  only	  NOTCH1	  reaches	  a	  significant	  P	  value	  after	  correcting	   for	   multiple	   testing	   and	   it	   drives	   the	   burden	   signal	   in	   both	  dorsoventral	  axis	  formation	  and	  prion	  diseases	  pathways.	  	  	  Table	   3-­‐32	   List	   of	   top	   genes	   driving	   the	   signal	   of	   rare	  missense	   variant	   burden	   in	   the	  NOTCH	  pathway.	  	  RMV:	  rare	  missense	  variants,	  FET:	  Fisher’s	  exact	  test	  
Gene	  
Cases	   Controls	   FET	  
	  right	  tail	   Odds	  ratio	  With	  RMV	   Without	  RMV	   With	  RMV	   Without	  RMV	  
NOTCH1	   22	   187	   39	   1041	   8.8	  ×	  10-­‐05	   3.1	  
TP53	   4	   205	   3	   1077	   0.01	   7.0	  
DLL1	   5	   204	   6	   1074	   0.02	   4.3	  
PTPN11	   3	   206	   2	   1078	   0.03	   7.8	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  Figure	   3-­‐16	   Mapping	   rare	   missense	   variants	   from	   cases	   (ToF	   replication	   cohort,	   n=209)	   and	  controls	   (DDD	   samples,	   n=1080)	   to	   the	   extracellular	   or	   cytoplasmic	   domains	   of	   NOTCH1.	   The	  majority	  of	  variants	  are	  in	  the	  extracellular	  domains	  where	  8.6%	  of	  the	  cases	  has	  rare	  missense	  variants	  compared	  with	  3.1%	   in	  controls	   (Fisher’s	  Exact	   test,	  P	   value=	  0.0007).	  The	  number	  of	  rare	  missense	  variants	  per	  domain	  is	  listed	  in	  Table	  3-­‐33	  below.	  	  SP:	  signal	  peptide,	  EGF-­‐LR:	  EGF-­‐like	  repeat,	  LNR:	  Lin-­‐Notch	  repeat,	  RAM:	  Rbp-­‐associated	  molecule,	  ANK:	  Ankyrin/CDC10	  repeat,	  TAD:	   transcription	   activation	   domain,	   PEST:	   Proline	   (P),	   glutamic	   acid	   (E),	   serine	   (S),	   and	  threonine	  (T)	  degradation	  domain.	  	  	  Table	  3-­‐33	  Number	  of	   samples	  with	   inherited	   rare	  missense	  variants	   in	   cases	   	   (209	  ToF	   trios)	  and	   controls	   (1,080	   from	   DDD)	   in	   NOTCH1	   domains.	   The	   domain	   boundaries	   were	   extracted	  from	  Uniport	  database	  (protein	  id:	  P46531)	  [430].	  	  LNR:	  Lin-­‐Notch	  repeat,	  ANK:	  Ankyrin/CDC10	  repeat.	  
Domain	   Start	   End	   Cases	  (ToF)	   Controls	  (DDD)	  EGF-­‐like	  4	   140	   176	   1	   0	  EGF-­‐like	  5	   178	   216	   1	   0	  EGF-­‐like	  7	   257	   293	   1	   4	  EGF-­‐like	  13	   490	   526	   0	   2	  EGF-­‐like	  16	   603	   639	   1	   3	  EGF-­‐like	  17	   641	   676	   1	   3	  EGF-­‐like	  18	   678	   714	   0	   1	  EGF-­‐like	  22	   829	   867	   0	   10	  EGF-­‐like	  24	   907	   943	   3	   2	  EGF-­‐like	  25	   945	   981	   1	   3	  EGF-­‐like	  26	   983	   1019	   1	   0	  EGF-­‐like	  27	   1021	   1057	   0	   1	  EGF-­‐like	  28	   1059	   1095	   0	   1	  EGF-­‐like	  33	   1267	   1305	   0	   1	  EGF-­‐like	  34	   1307	   1346	   1	   1	  EGF-­‐like	  35	   1348	   1384	   2	   0	  EGF-­‐like	  36	   1387	   1426	   2	   1	  LNR	  1	   1449	   1489	   1	   0	  LNR	  2	   1490	   1531	   1	   1	  ANK	  2	   1960	   1990	   0	   1	  ANK	  3	   1994	   2023	   0	   1	  ANK	  4	   2027	   2056	   1	   0	  HIF1AN-­‐binding	   2014	   2022	   0	   1	  	  As	  NOTCH1	  is	  the	  most	  significant	  gene	  that	  I	  identified	  in	  the	  analyses	  above,	  I	  examined	   the	   individual	   rare	   missense	   variants	   to	   look	   for	   clustering	   of	   rare	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variants	  in	  specific	  NOTCH1	  domains.	  The	  majority	  of	  rare	  missense	  variants	  in	  
NOTCH1	   occur	   in	   one	   of	   the	   extracellular	  NOTCH1	   domains	   (Figure	   3-­‐16	   and	  Table	   3-­‐33).	   However,	   there	   is	   no	   clear	   domain	   clustering	   difference	   between	  cases	   and	   controls	   except	   for	   the	   EGF-­‐like	   22	   domain,	   which	   has	   10	   rare	  missense	  variants	  in	  DDD	  control	  samples	  and	  none	  in	  the	  cases.	  All	  of	  EGF-­‐like	  22	  domain’s	   variants,	   however,	   are	   the	   same	   rare	  missense	   variant	   (p.E848K),	  present	  in	  dbSNP	  (rs35136134).	  If	  I	  omit	  this	  SNP,	  the	  difference	  between	  cases	  and	  controls	  in	  NOTCH1	  would	  become	  statistically	  more	  significant	  (P=	  2.9×10-­‐6	  ,	  Fisher’s	  exact	  test,	  right	  tail).	  	  	  
3.3.5 Summary	  of	  candidate	  genes	  and	  gene-­‐pairs	  The	   following	   table	   (Table	   3-­‐34)	   summarizes	   the	   findings	   collated	   from	   the	  analyses	   in	   this	   chapter	   and	   counts	   the	   number	   of	   probands	   (total	   of	   43	  candidate	  genes)	  under	  different	   inheritance	  scenarios.	   	  The	  most	  notable	  gene	  is	  NOTCH1	   (n=26	   samples)	   followed	  by	  ARHGAP35	   (n=6	   trios).	   Both	   genes	   are	  supported	  by	  findings	  from	  analyses	  of	  both	  de	  novo	  and	  inherited	  variants.	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Table	   3-­‐34	   Number	   of	   samples	   with	   rare	   coding	   variants	   in	   candidate	   genes	   identified	   in	  different	  analyses	  I	  performed	  on	  the	  samples	  from	  the	  primary	  and	  replication	  ToF	  replication	  studies.	  	  	  CNV:	   copy	   number	   variant,	   DN:	   de	   novo,	   DI:	   digenic	   inheritance	   analysis,	   PATH:	   pathway	  analysis,	   R-­‐HOM:	   Autosomal	   recessive	   homozygous,	   R-­‐COMP:	   Autosomal	   recessive	   compound	  heterozygous,	   X:	   X-­‐lined,	   TDT:	   Transmission	   disequilibrium	   test.	   Red	   cells	   denote	   genes	   with	  mutation	  in	  at	  least	  two	  or	  more	  ToF	  samples.	  	  
Gene	  





























ZMYM2	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
IKZF1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
TTC18	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
MYO7B	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
NOTCH1	   2	   	   	   	   	   2	   	   	   	   	   	   22	   26	  
DCHS1	   1	   	   	   	   	   	   	   1	   	   	   	   	   2	  
OSBPL10	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
TTC18	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
FAM178A	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
ANKRD11	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
ADCY5	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
PLCXD1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
ATP5G1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
TPRA1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
FLOT2	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
PLCG2	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
ARHGAP35	   1	   	   	   	   	   	   	   	   	   5	   	   	   6	  
SERAC1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
ITGB4	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
PHRF1	   1	   	   	   	   	   	   	   	   	   	   	   	   1	  
JAG1	   	   	   	   	   	   2	   	   	   	   	   	   	   2	  
AXIN1	   	   	   	   	   	   1	   	   	   	   	   	   	   1	  
VEGFA	   	   	   	   	   	   1	   	   	   	   	   	   	   1	  
PLEC	   	   	   	   	   	   	   	   	   2	   	   	   	   2	  
COL18A1	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
CTBP2	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
LAMP2	   	   	   	   	   	   	   	   	   2	   	   	   	   2	  
MAML1	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
PCDH15	   	   	   	   	   	   	   	   2	   	   	   	   	   2	  
PCSK5	   	   	   	   	   	   	   3	   	   	   	   	   	   3	  
PLEC	   	   	   	   	   	   	   	   2	   	   	   	   	   2	  
RAI1	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
ROR2	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
TCF3	   	   	   	   	   	   	   	   1	   	   	   	   	   1	  
MYH2/OBSCN	   	   	   	   	   2	   	   	   	   	   	   	   	   2	  
ZFPM2/CTBP2	   	   	   	   	   	   	   	   	   	   	   3	   	   3	  
NCOR2/ESR1	   	   	   	   	   	   	   	   	   	   	   4	   	   4	  
TTN	   	   	   4	   	   	   	   	   	   	   	   	   	   4	  
OBSCN	   	   	   2	   	   	   	   	   	   	   	   	   	   2	  
NEB	   	   	   2	   	   	   	   	   	   	   	   	   	   2	  
HDAC4	   	   	   	   1	   	   	   	   	   	   	   	   	   1	  
FOXC1	   	   	   	   3	   	   	   	   	   	   	   	   	   3	  
FOXC2	   	   	   	   3	   	   	   	   	   	   	   	   	   3	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3.4 Discussion	  	  	  Tetralogy	  of	  Fallot	  is	  the	  most	  common	  form	  of	  cyanotic	  congenital	  heart	  defect	  (~10%)	   [297].	   ToF	   can	   occur	   as	   part	   of	   other	   syndromes	   or	   in	   isolated	   non-­‐syndromic	   forms.	   	   Candidate	   re-­‐sequencing,	   linkage	   analysis,	   CGH	   arrays,	   and	  genome-­‐wide	   association	   studies	   have	   discovered	   several	   novel	   genes	   and	  regions	  in	  the	  past	  decades.	  However,	  the	  majority	  of	  isolated	  ToF	  cases	  remain	  without	  definitive	  genetic	  causes.	  	  	  In	  this	  chapter,	  I	  examined	  different	  hypotheses	  behind	  the	  genetic	  causes	  of	  ToF	  by	   implementing	   various,	   mainly	   trio-­‐based,	   analytical	   tests	   on	   the	   sequence	  data	   from	   29	   isolated	   ToF	   trios	   (exome-­‐sequencing)	   and	   later	   from	   custom	  targeted	   sequencing	   of	   122	   genes	   but	   in	   a	   larger	   number	   of	   samples	   in	   a	  replication	  study	  (209	  trios).	  	  	  
The	   quality	   control	   (QC)	   tests	   in	   the	   primary	   cohort	   were	   able	   to	   detect	   a	  contamination	   issue	   in	   one	   trio	   although	   it	   had	   been	  missed	   by	   other	   quality	  tests.	  The	  various	  QC	  reports	  at	  the	  DNA	  sample	  processing,	  sequence	  data	  (BAM	  files)	  and	  final	  called	  variants	  (VCF	  files)	  proved	  to	  be	  essential	  steps	  to	  remove	  outlier	  and	  contaminated	  samples	  before	  any	  further	  downstream	  analyses.	  The	  majority	  of	   samples	   in	   the	  replication	  cohort	   (n=750)	  were	  subjected	   to	  whole	  genome	   amplification	   (WGA)	   prior	   to	   sequencing	   and	   I	   did	   not	   detect	   any	  obvious	   changes	   in	   the	   quality	   matrices	   compared	   with	   whole	   exome	  sequencing.	  	  The	  trio	  study	  design	   formed	  the	  basis	  of	  all	  analyses	  discussed	   in	  this	  chapter	  and	  not	  just	  detection	  of	  de	  novo	  variants	  in	  the	  affected	  children.	  Although	  the	  primary	  cohort	  was	  relatively	  small	  (only	  29	  trios),	   I	  was	  able	  to	  detect	  two	  de	  
novo	  coding	  variants	  (a	  missense	  and	  a	  single-­‐base	  deletion	  of	  an	  acceptor	  splice	  site)	  in	  NOTCH1.	  I	  also	  detected	  one	  de	  novo	  missense	  in	  another	  CHD	  candidate	  gene,	  DCHS1.	  Additionally,	  a	  novel	  gene,	  ZMYM2,	  was	  found	  to	  harbor	  a	  de	  novo	  loss-­‐of-­‐function	   frameshift.	   The	   role	   of	   ZMYM2	   in	   the	   heart	   development	   was	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supported	  by	  knocking	  it	  down	  in	  zebrafish	  using	  morpholinos	  by	  my	  colleague	  Sebastian	   Gerety	   (appendix	   A).	   	   These	   functional	   experiments	   suggest	   that	  zmym2	   is	   essential	   for	   normal	   embryonic	   heart	   development,	   the	   absence	   of	  which	   causes	   severe	   defects	   leading	   to	   death	   of	   the	   embryo.	   	  Why	   do	   the	   fish	  present	   with	   such	   a	   severe	   phenotype	   compared	   to	   the	   patient?	   	   While	   the	  morpholino	  injections	  lead	  to	  a	  loss	  of	  correctly	  spliced	  mRNA	  approaching	  80-­‐90%,	   the	   heterozygous	   state	   of	   our	   patient,	   and	   thus	   higher	   level	   of	   function	  protein,	   could	   explain	   the	   milder	   phenotype	   seen,	   when	   compared	   to	   the	  zebrafish.	  	  Further	  ongoing	  work	  in	  mouse	  and	  zebrafish	  mutants	  should	  clarify	  these	  issues.	  	  Collectively,	  these	  de	  novo	  variants	  explain	  13%	  (4	  out	  of	  29	  trios)	  in	  the	  primary	  ToF	  cohort,	  which	  correspond	  to	  the	  predicted	  proportion	  of	  de	  novo	  variants	  in	  CHD	  cases	  from	  a	  recently	  published	  work	  by	  Zaidi	  et	  al	  [256].	  	  	  	  	  
The	   Mendelian-­‐based	   analysis	   of	   inherited	   variants	   using	   FEVA	   software	  identified	   a	   few	   genes	   with	   recurrent	   rare	   variants	   under	   the	   assumption	   of	  complete	   penetrance.	   All	   candidate	   genes	   under	   the	   recessive	   model	   carry	  compound	   heterozygous	   variants	   in	   three	   sarcomeric	   genes	   (TTN,	   NEB	   and	  
OBSCN).	   Although	   these	   genes	   have	   been	   associated	   with	   cardiomyopathies	  [419],	  their	  roles	  in	  structural	  heart	  defects	  are	  not	  yet	  confirmed.	  The	  large	  size	  of	  these	  genes	  is	  likely	  to	  explain	  why	  they	  show	  up	  with	  recurrent	  rare	  coding	  variants.	  	  	  	  The	   burden	   of	   rare	   and	   de	   novo	   Copy	   number	   variants	   (CNVs)	   detected	   by	  array	  CGH	  and	  SNP	  arrays	  are	  now	  a	  well-­‐known	  cause	  in	  5-­‐10%	  of	  isolated	  ToF	  cases	  [340,	  341].	  Using	  the	  read-­‐depth	  of	  exome	  data,	  CoNVex	  software	  was	  able	  to	  detect	  two	  de	  novo	  duplication	  events,	  one	  of	  which	  overlaps	  with	  HDAC4	  and	  three	  inherited	  small	  duplications	  that	  overlap	  with	  FOXC1	  and	  FOXC2.	  However,	  they	  need	  to	  be	  validated	  using	  alternative	  methods	   first	   (e.g.	  custom	  designed	  array	  or	  multiplex	  ligation-­‐dependent	  probe	  amplification,	  MLPA).	  	  I	  did	  not	  try	  to	  call	  CNVs	  in	  the	  replication	  cohort	  since	  it	  covers	  122	  genes	  only	  and	  the	  CNV	  boundaries,	  if	  any,	  would	  be	  difficult	  to	  ascertain.	  Moreover,	  most	  samples	  were	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subject	   to	   whole	   genome	   amplification,	   which	   is	   known	   to	  make	   calling	   CNVs	  robustly	  in	  other	  assays	  more	  difficult.	  	  	  The	  primary	  dataset	  on	  29	  trios	  was	  followed	  by	  a	  replication	  study	  in	  209	  trios	  with	   isolated	   ToF.	   The	   main	   goal	   of	   this	   study	   was	   to	   confirm	   if	   some	   of	   the	  candidate	  genes	  with	  de	  novo	  variants	  might	  be	  recurrent	  in	  a	  larger	  number	  of	  isolated	   ToF	   samples.	   Additionally,	   I	   wanted	   to	   investigate	   other	   hypotheses	  derived	  from	  candidate	  genes	  published	  using	  different	  methods	  (GWAS,	  linkage,	  animal	  models,	  etc.).	  I	  selected	  122	  genes	  as	  part	  of	  custom	  designed	  SureSelect	  baits	  from	  Agilent	  (USA)	  for	  sequencing	  using	  an	  NGS	  platform	  (HiSeq,	  Illumina).	  	  	  The	  replication	  study	  design	  based	  on	  the	  number	  of	  the	  genes	  and	  the	  number	  of	  sequenced	  samples	  would	  be	  expected,	  under	  the	  null	  hypothesis	  to	  detect	  1.3	  
de	   novo	   missense	   variants	   and	   0.1	   loss	   of	   function	   variants	   and	   I	   was	   able	   to	  
identify	   six	  de	  novo	   variants	   (half	  of	  them	  are	  putative	   loss	  of	   function).	  This	  suggests	  an	  overall	  enrichment	  of	  de	  novo	  variants	  of	  likely	  functional	  impact	  in	  the	  selected	  genes.	  None	  of	  the	  genes	  that	  were	  selected	  based	  on	  the	  presence	  of	  validated	  de	  novo	  coding	  variants	  in	  the	  primary	  cohort	  appeared	  again	  in	  the	  replication	  study	  except	  for	  NOTCH1.	  This	  puts	  an	  upper	  limit	  on	  the	  proportion	  of	  ToF	  that	  de	  novo	  variants	  in	  these	  other	  genes	  might	  explain.	  The	  replication	  study	  shows	  1.6%	  of	  ToF	  samples	  can	  be	  attributed	  to	  de	  novo	  coding	  variants	  in	  
NOTCH1	   (4	   out	   of	   238	   trio	   samples,	   three	   are	   loss	   of	   function).	   This	   shows	   a	  strong	   over-­‐representation	   of	   loss	   of	   function	   variants	   in	   the	   NOTCH1	   gene	  (P=9.4	  ×10-­‐8)	  given	  its	  length	  and	  the	  rate	  of	  mutation.	  Additionally,	  two	  de	  novo	  variants	  were	  detected	   in	   the	   JAG1	   gene,	  a	  NOTCH1	   ligand,	  but	   it	  did	  not	  reach	  genome-­‐wide	   significance	   (P=0.00017),	   which	   increases	   the	   percentage	   of	  isolated	  ToF	  cases	  that	  can	  be	  attributed	  to	  de	  novo	  coding	  variants	  in	  NOTCH1	  or	  its	  ligand	  to	  2.5%	  .	  	  	  Although	   I	   was	   not	   able	   to	   detect	   recurrent	   de	   novo	   coding	   variants	   in	   other	  strong	   candidate	   genes	   such	   as	   ZMYM2,	   VEGFA	   and	   AXIN1,	   their	   biological	  functions	  and	  knockout	  animal	  models	  strongly	  support	  their	  involvement	  in	  the	  heart	   development	   and	   suggest	   them	   as	   novel	   candidate	   genes	   in	   isolate	   ToF.	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Because	  of	   the	  well-­‐known	  extreme	   locus	  heterogeneity	   in	  CHD	   [431],	   a	   larger	  cohort	  of	  isolated	  ToF	  trios	  will	  be	  needed	  to	  detect	  additional	  recurrent	  de	  novo	  variants	  in	  these	  genes.	  	  Under	  Mendelian	   inheritance	  models,	  I	  was	  able	  to	  use	  the	  FEVA	  software	  to	  detect	  three	  recurrent	  genes.	  Three	  trios	  carry	  the	  same	  rare	  frameshift	  in	  PCSK	  gene	   under	   autosomal	   recessive	   homozygous	   model	   where	   all	   parents	   are	  heterozygous.	  However,	  because	   this	   is	  an	   indels,	   these	  variant	  are	   likely	   to	  be	  false	  positive	  due	  to	  mapping	  errors.	  The	  second	  gene	  was	  PLEC	  with	  recurrent	  compound	  heterozygous	  variants,	  but	  it	  is	  not	  unexpected	  for	  such	  a	  large	  gene.	  This	   is	   similar	   to	  what	   I	   have	   already	   observed	   in	   the	   primary	   ToF	   cohort	   for	  other	   large	  genes	   (TTN,	  NEB	   and	  OBSCN).	  However,	   the	  rule	  of	  PLEC	  gene	  rare	  coding	  variants	   in	   congenital	  heart	  defects	   cannot	  be	  excluded	  without	   further	  genetic	  evidence	  or	  functional	  experiments.	  The	  third	  gene	  was	  LAMP2	  where	  I	  detected	   rare	   coding	   variants	   under	   the	   X-­‐linked	   model	   assuming	   a	   skewed	  inactivation	   of	   the	   mother	   X	   chromosome.	   Albeit	   interesting,	   this	   possibility	  cannot	   be	   confirmed	   without	   further	   analysis	   of	   the	   polymorphic	   androgen	  receptor	   (CAG)n	   repeat	   region,	   located	   on	   the	   X	   chromosome	   (Xq11-­‐q12)	   to	  confirm	  paternal	  or	  maternal	  X-­‐chromosome	  skewed	  inactivation	  [432]	  .	  	  	  To	  test	  other	  variants	  under	  a	  more	  relaxed	  scenario	  of	  incomplete	  penetrance,	  I	  implemented	   a	   modified	   version	   of	   the	   transmission	   disequilibrium	   test	  
(TDT).	  The	  goal	  of	  this	  analysis	  was	  to	  detect	  any	  distortion	  in	  the	  transmission	  of	  rare	  coding	  variant	  alleles	  from	  heterozygous	  healthy	  parents	  to	  their	  affected	  offspring.	   Unlike	   the	   original	   TDT,	   I	   selected	   rare	   functional	   variants	   only	   and	  collapsed	   their	   counts	   per	   gene	   to	   increase	   the	   power	   of	   the	   test.	   	   This	   test	  detected	  a	  distorted	  transmission	  of	  rare	  missense	  variants	  in	  ARHGAP35,	  a	  gene	  recently	  shown	  to	  play	  a	  critical	  role	  in	  the	  development	  of	  cardiac	  stem	  cells	  via	  RhoA-­‐dependent	   and	   -­‐independent	   mechanisms,	   in	   five	   trios	   (~2.4%	   of	   the	  replication	   cohort).	   The	   transmission	   of	   rare	   silent	   variants	   in	  ARHGAP35	  was	  not	  distorted	   like	   the	  missense	  variants	  but	   the	  difference	  was	  not	   statistically	  significant	   either.	   This	   is	   most	   likely	   because	   of	   the	   small	   number	   of	   variants	  detected	  in	  ARHGAP35.	  Based	  on	  these	  results,	  	  the	  modified	  version	  of	  the	  TDT	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test	  looks	  like	  a	  promising	  tool	  to	  examine	  variants	  with	  incomplete	  penetrance.	  However,	   a	   larger	   sample	   size	   is	   likely	   to	   increase	   the	   power	   of	   this	   test	   and	  make	  the	  results	  statistically	  more	  significant.	  ARHGAP35	  was	  also	  suggested	  as	  a	  ToF	  candidate	  gene	  based	  on	  the	  results	  from	  the	  independent	  de	  novo	  analysis	  in	  the	  primary	  cohort	  where	  one	  child	  has	  a	  confirmed	  de	  novo	  stop	  gain	  variant.	  	  	  The	  Digenic	   Inheritance	  (DI)	  analysis	  helped	  me	  to	  explore	  the	  area	  between	  monogenic	   and	   polygenic	   models,	   which	   is	   rarely	   considered	   in	   CHD	   genetic	  literature.	  The	  goal	  of	  my	  DI	  analysis	  was	  to	  detect	  rare	  coding	  variants	  in	  gene	  pairs	  supported	  by	  known	  protein-­‐protein	  interactions	  as	  long	  as	  each	  variant	  is	  inherited	   from	   a	   different	   parent	   (similar	   to	   the	   concept	   of	   compound	  heterozygous	  inheritance	  but	  in	  two	  genes	  instead	  of	  one).	  Under	  the	  DI	  model,	  I	  identified	  one	  nominally	  significant	  gene	  pair	  from	  the	  primary	  ToF	  cohort	  and	  two	   nominally	   significant	   gene-­‐pairs	   from	   the	   replication	   cohort.	   These	   gene	  pairs	   are	   MYH2/OBSCN,	   ZFPM2/CTBP2,	   and	   NCOR2/ESR1,	   all	   of	   which	   are	  statistically	  enriched	  for	  rare	  missense	  variants	  in	  ToF	  samples	  when	  compared	  with	  1,080	  trios	  from	  the	  Deciphering	  Developmental	  Disorders	  project	  	  (DDD).	  To	  the	  best	  of	  my	  knowledge,	  this	   is	  the	  first	  systematic	  DI	  analysis	  of	  genes	  in	  any	  congenital	  heart	  defect	  study.	   	  The	  function	  and	  the	  context	   in	  which	  these	  gene	   pairs	   operate	   suggest	   a	   plausible	   biological	   relevance	   for	   CHD,	   especially	  
NCOR2	  and	  ZFPM2.	   	  I	  observed	  these	  gene-­‐pairs	  in	  6%	  in	  the	  primary	  cohort	  (2	  out	  of	  29	  in	  MYH2/OBSCB)	  and	  in	  3%	  of	  the	  ToF	  replication	  study	  (7	  out	  of	  209	  in	  ZFPM2/CTBP2	  and	  NCRO2/ESR1	  gene	  pairs)	  	  However,	  a	  larger	  sample	  size	  is	  needed	  to	  increase	  the	  power	  of	  any	  future	  DI-­‐based	   analysis.	   This	   is	   especially	   true	   for	   heterogenic	   disorders	   such	   as	   CHD	  where	  hundreds	  of	  candidate	  genes	  are	  expected	  to	  be	   involved	   in	   the	  disease.	  More	  importantly,	  functional	  experiments,	  either	  in	  vitro	  such	  as	  cellular	  assays	  or	   in	  vivo	   (e.g.	  animal	  models)	  are	  required	  to	  confirm	  the	  causality	  of	  variants	  under	  the	  DI	  model.	  	  	  Finally,	  the	  pathway	  analysis	  was	  more	  successful	  in	  the	  replication	  cohort	  than	  	  in	  the	  primary	  cohort.	  This	  is	  probably	  due	  to	  the	  small	  number	  of	  samples	  and	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large	   number	   of	   genes	   in	   the	   primary	   cohort.	   This	   analysis	   picked	   up	   two	  pathways:	  the	  dorsoventral	  axis	  formation	  and	  prion	  diseases	  pathways.	  Both	  of	  them	   include	   the	  NOTCH1	   gene,	  which	   I	   found	   to	  be	   the	  main	  gene	  driving	   the	  signal	  of	  rare	  missense	  burden	  in	  both	  pathways.	  NOTCH1	  carries	  rare	  inherited	  missense	  variants	  in	  22	  cases	  based	  on	  this	  analysis	  and	  another	  four	  novel	  rare	  variants	   detected	   by	   an	   independent	   de	   novo	   analysis	   (22	   out	   of	   238	   trios	   or	  ~9.2%	  of	  all	  ToF	  cases).	  	  	  Although	  NOTCH1	   is	  already	  a	  well-­‐known	  CHD	  gene,	   its	  mutations	  are	  usually	  associated	  with	   left	  ventricular	  outflow	  tract	  abnormalities	  such	  as	  aortic	  valve	  stenosis,	  coarctation	  of	  the	  aorta	  and	  hypoplastic	  left	  heart	  syndrome	  [361,	  433]	  more	  than	  with	  ToF	  cases.	  My	  analysis	  analysis	  has	  delineated	  its	  contribution	  to	  the	   isolated	   ToF	   cases	   in	   more	   detail	   under	   different	   inheritance	   models	  including	   Mendelian,	   de	   novo,	   digenic	   and	   pathway-­‐based	   burden.	   The	  contribution	   of	   each	   rare	   missense	   in	  NOTCH1	   needs	   further	   investigation	   by	  means	   of	   functional	   experiments	   (e.g.	   luciferase	   assays,	   modeling	   in	   animals),	  which	   are	   not	   usually	   provided	   for	   published	  mutations.	   These	   studies	   would	  help	   to	  determine	  how	   the	   effect	   of	   these	  mutations	   varies	  between	   cases	   and	  controls	  and	  help	  us	   to	  understand	  how	  different	  mutations	   cause	   left	  or	   right	  side	  structural	  defects	  in	  the	  human	  heart.	  	  	  The	  analyses	  described	  in	  this	  chapter	  also	  detected	  other	  genes	  with	  recurrent	  rare	   variants	   under	   incomplete	   penetrance	   in	   novel	   genes	   such	   as	  ARHGAP35	  and	   the	   ZFPM2/CTBP2	   gene-­‐pair	   under	   a	   digenic	   model.	   	   These	   scenarios	  represent	  a	  partial	  explanation	  for	  part	  of	  isolated	  ToF	  cases	  but	  certainly	  needs	  to	  be	  confirmed	  by	  further	  genetic	  evidence	  and/or	  functional	  experiments.	  	  	  The	  trio	  study	  design	  has	  proved	  to	  be	  very	  informative	  and	  a	  successful	  design.	  This	  design	  is	  amenable	  to	  many	  analytical	  approaches	  in	  order	  to	  test	  different	  hypotheses	   of	   the	   causes	   of	   diseases	   that	   range	   from	  monogenic	   to	   polygenic	  models.	  A	  larger	  sample	  size	  of	  isolated	  ToF	  trios	  will	   likely	  prove	  a	  productive	  approach	   to	   improving	   our	   understanding	   of	   the	   underlying	   genetic	  pathogenesis	  of	  isolated	  ToF.	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4 Combined	  genetic	  investigations	  of	  Atrioventricular	  Septal	  
Defects	  (AVSD)	  in	  trios	  and	  index	  cases	  	  
Collaboration	  note	  	  
This	   chapter	   contains	   work	   performed	   in	   collaboration	   with	   many	   people,	   most	  
notably	   Dr.	   Sebastian	   Gerety	   and	   Catherine	   Mercer.	   Sebastian	   performed	   the	  
luciferase	   assays	  while	   Catharine	  mapped	   the	   exact	   locus	   of	   a	   de	   novo	   balanced	  
translocation	  in	  a	  patient	  with	  coarctation	  of	  the	  aorta	  to	  NR2F2	  (appendix	  B).	  	  
4.1 Introduction	  	  	  Atrioventricular	  septal	  defects	  (AVSD),	  also	  known	  as	  ‘common	  atrioventricular	  canal’	   or	   ‘endocardial	   cushion	   defect’,	   characterize	   a	   group	   of	   congenital	  structural	  defects	  in	  the	  atrioventricular	  septum	  of	  the	  developing	  heart.	  About	  half	  of	  AVSD	  cases	  are	  syndromic,	  mainly	  associated	  with	  Down	  syndrome	  where	  AVSD	  is	  thought	  to	  result	  from	  the	  overexpression	  of	  genes	  on	  chromosome	  21	  (see	   Genetic	   factors	   section	   below).	   However,	   the	   other	   half	   of	   AVSD	   cases	   is	  mainly	   isolated	   (patients	   without	   extracardiac	   phenotypes)	   and	   its	   genetic	  architecture	  remains	  largely	  unknown.	  	  In	  this	  chapter,	  I	  describe	  how	  I	  used	  exome	  sequence	  data	  from	  non-­‐syndromic	  AVSD	  cases	  from	  two	  different	  family-­‐designs,	  trios	  and	  index	  cases,	  to	  discover	  genes	   enriched	   for	   rare,	   functional	   coding	   variants.	   Using	   this	   approach,	   I	  was	  also	   able	   to	   identify	   a	   novel	   gene,	  NR2F2,	   which	   causes	   AVSD	   and	   other	   CHD	  phenotypes	  in	  humans	  in	  a	  dosage-­‐sensitive	  fashion	  similar	  to	  other	  key	  cardiac	  developmental	  genes	  such	  as	  GATA4,	  NKX2.5	  and	  TBX1.	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4.1.1 Anatomical	  classification	  The	  major	  hallmark	  of	  all	  AVSD	   is	   the	  common	  atrioventricular	  valve	   (AV)	  but	  AVSD	   subtypes	   vary	   with	   respect	   to	   the	   level	   at	   which	   shunting	   between	   the	  atria	  or	  ventricles	  takes	  place.	  The	  main	  two	  clinical	  AVSD	  subtypes	  are	  complete	  and	  partial	  (Table	  4-­‐1	  and	  Figure	  4-­‐1).	  The	  complete	  subtype	  is	  characterized	  by	  a	  primum	  atrial	  septal	  defect	  (ASD)	  that	  is	  contiguous	  with	  a	  posterior	  (or	  inlet)	  ventricular	  septal	  defect	  (VSD),	  and	  a	  common	  AV	  valve.	  	  Typical	  partial	  AVSD	  is	  distinguished	  from	  complete	  AVSD	  by	  the	  absence	  of	  an	  inlet	  VSD.	  Another	  two	  types	   have	   been	   described:	   intermediate	   and	   transitional	   and	   both	   are	  considered	  subtypes	  of	   complete	  AVSD.	   In	   the	   intermediate	  subtype	  a	  bridging	  tongue	  of	  tissue	  divides	  the	  common	  AV	  valve	   into	  two	  distinct	  orifices.	  On	  the	  other	   hand,	   the	   transitional	   subtype	   has	   a	   small	   inlet	   VSD	   that	   is	   partially	  occluded	   by	   a	   dense	   tissue	   (chordal	   attachment	   to	   the	   septum)	   resulting	   in	   a	  defect	  that	  is	  similar	  to	  the	  physiology	  of	  a	  partial	  AV	  canal	  defect	  [434,	  435].	  	  	  Table	  4-­‐1	  Anatomical	  classification	  of	  AVSDs	  
AVSD Types Phenotype Components 
Complete 
Balanced subtype 
Complete failure of fusion between the superior and inferior endocardial cushions. Consists of  
*Primum ASD 
* Posterior (inlet) VSD 
* Common AV valve  
Unbalanced subtype 
In addition to balanced type defects in the balanced type. This type has hypoplasia in either the 
right or left ventricular. 
Partial 
Incomplete fusion of superior and inferior endocardial cushion and consists of: 
* Premium ASD 
* A single AV valve annulus with two separate valve orifices  
* Usually the anterior leaflet of the mitral valve is a cleft. 
Intermediate 
This is a rare form of AVSD that is similar to the complete AVSD  
* Large Premium ASD 
* Posterior (inlet) VSD 
But it also has a bridging tongue of tissue divides he common AVS valve into two distinct 
orifices.  The intermediate and complete AVSD have the physiology and clinical features of an 
ASD and a VSD [434]. 
Transitional 
Anatomically, it is subtype of the complete AVSD as it consists of: 
* Large premium ASD 
* Posterior (inlet) VSD 
* Cleft mitral valve  
But physiologically it is similar to the partial AVSD because of a dense chordal attachment to the 
VS that lead to small insignificant ventricular shunting and delineation of distinct left and right AV 
valve orifices. Both transitional and partial AVSD clinical picture of a large ASD. 
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  Figure	  4-­‐1	  Anatomic	  and	  physiologic	  similarities	  between	  the	  different	  forms	  of	  atrioventricular	  septal	  defect	  (AVSD).	  Image	  adapted	  from	  [436].	  	  The	  complete	  AVSD	  type	  is	  further	  subdivided	  using	  ‘Rastelli	  classification’	  based	  on	  the	  atrioventricular	  valve	  morphology	  and	  the	  relative	  ventricular	  size	  [437].	  The	  clinical	  severity	  varies	  depending	  on	  the	  size	  of	  the	  defect	  and	  whether	  it	  is	  associated	  with	  valvular	  defect	  and	  /	  or	  ventricular	  hypoplasia.	  	  	  	  
4.1.2 The	  prevalence	  of	  atrioventricular	  septal	  defects	  AVSD	   represent	   4-­‐5%	   of	   all	   congenital	   heart	   defects	   (CHD)	   and	   its	   prevalence	  ranges	   from	   0.3	   to	   0.4	   per	   1000	   live	   births	   [438,	   439]	   (Figure	   4-­‐2).	   However,	  AVSD	   prevalence	   is	   much	   higher	   in	   fetuses	   based	   on	   large	   fetal	  echocardiographic	   series	  where	   it	  was	   found	   to	  account	   for	  18%	  of	  CHD	  cases	  [440].	  The	  discrepancy	  in	  the	  prevalence	  may	  be	  attributed	  to	  the	  fact	  that	  many	  of	   the	   AVSD	   fetuses	   will	   not	   survive	   until	   birth	   either	   because	   they	   die	  prematurely	  or	  due	  to	  abortion.	  Postnatally,	  certain	  patient	  groups	  have	  a	  higher	  AVSD	   prevalence	   as	   in	   Down	   syndrome	   (44%	   of	   patients	   have	   CHD	   of	   which	  39%	  are	  AVSDs)	  [311]	  and	  two-­‐thirds	  of	  patients	  with	  heterotaxia	  exhibit	  one	  of	  the	  AVSD	  subtypes[441].	  	  	  
4.1	  Introduction	  	  
	   185	  
In	  a	  large	  population-­‐based	  birth	  defects	  registry	  in	  Texas	  (USA),	  1,636	  cases	  of	  AVSD	   were	   reported	   between	   2000-­‐2009[442].	   The	   most	   common	   AVSD	  subtype	   was	   complete	   AVSD	   (n=	   1,335,	   82%)	   [443].	   More	   than	   half	   of	   the	  complete	  AVSD	  cases	  were	  syndromic	  (Table	  4-­‐2).	  	  Table	   4-­‐2	   The	   frequency	   of	   syndromic	   and	   non-­‐syndromic	   complete	   AVSD	   reported	   between	  2000-­‐2009	  in	  Texas	  birth	  registry	  [443]	  
Complete	  AVSD	   n(%)	  
Syndromic	   772	  (57.8)	  	  	  	  	  Trisomy	  21	   	  	  	  693	  (51.9)	  	  	  	  	  Trisomy	  18	   	  	  	  31	  	  	  (2.3)	  	  	  	  	  Trisomy	  13	   	  	  	  10	  	  	  (0.7)	  	  	  	  	  Other	  chromosome	  abnormalities	  	   	  	  	  16	  	  	  (1.2)	  	  	  	  	  Other	  syndromes	   	  	  	  33	  	  	  (2.5)	  
Non-­‐syndromic	   563	  (42.2)	  	  	  	  	  Additional	  cardiac	  or	  non-­‐cardiac	  malformation	  	   	  	  	  516	  (91.6)	  	  	  	  	  Additional	  cardiac	  malformation	  only	   	  	  	  223	  (39.6)	  	  	  	  	  Visceral	  heterotaxy	   	  	  	  218	  (38.7)	  	  	  The	   recurrence	   risk	   (RR)	   of	   AVSD	   in	   first-­‐degree	   relatives	   is	   3-­‐4%	   when	   one	  child	  is	  affected.	  While	  an	  affected	  father	  doesn’t	  seem	  to	  increase	  the	  recurrence	  risk	  of	  AVSD,	  an	  affected	  mother,	  increases	  the	  RR	  up	  to	  10%	  [15]	  (Figure	  4-­‐2-­‐c).	  The	  male-­‐to-­‐female	  distribution	  of	  AV	  canal	  defect	   is	   approximately	  equal	   [64,	  
444]	   (Figure	   4-­‐2-­‐d).	   Partial	   AVSD,	   however,	   shows	   a	   slight	   skew	   with	   more	  males	   affected	   than	   females	   (male-­‐to-­‐female	   ratio	   is	   1.57)	   [64]	   but	   the	   small	  number	  of	  partial	  AVSD	  cases	  may	  explain	  this	  bias	  (n=18).	  	  
4.1	  Introduction	  	  
	   186	  
	  
	  Figure	   4-­‐2	   (a)	   proportion	   of	   different	   CHD,	   including	   complate	   atrioventricular	   septal	   defects	  (cAVSD)	  (red	  bar),	  in	  all	  cases	  registered	  in	  the	  PAN	  registery	  (n=7,245)	  during	  one	  year	  2006-­‐2007	  (b)	  the	  prevealance	  of	  cAVSD	  cases	  in	  10,000	  live	  births	  from	  the	  PAN	  registry	  compared	  to	  	  other	  CHD	  cases	  	  (red	  bar).	  (c)	  Recurrence	  risk	  of	  cAVSD	  in	  first	  degree-­‐realtives	  (d)	  cAVSD	  male-­‐to-­‐female	  ratio	  based	  on	  data	  from	  PAN	  registry	  [64].	  D-­‐TGA:	  dextro-­‐Transposition	  of	  the	  great	  arteries,	  cAVSD:	  complate	  atrioventricular	  septal	  defect,	  HLHS:	  hypoplastic	  left	  heart	  syndrome,	  PS:	   pulmonary	   stenosis,	   AS:	   aortic	   stenosis,	   CoA:	   coarctation	   of	   aorta,	   TOF:	   tetralogy	   of	   Fallot,	  ASD:atrial	  septal	  defects,	  VSD:	  ventricular	  septal	  defects.	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suggestive	   of	   AVSD,	   but	   chest	   radiograph	   and	   other	   advanced	   imaging	  approaches	  such	  as	  echocardiogram	  and	  magnetic	  resonance	  might	  be	  needed	  to	  confirm	  the	  clinical	  diagnosis	  [435].	  	  	  	  Prolonged	   delay	   in	   surgical	   treatment	   may	   cause	   patients	   to	   develop	  Eisenmenger’s	  syndrome	  that	  causes	  a	  permanent	  damage	  to	   the	   lung	  vascular	  circulation	  due	  to	  the	  long	  exposure	  to	  high	  blood	  pressure	  returning	  to	  the	  lung	  instead	  of	  the	  systemic	  blood	  circulation	  [445].	  	  	  The	  prognosis	  of	  children	  with	  untreated	  complete	  AVSD	  is	  usually	  poor.	  Half	  of	  them	  die	  in	  the	  first	  year	  of	  life	  because	  of	  either	  heart	  failure	  or	  pneumonia.	  If	  they	   survive	   the	   first	   two	   years,	   an	   irreversible	   pulmonary	   vascular	   disease	  becomes	  increasingly	  common	  and	  affects	  virtually	  all	  patients	  [446].	  The	  rate	  of	  5-­‐year	   survival	   is	   less	   than	   4%	   in	   uncorrected	   complete	   AVSD	   patients	   [447].	  	  However,	   long-­‐term	   survival	   after	   surgical	   repair	   has	   been	   excellent	   and	  cumulative	  20-­‐year	  survival	  of	  95%	  has	  been	  reported	  [448-­‐450].	  	  
4.1.4 Embryological	  development	  of	  the	  endocardial	  cushions	  	  The	   details	   of	   the	   development	   of	   the	   human	   heart	   have	   been	   described	   in	  chapter	  1.	  This	   section	   summarizes	   the	  main	  events	   in	   the	  development	  of	   the	  atrioventricular	  cushion	  and	  related	  heart	  septation	  events.	  	  At	  the	  ninth	  embryonic	  day	  (E9)	  of	  the	  developing	  heart	  in	  the	  mouse,	  the	  looped	  heart	  tube	  is	  segmented	  into	  four	  regions:	  the	  atrium,	  the	  atrioventricular	  canal	  (AVC),	   the	  ventricle	  and	  the	  outflow	  tract	  (OFT)	  (Figure	  4-­‐3).	  The	  heart	  tube	   is	  composed	  of	   an	   inner	   endocardial	   lining	   and	  an	  outer	  myocardial	   layer,	  which	  contain	  tissue	  swellings	  at	  the	  AVC	  lumen	  as	  well	  as	  in	  the	  proximal	  part	  of	  the	  OFT.	   These	   swellings	   are	   termed	   endocardial	   cushions	   and	   are	   formed	   by	   the	  accumulation	   of	   abundant	   extracellular	   matrix	   (cardiac	   jelly)	   inbetween	   the	  endocardium	  and	  myocardium.	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  Figure	  4-­‐3	  The	  formation	  of	  a	  mouse	  heart.	  Ventral	  and	  left	  lateral	  views	  at	  E9.	  The	  looped	  heart	  tube	   contains	   four	   anatomical	   segments:	   atrium,	   atrioventricular	   canal	   (AVC),	   ventricle,	   and	  outflow	  tract	  (OFT).	  Image	  adopted	  from	  [307].	  	  	  For	   the	   AVC	   to	   develop	   into	   septal	   and	   valve	   tissues,	   its	   cushions	   require	   a	  population	  of	  mesenchyme	  cells.	  This	  population	   is	  derived	   through	  epithelial-­‐to-­‐mesenchymal	   transformation	   (EMT)	   from	   cells	   at	   the	   inner	   wall	   of	   the	  developing	   heart	   tube	   (endocardial	   cells).	   These	   endocardial	   cells	   differentiate	  into	  mesenchymal	  cells	  and	  migrate	  into	  the	  cardiac	  jelly	  to	  proliferate	  and	  form	  the	  AVC	  cushions	  [451].	  In	  total,	  there	  are	  four	  mesenchymal	  tissues	  required	  for	  atrioventricular	  canal	  septation	  [307]:	  the	  superior	  and	  inferior	  atrioventricular	  endocardial	  cushions,	   the	  mesenchymal	  cap	  (MC),	  and	  the	  dorsal	  mesenchymal	  protrusion	  (DMP)	  [452,	  453](Figure	  4-­‐4).	  The	  EMT	  process	  also	  is	  a	  key	  part	  of	  the	   mesenchymal	   cap	   (MC)	   growth	   from	   the	   lower	   part	   of	   the	   atrial	   septum	  [453].	  The	  final	  mesenchymal	  set	  of	  cells	  required	  for	  AV	  canal	  septation	  in	  the	  dorsal	  mesenchymal	  protrusion	  (DMP)	  comes	  from	  the	  second	  heart	  field	  (SHF)	  which	  bulges	  into	  the	  atrial	  chamber	  as	  a	  mesenchymal	  protrusion	  [453,	  454].	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  Figure	  4-­‐4	  Superior	  and	  anterior	  oblique	  view	  of	  the	  AV	  cushion	  development.	  The	  AV	  canal	  will	  develop	  four	  cushions:	   the	  superior	  and	   inferior	  atrioventricular	  cushions	  (sAVC	  and	   iAVC)	  are	  the	   two	  major	  cushions	   in	   the	  central	  portion	  of	   the	  AVC	  and	  another	   two	  minor	  cushions,	   left	  and	  right	  lateral	  AV	  cushions	  (llAVC	  and	  rlAVC).	  The	  mesenchymal	  cap	  (MC)	  is	  a	  tissue	  that	  caps	  the	  leading	  edge	  of	  primary	  atrial	  septum	  (PAS)	  that	  grows	  from	  the	  atrial	  roof	  towards	  the	  AV	  canal.	  The	  dorsal	  mesenchymal	  protrusion	  (DMP)	  protrudes	   from	  the	  dorsal	  mesocardium	  into	  the	   atrial	   chamber.	   RA,	   right	   atrium;	   LA,	   left	   atrium;	  RV,	   right	   ventricle;	   LV,	   left	   ventricle;	   IVS,	  interventricular	  septum.	  (Adopted	  from	  [307])	  	  	  These	   four	   mesenchymal	   tissues	   play	   a	   major	   rule	   in	   the	   septation	   of	   the	   AV	  canal	   in	  which	   any	   defect	   in	   the	   cellular	  migration	   and	   /	   or	   proliferation	  may	  cause	  atrial,	  ventricular	  or	  AV	  septal	  defects	  [307].	  	  For	  example,	  the	  mitral	  and	  tricuspid	  orifices	  are	  separated	  when	  the	  mesenchyme	  of	  superior	  and	   inferior	  AV	  cushions	  fuses	  at	  the	  AV	  canal.	  A	  failure	  of	  the	  fusion	  between	  these	  cushions	  creates	   a	   common	   AV	   valve	   (AVSD).	   In	   a	   transverse	   section	   of	   the	   developing	  heart	  (Figure	  4-­‐5)	  the	  mesenchymal	  cap	  grows	  downward	  to	  reach	  and	  fuse	  with	  the	   AV	   canal	   anteriorly	   and	   creates	   part	   of	   the	   atrial	   septum.	   Similarly	   from	  below,	  an	  interventricular	  muscular	  septum	  emerges	  from	  within	  the	  ventricular	  chamber	  and	  grows	  superiorly	  to	  fuse	  with	  AV	  cushions,	  dividing	  the	  ventricular	  chamber	  into	  left	  and	  right	  ventricles	  [455,	  456].	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  Figure	  4-­‐5	  A	  transverse	  section	  at	  E11	  in	  the	  developing	  mouse	  heart.	  At	  this	  stage,	  the	  heart	  is	  partially	   partitioned	   by	   the	   primitive	   atrial	   septum	   (PAS),	   interventricular	   septum	   (IVS)	   and	  atrioventricular	   cushions	   (AV	   cushions).	   	   The	  AVC	   is	   divided	   into	   tricuspid	   and	  mitral	   orifices,	  forming	   ventricular	   inlets	   that	   connect	   the	   respective	   atrium	   to	   the	   ventricle.	   The	   opening	  between	   the	   PAS	   and	   AVC	   is	   the	   ostium	   primum.	   RA,	   right	   atrium;	   LA,	   left	   atrium;	   RV,	   right	  ventricle;	  LV,	  left	  ventricle.	  (Adopted	  from	  [307])	  	  	  
	  Figure	  4-­‐6	  Genes	  and	  pathways	  essential	  for	  cardiac	  septation	  and	  valve	  development	  [307]	  	  Studies	   of	   heart	   development	   in	   mouse	   models	   have	   linked	   90-­‐100	   different	  genes	   in	   the	   regulation	  of	  heart	   septation	  and	  valve	  development	   (Figure	  4-­‐6).	  	  Broadly	   speaking,	   these	   genes	   can	   be	   arranged	   into	   four	   groups:	   signaling	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pathways	  (e.g.	  NOTCH	  genes),	  transcription	  factors	  (e.g.	  GATA	  genes),	  epigenetic	  factors	   (e.g.	   microRNAs	   and	   histone	   modifiers)	   and	   adhesion	   or	   migration	  molecules.	   Many	   of	   these	   genes	   are	   discussed	   in	   chapter	   1	   and	   as	   part	   of	  different	  analyses	  in	  this	  thesis.	  Lin	  C.	  et	  al.	  have	  reviewed	  the	  role	  of	  these	  genes	  in	  much	  detail	  [307].	  	  
4.1.5 Causes	  of	  AVSD	  
4.1.5.1 Non-­‐genetic	  factors	  	  	  Many	   studies	   have	   addressed	   the	   involvement	   of	   environmental	   factors	   in	   the	  CHD	   (reviewed	   in	   chapter	  1)	  but	   few	  have	   targeted	  non-­‐genetic	   risk	   factors	   in	  AVSD	   specifically.	   The	   most	   detailed	   work	   in	   this	   regard	   was	   done	   in	   the	  Baltimore-­‐Washington	   Infant	   Study	   [9,	   297]	  where	   the	   authors	   detected	  many	  environmental	   risk	   factors	   for	   AVSDs	   such	   as	   maternal	   diabetes	   in	   non-­‐syndromic	  AVSD	  infants	  (odds	  ratio=20.6).	  	  Maternal	  urinary	  tract	  infection	  was	  also	  found	  to	  increase	  the	  risk	  of	  AVSD,	  although	  mildly	  (odds	  ratio=2.29).	  	  Other	  AVSD	  risk	  factors	  are	  listed	  in	  (Table	  4-­‐3)	  along	  with	  their	  respective	  odds	  ratios	  and	   confidence	   intervals.	   	   Sonali	   Patel	   extensively	   reviewed	   the	   AVSD	   non-­‐genetic	  risk	  factors	  extensively	  in	  her	  thesis	  [457].	  	  	  It	   is	   important	   to	   note	   that	   these	   studies	   vary,	   and	   sometimes	   even	   contradict	  each	  other’s	  conclusion.	  This	  can	  be	  attributed	  to	  the	  small	  sample	  sizes	  due	  to	  the	   rarity	   of	   AVSDs	   but	   also	   to	   the	   variation	   in	   the	   amount	   and	   length	   of	  exposure	  to	  these	  factors	  and	  how	  they	  were	  measured.	  	  Table	  4-­‐3	  Risk	  Factors	  and	  Exposures	  Associated	  With	  Atrioventricular	  Septal	  Defects	  
Condition	   Risk	  Factor/Exposure	   Odd	  ratio	  
95%	  Confidence	  
intervals	  
Maternal	  Illness	   Diabetes	  	   22.8	   7.4-­‐70.5	  Urinary	  tract	  infections	   2.29	   1.11-­‐4.73	  
Medications	  
Non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (Ibuprofen)	  	   2.49	   1.42-­‐4.34	  Antitussive	  medications	   6.3	   1.9-­‐21.6	  Antibiotic	  medications	  	   1.7	   1.1-­‐2.6	  
Non-­‐therapeutic	  
Drugs	  
Cigarette	  smoking	  (maternal)	  	   2.50	   1.21-­‐5.19	  Cocaine	   3.45	   1.05-­‐11.40	  
Occupational	   Paint/Varnishes	  (maternal)	  	   4.45	   1.36-­‐15.18	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4.1.5.2 Genetic	  factors	  
4.1.5.2.1 Syndromic	  AVSDs	  	  AVSDs	   can	   be	   part	   of	   syndromes	   caused	   by	   large	   chromosomal	   lesions,	   small	  microscopically	   visible	   events,	   or	   single	   point	   mutations.	   The	   Baltimore-­‐Washington	  Infant	  Study	  (BWIS)	  identified	  336	  children	  with	  AVSD	  among	  4,385	  infants	  presenting	  under	  1	  year	  of	  age	  (7.7%)	  where	  76%	  were	  syndromic	  [458],	  mainly	  Down	  syndrome	  (DS)	  [9].	  In	  DS,	  40-­‐50%	  of	  the	  patients	  have	  CHD	  and	  the	  most	   common	   type	   is	   AVSD	   (of	   which	   18%	   have	   a	   complete	   AVSD	   subtype)	  [311].	   Having	   DS	   increases	   the	   risk	   of	   AVSD	  more	   than	   2,000-­‐fold	   [459].	   The	  exact	  causes	  of	  CHD	  in	  DS	  are	  yet	  to	  be	  found,	  but	  many	  hypotheses	  have	  been	  suggested	   [460].	   For	   example,	   overexpression	   of	  DSCAM,	   Down	   Syndrome	   Cell	  Adhesion	  Molecule,	  was	  suggested	  as	  the	  candidate	  of	  CHD	  in	  DS	  [461].	  Similarly,	  
DSCR1	  gene	  in	  the	  DS	  critical	  region	  is	  thought	  to	  disturb	  VEGF-­‐A,	  an	  important	  regulator	  of	  endocardial	  cushions	  in	  the	  heart	  via	  the	  Calcineurin–NFAT	  pathway	  [104,	  462].	  	  Although	   having	   three	   copies	   of	   chromosome	   21	   genes	   increases	   the	   risk	   of	  AVSD	  and	  CHD	  in	  general,	  it	  is	  not	  sufficient	  to	  explain	  why	  half	  the	  DS	  patients	  have	   normal	   hearts.	   This	   has	   been	   suggested	   to	   be	   explained	   in	   part	   by	   the	  presence	  of	  rare	  deleterious	  coding	  variants	  in	  VEGF-­‐A	  pathway	  genes	  (COL6A1,	  
COL6A2,	   CRELD1,	   FBLN2,	   FRZB,	   and	   GATA5)	   in	   20%	   of	   the	   DS	   cases	   (n=141)	  compared	  to	  3%	  in	  healthy	  controls	  (n=141)[463].	  This	  might	   indicate	  that	  the	  triple	   dosage	   effect	   of	   genes	   on	   chromosomes	   21	   may	   need	   a	   burden	   of	   rare	  coding	  variants	  to	  cause	  AVSD	  and	  other	  CHD	  but	  these	  findings	  have	  yet	  to	  be	  replicated	  by	  independent	  groups.	  	  Other	  chromosomal	   lesions	  have	  been	  reported	  with	  AVSD.	  For	  example,	  distal	  deletion	   of	   chromosome	   3p25-­‐pter	   (3p−	   syndrome)	   causes	   low	   birth	   weight,	  mental	  retardation,	  telecanthus,	  ptosis,	  micrognathia,	  and	  AVSD	  in	  about	  third	  of	  the	   patients	   [464].	   A	   consistent	   association	   was	   also	   described	   between	   8p	  deletion	   (del8p)	   and	   AVSD	   [465,	   466],	   which	   span	   a	   well-­‐known	   CHD	   gene,	  
GATA4.	   Additionally,	   there	   are	   a	   few	   reported	   cases	   of	   AVSD	  with	   partial	   10q	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monosomy,	   partial	   13q	   monosomy,	   ring	   22,	   14q+,	   and	   1p+3p-­‐	   due	   to	   an	  unbalanced	  translocation	  [458].	  	  Some	  Mendelian	  diseases	  caused	  predominantly	  by	  point	  mutations	  may	  present	  with	   AVSD.	   Two	   heterotaxy	   patients	   (OMIM	   605376)	   with	   abdominal	   situs	  inverses	  and	  complete	  AVSD	  were	  found	  to	  have	  missense	  mutations	  in	  NODAL,	  a	  gene	  known	   to	  play	  a	   central	   role	   in	  early	  embryonic	  development,	  mesoderm	  and	   endoderm	   formation	   and	   left-­‐right	   axis	   patterning	   [467].	   	   Both	   recessive	  syndromes	   such	   as	   Ivemark	   syndrome	   (OMIM	   208530),	   Ellis-­‐van	   Creveld	  syndrome	   (OMIM	  225500),	  Kaufman-­‐McKusick	   syndrome	   (OMIM	  236700)	   and	  dominant	   syndromes	   such	   as	   CHARGE	   syndrome	   (OMIM	   214800)	   are	   also	  known	  to	  be	  associated	  with	  AVSD.	  	  	  
4.1.5.2.2 Non-­‐syndromic	  AVSDs	  	  Similar	   to	   other	   non-­‐syndromic	   CHD	   phenotypes,	   the	   long-­‐standing	   consensus	  on	  the	  genetic	  causes	  of	  isolated	  AVSD	  has	  focused	  on	  multifactorial	  inheritance,	  but	  this	  view	  has	  been	  challenged	  by	  the	  observation	  of	  several	  pedigrees	  with	  multiple	   affected	   individuals	   [468].	   These	   findings	   suggested	   that	   a	   major	  genetic	  locus	  could	  account	  for	  the	  disorder	  in	  some	  families.	  Different	  loci	  have	  been	  linked	  to	   large	  families	  with	   isolated	  AVSD	  [469-­‐474].	  The	  common	  trend	  of	  these	  studies	  is	  autosomal	  dominant	  inheritance	  with	  incomplete	  penetrance	  and	  variable	  expression	  [475].	  One	  of	  these	  loci	  associated	  with	  AVSDs	  is	  known	  as	  AVSD1	  locus	  on	  chromosome	  1p31-­‐p21	  (OMIM	  606215),	  which	  was	  identified	  by	  use	  of	  a	  combination	  of	  DNA	  pooling	  and	  shared	  segment	  analysis	  in	  a	  high-­‐density	  genome	  screen	  [476]	  but	  the	  exact	  causal	  gene	  has	  yet	  to	  be	  identified.	  	  	  A	   second	   locus	   AVSD2	   (OMIM	   606217)	   was	   identified	   through	   analysis	   of	  chromosomal	   breakpoints	   in	   3p-­‐	   syndrome,	   which	   results	   from	   a	   deletion	   of	  3p25-­‐pter	   [464,	   477,	   478].	   In	   this	   locus,	   CRELD1	   gene	   was	   proposed	   as	   the	  candidate	  gene	  for	  the	  AVSD2	  locus	  on	  the	  basis	  of	  its	  mapping	  to	  chromosome	  3p25	   and	   its	   expression	   in	   the	   developing	   heart	   [479].	  CRELD1	  encodes	   a	   cell	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surface	  protein	   that	   likely	   functions	   as	   a	   cell	   adhesion	  molecule.	  A	   subsequent	  study	  by	  Robinson	  et	  al.	  showed	  rare	  heterozygous	  missense	  mutations	  in	  about	  6%	  of	   isolated	  cases	  of	  AVSD	   in	   their	   cohort	   (two	  out	  of	  35)	   [475]	  but	   further	  screening	   studies	   showed	   a	   lower	   rate	   of	   mutations	   in	   non-­‐syndromic	   AVSD	  (ranged	   between	   1.5	   and	   4%	   [480-­‐482].	   However,	   most	   of	   these	   studies	   lack	  functional	  experiments	  of	  compelling	  statistical	  enrichment	  to	  confirm	  whether	  these	  mutations	  are	  actually	  pathogenic	  or	  not.	  	  	  The	  resequencing	  of	  known	  CHD	  candidate	  genes	  has	  also	  been	  used	  to	  look	  for	  rare	  coding	  mutations	  in	  isolated	  AVSD.	  Table	  4-­‐4	  lists	  some	  of	  these	  genes	  along	  with	   the	   proportion	   of	   patients	   with	   rare	   coding	   mutations	   in	   every	   cohort.	  These	  studies,	  however,	  were	  able	  to	  explain	  only	  2%	  of	  the	  isolated	  AVSDs	  on	  average.	  	  Another	  common	  feature	  shared	  between	  these	  studies	  was	  the	  lack	  of	  strong	   functional	   evidence	   for	  most	   variants.	   These	   factors,	   in	   addition	   to	   the	  incomplete	   penetrance	   and	   variable	   gene	   expressivity,	   make	   it	   hard	   to	   accept	  some	  of	  these	  genes	  as	  causes	  of	  isolated	  AVSD.	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Table	  4-­‐4	  Rare	  coding	  mutations	  detected	  in	  isolated	  AVSD	  candidate	  genes	  
Gene	   Mutated	  patients	  /	  analyzed	  patients	   %	  
Functional	  
evidence	   Reference	  
ALK2	   2/190	   1	   Luciferase	  assay	  	  
Smith	  et	  al.	  [483]	  
ALK3	   1/190	   0.5	   N/A	  
ADAM19	   1/190	   0.5	   N/A	  
ERBB3	   1/190	   0.5	   N/A	  
EGFR	   1/190	   0.5	   N/A	  
UGDH	   1/190	   0.5	   N/A	  
FOXP1	   1/190	   0.5	   N/A	  
ECE2	   1/190	   0.5	   N/A	  
APC	   1/190	   0.5	   N/A	  
CRELD1	  
2/35	   5.7	   Western	  blot	  analysis	  (protein	  mobility)	   Robinson	  et	  al.	  [475]	  1/49	   2.0	   N/A	   Zatyka	  et	  al.	  [482]	  
GATA4	  
2/43	   4.6	   No	  mutation-­‐specific	  assay	  (G4D	  mouse	  model)	   	  Rajagopal	  et	  al.	  [484]	  1/190	   0.5	   N/A	   Smith	  et	  al.	  [483]	  1/11	   9.0	   N/A	   Zhang	  et	  al.	  [485]	  
GATA6	   1/26	   3.9	   Luciferase	  assay	  	   Maitra	  et	  al.	  [486]	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Leuven	   Toronto	  	  	   GO-­‐CHD	  Complete	   2	   23	   2	   27	  Intermediate	   5	   11	   0	   16	  Partial	   2	   33	   11	   46	  Unbalanced	   1	   11	   0	   12	  Unknown	   0	   3	   21	   24	  Total	   10	   81	   34	   125	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Toronto	  	  	   GO-­‐CHD	  	   Leuven	  
Trio	   3	   0	   10	   13	  
Index	   78	   34	   0	   112	  
Total	   81	   34	   10	   125	  
	  
	  Using	  the	  same	   inclusion	  criteria,	   the	  replication	  cohort	   included	  a	   total	  of	  245	  patients.	  Barbara	  Mulder	  collected	  120	  samples	   from	  the	  CONCOR-­‐registry	  and	  DNA-­‐bank,	  a	  joint	  registry	  of	  the	  Dutch	  Heart	  Foundation	  and	  the	  Interuniversity	  Cardiology	  Institute	  Netherlands	  (ICIN)	  of	  adults	  with	  congenital	  heart	  disease	  of	  Caucasian	   ancestry.	   Sabine	   Klaassen	   and	   her	   colleagues	   collected	   another	   18	  samples	   from	   the	   National	   Registry	   for	   Congenital	   Heart	   Defects,	   Berlin,	  Germany.	   The	   remaining	   samples	   were	   collected	   from	   GO-­‐CHD	   and	   SickKids	  hospital	  (Table	  4-­‐7).	  	  	  Table	  4-­‐7:	  The	  breakdown	  of	  AVSD	  subtypes	  in	  the	  replication	  cohorts	  (all	  are	  index	  cases)	  
	  AVSD	  TYPE	  
Cohorts	  
Total	  
Berlin	   CONCOR	   Toronto	  	  	   GO-­‐CHD	   Nottingham	  &	  Leicester	  Complete	   6	   14	   2	   80	   2	   104	  Intermediate	   7	   0	   1	   0	   0	   8	  Partial	   5	   105	   1	   11	   4	   126	  Unbalanced	   0	   0	   0	   0	   1	   1	  Unknown	   0	   1	   1	   0	   4	   6	  
Total	   18	   120	   5	   91	   11	   245	  	  	  
Exome	  sequencing	  Samples	  were	  sequenced	  at	  the	  Wellcome	  Trust	  Sanger	  Institute.	  Genomic	  DNA	  from	  venous	  blood	  or	  saliva	  was	  obtained	  and	  captured	  using	  SureSelect	  Target	  Enrichment	  V3	  (Agilent)	  and	  sequenced	  (HiSeq	  Illumina	  75	  bp	  pair-­‐end	  reads).	  Reads	   were	   mapped	   to	   the	   reference	   genome	   using	   BWA	   [149].	   Single-­‐nucleotide	  variants	  were	  called	  by	  SAMtools	   [272]	  and	  GATK	  [153]	  while	   indel	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were	  called	  using	  SAMtools	  and	  Dindel	  [158].	  	  Variants	  were	  annotated	  for	  allele	  frequency	  using	  1000	  Genomes	  (June	  2012	  release),	  NHLBI-­‐ESP	  (6503)	  project	  and	   UK10K	   cohorts.	   The	   Ensembl	   Variant	   Effect	   Predictor	   [170]	   was	   used	   to	  annotate	   the	   impact	   on	   annotated	   genes	   and	   GERP	   used	   for	   nucleotide	  conservation	  scores	  [165].	  The	  variant	  calling	  and	  basic	  biological	  annotation	  of	  most	   samples	  were	   generated	   by	   the	  Genome	  Analysis	   Production	   Informatics	  (GAPI)	  pipeline	  (managed	  by	  Carol	  Scott	  et	  al.)	  except	  for	  34	  samples	  that	  were	  part	  of	  the	  UK10K	  RARE	  project,	  which	  went	  through	  UK10K	  pipeline	  (managed	  by	  Shane	  McCarthy	  et	  al.)[264].	  	  Copy	  number	  variants	  were	  called	  using	  CoNVex	  pipeline	  by	  Parthiban	  Vijayarangakannan	  [372].	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4.3 Results	  
4.3.1 Analysis	  overview	  The	  main	   goal	   of	  my	  AVSD	   analyses	  was	   to	   identify	   genes	  with	   rare	   or	   novel-­‐coding	   variants	   with	   a	   clear	   burden	   in	   cases	   compared	   with	   controls.	   This	  approach	   is	   based	   on	   a	   premise	   that	   part	   of	   CHD	   is	   caused	   by	   rare	   coding	  variants	  with	  large	  effect	  size	  (a	  monogenic	  model).	  However,	  this	  is	  hampered	  by	  the	  presence	  of	  many	  genes	  involved	  in	  heart	  development.	   	   	  Animal	  studies	  have	  identified	  hundreds	  of	  these	  genes	  and	  it	  is	  unlikely	  for	  any	  single	  gene	  to	  explain	  a	  large	  number	  of	  samples.	  On	  average,	  previous	  candidate	  resequencing	  studies	  had	  found	  rare	  coding	  variants	  in	  2%	  of	  the	  patients	  (see	  Non-­‐syndromic	  AVSDs	   section)	   assuming	   that	   we	   accept	   those	   variants	   as	   being	   genuinely	  pathogenic.	  	  Figure	   4-­‐7	   outlines	   the	  workflow	   and	  main	   analyses	   described	   in	   this	   chapter.	  The	  total	  number	  of	  isolated	  AVSD	  samples	  is	  125;	  however,	  different	  pipelines	  were	  used	  to	  call	  variants	   in	   this	  cohort.	  Ninety-­‐one	  samples	  went	   through	  the	  GAPI	  pipeline	   (the	  Genome	  Analysis	  Production	   Informatics,	  managed	  by	  Carol	  Scott	   et	   al.,	   described	   in	   chapter	   2)	   and	   34	   samples	   went	   through	   the	   UK10K	  pipeline	  (managed	  by	  Shane	  McCarthy	  et	  al.).	  	  	  Because	  the	  variant	  calling	  took	  place	  in	  two	  different	  calling	  pipelines,	  this	  led	  to	   some	   differences	   in	   the	   number	   of	   rare	   coding	   variants	   identified	   in	   each	  sample,	  which	   I	   described	   in	   chapter	  2.	  Mainly,	   the	  number	  of	   loss	   of	   function	  variants	   in	   samples	   from	   UK10K	   is	   two	   times	   more	   than	   samples	   from	   GAPI	  pipeline.	  Additionally,	  the	  UK10K	  pipeline	  seems	  to	  under	  call	  rare	  homozygous	  coding	   variants	   as	   well	   as	   the	   coding	   INDELs	   in	   general.	   For	   these	   reasons,	   I	  decided	   to	   test	   two	   different	   sets	   of	   controls.	   	   The	   first	   set	   of	   control	   samples	  used	   for	   the	   rare	   missense	   burden	   analysis	   was	   obtained	   from	   the	   UK10K	  Neurological	  project	  (N=894)	  and	  all	  of	  these	  samples	  went	  through	  the	  UK10K	  pipeline.	  Later,	  I	  used	  a	  different	  set	  of	  controls	  chosen	  randomly	  from	  parental	  samples	  from	  the	  Deciphering	  Developmental	  Disorders	  (DDD)	  project	  (all	  from	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GAPI	  pipeline)	  to	  see	  if	  changing	  the	  controls	  would	  improve	  the	  results	  burden	  of	  rare	  missense	  analysis.	  	  To	  prioritize	  these	  genes,	  I	  used	  the	  de	  novo	  pipeline	  I	  implemented	  (described	  in	  chapter	   2)	   to	   identify	   a	   list	   of	   genes	   with	   de	   novo	   coding	   variants	   and	   then	  intersect	  this	  list	  with	  genes	  from	  the	  burden	  analysis.	  	  The	  concept	  of	  narrowing	  down	  the	  search	  space	  for	  candidate	  genes	  using	  de	  novo	  analysis	  has	  been	  used	  successfully	   in	   Schizophrenia	   CNV	   studies	   (see	   for	   example	   [487]).	   Combining	  both	  de	  novo	  and	  burden	  analyses	  identified	  a	  single	  gene,	  NR2F2,	  which	  has	  one	  missense	   de	   novo	   variant	   in	   one	   trio	   and	   exhibit	   a	   burden	   of	   rare	   missense	  variants	   in	   another	   four	   cases	   (Fisher	   exact	   test	   P=0.00044).	   I	   increased	   the	  number	  of	   controls	  by	   including	  4,300	  samples	   from	   the	  NHLBI	  exome	  project	  (ESP)	   and	   was	   able	   to	   obtain	   a	   genome-­‐wide	   statistically	   significant	   signal	   in	  
NR2F2	   (Fisher	  exact	  test	  P=	  7.7	  ×	  10-­‐7).	   I	   then	  attempted	  replication	  in	  a	   larger	  number	  of	  samples	  isolated	  AVSD	  cases	  (N=245)	  along	  with	  additional	  functional	  experiments	  to	  scrutinize	  the	  role	  that	  these	  variants	  may	  play	  in	  vivo	  and	  /	  or	  in	  
vitro.	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  Figure	  4-­‐7	  Overview	  of	  the	  workflow	  and	  analyses	  described	  in	  this	  chapter.	  	  Red	  dashed	  box	  includes	  pipelines	  and	  tools	  that	  I	  described	  in	  chapter	  2.	  GAPI:	  Genome	  Analysis	  Production	   Informatics,	   FEVA:	   Family-­‐based	   Exome	   Variant	   Analysis,	   UK10K:	   UK10K	   variant	  calling	   pipeline.	   DDD:	   Deciphering	   Developmental	   Disorders	   (DDD)	   project,	   GO-­‐CHD:	   Genetic	  Origins	  of	  Congenital	  Heart	  Disease	  sample	  collection	  (Oxford)	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4.3.2 Quality	  control	  (QC)	  In	  order	  to	  obtain	  a	  high	  quality	  dataset	  for	  downstream	  analysis,	  several	  quality	  control	  assessments	  are	  required	  to	  detect	  issues	  such	  as	  contamination,	  sample	  swapping	  or	  failed	  sequencing	  experiments.	  DNA	  quality	  control	  is	  applied	  prior	  to	  exome	  sequence	  and	  data	  quality	  control	  is	  applied	  after	  exome	  sequencing	  at	  the	  level	  of	  both	  the	  sequence	  data	  (BAM	  files)	  and	  the	  called	  variants	  (VCF	  files).	  	  	  
DNA	  quality	  control	  The	  sample	  logistics	  team	  at	  the	  Wellcome	  Trust	  Sanger	  Institute	  tested	  the	  DNA	  quality	   of	   each	   sample	   using	   an	   electrophoretic	   gel	   to	   exclude	   samples	   with	  degraded	  DNA.	  The	  team	  also	  assessed	  DNA	  volume	  and	  concentration	  using	  the	  PicoGreen	   assay	   [277]	   to	   make	   sure	   every	   sample	   met	   the	   minimum	  requirements	   for	   exome	   sequencing.	   Additionally,	   26	   autosomal	   and	   four	   sex	  chromosomal	  SNPs	  were	  genotyped	  as	  part	  of	   the	   iPLEX	  assay	   from	  Sequenom	  (USA).	   This	   test	   helps	   to	   determine	   the	   gender	   discrepancies,	   relatedness	   or	  possible	  contaminations	  issues.	  Only	  two	  samples	  were	  excluded	  from	  the	  AVSD	  cohort.	  The	   first	  sample	  had	  a	  degraded	  DNA	  (AVSD_1)	  while	   the	  second	  failed	  the	  gender	  matching	  test	  (AVSD_59).	  Both	  samples	  are	  part	  of	  the	  Toronto	  AVSD	  collection	  (Table	  4-­‐5).	  	  	  
Sequence	  data	  quality	  control	  	  The	   second	   group	   of	   quality	   control	   tests	   was	   performed	   once	   the	   sequence	  reads	   had	   been	   generated	   by	   the	   next-­‐generation	   sequencing	   platform.	   Carol	  Scott	   at	   the	   Genome	   Analysis	   Production	   Informatics	   (GAPI)	   team	   and	   Shane	  McCarthy	   from	   the	  UK10K	   team	  have	  performed	   these	   tests	   to	   detect	   samples	  with	   too	   low	   sequence	   coverage.	   None	   of	   the	   cases	   failed	   any	   of	   these	  assessments.	  The	  average	  sequence	  data	  generated	  per	  exome	  is	  ~6	  	  Gb	  with	  65-­‐fold	  mean	  depth	  and	  85%	  of	  the	  exome	  covered	  by	  at	  least	  10	  reads.	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DNA	  variant	  quality	  control	  The	  third	  phase	  of	  quality	  control	  assesses	  the	  called	  variants	  in	  the	  Variant	  Call	  Format	  (VCF)	  files	  [161].	  The	  aim	  of	  these	  tests	  is	  to	  detect	  any	  outlier	  samples	  based	   on	   the	   counts	   of	   single	   nucleotide	   variants	   (SNV)	   or	   insertion/	   deletion	  variants	   (INDEL)	   in	   comparison	   to	   other	   published	   and	   /	   or	   internal	   projects.	  Since	   AVSD	   samples	   belong	   to	   different	   cohorts,	   part	   of	   the	   samples	   went	  through	  the	  UK10K	  pipeline	  (mainly	  samples	  from	  the	  GO-­‐CHD	  collection,	  n=34)	  while	   the	   rest	   went	   through	   GAPI	   pipeline	   (n=91	   cases	   from	   Toronto	   and	  Leuven).	   Both	   pipelines	   used	   different	   variant	   callers	   (GAPI	   used	   GATK	  /Samtools	   to	   SNVs	   and	   Dindel/Samtools	   to	   call	   INDELs	   while	   UK10K	   used	  GATK/Samtools	   to	   call	   both	   SNVs	   and	   INDELs	   and	   did	   not	   include	   Dindel).	  Additionally,	   both	   pipelines	   used	   different	   number	   and	   variable	   thresholds	   to	  remove	   lower	   quality	   variants	   (full	   details	   described	   in	   chapter	   2).	   These	  differences	   between	   GAPI	   and	   UK10K	   pipeline	   led	   to	   variability	   in	   the	   final	  number	   of	   coding	   variants	   (Table	   4-­‐8,	   Figure	   4-­‐8	   and	   Figure	   4-­‐9).	   	   	   The	  most	  obvious	   three	   differences	   are	   the	   number	   of	   loss	   of	   function	   variants,	   the	  heterozygous/homozygous	   ratio	   for	   rare	   variants	   and	   the	   type	   and	   number	   of	  indels.	  	  	  The	   UK10K	   pipeline	   called	   twice	   as	   many	   loss	   of	   function	   SNVs	   (LoF	   class	  includes	   stop	   gain	   and	   variant	   disturbing	   acceptor	   or	   donor	   splice	   sites)	  compared	  with	  the	  GAPI	  pipeline	  188	  and	  93,	  respectively.	  However,	  I	  observed	  that	   most	   of	   the	   difference	   could	   be	   attributed	   to	   common	   LoF	   while	   both	  pipeline	  reported	  similar	  number	  of	  rare	  LoF	  (UK10K	  called	  18	  and	  GAPI	  called	  14	  LOF	  variants).	  	  The	   second	   main	   difference	   I	   observed	   was	   the	   rare	   coding	  heterozygous/homozygous	   (het/hom)	   ratio	   (GAPI=7.4,	   UK10K=32.5).	   This	   big	  variation	   was	   not	   observed	   when	   I	   calculated	   the	   het/hom	   ratio	   for	   common	  coding	  variants	  (~1.5	  in	  both	  pipelines).	  The	  main	  reason	  behind	  this	  variation	  is	  likely	   caused	   by	   UK10K	   under-­‐calling	   rare	   homozygous	   SNVs.	   The	   rare	  heterozygous	  coding	  variants	  do	  not	  seem	  to	  be	  affected	  (the	  fraction	  of	  coding	  heterozygous	  variants	  that	  are	  rare	  in	  UK10K	  is	  6.7%	  and	  7.6%	  in	  GAPI).	   	   	  This	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suggests	  the	  possibility	  of	  observing	  a	  false	  positive	  burden	  of	  rare	  homozygous	  SNVs	  when	  cases	  from	  GAPI	  are	  compared	  with	  controls	  from	  UK10K	  pipelines.	  	  	  The	  third	  major	  difference	  in	  variants	  called	  by	  GAPI	  and	  UK10K	  is	  observed	  in	  indels.	   The	   GAPI	   pipeline	   calls	   4.4x	  more	   coding	   INDELs	   than	   UK10K	   (462	   in	  GAPI	  and	  105	   in	  UK10K).	  Additionally,	   the	  UK10K	  pipeline	   is	  enriched	   for	  rare	  indels	  in	  general	  (half	  of	  its	  coding	  indels	  are	  rare,	  <	  1%	  MAF	  in	  1000	  genomes,	  compared	  to	  18%	  in	  GAPI).	  Another	  difference	  is	  seen	  in	  the	  ratio	  of	  coding	  in-­‐frame	   to	   coding	   frame-­‐shift	   indels,	  which	   is	   used	   as	   an	   indicator	   of	   the	   calling	  quality	  of	  indels.	  As	  in-­‐frame	  indels	  have	  a	  less	  severe	  impact,	  on	  average,	  on	  the	  protein	  structure	  than	  frame-­‐shifting	  indels,	  we	  expect	  to	  see	  more	  in-­‐frame	  due	  to	   weaker	   negative	   selection.	   	   Indels	   called	   by	   GAPI	   pipeline	   meet	   this	  expectation	  (coding	   in-­‐frame/coding	   frameshift	   is	  1.46)	  while	  UK10K	  show	  the	  opposite	  trend	  (ratio	  0.44).	  	  	  	  Using	  Dindel	  in	  the	  GAPI	  pipeline	  likely	  causes	  much	  of	  these	  differences	  in	  indel	  numbers.	   Dindel	   is	   a	   dedicated	   caller	   for	   indels	   that	   uses	   a	   probabilistic	  realignment	  model	   to	   account	   for	   base-­‐calling	   errors,	  mapping	   errors,	   and	   for	  increased	   sequencing	   error	   indel	   rates	   in	   long	   homopolymer	   runs	   [158].	  	  Dindel’s	   superior	  performance	   comes	   at	   a	  price	  of	   high	   computation	  demands,	  which	   is	  why	   the	  UK10K	   informatics	   team	  has	  refrained	   from	  using	   it	  on	   large	  numbers	  of	  samples.	  	  	  In	  summary,	  due	  to	  different	  workflows,	  variant	  callers	  and	  filters	  used	  by	  GAPI	  and	  UK10K	  pipelines,	  many	  important	  variations	  are	  observed	  in	  the	  number	  of	  coding	   variants.	   Indels	   in	   the	   UK10K	   pipeline	   exhibit	   strong	   differences	   that	  would	   certainly	   affect	   downstream	   analysis.	   SNVs	   on	   the	   other	   hand,	   are	   less	  affected	   than	   indels.	   Both	   pipelines	   show	   similar	   ratios	   of	  transition/transversion,	  heterozygous/homozygous,	  and	  rare/common	  variants.	  However,	   when	   I	   consider	   genotypes	   separately,	   the	   rare	   homozygous	   SNVs	  appear	  to	  be	  under-­‐called	  in	  the	  UK10K	  pipeline.	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Table	  4-­‐8	  Quality	  control	  tests	  at	  different	  levels:	  sample-­‐based,	  sequence	  data	  and	  variant-­‐based	  levels.	   The	   most	   important	   variant	   calling	   differences	   between	   GAPI	   and	   UK10K	   pipeline	   are	  highlighted	   in	   red	   (rare	   heterozygous/homozygous	   ratio	   and	   in-­‐frame/frameshift	   ratio	   for	  indels).	  
Stages	   Goals	   Tasks	   Output	  
DNA	  
preparation	  	  
Amount	  and	  quality	  of	  DNA	  
Volume	  /	  concentration	   All	  samples	  achieved	  the	  minimum	  requirement	  of	  whole	  exome	  sequencing	  Genomic	  DNA	  integrity	  	   1	  sample	  excluded	  for	  degraded	  DNA	  (AVSD_1)	  
Quality	  assurance	   Gender	  
1	  sample	  excluded	  for	  gender	  mismatch	  with	  supplier	  sheet	  Contamination	   None	  of	  the	  cases	  show	  any	  contamination	  issues	  
Stages	   Goals	   Tasks	  








Base-­‐level	  stats	   Raw	  output	   ~6	  billion	   ~6	  billion	  Average	  coverage	  per	  base	   66	   64	  Read-­‐level	  stats	   Raw	  read	  count	   45	  millions	   44	  millions	  Duplication	  fraction	   6.8%	   5.8%	  
Variant	  
calling	  	  
Single	  nucleotide	  variants	  (SNVs)	  	  
Total	  number	  of	  coding	  SNVs	  	   21,346	   19,219	  Transition/Transversion	  ratio	  	   2.98	   3.12	  Heterozygous	  coding	  variant	  count	  (Het)	  	   13,019	   11,658	  Homozygous	  coding	  variant	  count	  (Hom)	  	   8,326	   7,561	  Het/hom	  ratio	  (all	  coding	  variants)	   1.56	   1.54	  %	  Of	  common	  coding	  SNVs	  (MAF	  >	  1%)	   94.9%	   96%	  Common	  loss-­‐of-­‐function	  variants	   79	   170	  Common	  functional	  variants	   9,569	   8,829	  Common	  silent	  variants	   10,185	   9,361	  %	  Of	  rare	  coding	  SNVs	  (MAF<	  1%)*	   5.1%	   4%	  Rare	  loss-­‐of-­‐function	  variants	   14	   18	  Rare	  functional	  variants	   677	   476	  Rare	  silent	  variants	   357	   257	  Heterozygous	  coding	  variant	  count	  (Het)	  	   997	   780	  Homozygous	  coding	  variant	  count	  (Hom)	  	   134	   24	  Het/hom	  ratio	  (rare	  coding	  variants)	   7.44	   32.5	  
Insertion	  and	  deletion	  (indels)	  	  
Total	  number	  of	  coding	  indels	  count	   462	   105	  %	  Of	  common	  coding	  INDELs	  (MAF	  >	  1%)	   82%	   49%	  Coding	  in-­‐frame	  indels	   274	   33	  Coding	  frameshift	  indels	   187	   72	  Coding	  in-­‐frame	  /	  frameshift	  ratio	   1.46	   0.45	  Rare	  coding	  indels	   82	   53	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Figure	   4-­‐8	  Quality	   control	   plots	   including	   global	   counts	   and	   various	   single	   nucleotide	   variants	   stats	  (see	  main	  text	  for	  description).	  Samples	  called	  by	  UK10K	  pipeline	  are	  plotted	  right	  to	  the	  dashed	  gray	  line.	  The	  remaining	  samples	  are	  called	  by	  GAPI	  pipeline.	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Figure	   4-­‐9	  Quality	   control	   plots	   for	   insertion	   and	   deletion	   variants.	   Samples	   called	   by	  UK10K	  pipeline	   are	   plotted	   right	   to	   the	   dashed	   gray	   line.	   The	   remaining	   samples	   are	   called	   by	   GAPI	  pipeline.	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Exclusion	  of	  contaminated	  control	  samples	  	  One	   of	   the	   quality	   control	   tests	   performed	   at	   the	   sample	   level	   (i.e.	   DNA)	   is	  genotyping	  30-­‐50	  SNPs,	  which	  helps	   to	  detect	  gender	  mismatching	  and	  sample	  identification.	  However,	  sample	  contamination	  is	  harder	  to	  be	  detected	  at	  earlier	  stages	   especially	   if	   it	   is	   minimal	   or	   if	   the	   contamination	   takes	   place	   during	  library	  preparation	  and	  /	  or	  sequencing.	  The	  1000	  genomes	  project	  has	  used	  a	  program	   called	   “verifyBAMid”	   developed	   by	   Jun	   et	   al.	   at	   the	   University	   of	  Michigan	   to	   test	   for	   contamination	   issues	   using	   NGS	   data	   [488].	   verifyBAMid	  checks	   whether	   the	   reads	   are	   contaminated	   as	   a	   mixture	   of	   two	   samples	   and	  generate	  a	  free-­‐mix	  score.	  Shane	  McCarthy	  from	  the	  UK10K	  team	  generated	  free-­‐mix	  scores	  and	  the	  het/hom	  ratio	  for	  all	  samples	  in	  the	  UK10K	  project	  including	  the	   UK10K	   neurological	   samples	   used	   as	   controls	   for	   this	   study	   (N=1,008).	   I	  plotted	  free-­‐mix	  scores	  and	  the	  het/hom	  ratio	  for	  all	  samples	  (Figure	  4-­‐10),	  and	  used	   a	   threshold	   of	   3%	   as	   suggested	   by	   verifyBAMid	   developers	   to	   detected	  possibly	  contaminated	  samples.	  This	  analysis	  identified	  89	  and	  I	  removed	  them	  from	  the	  downstream	  analysis.	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  Figure	   4-­‐10:	   The	   heterozygous/homozygous	   ratio	   (X-­‐axis)	   and	   free-­‐mix	   fraction	   for	   1,008	  samples	  in	  UK10K	  neurological	  samples.	  The	  horizontal	  dashed	  red	  line	  is	  a	  cutoff	  3%	  of	  free-­‐mix	  suggested	  by	  the	  ‘verifyBAMid’	  developers.	  	  Samples	  outside	  the	  two	  vertical	  dashed	  red	  lines	  at	  ±3	   standard	   deviation	   of	   heterozygous/homozygous	   ratio	   were	   excluded.	   (Shane	   McCarthy	  provided	  the	  free-­‐mix	  scores	  and	  het/hom	  ratios	  for	  the	  UK10K	  samples). 
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analysis.	   First	   I	   selected	   extracted	   shared	   SNPs	   between	  HapMap	   samples	   and	  the	   samples	   from	  UK10K	   (n=69,415	   SNPs)	   and	   removed	   non-­‐autosomal	   SNPs,	  mutliallelic,	  rare	  SNPs	  with	  MAF	  <	  5%	  and	  other	  steps	  (full	  workflow	  in	  Figure	  4-­‐11).	  These	  steps	  generated	  a	  high	  quality	  set	  of	  10,492	  SNPs	  to	  be	  used	  in	  the	  PCA	  analysis.	  This	  analysis	  showed	  that	  the	  majority	  of	  UK10K	  samples	  (n=919	  controls	  and	  n=34	  cases)	  overlapped	  well	  with	  European	  populations	  except	  for	  25	  control	  samples	  that	  I	  subsequently	  removed	  from	  any	  downstream	  analysis	  (Figure	   4-­‐12).	   Using	   the	   same	   workflow,	   I	   performed	   PCA	   analysis	   on	   the	  remaining	   samples	   from	   GAPI	   pipeline	   and	   all	   of	   the	   samples	   matched	   the	  HapMap	  Caucasian	  population	  (Figure	  4-­‐13).	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  Figure	  4-­‐12	  PCA	  analysis	  of	  919	  UK10K	  controls	  compared	  with	  main	  HapMap	  four	  populations.	  Control	   samples	   (UK10K)	  and	  AVSD	  cases	   from	  (GO-­‐CHD)	  cohort.	  Twenty-­‐five	  samples	  did	  not	  overlap	  with	   CEU	  population	   and	   therefore	  were	   excluded	   (blue	   points	   below	   solid	   horizontal	  red	  line) 
 
	  Figure	  4-­‐13	  PCA	  analyses	  of	  the	  AVSD	  cases	  compared	  with	  the	  HapMap	  four	  main	  populations.	  The	   Toronto	   (AVSD)	   samples	   overlap	   completely	   with	   the	   Caucasian	   population.	   I	   have	  performed	   similar	   analysis	   for	   the	   remaining	   samples	   from	   Leuven	   (10	   trios)	   and	   all	   of	   the	  samples	  overlapped	  with	  Caucasian	  population.	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Collapsing	  rare	  variants	  per	  gene	  to	  increase	  the	  power	  of	  the	  test	  
 To	  look	  for	  a	  gene-­‐based	  burden	  of	  rare	  coding	  variants	  (except	  silent),	  I	  filtered	  out	  the	  common	  variants	  (MAF	  >	  1%	  in	  the	  1000	  genomes	  or	  those	  that	  appear	  in	  >	  1%	  of	  the	  in	  the	  cases	  and	  controls)	  and	  then	  grouped	  the	  variants	  by	  type	  (SNVs	  or	  INDELs)	  and	  variant	  consequences	  (loss-­‐of-­‐function	  or	  functional).	  The	  loss-­‐of-­‐functional	   class	   includes	   stop	   gain	   and	   variants	   disturbing	   donor	   or	  acceptor	   splice	   sites	  while	   the	   functional	   class	   includes	   the	  missense	   and	   stop	  lost	   variants.	   This	   was	   done	   separately	   for	   dominant	   (heterozygous)	   and	  recessive	   (homozygous	   or	   double	   heterozygous)	   variants.	   This	   arrangement	  generated	   four	   groups	   of	   candidate	   genes	   (Heterozygous-­‐functional,	  Heterozygous-­‐LoF,	   Homozygous-­‐functional	   and	   Homozygous-­‐LoF).	   Next,	   I	  created	   four	   2	   by	   2	   tables	   of	   the	   number	   of	   cases	   or	   controls	   that	   carry	   the	  variant	   in	  every	  group.	  Finally,	   I	  calculated	  the	  p-­‐value	  using	  the	  Fisher’s	  Exact	  test	  (right-­‐tail	  only,	  since	  I	  am	  not	  looking	  for	  protective	  rare	  alleles).	  I	  decided	  not	  to	  include	  indels	  in	  this	  analysis	  given	  the	  big	  differences	  between	  GAPI	  and	  UK10K	  pipeline	  described	  above.	  	  	  A	   common	   statistical	   approach	   used	   in	   genome-­‐wide	   association	   studies	   to	  evaluate	  whether	  a	  statistical	  association	  test	  is	  generating	  unbiased	  p	  values	  is	  called	  the	  Quantile-­‐Quantile	  (Q-­‐Q)	  plot	  [489].	  	  In	  QQ	  plots,	  the	  distribution	  of	  test	  statistics	  generated	   from	  the	  thousands	  of	  association	  tests	  performed	  (e.g.	  Chi	  square	  or	  Fisher	  exact	   test)	   is	  assessed	   for	  deviation	   from	  the	  null	  distribution	  (which	  is	  expected	  under	  the	  null	  hypothesis	  if	  no	  variant	  is	  associated	  with	  the	  trait).	  	  	  Initially,	   I	   grouped	   AVSD	   cases	   from	   both	   GAPI	   (n=91)	   and	   UK10K	   pipelines	  (n=34)	  and	  compared	  them	  to	  controls	  from	  the	  UK10K	  pipeline	  (n=894).	  Figure	  4-­‐14	   (plot	   A)	   shows	   the	   QQ	   plot	   for	   the	   burden	   tests	   of	   rare	   heterozygous	  functional	   variants	   in	   all	   genes.	   This	   showed	   an	   inflation	   of	   the	   observed	   p-­‐values	   generated	   by	   the	   Fisher’s	   exact	   test	   when	   compared	   with	   the	   null	  distribution	   on	   the	   x-­‐axis.	   This	   is	   not	   unexpected	   given	   the	   known	   difference	  between	   the	   numbers	   of	   rare	  missense	   variants	   between	   the	   cases	   from	  GAPI	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compared	  with	  controls	  from	  the	  UK10K	  pipeline	  (GAPI	  samples	  have	  42%	  more	  rare	  missense	  variants	  per	   samples,	   see	   the	  variant-­‐based	  quality	   control	   tests	  section	  above).	  To	  confirm	  this	  hypothesis,	  I	  decided	  to	  test	  the	  cases	  from	  GAPI	  and	  UK10K	  separately	  which,	   indeed,	  showed	  a	  worse	   inflation	  when	  using	  the	  GAPI	   samples	   alone	   (Figure	   4-­‐14,	   plot	   B)	   and	   improved	   when	   the	   cases	   and	  controls	  are	  both	  from	  the	  same	  pipeline	  (Figure	  4-­‐14,	  plot	  C	  and	  Figure	  4-­‐15).	  	  	  Despite	   the	   slight	   improvement	   in	   the	   QQ	   plot	   when	   both	   cases/controls	   are	  from	  the	  same	  pipeline,	  the	  QQ	  plot	  is	  still	  showing	  signs	  of	  mild	  inflation	  (Figure	  4-­‐14,	  plot	  C).	  To	  see	  if	  the	  small	  number	  of	  cases	  (n=34)	  from	  UK10K	  caused	  this	  mild	   inflation,	   I	   increased	   the	   sample	   size	   by	   grouping	   all	   CHD	   samples	   I	   had	  from	   the	   UK10K	   pipeline	   (34	   AVSD	   and	   80	   cases	   of	   mixed	   CHD	   subtypes,	   all	  unrelated)	   (Figure	   4-­‐14,	   plot	  D	   and	  Figure	   4-­‐15),	  which	   improved	   the	  QQ	  plot	  greatly.	  
	  Figure	  4-­‐14	  Quantile-­‐Quantile	  (QQ)	  plots	  for	  the	  burden	  of	  rare	  heterozygous	  variant	  tests	  using	  four	   different	   sets	   of	   case	   samples.	   In	   all	   plots,	   the	   control	   samples	   are	   based	  on	  894	   samples	  from	  the	  UK10K	  neurological	  project.	  (A)	  QQ	  plot	  for	  125	  AVSD	  cases	  from	  both	  GAPI	  and	  UK10K	  shows	  marked	   inflation.	   (B)	   Same	   as	   plot	   A	   but	   includes	   cases	   from	  GAPI	   pipeline	   only	  which	  show	  worse	   inflation.	   (C)	   AVSD	   cases	   are	   limited	   to	   samples	   from	   UK10K	   only	   (n=34)	   which	  improves	   inflation	  since	  both	  cases	  and	  controls	  are	   from	  the	  same	  pipeline.	  (D)	  Represent	  the	  best	  QQ	  plot	  where,	  similar	  to	  plot	  C,	  both	  cases	  and	  controls	  are	  from	  the	  UK10K	  pipeline	  but	  I	  increased	   the	   number	   of	   cases	   by	   including	   all	   CHD	   samples	   from	   the	  UK10K	   pipeline	   (mixed	  phenotypes	  including	  the	  34	  AVSD	  cases).	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  Figure	   4-­‐15	   Combined	   QQ	   plots	   of	   four	   different	   sets	   described	   in	   Figure	   4-­‐14	   to	   show	   the	  changes	   in	  QQ	   curves	   relative	   to	   each	   set.	   The	  most	   inflated	   set	   of	   cases	   is	  when	   I	   considered	  GAPI	   samples	   alone	   (blue)	  while	   the	   least	   inflated	   set	   is	  when	   I	   considered	   cases	   and	   controls	  from	  the	  same	  UK10K	  pipeline	  (orange).	  	  Given	   the	  variability	  of	  QQ	  plots	   caused	  by	   combining	   the	   cases	   from	  different	  pipelines,	   I	   decided	   to	   use	   control	   data	   generated	   through	   the	   GAPI	   pipeline	  instead	  of	  the	  UK10K	  neurological	  controls	  to	  see	  if	  this	  would	  improve	  the	  QQ	  plots.	   I	   selected	   894	   parents	   at	   random	   from	   the	   Deciphering	   Developmental	  Disorders	  (DDD)	  project.	  Only	  one	  parent	  is	  selected	  from	  each	  trio	  to	  make	  sure	  I	   remove	   closely	   related	   parents.	   Using	   the	   same	   strategy	   described	   above,	   I	  grouped	  the	  AVSD	  cases	  into	  four	  sets:	  all	  AVSD	  from	  GAPI	  pipeline	  (n=91)	  and	  from	  UK10K	  (n=34)	   in	  one	  group,	  GAPI	  cases	  alone,	  UK10K	  cases	  alone	  and	  all	  AVSD	  with	  all	  other	  CHDs	  phenotypes	  we	  have	  sequenced	  so	  far	  as	  part	  of	  GAPI	  (n=263).	  The	  QQ	  plots	  (Figure	  4-­‐16	  and	  Figure	  4-­‐17)	  show	  marked	  improvement	  over	   the	   QQ	   plots	   where	   I	   used	   controls	   from	   the	   UK10K	   pipeline.	   Besides	  changing	   the	   pipeline	   used	   to	   call	   control	   samples,	   increasing	   the	   number	   of	  cases	  from	  91	  AVSDs	  to	  263	  samples	  with	  different	  CHD	  subtypes	  also	  seems	  to	  improve	  the	  QQ	  curve	  (Figure	  4-­‐16,	  plot	  D).	  	  	  Because	  most	  of	  the	  AVSD	  cases	  (n=91)	  went	  through	  GAPI	  pipeline,	  I	  decided	  to	  follow	  up	  the	  gene	  that	  shows	  a	  burden	  of	  rare	  missense	  compared	  to	  controls	  from	   the	   DDD	   (Figure	   4-­‐16,	   plot	   B).	   	   Table	   4-­‐9	   lists	   the	   top	   10	   genes	   with	  significant	  p-­‐values,	  however,	  after	  correcting	  for	  multiple	  testing	  only	  one	  gene	  shows	  a	  genome	  wide	  statistical	  significant	  p-­‐value,	  OR51E1,	  which	  encodes	  for	  



















AVSD cases from GAPI n=91 + UK10K n=34
AVSD cases from GAPI n=91
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an	  olfactory	  receptor	  and	  thus	  it	  is	  unlikely	  to	  be	  involved	  in	  the	  development	  of	  AVSD.	   Nonetheless,	   I	   used	   this	   list	   of	   genes	   to	   prioritize	   plausible	   candidate	  genes	  that	  I	  identified	  from	  subsequent	  analyses	  (e.g.	  de	  novo	  analysis).	  	  Table	  4-­‐9	  Top	   ten	  genes	  with	  a	  burden	  of	   rare	  missense	  variants	   in	  91	  AVSD	  cases	   from	  GAPI	  pipeline	   and	   894	   randomly	   selected	   parents	   from	   the	   DDD	   project	   used	   as	   controls	   from	   the	  same	  pipeline.	  	  
Genes	  




DDD	  (n=894)	   Fisher	  Exact	  (right	  side)	   Odds	  ratio	  Y	   N	   Y	   N	  
OR51E1	   9	   82	   5	   889	   4.57E-­‐07	   19.51	  
PRPSAP1	   6	   85	   1	   893	   3.46E-­‐06	   63.04	  
UCK1	   8	   83	   7	   887	   1.48E-­‐05	   12.21	  
TMEM104	   12	   79	   23	   871	   2.67E-­‐05	   5.75	  
LLGL2	   13	   78	   28	   866	   3.12E-­‐05	   5.15	  
C6orf62	   5	   86	   1	   893	   3.38E-­‐05	   51.92	  
TIE1	   10	   81	   16	   878	   4.29E-­‐05	   6.77	  
PLEKHB2	   8	   83	   10	   884	   7.94E-­‐05	   8.52	  
NR2F2	   5	   86	   2	   892	   0.000109702	   25.93	  
TOR2A	   5	   86	   2	   892	   0.000109702	   25.93	  	  These	   results	   indicate	   that	   using	   samples	   from	   different	   pipelines	   is	   likely	   to	  confound	   the	   results	   of	   the	   burden	   of	   rare	   missense	   test	   and	   lead	   to	   either	  spurious	   association	   results.	   Nonetheless,	   despite	   the	   drawbacks	   of	   this	  combining	  of	  cases	  from	  two	  pipelines	  analysis,	   I	  coupled	  the	  results	  described	  here	  with	  the	  results	  from	  the	  de	  novo	  analysis	  to	  identify	  genes	  enriched	  in	  both	  analyses	   and	   then	   examined	   the	   burden	   signal	   in	   more	   detail	   using	   external	  control	  samples	  (e.g.	  data	  from	  NHLBI	  exome	  server)	  (see	  below	  section	  4.3.5).	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  Figure	  4-­‐16	  Quantile-­‐Quantile	  (QQ)	  plots	  for	  the	  burden	  of	  rare	  heterozygous	  variant	  tests	  using	  four	   different	   sets	   of	   case	   samples.	   In	   all	   plots,	   the	   control	   samples	   are	   based	  on	  894	   samples	  from	  the	  Deciphering	  Developmental	  Disorders	   (DDD)	  project.	   (A)	  QQ	  plot	   for	  125	  AVSD	  cases	  from	  both	  GAPI	  and	  UK10K.	   (B)	  Same	  as	  plot	  A	  but	   include	  cases	   from	  GAPI	  pipeline	  only.	   (C)	  AVSD	  cases	  are	  limited	  to	  samples	  from	  UK10K	  only	  (n=34).	  (D)	  Both	  cases	  and	  controls	  are	  from	  the	   GAPI	   pipeline	   but	   I	   increased	   the	   number	   of	   cases	   by	   including	   all	   CHD	   samples	   from	   the	  GAPI	  pipeline	  (mixed	  phenotypes	  including	  the	  91	  AVSD	  cases).	  	  
	  Figure	   4-­‐17	   Combined	   QQ	   plots	   of	   four	   different	   sets	   described	   in	   Figure	   4-­‐16	   to	   show	   the	  changes	  in	  QQ	  curves	  relative	  to	  each	  set.	  









(A) AVSD Cases (GAPI n=91 + UK10K n=34) 


















(B) AVSD Cases (GAPI n=91) 


















(C) AVSD Cases (UK10K n=34) 


















(D) CHD Cases (GAPI n=263) 
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4.3.4 De	  novo	  analysis	  I	   used	   the	   DenovoGear	   (DNG)	   pipeline	   I	   developed	   previously	   (described	   in	  chapter	  2)	  to	  detect	  candidate	  de	  novo	  mutations	  from	  the	  BAM	  files	  of	  13	  trios	  with	  AVSDs.	  On	  average,	  DNG	  was	  able	  to	  detect	  180	  potential	  de	  novo	  variants	  per	  trio.	  	  To	  minimize	  the	  false	  positive	  rate,	  I	  applied	  a	  few	  filters	  to	  exclude	  low	  quality,	   non-­‐coding	   and	   /	   or	   common	   variants.	   These	   filters	   are	   (i)	   variant	  should	   not	   be	   in	   tandem	   repeat	   [490]	   or	   segmental	   duplication	   regions	   [491]	  from	   the	   UCSC	   tables[492],	   (ii)	   has	  minor	   allele	   frequency	   	   <	   1%	   in	   the	   1000	  genomes,	  NHLBI-­‐ESP	  (6503)	  and	  the	  UK10K	  cohort,	  	  (iii)	  fewer	  than	  10%	  of	  the	  reads	  supporting	  the	  alternative	  allele	  in	  either	  parent	  (otherwise	  I	  considered	  it	  to	  be	  much	  more	  likely	  to	  be	  an	  inherited	  variant),	  (iv)	  variant	  should	  be	  called	  by	  an	  independent	  pipeline	   in	  the	  VCF	  file	   in	  the	  child	  but	  not	  the	  parents,	  and	  (v)	  the	  variant	  is	  predicted	  to	  be	  coding	  by	  VEP	  tool	  [170].	  	  	  In	   addition	   to	   these	   five	   filters,	   DenovoGear	   software	   outputs	   a	   posterior	  probability	  score	   for	  each	  variant	  being	  a	  de	  novo	  (PP_DNM).	  This	  score	  can	  be	  used	  as	  an	  additional	  filter	  to	  reduce	  the	  number	  false	  positive	  rate.	  For	  example,	  removing	   variants	   with	   [<0.8]	   PP_DNM	   score	   increases	   the	   true	   positive	  proportion	  up	   to	   [80%]	  (personal	  communication	  with	  Aarno	  Palotie’s	   team	  at	  WTSI).	  However,	  this	  strategy	  might	  be	  practical	  with	  a	  large	  number	  of	  trios	  (i.e.	  hundreds)	  but	  for	  small-­‐scale	  project	  like	  AVSD	  trios,	  it	  is	  worth	  considering	  less	  stringent	   filters	   (I	   used	   the	   default	   PP_DNM	   >	   0.001)	   to	   include	   the	   majority	  coding	  variants	  that	  pass	  the	  basic	  five	  filters	  above.	  	  Figure	  4-­‐18-­‐A	  shows	  the	  distribution	  of	  the	  plausible	  de	  novo	  candidates	  per	  trio	  after	   applying	   the	   basic	   filters	   (32	   coding	   variants	   in	   total	   in	   13	   trios	  with	   an	  average	  of	  2.4).	  	  I	  designed	  the	  primers	  for	  this	  validation	  and	  my	  colleague,	  Dr.	  Sarah	   Lindsay,	   performed	   laboratory	  work.	   Upon	   the	   analysis	   of	   the	   sequence	  trace	  files,	  I	  verified	  40%	  of	  these	  de	  novo	  coding	  mutations	  (nine	  missense	  and	  four	   synonymous,	   Figure	   4-­‐18-­‐B	   and	   Table	   4-­‐10)	   which	   lowers	   the	   average	  DNMs	  per	  trio	  to	  ~0.92.	  This	  average	  number	  of	  coding	  single	  nucleotide	  de	  novo	  variants	  corresponds	  well	   to	  other	  trio-­‐based	  exome	  sequence	  projects	  such	  as	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Tetralogy	   of	   Fallot	   trios	   (chapter	   3)	   and	   other	   published	   studies	   (see	   de	  novo	  pipeline	   in	  chapter	  2	   for	  details)	  where	  the	  average	  of	  coding	  single	  nucleotide	  
de	  novo	  variants	  of	  ranges	  (0.63-­‐1.47).	  The	  remaining	  non-­‐verified	  variants	  were	  either	   false	   positives	   (not	   present	   in	   any	   member	   of	   the	   trio)	   or	   inherited	  variants	  (present	  in	  both	  the	  child	  and	  one	  parent).	  	  	  One	   trio	   in	   particular	   (CHDL5262758)	   carries	   four	   verified	  de	  novo	  mutations:	  two	   missense	   and	   two	   synonymous	   mutations.	   This	   is	   a	   rare	   event	   but	   still	  possible	   to	   observe.	   The	   frequency	   of	   de	   novo	   variants	   in	   large-­‐scale	   projects	  tends	   to	   have	   a	   long	   tail	   of	   samples	   with	   more	   than	   one	   DNM	   (up	   to	   seven	  verified	  DNMs	  in	  DDD	  project,	  personal	  communication	  with	  Matthew	  Hurles).	  	  	  The	  numbers	  of	  missense	  de	  novo	  variants	  are	  higher	  than	  the	  silent	  ones	  but	  the	  burden	   of	   de	   novo	   missense	   variants	   is	   not	   statistically	   significant.	   (exact	  binomial	   test,	   P=	   0.77)	   compared	   with	   the	   expected	   proportion	   of	   de	   novo	  missenses	   by	   Kryukov	   et	   al.	   [357].	   Only	   two	   genes	   with	   de	   novo	   missense	  variants	   show	   heart	   expression	   and	   /	   or	   a	   heart	   defect	   phenotype	   in	   mouse	  knockout	  mouse	  models	  (NR2F2	  and	  ZMYND8,	  Table	  4-­‐11).	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  Figure	  4-­‐18	  The	  distribution	  of	   the	  coding	  de	  novo	  mutation	   in	  13	  AVSD	  trios.	   (A)	  Plausible	  de	  

































































































































(B) DNMs in 13 AVSD trios (verified by capillary sequencing)
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Table	  4-­‐10:	  A	  List	  of	  verified	  coding	  DNMs	  in	  13	  AVSD	  trios.	  	  REF:	  reference	  allele,	  ALT:	  alternative	  allele,	  PP_DNM:	  posterior	  probability	  of	  de	  novo	  variants.	  
Sample	  ID	   CHR	   Position	   REF	  ALT	   PP_DNM	   Gene	   Predicted	  effect	  	  CHDL5262758	   1	   225339733	   G	   A	   1	   DNAH14	  
Missense	  
17	   31323917	   G	   A	   1	   SPACA3	  CHDL5262759	   20	   61522324	   A	   C	   0.386863	   DIDO1	  1	   202129839	   G	   A	   0.00998346	   PTPN7	  CHDL5262760	   2	   80101311	   A	   T	   1	   CTNNA2	  CHDL5262805	   9	   84207971	   T	   C	   0.00158238	   TLE1	  CHDL5262806	   2	   190585499	   T	   C	   1	   ANKAR	  CHDL5262829	   20	   45927610	   G	   A	   1	   ZMYND8	  SC_CHDT5370528	   15	   96880628	   C	   A	   1	   NR2F2	  CHDL5262758	   9	   91994096	   G	   A	   1	   SEMA4D	   Synonymous	  12	   122396226	   A	   G	   1	   WDR66	  CHDL5262830	   2	   182394345	   T	   A	   1	   ITGA4	  2	   172650206	   C	   T	   1	   SLC25A12	  	  	  	  Table	  4-­‐11:	  The	  heart	  expression	  and	  phenotype	  in	  the	  knockout	  mouse	  models	  of	  the	  genes	  with	  verified	  functions	  de	  novo	  mutations	  
Candidate	  	   Protein	  synopsis	   Expression	  	   knockout	  mouse	  model	  phenotype	  
SPACA3	   Sperm	  surface	  membrane	  protein	   No	  expression	  in	  the	  heart	  [493]	   Not	  available	  
DNAH14	   Ciliary	  dynein	  heavy	  chain	  14	   Undetected	  	  [494]	   Not	  available	  
CTNNA2	   Alpha-­‐catenin-­‐related	  protein	   Mainly	  in	  the	  nervous	  system	  [495]	   No,	  abnormalities	  of	  the	  brain	  includes	  a	  hypoplastic	  cerebellum	  [496]	  
DIDO1	   Death-­‐associated	  transcription	  factor	  1	   Undetected	  [494]	   Anomalies	  in	  spleen,	  bone	  marrow,	  and	  peripheral	  blood	  [497]	  
PTPN7	  
Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  7	   Undetected	  [494]	   Mice	  homozygous	  for	  disruptions	  display	  a	  normal	  phenotype	  [498]	  
TLE1	   Transducin-­‐like	  enhancer	  protein	  1	   Expressed	  in	  adult	  heart,	  brain	  and	  kidney	  [499]	   Not	  available	  
ZMYND8	   Protein	  kinase	  C-­‐binding	  protein	  1	   Expressed	  in	  multiple	  tissue	  including	  heart	  [500]	   Not	  available	  
NR2F2	   COUP	  transcription	  factor	  2	   Expressed	  in	  the	  mesodermal	  in	  most	  of	  developing	  internal	  organs	  [501]	   Yes,	  atrioventricular	  septal	  defects	  in	  the	  conditional	  KO	  model	  [501]	  
ANKAR	  
Ankyrin	  and	  armadillo	  repeat-­‐containing	  protein	   Undetected	  [494]	   Not	  available	  
	  
4.3.5 Intersection	  between	  the	  results	  of	  the	  case/control	  and	  de	  novo	  analyses	  	  To	   see	   if	   genes	  with	  de	  novo	  missense	   variants	   are	   enriched	   for	   rare	  missense	  variants,	  I	  intersected	  the	  results	  from	  both	  analyses	  (Table	  4-­‐12).	  Only	  one	  gene	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in	   cases,	  NR2F2	   appears	   to	   be	   enriched	   for	   rare	   missense	   variants	   under	   the	  dominant	  model,	  when	  compared	   to	   controls	  with	  a	  p-­‐value	  of	  ~	  1×10-­‐4	   (odds	  ratio	  of	  18.6).	  	  
 Table	  4-­‐12	  The	  burden	  test	  rare	  missense	  variants	  burden	  in	  candidate	  genes	  obtained	  from	  the	  de	  novo	  analysis	  (i.e.	  each	  gene	  has	  at	  least	  one	  validated	  coding	  variants).	  Only	  one	  gene	  shows	  a	  significant	  burden,	  NR2F2.	  
Genes	  
Samples	  with	  rare	  Heterozygous	  missense	  variants	  	  
Cases	   Controls	   Fisher	  Exact	  
(right	  side)	   Odd	  ratio	  Y	   N	   Y	   N	  
NR2F2	   5	   86	   2	   892	   0.00011	   25.93	  
PTPN7	   4	   87	   9	   885	   0.02545	   4.52	  
ZMYND8	   2	   89	   9	   885	   0.27006	   2.21	  
TLE1	   2	   89	   13	   881	   0.41049	   1.52	  
DIDO1	   6	   85	   44	   850	   0.31187	   1.36	  
SPACA3	   1	   90	   8	   886	   0.58362	   1.23	  
CTNNA2	   3	   88	   29	   865	   0.58093	   1.02	  
SIK1	   4	   87	   39	   855	   0.57453	   1.01	  
DNAH14	   5	   86	   64	   830	   0.78530	   0.75	  
ANKAR	   2	   89	   31	   863	   0.82697	   0.63	  	  	  To	   increase	   the	  power	  of	   the	  burden	  test,	   I	   included	  4,300	  European-­‐American	  samples	   from	  the	  NHLBI-­‐ESP	  project	   to	   the	  original	  control	   set	   (total	  n=5,194)	  [199].	   	   However,	   the	   NHLBI-­‐ESP	   project	   does	   not	   include	   sample-­‐level	  genotypes.	   Instead,	  NHLBI-­‐ESP	  provides	  alternative	  and	  reference	  allele	  counts	  for	   each	   variant	   in	   either	   African-­‐American	   or	   European-­‐American	   samples.	   I	  used	  this	  information	  to	  create	  a	  2	  by	  2	  table,	  similar	  to	  the	  sample-­‐based	  burden	  test	   above,	   but	   instead	   of	   counting	   the	   number	   of	   samples,	   I	   conservatively	  assumed	  each	  alternative	  allele	  in	  the	  NHLBI-­‐ESP	  set	  as	  an	  independent	  sample.	  Finally,	  I	  calculated	  the	  p-­‐value	  of	  the	  burden	  test	  with	  Fisher’s	  exact	  test.	  	  	  Again,	   I	   found	  NR2F2	   to	  be	   the	  only	  gene	  with	  a	  significant	  enrichment	  of	   rare	  missense	   mutations	   but	   with	   more	   significant	   p	   value	   (P=	   7.7	   ×	   10-­‐7,	   odds	  ratio=54.1)	   	   (Table	   4-­‐13).	   This	   analysis	   detected	   two	   additional	   rare	  missense	  mutations	   in	  controls	   from	  NHLBI-­‐ESP	  in	  addition	  to	  the	  original	  two	  missense	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variants	   in	   the	   UK10K	   controls.	   Only	   one	   of	   the	  missense	   variants	   in	   patients	  (p.Ala412Ser)	  has	  previously	  been	  observed,	   in	  a	  single	  individual,	   in	  the	  4,300	  European-­‐American	  exomes	  from	  the	  NHLBI-­‐ESP	  project.	  	  	  Table	  4-­‐13	  The	  Burden	  test	  of	  rare	  missense	  variant	  in	  genes	  with	  confirmed	  de	  novo	  variants	  in	  AVSD	  cases	  compared	  to	  larger	  number	  of	  controls	  (NHLBI-­‐ESP	  and	  UK10K	  Neurological	  control	  samples).	  
Gene	  


















NR2F2	   5	   120	   4	   5,190	   7.73E-­‐07	   54.063	  
ZMYND8	   2	   123	   63	   5,131	   0.666	   1.324	  
TLE1	   2	   123	   64	   5,130	   0.668	   1.303	  
PTPN7	   4	   121	   137	   5,057	   0.574	   1.220	  
DNAH14	   11	   114	   302	   4,892	   0.174	   1.563	  
CTNNA2	   3	   122	   116	   5,078	   0.759	   1.076	  
DIDO1	   8	   117	   332	   4,862	   1.000	   1.001	  
SPACA3	   1	   124	   69	   5,125	   1.000	   0.599	  
ANKAR	   3	   122	   260	   4,934	   0.291	   0.467	  
	  Since	   the	   exome	   sequence	  data	   in	   the	  NHLBI-­‐ESP	  project	  was	   generated	  using	  smaller	  whole	  exome	  capturing	  kits	  (~17,000	  genes	  compared	  to	  ~20,000	  in	  my	  data),	   I	  examined	  the	  coverage	  and	  depth	  of	  sequencing	  of	  NR2F2	  gene	   in	  both	  cases	  and	  controls	  to	  investigate	  the	  possibility	  of	  variant	  under-­‐	  or	  over-­‐calling	  in	   cases	   or	   controls	   which	   can	   distort	   the	   results	   from	   the	   burden	   analysis.	  Figure	  4-­‐19	  shows	  a	  comparable	  average	  depth	  per	  base	  pair	  across	  NR2F2	  gene	  in	  AVSD	  cases	   from	  GAPI	  and	  UK10K	  and	   the	  NHLBI-­‐ESP	  control	   (UK10K=57x,	  GAPI=56x	   and	   NHLBI-­‐ESP=67x).	   These	   analyses	   show	   that	   the	   coverage	   of	  
NR2F2	   was	   very	   similar	   in	   the	   three	   pipelines	   and	   so	   the	   enrichment	   of	   rare	  functional	  variants	  in	  CHD	  is	  unlikely	  to	  be	  driven	  by	  technical	  biases.	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  Figure	  4-­‐19	  The	  average	  depth	  of	  NR2F2	   gene	  per	  base	  pair	   in	   the	  AVSD	  cases	   from	  GAPI	  and	  UK10K	  pipelines	  in	  addition	  to	  control	  samples	  from	  NHLBI-­‐ESP	  project.	  	  	  
4.3.6 NR2F2	  mutations	  in	  the	  primary	  AVSD	  cohort	  The	  AVSD	  analyses	  above	   identified	  only	  one	  gene,	  NR2F2,	  as	  a	  plausible	  AVSD	  candidate	   supported	   by	   evidence	   from	   two	   independent	   analyses:	   de	   novo	  analysis	  in	  AVSD	  trios	  and	  the	  burden	  test	  in	  the	  AVSD	  index	  cases.	  	  Five	  NR2F2	  rare	   missense	   variants	   were	   found	   in	   cases	   and	   four	   missense	   variants	   in	  controls	  (both	  UK10K	  and	  NHLBI-­‐ESP	  sets)	  in	  this	  gene.	  One	  of	  the	  missense	  in	  cases	  arose	  de	  novo	  while	  the	  other	  four	  were	  in	   index	  cases.	  To	  determine	  the	  mode	  of	  transmission,	  our	  collaborators	  at	  the	  SickKids	  hospital	  Seema	  Mital	  and	  her	   team,	   contacted	   the	   families	   of	   the	   AVSD	   index	   cases.	   Three	   out	   of	   four	  families	  agreed	   to	  undergo	  a	   clinical	   examination	  and	   to	  provide	  DNA	  samples	  from	   the	   parents	   for	   validation	   by	   capillary	   sequencing.	   One	   variant,	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p.Asp170Val	   also	   arose	   de	   novo,	   two	   of	   the	   other	   three	   missense	   variants	  observed	   in	   patients	   (p.Asn251Ile	   and	   p.Ala412Ser)	   were	   inherited	   from	   an	  apparently	  healthy	  parent	  (Figure	  4-­‐20-­‐a	  and	  b),	  suggesting	  potential	  incomplete	  penetrance	  (capillary	  sequencing	  results	  are	  shown	  in	  Figure	  4-­‐25	  b-­‐f).	  	  Moreover,	   the	   amino-­‐acid	   changes	   observed	   in	   patients	   appear	   to	   be	   more	  disruptive	  than	  those	  observed	  in	  controls,	  as	  measured	  by	  the	  Grantham	  score,	  but	   with	   so	   few	   variants	   observed	   in	   controls,	   this	   trend	   is	   not	   statistically	  significant	  (Figure	  4-­‐20-­‐c).	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4.3.7 The	  effect	  of	  NR2F2	  mutations	  on	  the	  protein	  structure	  	  The	  missense	  variants	  seen	  in	  patients	  are	  distributed	  throughout	  NR2F2,	  with	  three	   falling	   in	   the	   ligand-­‐binding	   domain	   (p.Asn205Ile,	   p.Glu251Asp	   and	  p.Ser341Tyr).	  My	  colleague	  Jawahar	  Swaminathan	  was	  able	  to	  map	  two	  of	  these	  variants	   to	   a	   previously	   determined	   partial	   crystal	   structure	   for	   this	   domain	  [502]	   (Figure	   4-­‐21p.Asn205Ile	   is	   expected	   to	   perturb	   ligand	   binding	   whereas	  p.Ser341Tyr	  is	  predicted	  to	  destabilize	  the	  homodimerization	  domain).	  	  
	  Figure	   4-­‐21	   (A-­‐C)	   Two	   missense	   variants	   mapped	   onto	   the	   partial	   crystal	   structure	   for	   the	  NR2F2	  ligand-­‐binding	  domain	  10.	  p.Asn251Ile	  (purple)	  falls	   in	  the	  ligand-­‐binding	  groove	  of	  the	  dimer,	  which	  in	  the	  repressed	  conformation	  is	  occupied	  by	  helix	  AF2	  	  (red),	  and	  thus	  this	  variant	  is	   likely	   to	  perturb	   ligand-­‐binding.	  p.Ser341Tyr	  (blue)	   is	   likely	   to	  destabilize	  helix	  A10	  through	  steric	   hindrance	   and	   thus	   decrease	   the	   stability	   of	   NR2F2	   homodimerization.	   (D)	   The	  de	  novo	  mutation	   (p.Ser341Tyr,	   blue	   color)	   effect	   on	   dimerization	   as	   it	   likely	   causes	   extreme	   steric	  hindrances	  that	  is	  likely	  to	  affect	  the	  critical	  dimer	  residue	  Q342	  and	  helix	  A10	  as	  a	  whole.	  This	  mutation	  will	  likely	  result	  in	  the	  movement	  of	  A10	  and	  effect	  helices	  A7	  and	  A8	  as	  well.	  	  
A" B"
C" D"
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4.3.8 NR2F2	  exons	  and	  introns	  are	  very	  conserved	  	  Nuclear	  receptor	  (NR)	  genes	  are	  generally	  conserved	  but	  the	  COUP-­‐TF,	  NR2F2’s	  gene	   family,	   is	   the	  most	   conserved	  NR	   family.	   For	   example,	   the	   ligand-­‐binding	  domain	  DNA	  sequence	  of	  NR2F2	  or	  NR2F1	  is	  99.6%	  similar	  between	  vertebrates	  and	   >	   90%	   similar	   compared	   to	   Svp	   gene,	   the	   COUP-­‐TFs	   homologue	   in	   the	  arthropod	  D.	  melanogaster	   [503].	   	   Figure	   4-­‐22	   shows	   high	   GERP	   [165]	   scores,	  not	  only	  in	  the	  exons	  but	  also	  within	  NR2F2	  intronic	  regions	  and	  extends	  to	  the	  flanking	  regions.	  The	  average	  GERP	  score	  per	  gene	  length	  ranks	  NR2F2	  in	  the	  top	  10%	  of	  all	  genes	  (Figure	  4-­‐23).	  This	  high	  level	  of	  conservation	  of	  NR2F2	  domains	  between	  different	  species	  indicates	  very	  important	  biological	  functions	  and	  may	  explain	  why	  we	  observe	  very	  few	  missense	  variants	  in	  NR2F2	  across	  thousands	  of	  controls.	  	  	  
	  Figure	  4-­‐22	  GERP	   scores	  per	   single	   base	   across	  NR2F2	   (UCSC	   genome	  browser)	   showing	  high	  conserved	  scores	  in	  exons,	  introns	  and	  the	  flanking	  regions.	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  Figure	  4-­‐23	  Average	  GERP	  scores	  averaged	  by	  gene	  length,	  NR2F2	  denoted	  by	  the	  red	  color	  point	  (ranked	  1059	  out	  of	  17,480	  genes).	  	  	  
4.3.9 NR2F2	  rare	  coding	  variants	  in	  non-­‐AVSD	  cases	  There	  is	  considerable	  phenotypic	  heterogeneity	  in	  CHD	  whereby	  the	  same	  genes	  can	   be	   associated	   with	   diverse	   forms	   of	   CHD	   in	   humans	   e.g.	  GATA4,	  NOTCH1,	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4-­‐25-­‐a).	  In	  the	  second	  family	  from	  a	  Berlin	  CHD	  collection,	  and	  analyzed	  by	  both	  my	   colleague	   Marc-­‐Phillip	   Hitz	   and	   myself,	   we	   found	   a	   trio	   of	   two	   healthy	  parents	   of	   an	   affected	   child	   with	   hypoplastic	   left	   heart	   syndrome	   (HLHS)	   and	  identified	   a	   de	   novo	   splice	   site	   (c.2359+1G>A)	   that	   was	   later	   confirmed	   by	  capillary	   sequencing	  by	   Sarah	  Lindsay,	  which	   is	   likely	   to	   cause	   skipping	  of	   the	  third	  exon	  (Figure	  4-­‐25-­‐g).	   	   In	  addition	  to	  these	  two	  families,	  our	  collaborators	  David	  Wilson,	   and	   Catherine	   Mercer	   from	   the	   University	   of	   Southampton	   and	  David	  FitzPatrick	   from	   the	  University	  of	  Edinburgh	  were	  able	   to	   fine	  map	  a	  de	  
novo	   balanced	   translocation	   46,XY,t(14;15)(q23;q26.3)	   to	   the	   first	   intron	   of	  
NR2F2,	   thus	   likely	   generating	   a	   null	   allele	   (Figure	   4-­‐24)	   by	   truncating	   the	  transcript	  after	  the	  first	  exon	  in	  a	  patient	  with	  coarctation	  of	  aorta	  (CoA).	  	  	  Table	   4-­‐14	   NR2F2	   sequence	   alterations	   identified	   in	   individuals	   with	   AVSD	   and	   other	   heart	  structural	  phenotypes.	  









type	  	   GERP++	  1	   I:1	   M	   TOF	   Unknown	   208-­‐211	   70-­‐71	   K/KQ	   In-­‐frame	  insertion	   -­‐	  1	   II:1	   M	   cAVSD	   Inherited	   208-­‐211	   70-­‐71	   K/KQ	   In-­‐frame	  insertion	   -­‐	  1	   II:2	   M	   AS	  and	  VSD	   Inherited	   208-­‐211	   70-­‐71	   K/KQ	   In-­‐frame	  insertion	   -­‐	  2	   II:1	   F	   cAVSD	   De	  novo	   1022	   341	   S/Y	   Missense	   5.15	  3	   II:1	   M	   iAVSD	   De	  novo	   614	   205	   N/I	   Missense	   5.05	  4	   II:1	   F	   ubAVSD	   Inherited	   753	   251	   E/D	   Missense	   4.17	  5	   II:1	   F	   cAVSD	   Inherited	   1234	   412	   A/S	   Missense	   5.74	  6	   II:1	   M	   pAVSD	   Unknown	   509	   170	   D/V	   Missense	   5.00	  7	   II:1	   F	   HLHS	   De	  novo	   -­‐	   -­‐	   -­‐	   Splice	  donor	   4.06	  8	   II:1	   M	   CoA	   De	  novo	   -­‐	   -­‐	   -­‐	   Balanced	  translocation	  	   -­‐	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  Figure	   4-­‐26	   Number	   of	   cases	   and	   controls	   along	  with	   the	   number	   of	   NR2F2	   variants	   and	   the	  mode	  of	  transmission	  in	  the	  discovery	  cohort.	  Red	  boxes	  are	  de	  novo	  variants.	  TOF:	  tetralogy	  of	  Fallot,	   AVSD:	   atrioventricular	   septal	   defects,	   AS:	   aortic	   stenosis,	   VSD:	   ventricular	   septal	   defect,	  CHDs:	  congenital	  heart	  defects.	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4.3.11 Family-­‐based	  analysis	  using	  FEVA	  To	  account	  for	  the	  rare	  Mendelian	  inherited	  variants,	  I	  used	  the	  FEVA	  software	  that	  I	  developed	  (described	  in	  chapter	  2)	  to	  report	  a	  list	  of	  autosomal	  recessive	  candidate	  genes	  in	  the	  trios.	  Index	  cases	  were	  omitted	  in	  this	  analysis	  due	  to	  the	  lack	  of	  additional	  family	  information	  (e.g.	  paternal	  genotypes).	  Instead,	  I	  applied	  case/control	  analysis	  for	  the	  index	  cases	  (see	  next	  section).	  	  The	   filters	  used	  by	  FEVA	  were	  aimed	  to	  capture	  rare	  coding	  variants	  assuming	  both	   parents	   were	   unaffected	   and	   complete	   penetrance.	   Table	   2-­‐11	   lists	   the	  genotype	   combinations	   reported	   by	   FEVA	   under	   different	   inheritance	   models	  (see	  chapter	  2	  for	  details).	  The	  rare	  variants	  are	  defined	  based	  on	  a	  minor	  allele	  frequency	   <	   1%	   in	   the	   1000	   genomes	   and	   2,172	   parental	   samples	   from	   the	  Deciphering	   Developmental	   Disorders	   (DDD)	   project.	   Coding	   variants	   were	  defined	  as	  any	  loss-­‐of-­‐function	  (e.g.	  frameshift,	  splice	  site	  donor	  or	  acceptor	  and	  stop	   gain	   and	   complex	   indels)	   or	   functional	   variants	   (e.g.	   missense	   and	   stop-­‐loss).	  	  	  This	  analysis	   identified	  53	  genes	  under	  different	   inheritance	  models	   (12	  genes	  with	  homozygous	  variants,	  31	  genes	  with	  compound	  heterozygous	  and	  10	  genes	  on	  the	  X	  chromosome).	  Only	  one	  gene	  appears	  in	  more	  than	  one	  trio,	  MADCAM1,	  with	   the	   same	  homozygous	   frame-­‐shift	   in	   two	  unrelated	   trios.	  MADCAM1	  gene	  encodes	   mucosal	   addressin	   cell-­‐adhesion	   molecule-­‐1	   (MAdCAM-­‐1)	   that	   is	  constitutively	  expressed	   in	  the	  gastrointestinal-­‐associated	   lymphoid	  tissue.	  The	  knockdown	  mouse	  model	  [506]	  did	  not	  exhibit	  any	  structural	  phenotypes	  in	  the	  heart	   and	   thus	   this	   MADCAM1	   gene	   is	   unlikely	   to	   be	   involved	   in	   the	   AVSD	  phenotype.	   None	   of	   the	   other	   genes	   identified	   in	   FEVA	   output	   are	   known	   to	  cause	  CHD	  in	  human	  or	  in	  mouse	  models.	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Table	   4-­‐15	   The	   genotype	   combination	   in	   a	   complete	   trio	   reported	   by	   FEVA	   software	   under	  different	  models.	  Each	  trio	  includes	  an	  affected	  child	  (male	  or	  female)	  and	  two	  healthy	  parents.	  Each	   cell	   in	   the	   first	   column	   “genotype	   combinations”	   represents	   three	   genotypes	   in	   child,	  mother	   and	   father.	   “0”	   indicates	   a	   homozygous	   reference	   genotype,	   “1”	   is	   a	   heterozygous	  genotype,	  and	  “2”	  is	  a	  homozygous	  genotype	  in	  diploid	  chromosome	  (autosomal)	  or	  hemizygous	  in	  a	  haploid	  chromosome	  (e.g.	  X-­‐chromosome	  in	  a	  male	  child).	  Y-­‐chromosome	  and	  mitochondrial	  DNA	   are	   omitted	   from	   the	   table.	   Empty	   cells	   indicate	   that	   a	   given	   genotype	   combination	   is	  incompatible	   with	   Mendelian	   laws	   (e.g.	   1,0,0	   is	   de	   novo)	   or	   not	   expected	   under	   complete	  penetrance	   assumption	   (e.g.	   1,1,1	   is	   heterozygous	   in	   both	   the	   affected	   child	   and	   his	   parents).	  Only	   three	   genotype	   combinations	   were	   considered	   when	   I	   performed	   trios	   or	   multiplex	  analysis.	  	  
Genotype	  
combinations	   Autosomal	  
X-­‐	  chromosome	  
in	  an	  affected	  male	  child	  
X-­‐	  chromosome	  
in	  an	  affected	  female	  
child	  (1,	  0,	  0)	   	   	   	  (1,	  0,	  1)	   	   	   	  (1,	  0,	  2)	   	   	   	  (1,	  1,	  0)	   	   	   	  (1,	  1,	  1)	   	   	   	  (1,	  1,	  2)	   	   	   	  (1,	  2,	  0)	   	   	   	  (1,	  2,	  1)	   	   	   	  (1,	  2,	  2)	   	   	   	  (2,	  0,	  0)	   	   	   	  (2,	  0,	  1)	   	   	   	  (2,	  0,	  2)	   	   	   	  (2,	  1,	  0)	   	   Hemizygous	  inherited	  from	  a	  carrier	  mother	   	  (2,	  1,	  1)	   Homozygous	  in	  child	  and	  inherited	  from	  carrier	  parents	   	   	  (2,	  1,	  2)	   	   	   	  (2,	  2,	  0)	   	   	   	  (2,	  2,	  1)	   	   	   	  (2,	  2,	  2)	   	   	   	  (1,0,1)	  and	  (1,1,0)	   Compound	  heterozygous	  in	  the	  child	  in	  a	  given	  gene	   	   	  	  	  
4.3.12 Copy	  number	  variant	  (CNV)	  calling	  from	  exome	  data	  Another	  class	  of	  variants	  known	  to	  increase	  the	  risk	  of	  isolated	  CHD	  is	  rare	  copy	  number	   variants	   (CNVs)	   [122].	   I	   used	   CoNVex	   program	   [372],	   an	   algorithm	  developed	  by	  Parthiban	  Vijayarangakannan	  and	  Matthew	  Hurles,	  to	  detect	  copy	  number	   variation	   from	   exome	   and	   targeted-­‐resequencing	   data	   using	  comparative	   read-­‐depth.	   CoNVex	   corrects	   for	   technical	   variation	   between	  samples	   and	  detects	  CNV	   segments	  using	   a	  heuristic	   error-­‐weighted	   score	   and	  the	  Smith-­‐Waterman	  algorithm.	  The	  average	  number	  of	  called	  CNVs	  per	  sample	  is	  about	  150-­‐200	  CNVs	  (both	  deletions	  and	  duplication).	  Since	  the	  false	  positive	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rate	  (FPR)	   is	  generally	  high	   for	  most	  currently	  available	  methods	  that	  call	  CNV	  from	  the	  exome	  data,	  I	  used	  stringent	  filters	  to	  minimize	  the	  FPR.	  	  The	  first	  filter	  is	  the	  CoNVex	  score	  of	  10	  or	  more.	  This	  is	  a	  confidence	  score	  based	  on	  the	  Smith-­‐Waterman	   score	   divided	   by	   the	   square	   root	   of	   the	   number	   of	   probes	   where	  higher	   values	  mean	   better	   and	  more	   confident	   calls.	   	   I	   also	   excluded	   common	  CNV,	  defined	  as	  CNV	  that	  appear	  in	  less	  than	  1%	  of	  the	  population	  and	  appear	  in	  less	  than	  5%	  (~20	  samples)	  in	  the	  CHD	  exomes	  (i.e.	  internal	  control).	  	  After	   applying	   these	   filters,	   I	   first	   looked	   for	   potential	   de	   novo	   CNV	   in	   the	  children	  and	  I	  detected	  four	  possible	  de	  novo	  duplications	  (Table	  4-­‐16).	  None	  of	  these	  genes	  appear	  to	  be	  expressed	  in	  the	  heart	  nor	  do	  they	  have	  any	  published	  knockout	  mouse	  models.	  	  Table	  4-­‐16	  Plausible	  de	  novo	  exome	  CNV	  in	  13	  AVSD	  trios	  
Sample	  id	   Chr	   Start	   End	   Size	   Convex	  score	   Type	  
Internal	  
frequency	   Genes	  CHDL5262760	   10	   5201946	   5202266	   320	   10.54	   DUP	   8	   AKR1CL1	  
CHDL5262806	   X	   149012854	  149014164	   1,310	   20.13	   DUP	   19	   MAGEA8	  
CHDL5262830	   12	   9446101	   9446662	   561	   10.67	   DUP	   16	   RP11-­‐22B23.1	  
CHDT5370568	   9	   15017219	   15268088	   250,869	   17.68	   DUP	   1	   RP11-­‐54D18.2,	  RP11-­‐54D18.3,	  RP11-­‐
54D18.4,	  TTC39B,	  U6	  	  The	   next	   step	  was	   to	   look	   for	   the	   overlap	   between	   rare	   CNV	   and	   known	   CHD	  genes	  (400	  genes),	  which	  yielded	  three	  rare	  duplications	  and	  one	  deletion	  in	  125	  AVSD	   cases	   (Table	   4-­‐17).	   	   Sample	   SC_CHDT5370541	   carries	   a	   150Kb	   long	  duplication	   on	   chromosome	   21	   and	   includes	   RCAN1,	   also	   known	   as	   Down	  syndrome	   critical	   region	   1,	   DSCR1	   (Figure	   4-­‐27).	   This	   gene	   is	   a	   negative	  modulator	  of	  calcineurin/NFATc	  signaling	  pathway	  and	  expressed	  in	  embryonic	  brain	  and	  in	  the	  heart	  tube	  at	  E9.5-­‐E10.5.	  The	  DSCR1	  expression	  in	  the	  heart	  has	  been	   detected	   in	   the	   truncus	   arteriosus,	   bulbus	   cordis	   and	   the	   primitive	  ventricle,	  which	  correlate	  with	  regions	  of	  endocardial	  cushion	  development	  and	  shown	   to	  be	  necessary	   for	   the	  normal	  development	  of	  heart	  valves	   [104,	  462].	  Moreover,	   the	  mice	  null	  model	   that	   lacks	  NFATc1	  expression	  dies	  secondary	   to	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heart	   cushion	   defects	   [507].	   The	   calcineurin/NFATc	   is	   known	   to	   regulate	   the	  Vascular	   Endothelial	   Growth	   Factor	   (VEGF-­‐A),	   a	   known	   key	   regulator	   of	  endothelial	   cells.	   The	   VEGF-­‐A	   levels	   need	   to	   be	   regulated	   precisely	   to	   ensure	  normal	  development	  of	  the	  heart	  cushions.	  Both	  over-­‐	  and	  under-­‐	  expression	  of	  the	   VEFG-­‐A	   was	   shown	   to	   cause	   cushion	   development	   defects	   [508].	   The	  presence	   of	   this	   small	   CNV	  may	   explain	   the	   AVSD	   phenotype	   observed	   in	   this	  patient.	   However,	   the	   burden	   of	   rare	   CNV	   overlapping	   this	   gene	   in	   CHD	   cases	  from	   the	   online	   Decipher	   database	   was	   not	   statistically	   significant	   when	  compared	  with	  healthy	  controls.	  	  	  
	  Figure	   4-­‐27	   A	   150	   Kb	   duplication	   region	   detected	   on	   chromosome	   21	   and	   overlap	   with	   the	  critical	  region	  of	  Down	  syndrome	  (including	  RCAN1	  gene).	  The	  blue	   line	   is	  the	   log2	  ratio	   in	  the	  patient	  (SC_CHDT5370541)	  with	  partial	  AVSD	  from	  SickKids	  hospital	  in	  Toronto	  collection.	  The	  grey	  lines	  log2ratio	  score	  for	  the	  same	  region	  in	  other	  CHD	  cases.	  	  	  The	  only	  deletion	  I	  found	  overlapping	  with	  a	  known	  CHD	  gene	  is	  a	  27	  kb	  deletion	  that	  overlaps	  part	  of	  EVC	  and	  CRMP1	  genes	  (Figure	  4-­‐28).	  EVC	  is	  a	  known	  gene	  for	   Ellis-­‐van	   Creveld	   Syndrome	   which	   is	   an	   autosomal	   recessive	   syndrome	  where	   patients	   exhibit	   disproportionate	   limb	   dwarﬁsm,	   post-­‐axial	   polydactyly,	  ectodermal	  dysplasia	  and	  congenital	  cardiovascular	  malformations	  in	  60%	  of	  the	  patients	  of	  which	   the	  majority	  are	  AVSD	  [509].	  However,	   the	  mouse	  model	  did	  not	  show	  a	  heart	  phenotype	  [510],	  EVC	  expression	  is	  detected	  in	  the	  secondary	  heart	   field,	   dorsal	  mesenchymal	   protrusion	   (DMP),	  mesenchymal	   structures	   of	  the	  atrial	  septum	  and	  the	  AV	  cushions	  [511].	  Although	  the	  patient	  is	  not	  known	  to	  have	  Ellis-­‐van	  Creveld	  syndrome,	  I	  searched	  the	  EVC	  gene	  for	  variants	  on	  the	  non-­‐deleted	  allele	  (which	  may	  be	  hemizygous	  and	  appear	  to	  be	  homozygous,	   if	  they	  overlap	  the	  deletion)	  to	  see	  if	  the	  patient	  carries	  a	  combination	  of	  deletion	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and	   a	   rare	   coding	  mutation	   (Table	   4-­‐18).	   I	   didn’t	   find	   any	   known	  pathological	  mutation	  (HGMD	  version	  2010.1)	  nor	  rare	  functional	  or	  loss	  of	  function	  variants.	  These	   findings	   suggest	   it	   is	   unlikely	   that	   the	   patient	   has	   Ellis-­‐van	   Creveld	  Syndrome;	  but	  nonetheless	  this	  deletion	  may	  play	  a	  contributory	  role	  within	  an	  oligogenic	  framework.	  	  
	  Figure	  4-­‐28	  The	  log2ratio	  score	  of	  a	  27	  Kb	  deletion	  overlapping	  two	  genes,	  EVC	  and	  CRMP1.	  The	  grey	   lines	   log2ratio	  score	  for	  the	  same	  region	  in	  other	  CHD	  cases.	  The	  red	  line	   is	  the	  patient	   in	  which	  the	  variant	  was	  called.	  	  Table	  4-­‐17	  Rare	  CNV	  overlapping	  with	  known	  CHD	  genes	  
	  	  I	   also	   looked	   for	   rare	   coding	   variants	   under	   the	   dominant	   inheritance	   model	  overlapping	  with	  rare	  CNVs	  (i.e.	  possible	  compound	  heterozygous).	  I	  found	  nine	  rare	  CNVs	  with	  size	   ranges	   from	  1	  Kb	   to	  2.5	  Mb	   that	  overlap	  with	  at	   least	  one	  rare	  coding	  variant	  under	  the	  dominant	  model	  (i.e.	   inherited	  as	  a	  heterozygous	  from	   one	   parents).	   	   However,	   these	   CNVs	   were	   detected	   in	   many	   other	   CHD	  samples	  and	  also	  overlap	  with	  common	  CNV	  controls	  and	  hence	  are	  unlikely	  to	  be	  causal.	  	  
Sample	  id	   Chr	   Start	   End	   Size	   Convex	  score	   Type	  
Internal	  
frequency	   Genes	  SC_CHDT5370524	   1	   100316428	   100387368	   70,940	   25.07	   DUP	   1	   AGL	  












186E3.1,	  U7,	  Y_RNA,	  
snoU13	  SC_CHDT5370591	   4	   5730885	   5758199	   27,314	   13.96	   DEL	   1	   CRMP1,	  EVC	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  Table	  4-­‐18	  List	  of	  variants	  called	  in	  EVC	  gene	  in	  sample	  (SC_CHDT5370591)	  with	  27	  Kb	  deletion	  detected	  by	  the	  exome	  CNV.	  	  
CHR	   POS	   REF	   ALT	  FILTER	   Gene	   Consequences	  	   AF_MAX	   Genotype	  	   In	  deletion	  4	   5730954	   G	   A	   PASS	   EVC	   INTRONIC	   0.261155	   HOM	   Yes	  4	   5743509	   C	   T	   PASS	   EVC	   SYNONYMOUS	   0.998252	   HOM	   Yes	  4	   5743512	   T	   C	   PASS	   EVC	   NON_SYNONYMOUS	   0.947552	   HOM	   Yes	  4	   5747078	   A	   G	   PASS	   EVC	   INTRONIC	   0.699187	   HOM	   Yes	  4	   5747131	   C	   A	   PASS	   EVC	   INTRONIC	   0.611549	   HOM	   Yes	  4	   5750003	   A	   G	   PASS	   EVC	   SYNONYMOUS	   0.360892	   HOM	   Yes	  4	   5754544	   T	   C	   PASS	   EVC	   INTRONIC	   0.469816	   HOM	   Yes	  4	   5755542	   C	   A	   PASS	   EVC	   NON_SYNONYMOUS	   0.989837	   HOM	   Yes	  4	   5785442	   G	   A	   PASS	   EVC	   NON_SYNONYMOUS	   0.455801	   HOM	   Yes	  4	   5798627	   G	   A	   PASS	   EVC	   INTRONIC	   0.396341	   HET	   No	  4	   5800384	   G	   A	   PASS	   EVC	   SYNONYMOUS	   0	   HET	   No	  4	   5803669	   T	   C	   PASS	   EVC	   SPLICE_SITE:INTRONIC	   0.704724	   HET	   No	  4	   5803904	   C	   T	   PASS	   EVC	   INTRONIC	   0.704724	   HET	   No	  4	   5812195	   A	   G	   PASS	   EVC	   INTRONIC	   0.699187	   HET	   No	  4	   5812778	   G	   A	   PASS	   EVC	   3PRIME_UTR	   0.626016	   HET	   No	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4.4 Discussion	  	  AVSDs	   are	   an	   important	   subtype	   of	   CHD	   with	   a	   poorly	   understood	   genetic	  architecture.	  They	  represent	  4-­‐5%	  of	  all	  CHD	  and	  account	  for	  a	  large	  proportion	  of	  CHD	  in	  many	  syndromes	  such	  as	  Down	  and	  heterotaxy	  syndromes.	  The	  search	  for	   genetic	   causes	   in	   syndromic	   AVSD	   has	   been	   difficult.	   For	   example,	   the	  presence	  of	  three	  copies	  of	  chromosomes	  21	  increases	  the	  risk	  of	  AVSD	  but	  is	  not	  enough	  to	  explain	  why	  half	  of	  the	  Down	  syndrome	  patients	  do	  not	  exhibit	  other	  AVSD	  or	  other	  CHD.	  Many	  hypotheses	  have	  been	  suggested	  such	  as	  that	  a	  burden	  of	  rare	  missense	  in	  VEGF-­‐A	  pathway	  genes	  (on	  chromosome	  21)	  may	  play	  a	  role,	  but	   they	   are	   not	   conclusive	   [463].	   On	   the	   other	   hand,	   it	   has	   been	   even	   more	  difficult	  to	  find	  the	  causative	  gene	  isolated	  non-­‐syndromic	  AVSD	  cases.	  Only	  few	  studies	  were	  able	   to	   find	  plausible	  genetic	  causes	   in	  ~2%	  of	   the	   isolated	  AVSD	  cases	   on	   average	   in	   genes	   such	   as	   CRELD1	   and	   GATA4.	   In	   this	   chapter,	   I	  
combined	  exome	  data	  analysis	  from	  hybrid	  family	  designs	  of	  13	  trios	  and	  112	  index	   cases	   to	   find	   genes	   enriched	   for	   rare	   coding	   variants	   (except	   silent	  variants).	  	  	  
What	  are	   the	   lessons	   from	   the	  burden	  analysis	  of	   rare	   coding	  variants	   in	  
the	  case/control	  analysis?	  	  There	   are	  many	   factors	   that	   could	   adversely	   affect	   a	   case/control	   analysis	   and	  should	   be	   addressed	   beforehand.	   These	   factors	   include	   sample	   contamination	  issues	   and	   population	   stratification.	   In	   this	   chapter	   I	   described	   two	   essential	  tests	   that	   removed	   ~11%	   of	   the	   control	   samples:	   the	   free-­‐mix	   scores	   used	   to	  detect	   possible	   sample	   contamination	   and	   the	   principal	   component	   analysis	  (PCA)	   to	   detect	   possible	   population	   stratification.	   The	   free-­‐mix	   scores	   were	  generated	  by	   ‘verifyBAMid’	   software	   [488]	  by	   the	  UK10K	   team,	  which	   enabled	  me	  to	  remove	  ~8%	  (n=89	  out	  of	  1,008)	  of	  the	  UK10K	  neurological	  controls	  for	  possible	   contamination.	   Moreover,	   the	   PCA	   analysis	   worked	   very	   well	   and	  showed	   the	   relationship	   between	   the	   case/control	   samples	   in	   our	   exome	  projects	  to	  the	  four	  main	  populations	  from	  the	  HapMap	  project	  (CEU,	  YRI,	  CHB	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and	  JPT)	  using	  ~10,000	  common	  SNPs	  that	  are	  shared	  between	  them.	  This	  PCA	  analysis	  removed	  another	  ~3%	  of	  the	  controls	  (n=25)	  as	  possibly	  non-­‐Caucasian	  samples.	  	  	  Additionally,	  I	  observed	  another	  two	  factors	  with	  measurable	  effects	  that	  can	  be	  observed	  in	  the	  QQ	  plots	  of	  the	  case/control	  test	  results:	  the	  type	  of	  the	  pipelines	  used	  to	  call	  variants	  and	  the	  sample	  size	  of	  the	  cohort.	  The	  effect	  of	  the	  pipelines	  was	  observed	  when	  I	  evaluated	  different	  combinations	  of	  sample	  from	  both	  the	  GAPI	  and	  UK10K	  pipelines.	  Most	  of	  the	  QQ	  plots	  showed	  inflation	  (i.e.	  too	  many	  positive	  signals)	  when	  I	  used	  samples	  from	  two	  different	  pipelines.	  On	  the	  other	  hand,	  the	  QQ	  plots	  improved	  (showed	  less	  inflating)	  when	  I	  tested	  the	  variants	  in	  cases	   and	   controls	   called	   by	   the	   same	   pipeline.	   This	   is	   expected	   given	   what	   I	  already	   have	   learned	   from	   the	   comparisons	   of	   these	   pipelines	   (described	   in	  chapter	   2),	   which	   showed	   that	   GAPI	   pipeline	   calls	   ~42%	  more	   rare	  missense	  variants	   than	  the	  UK10K	  pipeline.	  This	  can	  partially	  explain	  why	  I	  observed	  an	  inflated	  QQ	  plots	  when	  comparing	  AVSDs	  cases	  from	  GAPI	  pipeline	  with	  controls	  from	  the	  UK10K	  pipeline.	  	  	  The	  second	  factor	  is	  the	  sample	  size	  of	  the	  cohort	  used	  in	  this	  analysis.	  QQ	  plots	  with	   small	   sample	   size	   <	   100	   showed	   a	   worse	   QQ	   inflation	   and	   improved	  dramatically	  when	   I	   increased	   the	   cases	   to	  ~260.	   	   These	   findings	   are	   also	   not	  surprising	  and	  I	  expect	  that	  increasing	  the	  sample	  size	  to	  a	  few	  more	  hundreds,	  possibly	  a	  few	  thousands,	  would	  be	  more	  appropriate	  sample	  size	  for	  this	  test.	  	  	  
What	   are	   the	   benefits	   of	   combining	   the	   de	   novo	   analysis	   with	   the	  
case/control?	  	  Although	  the	  burden	  analysis	  of	  rare	  missense	  variants	  has	  identified	  NR2F2	  as	  one	  of	  the	  enriched	  genes	  for	  rare	  missense	  variants	  in	  the	  cases,	  the	  NR2F2	  gene	  was	  not	   the	   top	   candidate	   gene	   and	   it	   did	   not	   reach	   a	   genome-­‐wide	   statistical	  significance.	   	   This	   case/control	   analysis	   identified	   five	   AVSD	   cases	   and	   two	  controls	   with	   rare	   missense	   variants	   (fisher	   exact	   test,	   P=	   0.00011,	   when	  considering	  AVSD	  cases	  from	  GAPI	  pipeline	  only).	  This	  modest	  result	   led	  me	  to	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overlook	  NR2F2	  gene	   initially.	  Only	  when	  I	  performed	  the	  de	  novo	  analysis	  and	  found	  that	  one	  of	  the	  five	  rare	  missense	  variants	  in	  AVSD	  cases	  was	  actually	  a	  de	  
novo	  variant,	  that	  this	  gene	  made	  it	  back	  to	  the	  top	  of	  the	  AVSD	  candidate	  gene	  list.	  	  This	  shows	  that	  even	  when	  the	  sample	  size	  of	  this	  AVSD	  cohort	  is	  underpowered	  for	   the	   case/control	   analysis,	   intersecting	   gene	   lists	   from	   both	   de	   novo	   and	  case/control	  analyses	  can	  salvage	  the	  latter.	  	  	  	  
How	  NR2F2	  mutations	  cause	  the	  congenital	  heart	  defects?	  	  
NR2F2	   belongs	   to	   a	   small	   family	   of	   the	   steroid/thyroid	   hormone	   receptor	  nuclear	   superfamily	   which	   includes	   two	   related	   but	   distinct	   genes:	  NR2F1	   (or	  
COUP-­‐TFI)	  and	  NR2F2	  (or	  COUP-­‐TFII).	  Both	  genes	  are	  involved	  in	  many	  cellular	  and	   developmental	   processes.	   While	   NR2F1	   is	   mainly	   involved	   in	   neural	  development,	   NR2F2	   is	   expressed	   and	   involved	   in	   the	   organogenesis	   of	   the	  stomach,	   limbs,	   skeletal	   muscles	   and	   the	   heart	   (reviewed	   in	   ref	   [512]).	   The	  ligand	   for	  NR2F2	   is	  not	  yet	  known.	  The	  missense	  variants	   seen	   in	  patients	  are	  distributed	   throughout	  NR2F2,	  with	   three	   falling	   in	   the	   ligand-­‐binding	   domain	  (p.Asn205Ile,	  p.Glu251Asp	  and	  p.Ser341Tyr)	  of	  which	   two	  can	  be	  mapped	   to	  a	  previously	   determined	   partial	   crystal	   structure	   for	   this	   domain	   [502]	   (Figure	  4-­‐20	   d-­‐f):	   p.Asn205Ile	   is	   expected	   to	   perturb	   ligand	   binding	   whereas	  p.Ser341Tyr	  is	  predicted	  to	  destabilize	  the	  homodimerization	  domain.	  	  The	   Nr2f2	   mouse	   null	   model	   leads	   to	   embryonic	   lethality	   with	   severe	  hemorrhage	   and	   failure	   of	   the	   atria	   and	   sinus	   venosus	   to	   develop	   past	   the	  primitive	   tube	   stage	   [513].	   A	   more	   recent	   hypomorphic	  Nr2f2	   mouse	   mutant	  exhibits	   a	   more	   specific	   heart	   phenotype	   with	   atrioventricular	   septal	   and	  valvular	  defects	  due	  to	   the	  disruption	  of	  endocardial	  cushion	  development	   in	  a	  dosage-­‐sensitive	   fashion.	   This	   is	   partially	   driven	   by	   defective	   endothelial-­‐mesenchymal	   transformation	   (EMT)	   and	   the	   hypocellularity	   of	   the	  atrioventricular	   canal	   accompanied	   by	   down	   regulation	   of	   Snai1	   [501].	   Our	  knockdown	  and	  over-­‐expression	  studies	  of	  nr2f2	  in	  zebrafish	  confirmed	  that	  the	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developing	  vertebrate	  embryo	  is	  exquisitely	  sensitive	  to	  nr2f2	  dosage	  (data	  not	  shown),	  such	  that	  knockdown	  rescue	  experiments	  are	  precluded.	  	  In	   addition	   to	   the	   direct	   role	   of	  NR2F2	   mutations	   in	   causing	   congenital	   heart	  defects,	   given	   its	   dosage	   sensitivity,	   NR2F2	   may	   potentially	   also	   act	   as	   an	  environmentally	  responsive	  factor	  by	  mediating	  the	  effect	  of	  known	  non-­‐genetic	  CHD	  risk	  factors	  such	  as	  high	  glucose	  [514]	  and	  retinoic	  acid	  levels	  [515].	  Insulin	  and	   glucose	   levels	   are	   known	   to	   negatively	   control	  NR2F2	   expression	   via	   the	  Foxo1	   pathway	   in	   hepatocyte	   and	   pancreatic	   cells	   [516].	   Furthermore,	  NR2F2	  has	   been	   shown	   to	   play	   a	   critical	   role	   in	   retinoic	   acid	   signaling	   during	  development	  [517].	  Further	  investigations	  are	  needed	  to	  determine	  how	  glucose	  and	  retinoic	  acid	  levels	  may	  alter	  NR2F2	  expression	  in	  the	  developing	  heart.	  	  
Is	  there	  a	  genotype-­‐phenotype	  correlation	  between	  the	  coding	  variants	  in	  
NR2F2	  and	  the	  CHD	  subtypes?	  	  	  In	  addition	  to	  the	  five	  AVSD	  families	  with	  rare	  missense	  variants	  in	  NR2F2	  gene	  (two	  arose	  de	  novo,	  two	  were	  inherited	  and	  one	  unknown	  inheritance),	  with	  the	  help	  of	  my	  collaborators,	  we	  found	  three	  non-­‐AVSD	  families	  with	  rare	  inherited	  or	   de	   novo	   variants	   in	   NR2F2.	   	   The	   first	   was	   a	   novel	   coding	   3bp	   insertion	  (p.Lys70LysGln)	   in	   a	   parent	  with	   Tetralogy	   of	   Fallot	   	   that	   also	   co-­‐segregate	   in	  two	   affected	   sons	   (one	   with	   AVSD	   and	   one	   with	   aortic	   stenosis	   and	   ventricle	  septal	   defect).	   The	   second	   variant	   was	   a	   de	   novo	   balanced	   translocation	  46,XY,t(14;15)(q23;q26.3)	   at	   the	   first	   intron	   of	   NR2F2	   in	   a	   patient	   with	  coarctation	  of	  aorta.	  The	   third	  variant	  was	  a	  de	  novo	   splice	  site	   (c.2359+1G>A)	  that	   is	   likely	   to	   skip	   the	   third	   exon	   which	   later	   was	   seen	   in	   a	   child	   with	  hypoplastic	  left	  heart	  syndrome	  (Table	  4-­‐14,	  Figure	  4-­‐25	  and	  Figure	  4-­‐26).	  	  Moreover,	  a	  previous	  case	  report	  of	  a	  child	  with	  a	  terminal	  deletion	  of	  15q	  and	  septal	  defects	  (VSD	  and	  ASD)	  proposed	  NR2F2	  as	  a	  candidate	  gene	  for	  CHD	  as	  it	  falls	  within	  a	  critical	   interval	  deleted	  in	  the	  subset	  of	  patients	  that	  have	  CHD	  in	  addition	  to	  the	  canonical	  syndromic	  features	  [518].	  Based	  on	  a	  literature	  survey	  
4.4	  Discussion	  	  
	   242	  
of	  rare	  variants	  overlapping	  NR2F2	  gene	  in	  human	  (carried	  out	  by	  Dr.	  Catherine	  Mercer,	  personal	  communication)	  Dr.	  Matthew	  Hurles	  and	  myself	  compared	  the	  cardiac	  phenotypes	  of	  thirteen	  patients	  with	  loss-­‐of-­‐function	  variants	  (including	  published	   whole	   gene	   deletions)	   and	   eight	   patients	   with	   coding	   sequence	  variants	   revealed	   an	   intriguing	   genotype-­‐phenotype	   correlation.	   Most	   patients	  with	   loss-­‐of-­‐function	   variants	   had	   Left	   Ventricular	   Outflow	   Tract	   Obstruction	  (LVOTO,	   N=9),	   but	   none	   had	   AVSD,	   although	   most	   (N=8)	   had	   ASD	   or	   VSD.	  Conversely,	  six	  out	  of	  eight	  patients	  with	  coding	  sequence	  variants	  had	  AVSD,	  but	  only	   one	   had	   LVOTO	   and	   one	   had	  VSD.	   This	   observation	   that	   the	  more	   severe	  mutations	   result	   in	   LVOTO	   in	   addition	   to	   septal	   defects	   merits	   further	  investigation	  in	  larger	  numbers	  of	  patients	  with	  NR2F2	  mutations.	  	  
Does	  the	  negative	  result	  in	  the	  replication	  study	  suggest	  a	  ‘winner's-­‐curse’?	  	  The	   number	   of	   rare	   missense	   variants	   I	   observed	   in	   the	   NR2F2	   gene	   from	  controls	  was	  extremely	  rare	  (only	  ~0.0009%	  based	  on	  the	  analysis	  of	  more	  than	  10,000	   samples	   from	   different	   internal	   and	   external	   whole	   genome/exome	  sequencing	  projects).	  On	  the	  other	  hand,	  the	  analysis	  of	  the	  primary	  AVSD	  cohort	  (n=125)	   identified	   five	  patients	  with	   either	   rare	   inherited	  or	  de	  novo	  missense	  variants	   in	   the	   NR2F2	   gene	   (4%).	   This	   is	   percentage	   is	   unusually	   high	   when	  compared	   with	   candidate	   re-­‐sequencing	   studies	   in	   CHD	   where	   the	   average	  number	  of	   patients	  detected	  with	   rare	   coding	   variants	   is	   usually	   around	  ~2%.	  Hence,	   it	  was	   surprising	   that	   the	   replication	   study	   of	   245	   AVSD	   cases	   has	   not	  identified	  a	  single	  case	  with	  rare	  missense	  variant	  in	  the	  NR2F2	  gene.	  	  	  One	  important	  explanation	  for	  the	  negative	  results	  in	  the	  replication	  experiment	  is	   the	  winner’s	  curse,	  a	  well-­‐known	  phenomenon	   in	   the	  world	  of	  genome-­‐wide	  associations	  studies	  [519].	  This	  phenomenon	  is	  an	  ascertainment	  bias	  that	  leads	  overestimating	   the	   penetrance	   and	   allele-­‐frequency	   parameters	   for	   the	  associated	   variant,	   which	   usually	   lead	   to	   negative	   results	   in	   the	   subsequent	  results.	  Did	  I	  underestimate	  the	  number	  of	  samples	  required	  for	  the	  replication	  study	  in	  isolated	  AVSDs?	  Most	  likely.	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Another	   factor	   that	   to	   the	   negative	   results	   is	   the	   difference	   between	   the	  sequencing	  methods	  used	  to	  screen	  NR2F2	  gene	  for	  rare	  coding	  variants	   in	  the	  primary	   and	   replication	   cohort.	   	   My	   collaborators	   (Dr.	   Sarah	   Lindsay	   at	   the	  Wellcome	  Trust	  Sanger	  Institute	  and	  Ashok	  Kumar	  at	  the	  University	  of	  Toronto)	  have	   used	   capillary	   sequencing	   to	   screen	   the	  NR2F2’s	   three	   exons.	   	   They	   both	  have	   reported	   difficulties	   in	   the	   NR2F2	   sequencing	   due	   to	   high	   GC	   content	  resulted	  in	  a	  high	  failure	  rate	  of	  sequencing	  experiments.	  The	  is	  unlike	  the	  exome	  sequence	  data,	  which	  showed	  very	  good	  sequence	  coverage	  of	  NR2F2	  exons	  and	  all	  coding	  variant	  detected	  in	  the	  cases	  were	  confirmed	  to	  be	  true	  positive.	  	  This	  suggests	   that	   we	   might	   have	   missed	   true	   missense	   variant(s)	   by	   using	   the	  capillary	   sequencing	   in	   such	   difficult	   regions	   and	   an	   alternative	   screening	  methods	   (such	   as	   custom	   designs	   baits	   or	   MIP	   coupled	   with	   NGS)	   is	   a	   better	  alternative	  approach	  for	  the	  next	  replication	  study	  in	  NR2F2.	  	  	   	  
Are	  there	  other	  AVSDs	  candidate	  genes	  found	  in	  this	  cohort?	  	  The	   family-­‐based	   analysis	   (FEVA)	   analysis	   of	   rare	   recessive	   variants	   did	   not	  identify	   any	   strong	   AVSD	   candidate	   gene,	   which	   is	   not	   unexpected	   given	   the	  small	  number	  of	  trios	  included	  in	  this	  cohort	  (n=13).	  	  The	  CNV	  analysis	  based	  on	  exome	   data	   identified	   few	   interesting	   variants	   such	   as	   a	   27kb	   deletion	   that	  overlaps	  with	  EVC	  gene,	  a	  known	  gene	  for	  the	  Ellis-­‐van	  Creveld	  syndrome	  where	  CHD	  occur	  in	  ~60%	  and	  most	  are	  AVSD.	  Although	  Ellis-­‐van	  Creveld	  syndrome	  is	  known	   to	   be	   a	   recessive	   syndrome,	   there	   are	   examples	   of	   hypomorhpic	  mutations	   in	   the	  EVC	   gene	   that	   are	   found	   to	   cause	  a	  phenotype	  of	   cardiac	   and	  limb	   defects	   that	   is	   less	   severe	   than	   typical	   Ellis-­‐van	   Creveld	   syndrome	   [520].	  However,	   this	   deletion	   needs	   to	   be	   confirmed	   using	   an	   independent	   method	  (MLPA	  or	  array	  CGH)	  before	  considering	  it	  any	  further.	  	  	  	  	  
Future	  directions	  	  Increasing	  the	  sample	  size	  of	  the	  replication	  cohort	  and	  also	  including	  non-­‐AVSD	  cases	   are	   likely	   to	   essential	   for	   future	   NR2F2	   replication	   studies	   in	   order	   to	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understand	   the	   involvement	  of	   this	   gene’s	  mutations	   in	   various	  CHD	  subtypes.	  	  The	   two	   study	   designs	   used	   in	   this	   chapter,	   the	   trios	   and	   the	   case/control,	  showed	  very	  promising	  results	  and	  using	  them	  in	  future	  isolated	  AVSD	  studies,	  whether	   in	   combination	   or	   separately,	   is	   expected	   to	   lead	   to	   the	   discovery	   of	  other	  genes.	  More	  importantly,	  calling	  the	  exome	  variants	  across	  all	  samples	  by	  the	   same	   pipeline	   is	   strongly	   advised	   to	   avoid	   spurious	   false	   positive	   findings	  introduced	   by	   the	   subtle	   differences	   in	   filters	   thresholds	   and	   various	   other	  components	  of	  the	  calling	  pipelines.	  	  	  In	   summary,	   these	   findings	   add	   NR2F2	   to	   the	   short	   list	   of	   dosage-­‐sensitive	  regulators	  such	  as	  TBX5,	  TBX1,	  NKX2-­‐5	  and	  GATA4	  that	  have	  been	  shown,	  when	  mutated,	   to	   interfere	   with	   normal	   heart	   development	   and	   that	   lead	   to	   the	  formation	  of	  CHD	  in	  both	  mice	  and	  humans.	  By	  virtue	  of	  their	  dosage	  sensitivity,	  these	   master	   regulators	   potentially	   play	   a	   key	   role	   in	   integrating	   genetic	   and	  environmental	  risk	  factors	  for	  abnormal	  cardiac	  development.	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5 |	  Discussion	  	  	  In	  this	  thesis	  I	  explored	  different	  subtypes	  of	  congenital	  heart	  defect	  (CHD)	  using	  next-­‐generation	   sequencing	   (NGS)	   data	   with	   a	   focus	   on	   family-­‐based	   study	  designs	   such	   as	   parent-­‐offspring	   trios.	   	   Even	   with	   the	   relatively	   small	   sample	  sizes	   of	   the	   cohorts	   studied	   in	   this	   thesis,	   I	   was	   able	   to	   detect	   three	   clearly	  pathogenic	  genes:	  NOTCH1	  and	  JAG1	  in	  isolated	  tetralogy	  of	  Fallot	  and	  NR2F2	  in	  isolated	  atrioventricular	  septal	  defects.	  	  	  
What	  did	  I	  learn	  about	  exome	  analysis	  pipelines?	  	  At	  the	  beginning	  of	  my	  PhD	  studies,	  variant	  calling	  from	  whole	  genome	  or	  whole	  exome	   sequencing	  data	  was	   still	   in	   its	   infancy.	   It	  was	   not	   clear	  what	  were	   the	  best	   practices,	   pipelines,	   tools	   or	   filtering	   strategies	   required	   to	   achieve	   high	  levels	   of	   sensitivity	   and	   specificity	   for	   variant	   identification.	   This	   led	   me	   to	  investigate	   different	   aspects	   of	   the	   variant	   calling	   workflow	   to	   determine	  appropriate	  callers	  and	  filters	  to	  achieve	  high	  specificity	  and	  sensitivity.	  	  	  Initially,	   I	  assessed	  sequence	   and	   variant	   calling	   parameters	   such	  as	  phred-­‐like	  quality	  (QUAL),	  strand	  bias	  (SB),	  quality-­‐by-­‐depth	  (QD)	  and	  genotype	  quality	  (GQ)	   in	   order	   to	   set	   thresholds	   to	   eliminate	   low	   quality	   variants.	   These	   filters	  and	  thresholds	  worked	  well	  for	  the	  early	  sample	  releases,	  but	  as	  the	  underlying	  probabilistic	   models	   for	   calling	   and	   filtering	   variants	   improved,	   these	   filters	  changed	   accordingly	   and	   they	   will	   probably	   continue	   to	   change	   in	   the	  foreseeable	  future.	  Newer	  parameters	  of	  sequence	  data	  and	  variant	  calling	  have	  emerged	  and	  they	  are	  replacing	  many	  previous	  filtering	  strategies	  (for	  example	  the	  Variant	  Quality	  Score	  Recalibration	  (VQSR)	  filter	  from	  GATK	  caller	  has	  been	  suggested	  as	  a	  superior	  quality	   filter	   for	  single	  nucleotide	  variants	   from	  exome	  sequencing,	   but	   not	   indels).	   Currently,	   choosing	   the	   right	   set	   of	   filters	   and	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thresholds	   is	   an	   area	   that	   needs	   to	   be	   revisited	   on	   a	   regular	   basis	   in	   order	   to	  adhere	  to	  the	  best	  practices	  available.	  	  	  Another	   important	   part	   of	   variant	   calling	   workflows,	   which	   is	   usually	  overlooked,	  is	  how	  to	  merge	  variants	  identified	  by	  two	  or	  more	  callers	  (e.g.	  Samtools	   and	   GATK).	   If	   the	   two	   callers	   disagree	   on	   an	   alternative	   allele	   or	   a	  genotype,	  which	  caller	  should	  be	  used	  as	  the	  default?	  When	  I	  started	  my	  projects	  I	   decided,	   naively,	   to	   use	   GATK	   as	   the	   default	   caller	   over	   both	   Samtools	   and	  Dindel,	   for	   samples	   called	   by	   the	   Genome	   Analysis	   Production	   Informatics	  (GAPI)	  pipeline.	  However,	  when	  I	  investigated	  this	  issue	  in	  more	  detail	  later	  on,	  I	  discovered	   a	   complex	   relationship	   between	   the	   type	   of	   the	   caller	   used	   as	   a	  default	   caller,	   and	   the	   number	   and	   type	   of	   rare	   coding	   variants	   identified	   and	  reported	  for	  downstream	  analysis.	  For	  example,	  Samtools	  tends	  to	  call	  more	  rare	  loss	  of	   function	  variants	   (~8	  per	  sample	  on	  average)	   that	  are	  either	  missed	  by	  GATK	  or	  have	  been	  flagged	  by	  GATK	  as	  low	  quality	  variants.	  I	  was	  able	  to	  show	  that	  these	  variants	  exhibit	  a	  low	  transition/transversion	  ratio,	  which	  is	  indeed	  a	  sign	  of	  being	  low	  quality	  variants.	  In	  studies	  with	  a	  small	  number	  of	  samples	  this	  might	   not	   be	   a	   major	   issue,	   but	   for	   large-­‐scale	   projects	   with	   hundreds	   or	  thousands	  of	  samples	  such	  as	  the	  Deciphering	  Developmental	  Disorders	  project	  with	   12,000	   affected	   children,	   this	   can	   have	   a	   huge	   effect	   on	   the	   amount	   of	  downstream	   work	   required	   for	   validation	   and	   /	   or	   functional	   experiments.	  These	  findings	  hold	  true	  for	  the	  version	  of	  the	  callers	  used	  to	  call	  variants	  in	  my	  samples,	  but	  it	  is	  expected	  to	  change	  when	  using	  a	  different	  version	  of	  the	  same	  caller,	   and	   thus	   it	   is	   important	   to	   perform	   this	   detailed	   analysis	   whenever	   a	  newer	  version	  of	  a	  variant	  caller	  is	  implemented.	  	  	  Small	  decisions	  such	  as	  what	  threshold	  of	  a	  filter	  should	  be	  used,	  or	  which	  is	  the	  default	  variant	  caller,	  can	  lead	  to	  big	  differences	  in	  the	  type,	  number	  and	  quality	  of	  the	  variants	  identified	  in	  whole	  exome	  data,	  especially	  the	  rare	  coding	  variants	  of	   greatest	   interest	   in	   rare	   disease	   studies.	   This	  was	   clearly	  manifested	  by	   the	  variant	  differences	  I	  identified	  between	  two	  analytical	  pipelines	  that	  were	  used	  to	  call	  variants	  from	  the	  CHD	  samples	  described	  in	  this	  thesis:	  	  Genome	  Analysis	  Production	   Informatics	   (GAPI)	   and	   UK10K.	   Both	   pipelines	   used	   different	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numbers	  and	  versions	  of	  the	  variant	  callers	  and	  they	  also	  adopted	  variable	  filters	  and	   thresholds.	  Each	  difference	  might	  have	  a	   small	   effect	  on	   its	  own,	  but	   their	  cumulative	   effects	   are	   appreciable.	   The	   most	   obvious	   differences	   I	   observed	  were	   in	   the	   number	   of	   rare	   coding	   variants	   in	   the	   GAPI	   pipeline	  which	   called	  (~42%)	   rare	   missense	   variants	   and	   almost	   4.4-­‐fold	   more	   coding	  insertion/deletion	   (indels)	   than	   the	   UK10K	   pipeline.	   When	   samples	   are	   used	  from	   both	   pipelines,	   as	   they	   were	   in	   the	   burden	   analysis	   of	   rare	   missense	  variants	  in	  chapter	  4,	  I	  noticed	  an	  inflation	  of	  quantile-­‐quantile	  (Q-­‐Q)	  plots.	  An	  obvious	   explanation	  was	   that	   the	   inflation	  was	   caused	   by	   the	   high	   number	   of	  rare	  missense	  variants	  in	  the	  GAPI	  pipeline	  compared	  with	  the	  controls	  from	  the	  UK10K	   pipeline.	   However,	   it	   is	   likely	   that	   the	   explanation	   is	   probably	   more	  complex,	  and	  is	  caused	  by	  multiple	  factors.	  More	  work	  is	  required	  to	  investigate	  the	  origin	  of	  these	  differences.	  	  	  
What	  did	  I	  learn	  about	  tetralogy	  of	  Fallot?	  	  The	   two-­‐stage	   study	   design	   I	   used	   to	   investigate	   the	   genetic	   architecture	   of	  isolated	  tetralogy	  of	  Fallot	  enabled	  me	  to	  detect	  two	  clearly	  pathogenic	  genes:	  
NOTCH1	  and	  its	  ligand	  JAG1	  in	  a	  cohort	  of	  238	  parent-­‐offspring	  trios.	  	  	  Although	  both	  genes	  have	  been	  associated	  with	  congenital	  heart	  defects	  in	  the	  past,	  their	  involvement	   in	   the	   isolated	   tetralogy	   of	   Fallot	   is	   less	   well	   appreciated.	   Rare	  coding	  variants	  in	  NOTCH1	  have	  been	  linked	  to	  familial	  forms	  of	  left	  ventricular	  outflow	  tract	  malformations	  more	  often	  than	  with	  the	  malformations	  of	  the	  right	  side	  of	  the	  heart.	  Similarly,	  mutations	  in	  JAG1	  are	  usually	  associated	  with	  Alagille	  syndrome	  where	   CHD	   occurs	   in	   ~90%	   of	   the	   patients	   (6-­‐17%	   are	   ToF)	  more	  often	   than	  with	  non-­‐syndromic	   tetralogy	  of	  Fallot.	   I	  was	  able	   to	  detect	  de	  novo	  coding	  variants	  (except	  silent	  variants)	  in	  these	  genes	  in	  2.5%	  of	  patients	  in	  this	  cohort.	  These	  variants	  included	  four	  de	  novo	  coding	  variants	  in	  the	  NOTCH1	  gene	  and	   two	   de	  novo	   coding	   variants	   in	   the	   JAG1	   gene.	   Interestingly,	   two-­‐thirds	   of	  these	   de	   novo	   variants	   are	   loss-­‐of-­‐function,	   which	   showed	   up	   as	   a	   highly	  statistically	   significant	   burden	   of	   de	  novo	   loss-­‐of-­‐function	   in	   the	  NOTCH1	   gene	  (P=3.8	  ×10-­‐9).	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More	   interestingly,	   a	   theme	   has	   emerged	  when	   I	   combined	  de	  novo	   variant	  analysis	  with	   other	   analyses	   that	   target	   rare	   coding	   variants	  with	   presumably	  intermediate	   effect	   size	   (i.e.	   incomplete	   penetrance).	   I	   identified	   two	   genes,	  
NOTCH1	   and	   ARHGAP35,	   both	   with	   de	   novo	   functional	   or	   loss-­‐of-­‐function	  variants,	  and	  both	  were	  also	  enriched	  for	  rare	  inherited	  missense	  variants.	  The	  case/control	   analysis	   identified	   NOTCH1	   as	   being	   enriched	   for	   rare	   missense	  variants	   (P=8.8	   ×	   10-­‐05).	   On	   the	   other	   hand,	   the	   modified	   transmission	  disequilibrium	   test	   (TDT)	   identified	   an	   over-­‐transmission	   of	   rare	   missense	  variants	  in	  the	  ARHGAP35	  	  (P=0.02).	  	  	  Collectively,	  these	  genes	  have	  five	  de	  novo	  variants	  where	  all	  but	  one,	  are	  loss-­‐of-­‐function	   variants.	   This	   observation	   suggests	   that	   two	   classes	   of	   variants	  contribute	   to	   the	   isolated	   tetralogy	   of	   Fallot.	   The	   first	   group	   is	   rare	   coding	  variants	  with	  large	  effect	  size,	  mainly	  loss-­‐of-­‐function,	  that	  are	  able	  to	  cause	  the	  phenotype	   when	   they	   occur	   de	   novo.	   The	   second	   group	   is	   rare,	   typically	  missense,	  variants	  that	  increase	  the	  risk	  of	  isolated	  tetralogy	  of	  Fallot	  but	  are	  not	  sufficient	   to	   cause	   the	   phenotype	   by	   themselves.	   	   This	   group	   might	   require	  additional	  in	  cis-­‐	  or	  trans-­‐	  variants	  in	  order	  to	  cause	  the	  phenotype.	  One	  way	  to	  investigate	   this	   possibility	   is	   the	   digenic	   inheritance	  model	   that	   I	   described	   in	  
chapter	   3.	   Although	   the	   digenic	   inheritance	   analysis	   has	   identified	   a	   few	  interesting	  gene	  pairs	  such	  as	  ZFPM2-­‐CTBP2	  that	  are	  enriched	  for	  rare	  missense	  variants	   in	   cases	   compared	   with	   1,080	   controls,	   the	   sample	   size	   is	   clearly	  underpowered,	  so	  I	  was	  not	  able	  to	  obtain	  signals	  that	  are	  statistically	  significant	  at	  the	  genome-­‐wide	  level.	  	  
What	  did	  I	  learn	  about	  isolated	  atrioventricular	  septal	  defects?	  	  Similarly,	  combining	  de	  novo	  analysis	  with	  case/control	  analysis	  enabled	  me	  to	  identify	  NR2F2	  as	  a	  novel	  candidate	  gene	  for	   isolated	  atrioventricular	   septal	  
defects	  (AVSD)	  in	  human	  (chapter	  4).	   	  Although	  the	  case/control	  analysis	  of	  a	  burden	  of	  rare	  missense	  variants	  burden	  did	  not,	  on	  its	  own,	   identify	  NR2F2	  as	  the	  most	  significant	  gene,	  it	  was	  the	  subsequent	  de	  novo	  analysis	  that	  identified	  this	  gene	  as	  the	  most	  intriguing	  candidate	  gene	  in	  this	  cohort.	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What	  did	  I	  learn	  about	  study	  designs?	  	  The	  two	  most	  informative	  study	  designs	  I	  evaluated	  in	  my	  thesis	  are	  the	  trio-­‐based	   and	   the	   case/control	   designs.	  The	   trio	   family-­‐based	  design	   is	   a	   versatile	  design	  since	  it	  is	  amenable	  to	  different	  analyses	  aimed	  to	  investigate	  rare	  coding	  variants	  with	  large	  size	  effect	  as	  well	  as	  variants	  with	  intermediate	  effect	  sizes.	  	  
De	  novo	   analysis	   is	   the	  main	   test	   used	   to	   investigate	   variants	  with	   large	   effect	  size.	  	  Less	  commonly	  used,	  the	  modified	  transmission	  disequilibrium	  test	  (TDT)	  tries	  to	  identify	  over-­‐transmission	  of	  rare	  variants	  from	  healthy	  parents	  to	  their	  affected	  children,	  as	  well	  as	   the	  digenic	   inheritance	  analysis	  which	   targets	  rare	  variants	   in	   affected	   children	   inherited	   from	   two	   different	   parents.	   The	  case/control	   analysis	   worked	   surprisingly	   well	   given	   the	   small	   size	   of	   the	  cohorts	   in	   this	   thesis.	   	   Its	   success	   is	   most	   likely	   attributed	   to	   being	   used	   in	  combination	  with	  the	  results	  from	  the	  de	  novo	  analysis.	  Nonetheless,	  performing	  case/control	   analysis	   in	   larger	   sample	   size	   of	   homogenous	   CHD	   cohorts	   is	  expected	  to	  identify	  additional	  genes	  involved	  in	  congenital	  heart	  defects.	  	  Other	  study	  designs	  I	  used	  such	  as	  affected	  parent-­‐child	  and	  affected	  sib-­‐pairs	  were	  not	  as	  successful,	  but	  this	  is	  likely	  to	  be	  due	  to	  the	  small	  sample	  size	  of	  these	  studies,	  and	  the	  difficulty	  in	  identifying	  additional	  families	  with	  similar	  mutations.	  	  
	  
What	  were	  the	  limitations	  of	  my	  work?	  
	  Next-­‐generation	   sequence	   (NGS)	   platforms	   have	   revolutionized	   the	   way	   we	  identify	  causal	  genes	  in	  monogenic	  disorders.	  This	  technology	  has	  helped	  me	  to	  identify	  different	  causal	  genes	  in	  two	  non-­‐syndromic	  CHD	  subtypes.	  Nonetheless,	  NGS	  platforms	   impose	  some	  major	  analytical	   challenges.	  The	  most	   important	  one	  is	  the	  fact	  that	  my	  analysis,	  in	  common	  with	  all	  such	  analyses,	  has	  identified	  too	  many	  variants	  of	  unknown	  significance	  (VUS).	  This	  reflects	  our	  current	  state	  of	   very	   limited	   understanding	   of	   the	   function	   of	   most	   genes	   and	   the	  consequences	   of	   most	   variants.	   One	   way	   to	   overcome	   this	   problem	   in	   gene	  discovery	   analysis,	  will	   be	   to	   increase	   the	   sample	   size	   in	   order	   to	   increase	   the	  power	  of	  genetic	  analyses.	  International	  collaborations	  and	  data	  sharing	  will	  be	  important	  for	  increasing	  sample	  sizes.	  For	  VUS	  in	  known	  CHD	  genes,	  functional	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assays	  in	  vivo	  or	  in	  vitro	  may	  help	  to	  confirm	  their	  pathogenicity,	  although	  even	  these	  assays	  will	  have	  their	  associated	  false	  positives	  and	  false	  negatives.	  	  	  
How	  do	  my	  findings	  relate	  to	  other	  peoples	  work?	  	  Recently,	  Zaidi	  et	  al.	  used	  NGS	  to	  sequence	  the	  whole	  exome	  in	  a	  trio	  cohort	  of	  362	   severe	   cases	   of	   syndromic	   and	   non-­‐syndromic	   CHD	   and	   predicted	   that	  de	  
novo	  point	  mutations	   in	  several	  hundreds	  of	  genes	  may	  contribute	   to	  ~10%	  of	  severe	   CHD	   cases	   [256].	   This	   estimation	   is	   difficult	   to	   ascertain	   using	   the	  samples	  described	  in	  my	  thesis,	  since	  I	  have	  a	  much	  smaller	  sample	  size	  of	  trios	  (n=43	  complete	  trios	  with	  whole	  exome	  sequence	  data).	  	  Nonetheless,	  I	  was	  able	  to	   identify	   likely	   pathogenic	   de	  novo	   variants	   in	  NOTCH1	   and	   JAG1	   in	   2.5%	   of	  isolated	   tetralogy	   of	   Fallot	   (six	   out	   of	   238	   trios)	   and	   about	   ~12%	   in	  atrioventricular	   septal	   defects	   trios	   (two	   out	   of	   16	   complete	   trios	   that	   were	  available	   with	   either	   exome	   data	   or	   capillary	   sequencing)	   but	   given	   the	   other	  candidate	  genes	  that	  I	   identified	  with	  de	  novo	  variants	  (e.g.	  ZMYM2,	  ARHGAP35,	  
HDAC3).	  My	  results	  are	  broadly	  consistent	  with	  the	  conclusion	  by	  Zaidi	  et	  al.	  	  
Future	  directions	  	  Selecting	  an	  optimal	  variant	  calling	  pipeline	  is	  not	  an	  easy	  task	  and	  once	  one	  is	  implemented,	   any	   potential	   upgrade	   or	   new	   pipeline	   needs	   to	   be	   assessed	   in	  considerable	  detail	  to	  ensure	  that	  data	  quality	  is	  improved.	  Equally	  importantly,	  using	   a	   single,	   consistent,	   pipeline	   is	   essential	   in	   order	   to	   obtain	   consistent	  datasets,	  which	  helps	  to	  avoid	  complicating	  any	  downstream	  analyses.	  	  	  Future	  CHD	  studies	  will	  require	  larger	  sample	  sizes,	  possibly	  of	  the	  order	  of	  a	  few	  thousand	  samples,	  in	  order	  to	  achieve	  enough	  power	  to	  identify	  a	  substantial	  fraction	   of	   recurrently	   mutated	   causal	   genes.	   Given	   the	   rarity	   of	   many	   CHD	  subtypes,	  a	  national	  and	  international	  network	  of	  collaborators	  is	  necessary	  to	   collect	   enough	   samples	   for	   parent-­‐offspring	   complete	   trios	   and/	   or	   case-­‐control	  designs,	  both	  of	  which	  have	  been	  shown	  to	  be	  suitable	  study	  designs	  for	  isolated	  CHD.	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  Beside	  the	  genetic	  components	  required	  to	  support	  newly	  identified	  CHD	  genes	  in	  trios	  and	  case/control	  study	  designs,	  functional	  experiments	  are	  essential	  to	  confirm	   the	   pathogenic	   effect	   of	   genes	   in	   animal	   models	   using	   knockout	   or	  knockdown	  experiments	  in	  mouse	  and	  zebrafish	  models.	  Where	  appropriate,	  the	  pathogenic	   effect	   of	   specific	   variants	   can	   also	   be	   investigated	   using	   cell-­‐based	  assays	  such	  as	  luciferase	  activity	  experiments.	  Moreover,	  integrating	  exome	  and	  genome	  sequence	  data	  with	  gene	  expression	  data	  using	  RNA-­‐Seq	  from	  fetal	  heart	  tissues	   at	   different	   developmental	   stages	   are	   likely	   to	   be	   a	   helpful	   tool	   to	  prioritize	   candidate	   genes.	   Integrating	   high-­‐throughput	   genetics,	   functional	  genomics	   and	   cellular	   and	   animal	   modeling	   will	   require	   concerted	   effort	   and	  collaboration.	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The	  following	  work	  was	  perfomed	  by	  Sebastian	  Gerety	  as	  part	  of	  chapter	  3.	  
Methods:	  Functional	  experiments	  	  	  Morpholino	  oligonucleotides	  (MO)	  were	  purchased	  from	  Gene	  Tools	  (Oregon,	  USA).	  	  One-­‐	  to	  four-­‐cell	  embryos	  were	  microinjected	  with	  1.8	  nl	  of	  morpholino	  diluted	  in	  water.	  	  The	  sequences	  of	  morpholinos	  used	  were	  zmym2	  MO1:	  	  CTGAGTGTGGATGAATTACCAGATC,	  zmym2	  MO2:	  ATTAAAATGACGTACTTCTTGCACA	  and	  tp53	  GCGCCATTGCTTTGCAAGAATTG	  [521].	  To	  eliminate	  off-­‐target	  effects	  of	  morpholinos	  [522]	  we	  co-­‐injected	  zmym2	  MOs	  with	  tp53	  MO.	  	  The	  efficacy	  of	  the	  splice-­‐blocking	  zmym2	  MO1	  was	  tested	  by	  RT-­‐PCR.	  	  Embryos	  were	   injected	  with	   zmym2	  MO1	  or	   control	  MO,	   and	  grown	  until	   24	  hpf.	   	   	  RNA	  was	  extracted,	  and	  subject	  to	  RT-­‐PCR	  with	  exonic	  primers	  spanning	  the	  targeted	  splice	   site,	   to	   detect	   correctly	   spliced	  mRNA.	   	   Additionally,	   to	   detect	   increased	  unspliced	  RNA,	  the	  above	  exonic	  primer	  was	  paired	  with	  a	  downstream	  intronic	  primer.	  PRIMERS:	  ZMYM2	  MO1	  Forward:	  CAAAAGTGGCGCTCTACCGTCTC	  ZMYM2	  MO1	  Reverse	  exonic:	  GACGCCGATTGGGAGATCCATG	  	  
Results:	  Zebrafish	  morpholino	  knockout	  experiments	  	  To	   assess	   whether	   ZMYM2	   has	   a	   role	   in	   heart	   development,	   my	   colleague,	  Sebastian	  Gretey,	  chose	  to	  perform	  loss	  of	  function	  experiments	  in	  the	  Zebrafish	  
Danio	   Rerio.	   Their	   rapid,	   external	   development	   and	   a	   near-­‐transparent	   body	  combined	   with	   rapid	   antisense	   oligo-­‐mediated	   loss	   of	   function	   permits	   us	   to	  analyse	  gene	  function	  without	  the	  need	  for	  complex	  knockout	  technology.	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Using	   the	   Ensembl	   browser,	   he	   first	   identified	   the	   zebrafish	   orthologue	   of	  
ZMYM2,	   also	   called	   zmym2	   (ENSDARG00000027353).	   	  The	  predicted	   zebrafish	  protein	  has	  a	  50%	  amino	  acid	  identity	  with	  human	  ZMYM2,	  and	  shared	  synteny	  between	  the	  two	  species.	   	  Using	  the	  ENSEMBL	  predicted	   intron/exon	  structure	  of	   the	  zebrafish	  gene,	  Sebastian	  designed	   two	  antisense	  morpholinos,	   targeting	  the	  splice	  site	  at	  the	  end	  of	  the	  first	  and	  second	  coding	  exons.	  	  Injection	  of	  either	  of	  these	  morpholinos	  is	  predicted	  to	  cause	  intron	  retention,	  leading	  to	  premature	  truncation	  of	  the	  zmym2	  transcript	  [523].	  	  	  	  To	  determine	  if	  the	  morpholinos	  are	  effective	  at	  blocking	  splicing,	  he	  performed	  RT-­‐PCR	   on	   injected	   embryos,	   which	   confirmed	   that	   zmym2	   morpholino#1	  injected	   embryos	   have	   an	   increase	   in	   unspliced	   mRNA	   and	   a	   decrease	   in	  correctly	   spliced	   mRNA	   across	   the	   target	   region	   (see	   Methods).	   	   These	   data	  confirm	   that	   zmym2	   morpholino	   injection	   should	   decrease	   Zmym2	   protein	  expression	  in	  the	  zebrafish	  embryo.	  	  During	   heart	   morphogenesis	   in	   the	   zebrafish,	   a	   centrally	   aligned	   linear	   heart	  tube	   undergoes	   a	   lateral	  movement	   termed	   'jogging',	   positioning	   it	   on	   the	   left	  side	   of	   the	   body	   by	   24	   hours	   post	   fertilisation	   (hpf)	   [524,	   525].	   	   Subsequent	  looping	   events	   in	   the	   second	   24	   hours	   of	   development	   results	   in	   an	   S-­‐shaped	  heart	   structure	   resembling	   other	   vertebrate	   embryonic	   hearts,	   with	   ongoing	  blood	   flow.	   	   A	   number	   of	   genes	   implicated	   in	   ToF	   are	   linked	   to	   left-­‐right	  asymmetry.	   	   To	   see	   whether	   the	   developing	   hearts	   in	   zmym2	   morpholino	  injected	  embryos	  display	  any	  morphological	  defects,	   including	  aberrant	   jogging	  of	   the	   heart	   tube,	   or	   subsequent	   heart	   looping,	   both	   of	   which	   are	   strongly	  dependent	   on	   left-­‐right	   asymmetry,	   he	   stained	   the	   heart	   tissue	   of	   zmym2	   or	  control	  morpholino	  injected	  embryos	  by	  in	  situ	  hybridization	  with	  a	  CMLC2	  RNA	  probe.	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Figure	   A-­‐1	   Heart	   jogging	   and	   looping	   of	   the	   heart	   in	   the	   wild	   type	   and	   ZMYM2	   morpholino	  injected	  embryos.	  	  	  At	   24	   hpf,	   94.9%	   of	   control	   injected	   embryos	   (n=91	   embryos,	   2	   experiments)	  show	   a	   left	   jogging	   heart,	   while	   only	   69.5%	   of	   zmym2	  MO1	   injected	   embryos	  show	   left	   jogging,	   with	   the	   remainder	   either	   central,	   or	   right	   jogging	   (n=70	  embryos,	  2	  experiments).	   	  When	  analysed	  for	  heart	  looping	  at	  48	  hpf,	  91.8%	  of	  control	  MO	   injected	   embryos	   (n=141,	   3	   experiments)	   showed	   correct	   looping,	  while	   only	   48.5%	   of	   zmym2	   MO1	   injected	   embryos	   showed	   correct	   looping	  (Figure	  A-­‐1).	   	   The	   remaining	   zmym2	  MO1	   injected	   embryos	  displayed	   a	   linear	  heart	   tube,	   in	  which	   looping	   had	   not	   occurred.	   	   The	   severity	   of	   the	   heart	   and	  other	  embryonic	  defects	  in	  zmym2	  MO	  injected	  zebrfish	  results	  in	  dead	  or	  dying	  embryos	  by	  the	  fifth	  day	  post	  fertilisation.	  	  	  	  
	  Appendix	  B	  	  
	   256	  
Appendix	  B 
The	  following	  work	  was	  perfomed	  by	  Sebastian	  Gerety	  as	  part	  of	  chapter	  4.	  
Methods:	  NR2F2	  expression	  plasmids	  and	  luciferase	  constructs	  	  My	  colleague,	  Sebastian	  Gerety,	  generated	  expression	  plasmids	  for	  NR2F2	  and	  its	  variants,	  the	  human	  wildtype	  NR2F2	  coding	  sequence	  was	  PCR	  amplified	  from	  a	  full	  length	  EST	  (Genbank	  acc.#BC042897),	  and	  cloned	  by	  Gibson	  assembly	  (New	  England	   Biolabs)	   into	   a	   CMV-­‐driven	   pCS2-­‐Cherry	   plasmid.	   	   To	   recreate	   the	  mutant	  forms	  of	  NR2F2	  (p.Lys70LysGln,	  	  p.Asp170Val,	  p.Asn205Ile,	  p.Glu251Asp,	  p.Ser341Tyr,	   and	   p.Ala412Ser),	   he	   amplified	   two	   PCR	   fragments	   overlapping	  each	  mutation,	  and	  cloned	  these	  as	  above.	  	  These	  expression	  constructs	  produce	  fusion	   proteins	   with	   fluorescent	   cherry	   domain	   [526]	   in	   order	   to	   monitor	  expression	   and	   localisation.	   	   To	   create	   the	  NGFI-­‐A	   and	  APOB	   promoter	   driven	  Luciferase	   plasmids,	   he	   cloned	   synthetic	   DNA	   fragments	   for	   the	   rat	   NGFI-­‐A	  upstream	   genomic	   region	   from	   -­‐389	   to	   +43	   [527],	   and	   the	   human	   APOB	  upstream	  region	  from	  -­‐139	  to	  +121	  [528],	   into	  a	  promoterless	  pGL3	  Luciferase	  plasmid	  (Promega)	  by	  Gibson	  assembly	  (New	  England	  Biolabs).	  	  	  
Methods:	  Luciferase	  assays	  HEK293T	  and	  HEPG2	   cells	  were	  plated	   in	  96-­‐well	   plates,	   and	   transfected	  with	  30ng	   of	   either	   NGFI-­‐A	   or	   APOB	   luciferase	   plasmids,	   0.75	   ng	   of	   RL-­‐TK	   renilla	  plasmid	  (Promega),	  and	  either	  30ng	  of	  NR2F2	  expression	  plasmid	  (wildtype	  or	  variants)	  or	  30ng	  of	  Cherry	  plasmid	  as	  a	  control.	  Two	  days	  after	  transfection,	  the	  cells	   were	   lysed	   and	   assayed	   for	   luciferase	   activity	   using	   the	   Dual-­‐Luciferase	  Reporter	  Assay	  System,	  according	  to	  the	  manufacturer’s	  instructions	  (Promega).	  	  Each	   transfection	   was	   done	   in	   replicates	   (minimum	   three	   times)	   and	   the	  experiments	  were	  repeated	  3-­‐4	  times.	  	  Luciferase	  readings	  were	  first	  normalized	  to	   the	   transfection	   control	   (renilla	   plasmid).	   	   Relative	   Response	   Ratios	  (Promega)	  were	  calculated	  based	  on	  negative	  and	  positive	  controls	  (cherry	  and	  
NR2F2	   plasmid	   transfections),	   and	   outliers	   across	   all	   experiments	   were	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identified	   by	   a	  median	   absolute	   deviation	   ratio	   >3.	   	   A	   t-­‐test	  was	   performed	   to	  identify	  significant	  differences	  between	  variants	  and	  between	  promoters.	  	  
Results:	  Luciferase	  assays	  Despite	   the	   availability	   of	   computational	   methods	   predicting	   the	   effect	   of	  missense	   variants	   on	   protein	   function,	   interpreting	   the	   significance	   of	   these	  mutations	   in	   human	   disease	   is	   notoriously	   difficult.	   	   My	   colleague	   Sebastian	  Gerety	   tested	   the	   consequence	   of	   the	   identified	  NR2F2	   variants	   in	   a	   functional	  assay.	   	  Nr2f2	   is	  a	   transcriptional	  regulator,	  with	  both	  activating	  and	  repressive	  effects	  on	  target	  gene	  expression	  [512].	  	  A	  number	  of	  NR2F2	  responsive	  genomic	  elements	  have	  been	  identified,	  which	  when	  placed	  upstream	  of	  a	  reporter	  gene	  can	   quantitate	   transcriptional	   regulator	   function	   of	   Nr2f2	   variants	   [502,	   527,	  528].	   	   Using	   the	   most	   widely	   employed	   element,	   the	   promoter	   region	   of	   the	  
NGFI-­‐A	  gene	  [527],	   to	  drive	  a	   luciferase	  reporter	   in	  HEK293	  cells,	  he	  compared	  its	   level	   of	   activation	   by	   wildtype	   NR2F2	   with	   that	   of	   the	   patient-­‐derived	  variants.	  	  Sebastian	  observed	  robust	  luciferase	  activation	  by	  wildtype	  Nr2f2,	  and	  equivalent	   levels	   of	   activity	   from	   variants	   p.Asp170Val	   and	   p.Ala412Ser.	  	  However,	   two	   variants	   (p.Glu251Asp	   and	   p.Ser341Tyr)	   show	   a	   significantly	  lower	   activity	   in	   this	   assay	   (20-­‐24%	   reduction,	   p<0.01),	   while	   variants	  p.Lys70LysGln	   and	   p.Asn205Ile	   have	   an	   increased	   activity	   (13-­‐15%	   increase,	  p<0.03)	  (Figure	  B-­‐1).	  	  	  As	   the	   function	  of	  nuclear	   receptors	   involves	   a	   complex	   interaction	  with	  other	  transcriptional	   coregulators,	   he	   hypothesized	   that	   the	   consequence	   of	   Nr2f2	  mutations	   might	   be	   promoter	   context	   dependent.	   	   Sebastian	   therefore	  performed	   the	   luciferase	   assay	   on	   an	   alternative	   promoter	   fragment	   from	   the	  
APOB	  gene,	  that	  has	  previously	  been	  shown	  to	  be	  bound	  by	  Nr2f2	  and	  used	  for	  structure-­‐function	  studies	  [528].	  	  In	  agreement	  with	  our	  prediction,	  the	  activities	  of	   the	   variants	   on	   the	   APOB	   promoter	   in	   HEK293	   cells	   were	   significantly	  different	   from	   those	   using	   the	   NGFI-­‐A	   promoter	   (Figure	   B-­‐1).	   	   Variants	  p.Asp170Val,	   p.Asn205Ile,	   p.Glu251Asp	   and	   p.Ser341Tyr	   all	   show	   strong	  reductions	   in	   transcriptional	   activity	   compared	   to	   wildtype	   Nr2f2	   (26-­‐52%	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reduction,	   p<0.001),	   and	   p.Ala412Ser	   now	   has	   significantly	   higher	   activity	  (12.9%	  increase,	  p=0.006).	  	  Strikingly,	  variant	  p.Asn205Ile	  reduces	  the	  activity	  of	  Nr2f2	  on	  the	  APOB	  promoter	  while	  increasing	  it	  on	  the	  NGFI-­‐A	  promoter	  (down	  26%	  versus	  up	  15%,	  p=0.0003).	  	  	  	  Taken	   together,	   these	  data	   indicate	   that	  all	   six	  Nr2f2	  coding	   sequence	  variants	  identified	  have	  a	  measurable	  impact	  on	  the	  transcriptional	  activator	  function	  in	  at	   least	   one	   assay	   Further	   modeling	   work	   will	   be	   required	   to	   clarify	   whether	  these	  differences	  translate	  to	  distinct	  biological	  mechanisms	  of	  disease,	  affecting	  a	  single	  or	  multiple	  molecular	  interactions	  required	  for	  heart	  morphogenesis.	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